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SCOPE OF THE SYMPOSIUM 
Meat producing animals have, since their domestication, changed dramatically in their capacity 
for providing high quality products in an efficient way. Systematic breeding proved to be a successful tool 
in selecting for physiologically more efficient animals. 
Biotechnology offers for the first time opportunities for controlling the efficiency of growth and the quality 
of the products in a more direct and selective way. A range of interrelated technologies is emerging, 
affecting the same endogenous mechanisms. In several symposia it has been demonstrated that the 
technologies have unprecedented potential for efficient, safe and sustainable production of animal pro-
ducts, provided that the proper choices are made. 
The participation of the scientific world seems to be more needed then ever in plotting the right course 
through this field of promising possibilities, while avoiding the pitfalls in the road to the future. An adequate 
communication with both producer and consumer is essential for playing this role in an effective and 
credible way. 
The implications and the acceptability of the emerging technologies, have been analyzed for swine 
production in an international symposium in Wageningen in the Netherlands in December 1988. Research 
in the field has intensified since, and has increasingly covered other meat producing animals as well. 
Participants and sponsors of the Wageningen symposium felt that a follow up, largely based on the same 
organizational approach, should cover these recent developments. 
The European Association for Animal Production (EAAP) and the American Society of Animal Science 
(AS AS) decided to adopt the symposium as a joint venture, together with their Australasian counterpart 
(AASAS). Support for the concept has been received from the European Community (EC-DG XII), the 
Food and Drug Administration of the USA (FDA-CVM), the United States Department of Agriculture 
(USDA) and from the Biotechnology Industry. 
An international scientific consensus on relevant questions and answers on key issues for public 
and regulatory acceptance of the new technologies forms the main objective of the symposium. Such a 
scientific consensus is probably a prerequisite for harmonizing standards in international trade and for 
providing a sound base for consumers perception. The symposium offers as well an opportunity for 
identifying targets for int ernational cooperation in research, which is increasingly necessary for meeting 
the challenge of these technologies adequately. 
To facilitate intense scientific communication among participants, a compact symposium is organi-
zed , with a limited number of invited participants. 
For the scientific coherence of the program, it is focused on biotechnologies affecting the somatotropin 
axis. Three approaches are here under development, viz. via genetic impact, via the administration of the 
constituents of the axis (somatotropin, its releasing factor, insulin like growth factors) and via immuno-
modulation of these factors. 
Because of the common denominator in the mode of action these technologies show commonalities in 
impact on efficacy and safety aspects as well. The program puts special emphasis on safety for man, target 
animals and environment and on the perception of these key aspects in acceptability. The socioeconomic 
implications are discussed from various points of view. 
SESSION I 
PERSPECTIVES OF INTRODUCING BIOTECHNOLOGY IN 
MEAT PRODUCTION 
* 
* 
* 
* 
Introductory Statement 
Perspectives for introduction 
Technical perspectives 
Global regulation and acceptability 
PERSPECTIVES FOR INTRODUCTION SESSION CONCLUSION 
SUMMARISED AND ADOPTED CONCLUSIONS 
FROM PAPERS AND DISCUSSION 
ON 
PERSPECTIVES OF INTRODUCING 
BIOTECHNOLOGY IN MEAT PRODUCTION 
Chairman: 
A. A. M. van Agt, Head Delegation of the European 
Communities to the United States 
Conclusions drafted and presented: 
P. van der Wal, Agricultural University Wageningen 
The demand for more and better food will rapidly be increased 
by the expected growth of the world population to 15 billion in the first 
half of the next century. The available acreage of land for food 
production is limited and overused already in many regions. 
Biotechnology is an indispensable tool for meeting the resulting 
challenges for food production by: 
- Increasing the efficiency in using land and its products. 
- Improving product quality and safety of food. 
- Decreasing the threat for environmental pollution with nitrates, 
methane and carbon dioxide. 
An effective control of the Somatotropin -IGF axis in food 
producing animals can lead to a more efficient production of better, in 
particular leaner products. Potentially effective strategies to achieve 
these objectives are: 
- Intrinsic: Advanced marker assisted breeding and production of 
transgenic animals. 
- Extrinsic: Administration of Somatotropins, Growth Hormone 
releasing Factors (GRF) or Insulin like Growth Factors (IGF). 
Immunomodulation of the potency of these constituents. 
A global approach to regulation and acceptability aspects is 
necessary: 
- For creating mutual confidence between consumers and producers. 
- To remove unjustified trade barriers. 
- To promote uniform control of use of new technologies. 
VAN DER WAL 
In a global approach a common reference point for governments, 
producers, industry and consumers can be found in the 
FAO I WHO Codex Alimentarius Commission. 
Providing advice and assistance in developing countries in this field is 
of particular relevance, especially in the area of livestock production 
where these countries can benefit greatly. 
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INTRODUCTORY STATEMENT 
A.A.M. van Agt 
Head of Delegation of the Commission of the European Communities to the United 
States, Washington D.C., USA 
It is my pleasure to chair the introductory session of this important international 
conference. Faced with the formidable expertise of the speakers who will be following me. I 
shall not make any attempt to introduce the scientific and technical aspects of biotechnology 
in animal production; but will seek, rather, to set these in a wider context. 
It is a particular pleasure to participate in a conference whose programme chairman is our 
conference president, Dr. Charles Hess. Prior to his summons to Washington by the present 
administration, Dr. Hess was Dean of the University of California at Davis, an internationally 
reputed centre for agricultural research. I am tempted to say it is probably the second-best 
agricultural university in the world; for if I wasn't wearing my "European" hat, I would 
recall that in my native land, we have an Agricultural University at Wageningen whose 
reputation and excellence are second to none, and whose skills underpin the quality and 
competitiveness of Dutch agricultural exports, which in so many sectors are indisputably the 
finest of the world - but I digress. If you want to know more about Wageningen, ask Peter van 
der Wal. 
In fact our statisticians tell me that the European Community is number two in agricultural 
exports, behind the United States - but to quote the slogan of a well-known American car-hire 
firm, "We're Number 2 - we try harder". Incidentally, on agricultural imports, we are number 
1 - but let me not spoil the atmosphere of this friendly conference by discussing who is more 
agriculturally protectionist - especially not in this delicate final week of the GATT 
negotiations. 
Dr. Hess amongst his many new duties co-chairs a US-EC Task Force on Biotechnology 
Research, which held its first meeting here in Washington just three months ago. That Task 
Force was the brainchild of European Commission Vice-President Filippo Pandolfi, and of 
President Bush's Science Advisor Dr. Allan Bromley. The success of the first meeting has 
underlined the growing extent of our common interest in scientific exchange and 
collaboration, particularly in a fast-moving, inter-disciplinary field such as biotechnology. 
The natural internationalism of scientific endeavour is a model which we should seek to 
extend into other fields of international relations and cooperation, by no means limited to EC 
and US, but extending to the wider global community. It is one of the strengths of this 
conference that so many different nations are represented here today. 
The subject of our conference is one which has been associated with controversy, and no 
doubt will continue to be so. It represents one of the leading edges where the impressive 
progress of science and technology comes into contact, possibly into conflict, with 
traditional agricultural practices and with the conservatism and natural suspicion of the 
consumer. Many of our fellow-citizens, on both sides of the Atlantic, are ambivalent about 
biotechnology, and it is important for political leaders to be aware of that ambivalence, and 
to address it constructively. 
VAN AGT 
On the positive side, nobody considering the long-term, global balance of food supply and 
demand can doubt the vital need for a continuing, sustained effort of agricultural research 
and biotechnology. The latest population projections from the United Nations indicate that, 
over the next century, the human population may rise to over 14 billion - two-and a-half 
times our current population. Over the next decade, each year will see an addition of 90 to 
100 million people. In both agricultural and health care, biotechnology represents our best 
hope for coping with these inescapably increasing demands. We are degrading our planet 
with a current population of 5.7 billion people, many of them living in deplorable conditions 
of health and nutritional status: how are we to cope with a doubled population, if not by a 
massive development and application of our knowledge of living systems and their 
responsible, sustainable management? 
In this conference, we bring together many people from diverse backgrounds - politicians, 
scientists, regulators, consumers. Many of us carry several of these labels simultaneously. 
Let us not forget the other essential partner with whom the farmer has to work, and on whose 
efforts we depend: the food animal. The cow in particular is a most remarkable example of 
biotechnology: one of the Commission's early study reports describes her as a "mobile, 
edible, self-reproducing fermenter". Throughout much of human history, we have depended 
on ruminants, on the cellulase enzymes in the microbes of the rumen, to give us access to that 
great proportion of the world's biomass which is produced as cellulose. As the prophet Isaiah 
precisely expressed it, "All flesh is grass". In the cow or elsewhere, we can admire nature as 
our exemplar in biotechnology; we can learn much from her, and we can seek continually to 
improve upon or to adapt her, to shape the world and its flora and fauna more precisely to 
human needs. But we need also to reflect upon limits and constraints. 
In Europe, we are currently considering whether and how we should update the 1976 
Convention on the welfare of animals kept for farming purposes, to take account of modern 
technological developments. For these tools are sharp, and if misapplied they could be 
unacceptably hurtful. I am pleased to note that a later session of this conference is devoted to 
the safety and welfare of the animal; and this is not unrelated to the topic of Session Five, on 
Social and Consumer Acceptance. 
A well-known brand of French cheese is "La Vache Qui Rit": the Laughing Cow. At a 
practical level, of course the good farmer has every interest in keeping his animals healthy in 
body and contented in spirit. But as the success of that brand name suggests, the consumer, 
too, is increasingly interested in the methods and conditions of production of his food. From 
what we have seen of biotechnology so far, there is no reason to fear that it will raise any new 
issues of animal welfare, and indeed ample potential for it to improve welfare if properly 
used. But biotechnology must certainly observe all the existing laws and constraints, and 
precisely because it is a new and powerful technology, it raises concerns and suspicions 
which the scientist should not too hastily dismiss as irrational. 
I have emphasised the beneficial potential of biotechnology, our essential need for it; yet 
at the same time, as with any powerful technology, we have to learn how to manage it, to 
maximise the benefits, and to identify and limit any unwanted side effects. 
This societal learning is a slow business. The scientists and innovators will be impatient 
of restraint and delay, and indeed both global human needs and our economic interest in 
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competitiveness argue for maximum speed. Biotechnology's safety record is so far excellent. 
But we have to carry public opinion with us. At an aggregate level, of course there is a 
continuing and worldwide progressive accumulation of knowledge, and a resultant 
continuous stream of innovations seeking to come on the market. Yet not every innovation 
will succeed, as commercial entrepreneurs know too well; and not every innovation should 
succeed, if it goes beyond the limits of welfare and acceptability. 
The "limits of acceptability" is a vague phrase, for which I do not apologize; the reality is 
volatile, and acceptability may be influenced by many factors. Among the most important of 
the factors affecting acceptance are trust, confidence and understanding. These factors 
cannot be bought. They must be earned, patiently, through habits of comprehensible 
communication, transparency and dialogue. 
I am delighted to see that this commitment is obviously shared by the organisers of this 
conference, and I congratulate them on that. This conference comes at a time of great 
international negotiations on trade, with the inevitable accompanying tensions; it comes at a 
crucial time for the acceptability of new biotechnological methods in agriculture; it is held in 
the capital city of the most powerful nation on earth. It is therefore very much in the 
spotlight of public attention, and will command a worldwide audience. If the performance of 
the coming speakers and the participation of the audience can live up to these high hopes and 
expectations, this conference can do a great deal of good. 
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PERSPECTIVES OF INTRODUCING BIOTECHNOLOGY IN 
MEAT PRODUCTION 
Charles E. Hess, 
U.S. Department of Agriculture, Washington, D.C., U.S.A. 
Summary and Conclusions 
The world has a constant need for more and better food. This is a simple and yet easily 
forgotten fact. The USDA Economic Research Service projects that world population will 
reach 7,2 billion by 2010. Population is increasing; prime agricultural land is not. More and 
more, we will rely on technology for necessary increases in productivity. 
Previously existing methods of gene transfer have been used for thousands of years to 
alter animals to better serve human needs. The new techniques of biotechnology involve no 
radical departure from historical practices, but simply enable animal breeders to do the same 
things they have always done - but more quickly, easily, and surely. It is reasonable to expect 
that the new tools will continue to be used in this same way. 
In 1965, Nobel laureate Francois Jacob observed: "A revolution in science is not simply 
an accumulation of data, a harvest of results, a change in the landscape. It is a change in the 
way people think, in the way they look at things. It is a change in vision itself." 
That kind of change of vision is what we want to bring about. My own experience has 
been that the more people understand about science the more they feel positive about it - and 
the better they can "view things in their true relation." What we need to "see clearly," is that 
the communication ofthat knowledge is up to us. 
When the public is knowledgeable and informed, the word biotechnology in connection 
with food should not raise a red flag of fear, but rather conjure up thoughts of lower food 
costs, safer food, more nutritious food supplies, and a healthier environment. 
Keywords: Biotechnology, meat production, perspective, policy. 
Introduction 
The dialogue in this symposium will go a long way toward building an international 
scientific consensus on the key issues facing the development and adoption of 
biotechnology for animal production. As members of professional societies, regulatory 
agencies, government, commodity groups, and trade associations, it is part of our 
responsibility to get ideas out on the table where they can be examined in the light of day. 
In opening this important symposium by talking about "Perspectives of Introducing 
Biotechnology in Meat Production", I want to remind you that in the dictionary, one of the 
HESS 
definitions of "perspective" is "the ability to see clearly; the capacity to view things in their 
true relation". That is the kind of vision I hope we can bring to our discussions this week. 
Animal production and biotechnology 
Since the late 1970's, global production of meat products has increased by approximately 
26 percent, and in general, prospects for the future continue to point to large meat supplies, 
with slight increases in production. In the April-June 1990 issue of USDA's National Food 
Review (13:2), Vocke reports that as incomes increase in countries around the world, so does 
the demand for a higher quality diet, often including animal products. 
In the United States, animal products have always been a mainstay of the diet. The 
National Academy of Sciences 1988 publication "Designing Foods: Animal Product Options 
in the Marketplace" states that about 36 percent of the food energy - and between 36 and 100 
percent of each of the major nutrients - in the U.S. food supply come from animal products. 
For centuries, people have sought to improve animals and the food products from them 
by selecting and breeding only the best. Throughout history, humans have taken advantage 
of genetic diversity and genetic exchange through breeding to develop animals that grow 
bigger, produce more, provide leaner and better quality products, use resources more 
efficiently, show increased fecundity, or demonstrate resistance to disease and stress. 
The various tools placed at our disposal by biotechnology do not change these purposes. 
Instead, they offer new techniques for modifying biological traits in a much more directed 
manner than is possible with conventional animal breeding. The new tools also enable us to 
ask questions and find answers in a way that was not possible in the past. 
Externalities 
Yet, if biotechnology offers us such wonderful possibilities, why do we hold symposia 
such as this one to continue to discuss its implications and acceptability? 
Over the years, I have concluded that if we truly want to understand the motivating forces 
at work in improving animal agriculture and its products, we need to go beyond a simple 
preoccupation with science. There are powerful outside forces - what the economists call 
"externalities" - which often have both positive and negative effects upon agricultural 
research and its use. 
These externalities affect not only the way in which we do our work, but what work we 
decide to do. Research and production policies are not formulated in any pure and solitary 
test tube. They spring from the messy and often disorderly real world of conflicting demands 
and unclear choices. We no longer operate - in fact, we probably never really did - in 
isolation from an increasingly concerned public. Our course is continually influenced by the 
changing winds of public opinion and national and agricultural policy. 
10 
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There are a variety of public concerns which we must address and take into account if we 
are to "see clearly" what the perspectives are for introducing biotechnology in meat 
production and to understand the impact of these larger issues. 
Environment 
Having just observed the 20th anniversary of Earth Day this year, the environment is very 
much in our collective consciousness. More and more, we are aware of its influence on us, 
as well as our own impact on it. 
One example which is causing a certain amount of amusement in the press is the role of 
livestock in global climate change. Along with flooded rice fields and termites, livestock is 
one of the major agricultural contributors of methane into the environment. This could be an 
important factor in greenhouse gas accumulation because methane traps 20 times more heat 
energy than carbon dioxide. To help alleviate this, it may be possible to genetically modify 
ruminant micro-organisms to shunt methane into energy (thus improving animal production 
efficiency) rather than releasing it as a gas. / 
Furthermore, through tools such as genetic engineering and embryo transplants, animals 
can be bred to be stress-resistant, thereby enabling them to live in different or less hospitable 
climates. This ability may become even more important as we get a better understanding of 
the potential impacts of global climate change, and it is already relevant in some of the less 
developed nations which experience droughts and other climate extremes. 
Another environmental example which springs to mind involves bovine somatotropin 
(bST). Excellent progress has been made by using biotechnology to produce commercial 
quantities of growth hormones and other proteins which are essentially identical to 
substances naturally produced in the animal. Bovine somatotropin can improve the 
efficiency of dairy cows by improving the milk-to-feed ratio by 5 to 15 percent. 
The use of bST does not necessarily mean more milk. It can mean the same amount of 
milk with fewer cows - and therefore fewer waste disposal problems. This helps alleviate 
ground water contamination. In Holland, for example, the disposal of animal manure is a 
major problem, and one which could be helped through the environmentally beneficial 
effects of bST. 
Competitiveness 
Fewer cows would also mean fewer feed requirements and lower production costs, thus 
helping farmers to compete in world markets. The way for any country to remain 
competitive in the international marketplace is to reduce production costs and enhance 
product quality, and we need every ounce of careful management and efficient resource use 
we can muster to make this possible. We will have to compete on the basis of our technology 
- including biotechnology. In addition, as we increase efficiency in a free market system, the 
ultimate beneficiary is the consumer who will enjoy food at a lower cost. 
11 
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Another example in which the tools of biotechnology are being used to increase 
efficiency is the ability to predetermine the sex of offspring. This offers the livestock 
industry greater flexibility and faster genetic improvement of offspring. Scientists working 
for USD A's Agricultural Research Service (ARS) at Beltsville are making good progress in 
accurately predicting sex ratios by the analysis of the DNA of sorted sperm, thus moving us 
closer to a practical method for sexing livestock semen. 
Disease diagnosis and prevention 
In the search for efficiency of production, biotechnology is useful in the improved 
diagnosis, control, and eventual eradication of animal diseases. The Office of Technology 
Assessment (OTA) of the U.S. Congress calculates that animal diseases cost American 
agriculture $17 billion each year. 
One way of applying biotechnology to animal health is through improved diagnostic 
tools. Specific and unique segments of the chromosomal DNA from disease-causing 
organisms have been identified, cloned, and produced in large numbers. These labelled DNA 
fragments, or probes, can be used to determine the presence of disease organisms in animal 
tissues or fluids. More sensitive and rapid than conventional isolation and typing methods, 
these probes have been successfully applied to various important livestock diseases such as 
anaplasmosis, a disease of cattle which causes deaths, abortions, and weight loss - and 
leptospirosis, a disease which causes abortion and other reproductive failures in cattle and 
swine. Earlier diagnosis right on the farm, rather than sending specimens to distant 
laboratories, means many important diseases will be discovered at the earliest stages, when 
they can be treated without large applications of drugs and chemicals. 
Control of disease is also important in improving the safety of the food supply. ARS 
research demonstrates that it is possible to identify swine with a genotype that is resistant to 
trichinosis. With further research, this genotype could be incorporated into domestic swine 
populations. 
Health and nutrition 
These possibilities lead us into health and nutrition. No where else is there a clearer 
demonstration of the impact of externalities - in this case public opinion/choice - on an 
industry, or on the science supporting that industry, than the current public obsession with 
diet and health. Look at the impact of the concern over cholesterol on the sale of eggs or the 
amount of shelf space devoted to lowfat milk. This is both a challenge and an opportunity. 
I mentioned earlier the many nutrients in the food supply - a major portion of the dietary 
protein, calcium, phosphorous, essential amino acids, trace minerals and vitamins - that 
come from animal products. But they also contribute more than half the total fat, nearly 
three-fourths of the saturated fatty acids, and all of the cholesterol - dietary components that 
may increase the risk of heart disease and cancer for some individuals. 
12 
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Dr. Perry Adkisson, Chancellor of the A&M University System, and this year's Hatch 
Lecturer at the recent meeting of the National Association of State Universities and Land 
Grant Colleges (NASULGC) in Kansas City, MO, spoke on the topic "Warning: Eating May 
be Harmful to Your Health." He urged animal and plant scientists to work more closely with 
nutritionists and physicians to design foods for health. Earlier, I referred to the National 
Academy of Sciences report on "Designing Foods: Animal Product Options in the 
Marketplace." It suggests a research agenda to turn the challenge of the growing recognition 
of the important role of diet in human health into an opportunity to design and market foods 
which address health concerns. Biotechnology holds great promise for the development of 
foods to meet dietary and health goals by improving the nutritional attributes of animal 
products. 
Another naturally occurring hormone that has been produced, porcine somatotropin 
(pST), may help to improve human health, while at the same time lowering the farmer's cost 
of production. Porcine somatotropin not only improves the feed efficiency in hogs by 15 to 
35 percent - but, perhaps more importantly in this age of health consciousness, it increases 
protein deposition and reduces fat deposition, allowing pST-treated hogs to provide 
consumers with leaner cuts of pork. This ability to produce lean pork has enormous 
implications for improving human health by reducing dietary fat and cholesterol. 
Animal genome mapping 
As was emphasized in the study put out in 1987 by the National Research Council's 
Committee on a National Strategy for Biotechnology in Agriculture, gene mapping is 
essential as the foundation for genetic manipulation. Thus far, however, identifying, 
isolating, or mapping genes of significance to animal agriculture has received less attention 
than has been given to plant genome mapping. 
ARS and the Cooperative State Research Service (CSRS) are attempting to remedy that. 
They have provided funds to establish a U.S. Committee on Conservation of Animal 
Germplasm, with subcommittees on Germplasm Conservation and Mapping the Animal 
Genome. 
The mapping of animal genomes (85 percent of those in cattle and swine are identical to 
those in the human) will permit evaluation of genes that regulate animal traits and enable 
farmers to produce quality animals in an efficient, competitive, and environmentally 
sensitive way. 
Policy context 
These are only a few examples of what biotechnology could mean for animal agriculture. 
But what can we do to ensure that biotechnology reaches its full potential? I would like to 
conclude by discussing two concepts which are key to the future of biotechnology - effective 
regulation and public acceptance. 
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Effective regulation 
From one perspective, effective regulation and public acceptance are two ways of saying 
the same thing. In my experience, people fear the unknown. Thus, we must ensure that our 
systems of oversight are as visible as possible, so that the public has a chance to understand 
what we are doing to ensure their safety and protect the environment. 
In the United States we are working on a uniform scope for our coordinated framework 
of regulatory oversight and are developing guidelines for field testing genetically modified 
organisms. We view these as critical steps in developing a regulatory structure based on 
sound scientific principles, in which oversight is commensurate with the level of risk. 
One goal of these discussions is to strengthen public confidence that science is being 
pursued safely and that the products of agricultural biotechnology, like the products of other 
technologies, meet the three accepted regulatory criteria of safety, efficacy, and quality. But 
an equally important goal of these scope discussions is to ensure that we do not create a 
burdensome system of oversight for biotechnology which stifles innovation and requires 
scientists to provide unnecessary paperwork on projects we already know, through long 
experience, are really very safe. 
This is a difficult balance to achieve, but I am confident we in the United States will 
continue to make it work. I hope the European Community and the rest of the world will join 
us in this endeavour, and avoid injecting non-scientific elements into the regulatory 
framework for biotechnology, The effects of establishing a fourth criterion - socio-economic 
need - for bST and possibly other products would be profoundly negative, not just on animal 
biologies, but on all biotechnology research. 
Would private firms, or for that matter, governments, pursue research programs if the 
resulting products might be rejected because of perceived social or economic concerns? My 
bet is that most would not and that many promising advances would be lost to society. While 
we must take social and economic issues into account, we cannot allow them to bring the 
advancement of science and technology to a grinding halt. 
Adding a fourth criterion would also inevitable lead to continued trade disputes as each 
new product comes up for review. The U.S. goal in the current Uruguay round of talks on the 
General Agreement on Tariffs and Trade (GATT) is to help build a global trading system in 
which merchants of all nations can sell agricultural products, including safe and effective 
products of biotechnology, with a minimum of restriction and with every transaction subject 
to the same rules. Such a system of harmonized standards would be a strong incentive for 
research and development of biotechnology. 
Public acceptance 
To my mind, the single most critical issue confronting biotechnology is the anxiety of a 
concerned public. And unfortunately, that is often based upon the perception of risk rather 
than the reality. Take the recent spate of food scare stories - alar or bST. Here you have 
public policy being created by actresses and PR firms. 
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Part of the answer to this barrage is to improve public education programs to counteract, 
or better yet, prevent, misinformation. For example, in the area of food safety we need to get 
across the story that where problems such as microbial contamination and disease-producing 
bacteria exist, biotechnology offers some exciting new tools for preventing and detecting 
them - and it can improve food quality at the same time. 
As scientists and end users of technology, it is part of our role to get across to the public 
the facts it needs to make informed decisions in areas like this - to help people look at the big 
picture - the long term - and weigh the benefits and costs. We must help the public to 
understand that a genetically engineered cow is still a cow, and that this research is being 
conducted by responsible scientists operating under a strict and credible system of safety 
guidelines in the pursuit of biotechnology's benefits. 
Our ability to responsibly tap the full potential of technology depends more than we 
might like to admit on public support - whether it be social, financial, or political. That is 
why we must recognize and take into account the "external" issues I have outlined. 
Fortunately, in the United States, we have a Secretary of Agriculture, Clayton Yeutter, and 
a President, George Bush, who have a deep appreciation for the role of science. They 
consistently emphasize research, education, and technology as the means by which 
agriculture can produce in a socially, economically, and environmentally responsible way. 
In fact, in the recent 1990 Farm Bill, there is included a $73 million National Initiative for 
Research on Agriculture, Food, and the Environment. Of that total, $20 million is directed 
to research on animal systems, including the genome mapping I mentioned earlier. 
Looking at the future, an OTA staff paper on transgenic animals suggests that economic 
incentives are likely to dictate the order in which different advances are made, with 
agricultural animals such as livestock and poultry near the front of the line. And in the near 
term, research will focus on traits involving a single gene - because it is technically simpler 
than work involving complex traits influenced by more than one gene. 
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TECHNICAL PERSPECTIVE OF BIOTECHNOLOGY FOR 
CONTROL OF GROWTH AND PRODUCT QUALITY IN MEAT 
PRODUCTION 
D. R. Campion and J. Novakofski 
Department of Animal Sciences, University of Illinois, Urbana, Illinois 
Summary 
Producing leaner, high quality meat to satisfy consumer demands and improve public 
health is a great challenge to animal agriculture. The same biological propensity for humans 
to deposit fat makes it difficult to achieve quantum improvements in animal composition. 
Fortunately, new technologies for identifying, examining and transferring genes have 
increased our understanding of biological processes and provided unprecedented ability to 
modify these processes. Administration of exogenous somatotropin to finishing/pigs causes 
desirable changes in performance and composition. Treated pigs grow faster, while eating 
less, resulting in an increased gain to feed ratio typically around 10%. Additionally, carcasses 
from these pigs have greatly decreased adipose mass and increased muscle mass. 
Somatotropin plays a major role in endocrine regulation of growth and development, 
although many of its important functions are probably indirect, acting through the 
insulin-like growth factors (IGFs) or through modulation of other endocrine axes. Recently, 
research has shown that many tissues make as well as respond to IGFs and the view is 
increasingly accepted that the effects of IGFs are mediated by both endocrine and paracrine 
effects. There is considerable evidence that the IGF axis is the main point of integration 
between endocrine control of growth and nutritional status. Both protein and energy intake 
influence circulating IGF levels emphasizing the importance of adequate nutrition when 
using somatotropin. Physiological effects of IGF are further modulated by the IGF binding 
proteins which may provide an additional mechanism regulating IGF because they have 
different patterns of hormone or nutrient dependence. Regulating other components of the 
somatotropin axis may be as useful to enhance efficiency and leanness as well as 
administration of exogenous somatotropin. To be acceptable for use somatotropin must also 
be safe for target animals and cost effective. Furthermore, meat products from the animals, in 
order to be acceptable to consumers, must be healthful as well as palatable. Research about 
animal safety has led to important discoveries about links between the immune system and 
somatotropin. It appears that somatotropin may enhance function of macrophages and 
polymorphonuclear neutrophils. While it is abundantly clear that food products from 
somatotropin treated animals are safe for human consumption consumer acceptance of these 
products will be determined by perceptions of safety and the actual quality of the products. 
Keywords: Biotechnology, meat production, technical perspective. 
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Introduction 
In the past decade, at least 8 major reports on public health have recommended reducing 
dietary fat intake in the United State (NRC, 1988). A consensus of these reports is to reduce 
animal fat consumption by 20 to 25%. This goal has clearly been taken to heart (no pun 
intended) by consumers. The tremendous marketing appeal of "Lite," the number of low fat 
products being introduced and the financial health of the diet industry are all clear evidence 
of this. Surveys by commodity groups indicate that up to three out of four consumers trim 
additional fat from meat products when they get home (NLS&MB, 1987) and this is despite 
a greater amount of fat trimming by retailers (AMI, 1989). Producing leaner, high quality 
meat to satisfy consumer demands and improve public health is a great challenge to animal 
agriculture. 
The same biological propensity for humans to deposit fat makes it difficult to achieve 
quantum improvements in animal composition. Fortunately, new technologies for 
identifying, examining and transferring genes have increased our understanding of biological 
processes and provided unprecedented ability to modify these processes. The benefits to 
society of this biotechnology applied to medicine are apparent every day as increased health 
and quality of life. For agriculture, biotechnology offers the necessary tools to alter the 
composition of animal products. Production of commercial quantities of somatotropin offers 
the potential to improve leanness and at the same time has increased our understanding of 
how this endogenous protein regulates metabolism. However, both technical and social 
challenges lie ahead before somatotropin can be used commercially. The purpose of this 
paper is to provide an overview of what somatotropin does, some recent advances regarding 
its mode of action, and to identify some of the technical obstacles to its practical application. 
Effects of Administering Exogenous Somatotropin to Pigs 
It is apparent that administration of exogenous somatotropin to finishing pigs causes 
desirable changes in performance and composition. Treated pigs grow faster while eating 
less resulting in an increased gain to feed ratio typically around 10% (Chung et al., 1985; 
McLaren et al., 1987; Boyd and Bauman, 1989). Additionally, carcasses from these pigs have 
greatly decreased adipose mass and increased muscle mass (Grebner et al., 1987; Novakofski 
et al., 1988). Increased leanness is the most dramatic change in somatotropin treated animals. 
Figure 1 illustrates the magnitude of somatotropin effects on subcutaneous fat thickness 
relative to the fat thickness in commercial pigs. Control pigs in this experiment were about 
average. In comparison, pigs treated with even moderate levels of somatotropin by daily 
administration were leaner than 95% of commercial hogs as indicated in Figure 1, tenth rib 
fat depth distribution in commercial pork. 
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Figure 1. Comparison of fat reduction resulting from somatotropin treatment (Novakofski et al., 1988) 
with the distribution of fat In commercial hogs (DeVol et al., 1988b). 
Mechanisms of Somatotropin Action 
Somatotropin plays a major role in endocrine regulation of growth and development, 
although many of its important functions are probably indirect, acting through the 
insulin-like growth factors or through modulation of other endocrine axes. 
Control of endogenous somatotropin 
Somatotropin is an endogenous polypeptide secreted by the anterior pituitary gland 
(Millard, 1989). Regulation of somatotropin secretion is complex and is under both positive 
and negative control as well as feedback modulation (Figure 2). Areas of the brain such as the 
amygdala and hippocampus may modulate somatotropin secretion depending on circadian 
rhythms and/or stress. The hypothalamus produces both a somatotropin release stimulating 
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Figure 2. Regulation of somatotropin release. 
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hormone (GRH) and a release inhibitor (somatostatin or SRIF). In the hypothalamus, GRH 
and somatostatin secretion are neurally regulated by serotonin, dopamine and catecholamine. 
Hypothalamic factors are under negative feedback by somatotropin or other components of 
this axis. In addition to direct regulation of the pituitary, several other endocrine systems 
modulate somatotropin secretion or peripheral effects. Thyroid hormones affect both 
somatotropin secretion and the sensitivity of target cells (Wolf et al., 1989). Depending on 
level, oestrogen can either augment the somatotropin axis by increasing secretion or impair 
the axis by reducing peripheral responses. Testosterone does not have an acute effect on 
somatotropin secretion but it can function to "imprint" the pituitary or hypothalamus with a 
male pattern of somatotropin secretion or to "imprint" tissues to have male response patterns 
(Jansson et al., 1984). 
The Insulin-like growth factors 
Hypophysectomy of young animals or congenital defects of the pituitary results in 
individuals with short stature, indicating the role of somatotropin in normal growth. 
However, in some biological and nutritional conditions, somatotropin levels are not related 
to development of stature, or long bone growth indicating somatotropin is not a direct 
mediator of growth. For example, in protein/calorie deficiency, somatotropin levels may be 
elevated, presumably to facilitate use of stored lipid, although growth is reduced. Similarly 
in some smaller animal strains, somatotropin levels maybe the same or higher than in large 
or normal sized individuals (Guyda and Rappaport, 1989). 
Research into these questions as well as others led to the discovery of the insulin-like 
growth factors (IGF-I and IGF-II) which are the major endocrine class directly regulating 
growth. IGFs stimulate proliferation and differentiation of many cell types. Furthermore, 
they stimulate protein synthesis and production of connective tissue or bone matrix and play 
a role in adipose tissue development. Levels of IGF in the circulation are controlled by 
somatotropin and insulin and are dependent on both protein and calorie intake (Figure 3), 
emphasizing the importance of proper nutrition in maximizing response to exogenous 
somatotropin. 
Unlike most peptide hormones IGFs are not stored in a single tissue or organ. In the 
classic view of this axis, IGF-I is produced by the liver in response to somatotropin 
stimulation when nutritional conditions are suitable for growth of the animal. The IGF is 
bound to carrier proteins in the blood and carried to peripheral tissues by the circulation in 
classic endocrine fashion (Froesch et al., 1985). Recently, research has shown that many 
tissues make as well as respond to IGFs. This has resulted in an important change in our 
views of how somatotropin as well as the IGF's function in regulation. 
Endocrine and paracrine IGF 
The view is increasingly accepted that the effects of IGF's mediated by paracrine 
production may be as important as the endocrine effects of circulating IGF (Holly and Wass, 
1989). It has been estimated that the liver generates about 1/2 to 2/3 of the growth hormone 
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dependent circulating IGF-I (D'Ercole et al., 1984). IGFs are made in response to 
somatotropin in both muscle and adipose tissue, which are the economic targets of 
somatotropin. Furthermore, somatotropin and IGF play a role in modulating immune 
function, which is a particularly important consideration when evaluating the effects of 
exogenous somatotropin on animal health. 
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Figure 3. Interaction of somatotropin and nutrient status to control IGF and IGF binding proteins. 
Endocrine effects are mediated by a hormone secreted into the circulatory system. A 
paracrine mechanism differs from an endocrine mechanism in that the hormone or factor 
produced mediates events within the same tissue rather than in a different organ and is not 
transported in the circulation. Paracrine factors may be identical to endocrine factors and in 
the case of IGF's the distinction becomes less clear because in a given tissue part of the 
effects produced may be endocrine arid part may be paracrine. Paracrine mechanisms have 
been postulated in somatic tissues for many years and are used to explain such examples as 
hypertrophy of a single muscle group in weight lifters. 
Modulation of IGF 
Considerable information is available regarding regulation of circulating levels of IGF-I 
(Froesch et al., 1985; Guyda and Rappaport, 1989). Blood levels typically parallel 
circulating levels uf somatotropin. However, in some species (rats) during fasting or diabetic 
conditions, IGF-I levels are decreased unrelated to somatotropin. Similarly, IGF-I mRNA 
levels in the liver and in most tissues which have been examined are typically responsive to 
somatotropin (Hynes et al., 1987; Mathews et al., 1986). Hypophysectomy reduces serum 
IGF to about 3% of normal and reduces tissue IGF content to between 12% and 79% of 
normal levels. Hypophysectomy reduces IGF content or IGF mRNA level more in the liver 
than in tissues such as adipose tissue (D'ercole et al., 1984; Yang and Novakofski, 1990) 
which suggests that the liver is particularly sensitive to somatotropin. 
Somatotropin probably regulates paracrine IGF levels as well as circulating IGF 
concentration. Isgaard et al. (1986) infused somatotropin directly into epiphyseal cartilage. 
There was enhanced growth at the site of somatotropin infusion relative to the contra-lateral 
control cartilage which would also have been affected by any increase in circulating 
somatotropin or any hepatic IGF resulting from the infused somatotropin. Kasser et al. 
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(1989) performed an intriguing experiment in which rats were infused with somatotropin 
either subcutaneously (which would expose the periphery to higher somatotropin levels) or 
by an intraperitoneal route (which would preferentially expose the liver to higher 
somatotropin levels). The subcutaneous route of administration gave a greater growth 
response at high doses of somatotropin, indicating that IGF production by peripheral tissues 
may also be important in the response to somatotropin. These and similar experiments 
(Isaksson et al., 1986; Schlecter et al., 1986) provide strong evidence for a somatotropin 
mediated paracrine IGF mechanism. 
Although the classic concept of the IGF axis emphasizes the role of somatotropin for 
normal growth, it is important to remember that somatotropin accounts for only about 
one-third of growth potential in most animal species. Hypophysectomized animals still attain 
two-thirds of normal size. Growth in hypophysectomized animals may in part be the result of 
non-somatotropin mediated IGF production (both paracrine and endocrine). 
Similarly, paracrine IGF may also be modulated by pathways not involving somatotropin. 
Compensatory hypertrophy of muscle induces a 2-3 fold increase in IGF-I mRNA levels 
above control values (DeVol et al., 1988a). This increase is seen in hypophysectomized as 
well as intact animals indicating that somatotropin is not involved in the response. Paracrine 
IGF production clearly plays a role in growth of white adipose tissue (Gaskins et al., 1990) 
as well as growth of brown adipose in response to cold (DeVol et al. 1988c). 
Non-somatotropin related modulation of IGF-I by oestrogen has been described in the uterus 
(Murphy et al., 1987). 
Integration of nutrition and endocrine regulation of IGF 
There is considerable evidence that the IGF axis is the main point of integration between 
endocrine control of growth and nutritional status. Both protein and energy intake influence 
circulating IGF levels (Isley et al., 1983). The dependence of somatotropin response on 
adequate nutrition is clear although the relationship of somatotropin and nutrition is 
complex. The energy effect is partially, but not completely, mediated by insulin since diabetic 
animals have low IGF (Phillips et al, 1985) but insulin is not sufficient to restore IGF in 
protein deficient animals (Maiter et al., 1989). Treatment with additional somatotropin does 
not overcome the effects of nutrient restriction (Mérimée et al., 1982) indicating separate 
paths for the effects of somatotropin and nutrition. Supporting this idea at the molecular 
level, both somatotropin and insulin affect IGF-I transcription independently (Johnson et al., 
1989). 
The mechanism of nutrition effects on IGF have not been investigated as extensively as 
the effects of somatotropin. As in the case of somatotropin modulation, changes in liver IGF 
are relatively sensitive to nutrition. Liver levels were reduced 8 fold in fasted rats compared 
to fed rats while muscle IGF was reduced less than 3 fold from the fed state (Lowe et al., 
1988). Levels of IGF-I mRNA in adipose were also modulated less than liver during fasting 
(Yang and Novakofski, 1990). 
It is likely that a part of the nutrient dependence of IGF is indirectly related to the 
regulation of nutrient availability by insulin and somatotropin. Insulin modulates glucose 
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and amino acid uptake while somatotropin modulates lipogenesis and lipolysis which 
determines availability of fatty acids as an alternative fuel to glucose. Furthermore, 
somatotropin and insulin also have indirect influences on peripheral metabolism that may be 
more important than direct effects. Somatotropin has relatively small effects on lipolysis but 
it has a large effect on tissue sensitivity to lipolytic hormones. For example, in vivo lipolytic 
responsiveness is increased 6 to 7 fold in somatotropin treated animals while normal glucose 
clearance requires higher insulin release (Novakofski et al., 1988; Sechen et al., 1990). 
Similarly, blood levels of T3 are elevated in somatotropin treated animals, although changes 
in T3 are normal following TRH challenge (Brenner et al., 1988). 
IGF binding proteins 
Physiological effects of IGF are further modulated by the IGF binding proteins. 
Circulating IGF complexed to binding proteins is probably not recognized by receptors and 
is thought to be inactive (Holy and Wass, 1989). Somatotropin also has circulating binding 
or carrier proteins. However, meat animals appear to have only relatively low affinity 
somatotropin binding proteins in contrast to humans that also have high affinity proteins 
(Baumann, 1990). There are several IGF binding proteins which may provide a mechanism 
for fine tuning IGF because they have different patterns of hormone or nutrient regulation. 
There are three distinct plasma IGF binding proteins (IGFBP), which have been well 
characterized, although meat animal binding proteins may have different properties 
(McCusker et al., 1990). IGFBP-1 (also called somatotropin independent BP) and IGFBP-2 
are highest in fetal circulation while IGFBP-3 (also called somatotropin dependent BP) is 
highest postnatally (Yang et al., 1989). IGFBP-1 is expressed exclusively in the liver while 
IGFBP-3 is made in many tissues. IGFBP-1 is unaffected by nutrition or somatotropin but it 
is inversely related to insulin concentration and it changes more rapidly than IGF in response 
to changes in insulin. In contrast IGFBP-3 is increased by somatotropin, IGF-I, insulin and 
other growth factors (Clemmons et al., 1989). 
Depending on physiological conditions, the IGFBP's can enhance or inhibit the 
physiological effects of IGF. For example, during fasting when total IGF-I declines slowly, 
IGFBP-I increases rapidly as insulin decreases. This blunts response to IGF-I, effectively 
decreasing IGF function faster than IGF concentration. Conversely, IGFBP-3 increases 
concurrently with IGF-I in response to somatotropin and this would moderate the acute 
effects of increasing IGF, but would also prolong these effects by delaying removal and 
degradation of the IGF binding protein complex. 
Challenges and Opportunities Regarding Somatotropin 
It is clear that somatotropin can affect desirable changes in efficiency and composition. 
However, to be useable, somatotropin must also be safe for target animals and cost effective. 
Furthermore, meat products from the animals must be acceptable for consumers as well as 
healthful and they must be palatable. 
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Delivery systems 
Because somatotropin is a protein it is not orally active. This is clear from both direct test 
and the continued need to inject short stature children being treated with human 
somatotropin. A method to continuously deliver somatotropin would make it easier to use, 
although it is an open debate whether a delivery system will be required for cost effectiveness 
or commercial success. 
Daily administration is fast, efficacious and does not stress the pigs. Within a few days, 
animals adapt to the point where many will not even get up if they are lying down. However, 
it does require labour on a daily basis. The usefulness of delivery systems or devices will 
depend on the duration and kinetics of delivery. Longer delivery time will reduce labour 
inputs although such devices will likely be more expensive and because agriculture is a very 
efficient business the real technical challenge of making a delivery system is keeping the cost 
low. 
Development of delivery systems is mostly proprietary research by different corporations 
although some important considerations and general approaches are apparent. First, the 
amount of material needed for even relatively long delivery is not large. A one month dose 
could weigh less than 1/2 g assuming a 3 mg/day dose and a 25% concentration of active 
ingredient. Second, the most desirable delivery system would mimic the pulsatile nature of 
endogenous release or daily treatment. Next best would be a zero order device that would 
release somatotropin at a constant rate. Real world devices or systems will probably perform 
less well than the ideal. 
For the purpose of discussion, these products can be discussed as delivery systems or 
devices. Systems are absorbable formulations to control delivery kinetics. These might 
include layered solid state products that dissolve slowly as a result of various polymer 
coatings. Liquid delivery systems are likely to resemble those for antibiotics, and might be 
composed of a suspension, an emulsion or possibly liposomes. Delivery devices are 
non-absorbable structures and may potentially provide longer release than formulation. 
Although not practical for production use, the Alzet Osmotic Pump (Alza, Palo Alto, CA) is 
a device that has been used experimentally. 
Somatotropin and the immune system 
To be approved for use, somatotropin must be safe for target animals. Research into this 
area has led to important and far reaching discoveries about regulation of the immune 
system. Five years ago, researchers at the University of Illinois discovered an important link 
between the immune system and somatotropin. 
It has been known for years that the size of the thymus gland in both humans and animals 
becomes smaller with age, and it was thought that this process was irreversible. However, 
experiments suggested that administration of somatotropin might permit the thymus gland to 
grow again in aged animals (Kelley et al., 1985). Only remnants of the thymus gland could 
be detected in control aged rats (equivalent to a 54 year-old human). However, aged rats that 
had been implanted with somatotropin secreting pituitary cells regenerated their thymus 
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glands to the point that they were indistinguishable from those of young rats. Furthermore, 
the capability of T lymphocytes to grow, an aspect of the immune response that deteriorates 
during aging, was significantly improved. It now appears that the real cellular target for the 
action of somatotropin may be the macrophage (Davila et al., 1990; Edwards et al., 1991). 
These experiments provided the impetus to study whether somatotropin affects the 
immune system of farm animals. Initial experiments concentrated on studying phagocytic 
cells of pigs because these types of cells are critically important for destroying many types of 
bacterial and fungal pathogens. Porcine somatotropin that had been shown to increase 
growth rate and reduce carcass fat also increased the capability of macrophages to produce a 
superoxide anion free radical (Edwards et al., 1988). This molecule plays an important role 
in the killing of bacteria by porcine macrophages. It has now been shown in pigs, cattle and 
human s (University of Illinois faculty and graduate students ! ) that recombinant somatotropin 
increases the secretion of superoxide anion by another type of phagocytic cell know as the 
polymorphonuclear neutrophil (Fu et al., 1991). In pigs, these somatotropin-treated cells 
appear to be more efficient in killing Escherichia coli in vitro. Lymphocytes from 
somatotropin treated dairy cattle are also more responsive to mitogen stimulation (Burton et 
al., 1991). 
Other experiments have challenged young pigs with Pasteurella multocida or bacterial 
toxin causing turbinate atrophy (Dau, 1989). These experiments indicate that disease does 
not prevent somatotropin effects on efficiency or composition. Immune response was not 
enhanced by somatotropin in these animals, indicating that either young animals already 
have maximally functioning immune response or that the challenges were sufficiently severe 
to overcome any enhancement. 
Value based marketing systems 
It is important that producers be rewarded appropriately for the benefits of using 
somatotropin. Current livestock purchasing practices are based primarily on a subjective 
evaluation of merit and have led to pricing on the "average". Unfortunately, good animals are 
penalized and poor ones are rewarded by average pricing. Average pricing also amounts to 
"buying pounds" so there is little reward for producing animals with better composition. 
Because of this, only improved efficiency resulting from somatotropin would be rewarded 
and improved composition would not. 
Increased use of "value based marketing" would address this type of problem. Actual 
value of an animal is based on the quantity and quality of retail products that are produced. 
Grading systems are designed to assess or predict yield and quality of retail products. Most 
evaluation technologies can account for 60-80% of variation in composition so there is 
considerable interest in developing more flexible grading systems that are rapid and accurate. 
Even conventional grading approaches may have to be modified for use with 
somatotropin treated animals. Most technologies to estimate composition are based on the 
fact that animal growth is allometric; ie. growth of all parts is proportional to other parts over 
narrow ages or sizes. Therefore, a small number of measures of fat and lean can be used to 
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predict whole animal composition. However, if the proportionality of growth between parts 
is changed the accuracy of prediction is degraded. 
Product quality and consumer acceptance 
In order for somatotropin to be used in agriculture it must be acceptable to consumers. 
Somatotropin itself must be acceptable and this will depend on perception of safety. 
Problems such as the eosinophilia possibly caused by an "e peak" contaminant in specific 
commercial production lots of tryptophan have heightened concern about biotechnology 
among consumers and emphasize the need for both manufacturing care and consumer 
education. Acceptance will also be determined by the quality of products from somatotropin 
treated animals. 
It is abundantly clear that food products from somatotropin treated animals are safe for 
human consumption (Juskevich and Guyer, 1990). In fact these products are probably more 
healthful because they are leaner. Neither somatotropin nor IGF proteins are orally active. 
They are proteins and are digested just as any other protein. Further, there are no biologically 
active proteolytic fragments of either protein. 
Consumer perception of meat quality is a more difficult matter. Overall quality of meat is 
a matter of perception, a mental assessment of aggregate appearance and eating quality. If 
one doubts the contribution of appearance to the taste of meat quality, they need only 
contemplate the taste of green eggs. Many consumers perceive meat with less subcutaneous 
fat as being better so somatotropin will be positive in this aspect. Eating quality is a 
combination of texture, juiciness and flavours and these characteristics are not markedly 
effected by somatotropin. Tenderness is probably the most important quality parameter and 
an effect on tenderness can be measured. However, it is insignificant compared to the normal 
variation in pork tenderness (Figure 4). Similarly with good quality preparation, juiciness 
and flavour of meat from somatotropin treated animals is quite acceptable. 
Characteristics of commercial pork 
ro 
m 
a c 
(5 
o 
M 
2 
CD 
ra 
5 
] 
3.0 6.0 
PST dosage, mg/pig/day 
9.0 10 20 30 40 
Percentage of total in group 
50 
Figure 4. Comparison of change In tenderness resulting from somatotropin treatment (Novakofskl et 
al.. 1988) with the variation in tenderness in commercial pork (DeVol et al., 1988). 
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Future Approaches to Modifying Somatotropin 
Regulating other components of the somatotropin axis may be as useful to enhance 
efficiency and leanness as administration of exogenous somatotropin. Several possibilities 
are suggested by looking at the somatotropin IGF axis. These can be divided into extrinsic 
and intrinsic strategies. 
Extrinsic strategies could involve administration of axis components such as GRF or IGF 
instead of somatotropin. Treatment to modulate the potency of endogenous or exogenous 
somatotropin would be another possibility. This could be done by giving catecholamine such 
as the B agonists or thyroid hormones. Increasing binding protein levels (ie IGFBP-3) might 
also enhance somatotropin effects. Immunization against axis antagonists such as 
somatostatin or receptors mediating degradation pathways in non-target tissues are other 
possibilities. 
Intrinsic strategies to modify the somatotropin axis would involve either augmented 
genetic selection or production of transgenic animals. Animals transgenic for axis 
components would be similar to animals treated with exogenous proteins or peptide. 
Transgenic methods also offer the possibility of enhancing intracellular transduction 
pathways or expression of various responsive genes. Using knowledge about the mechanism 
of somatotropin action might also permit marker assisted selection based on growth or 
muscle quality linked genes. Similarly, these methods could be used to maximize the 
interaction of somatotropin and nutrients in regulating IGF in order to reduce dietary protein 
requirements. 
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GLOBAL APPROACH FOR THE REGULATION AND 
ACCEPTABILITY ASPECTS OF BIOTECHNOLOGY 
J.R. Lupien, 
Food Policy andNutrition Division, Food and Agriculture Organization of the United 
Nations, Rome, Italy 
Summary 
Biotechnology in Animal Production offers multiple opportunities for farmers and animal 
health specialists to have a wide range of technologies available for use, from traditional 
cross-breeding to biotechnologically produced vaccines and aids to production. There needs 
to be a global approach to the regulation and acceptability aspects of biotechnology to create 
an atmosphere of mutual confidence between producers, manufacturers and consumers, to 
remove unjustified technical barriers to trade, to promote uniform control of application of 
new biotechnology techniques, and to prevent concern and confusion amongst consumers as 
to whether the measures taken in one country are equivalent to those taken in another. In a 
global approach, recognition needs to be made of regional and national considerations, and a 
common reference point found. The work of FAO, and in particular the FAO/WHO Codex 
Alimentarius Commission, provides a focal point for governments, producers, industry and 
consumers, to work together in creating international rules for the acceptability of the use of 
biotechnology in animal production. 
Keywords:Biotechnology, global regulation, global acceptability 
Development of biotechnology 
The development of biotechnology is the extension of a continual process of traditional 
and modern technologies to investigate and manipulate organisms at various levels, from the 
organism itself to the molecular level, and to make or modify biological products to meet 
particular needs. The main impetus for the current enthusiasm about biotechnology has been 
the development of recombinant DNA techniques during the 1970's and 1980's, which offer 
the possibility of moving any gene from any organism to any other organism. 
Modern biotechnology, particularly genetic engineering, is an undertaking with 
far-reaching economic and social implications. In food and agriculture, as in other fields, it 
presents both opportunities and challenges. It represents new ways of solving old problems. 
Modern biotechnologies provide opportunities to study and understand biological 
principles and processes, and constitute powerful tools, directly or as adjuncts to traditional 
technologies, for improved and sustained agricultural production and utilization. 
Biotechnology promises to improve agricultural productivity; decrease our dependence on 
pesticides and other potentially harmful chemicals by genetically redesigning plants and 
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animals to better resist natural and man-made enemies; improve safety, nutritional and other 
qualities of agricultural products; improve handling, storage and processing and most 
agricultural commodities; decrease our dependence on non-renewable resources; enhance 
our ability to harness marginal lands and other non-congenial agro-ecological settings for 
food production; conserve and judiciously exploit biodiversity; and increase our overall 
food, nutritional, and ecological security. 
Biotechnology in Animal Production offers opportunities for the control of reproduction, 
selection and breeding, application to animal health and treatment of zoonotic diseases, 
improved feed and nutrition, and improved growth rates and production. None of these areas 
are new: Great strides have already been made using conventional breeding techniques, 
together with changes in diet and husbandry, to modify the characteristics of animals used in 
food production and the quality of their output. Changes in such diverse characteristics as 
maturity, fecundity and muscle distribution are observable in many domesticated animals 
compared both to their wild ancestors and to breeds commonly used a century or so ago. 
Conventional breeding and selection techniques have enabled animal breeders to produce 
strains to meet producers' demands. This is especially marked in poultry where the industry 
has developed early maturing birds which, compared with the breeds used formerly, produce 
more eggs or can be taken to slaughter earlier. Also, strains of cattle are available to suit high 
or low intensity agricultural systems and the demands of those wishing to produce milk 
and/or beef. Milk yields have been improved when required and the fat content of milk and 
flesh altered to take account of changing demands. The changes introduced into cattle and 
poultry by the breeder have been parallelled in other commercially important species, and 
newer biotechnology techniques will enable even more rapid improvements in desirable 
traits. 
Need for effective and realistic regulatory schemes 
Despite its promise, biotechnology has been characterized by conflict ever since its 
inception; early work was followed almost immediately by intense scientific and public 
debate over the need for regulation. This is understandable, as biotechnology is a powerful 
new means of manipulating life and has profound moral, ethical and safety implications. It 
generates fear because of its potential misuse and the unknown threats it may pose to public 
health and the environment. This fear has to be overcome if biotechnology is to develop and 
be used productively. The creation of a climate of public trust is therefore one of the critical 
tasks to be undertaken so as to realize the great promises which biotechnology offers to 
industry, agriculture, health and other sectors. It is in this context that biosafety regulations 
have to be discussed, and consumer concerns addressed. 
Given the nature of the potential contribution of biotechnology to economic and social 
development in the less advanced countries, the need and importance of effective and 
realistic regulatory schemes goes well beyond the moral imperative to safeguard individual 
and public health and the environment. First, the strengthening and further development of 
biotechnology in particular, and of science and technology in general, requires the support 
and trust of the general public. The existence of clear and comprehensive regulations to 
safeguard the general interest will be perceived as a sign that scientists are sincerely 
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concerned for the public at large and are not the self-serving and socially insensitive 
community they are often accused of being. Only when this happens will there be the 
continued support and flow of domestic resources which is a necessary conditions for 
sustained national technological development. Secondly, local safety regulations are needed 
so as to establish clear rules for international companies and research institutions. This, 
together with a framework for the legal protection of innovations in biotechnologies, is going 
to be one of the critical requisites for investment and location of production and research 
facilities in developing countries by these companies, an alternative which could be the most 
important means of gaining access to these technologies. Finally, there is the international 
trade dimension. Safety and sanitary regulations have been used to restrict access to given 
markets in the past and surely will eventually be used in this case also. The existence of them 
in developing countries can be an important bargaining element in negotiations for access to 
specific markets. 
There needs to be a global approach to the regulation and acceptability aspects of 
biotechnology to create an atmosphere of mutual confidence between producers, 
manufacturers and consumers; to remove unjustified technical barriers to trade; to limit 
confusion in the minds of consumers as to whether the measures taken in one country are 
equivalent to those taken in another; and to improve productivity with net positive benefits 
in regard to the efficient use of limited natural resources. In a global approach, recognition 
needs to be made of regional and national considerations, and a common reference point 
found. Certain factors are common to all countries: aspects of human safety; interest in 
improved domestic and international trade in commodities produced with the aid of 
biotechnology; protection of the environment, balancing net benefits to agriculture and 
sustainable rural development; and adequate nutrition and access to safe food at reasonable 
prices. 
Human health 
In regard to human health, food safety and their relationship to broader concerns, a Joint 
FAO/WHO Expert Consultation on Assessment of Biotechnology in Food Production and 
Processing as Related to Food Safety was held in Geneva from 5-10 November 1990. Its 
report will be issued shortly. The Consultation noted that while significant changes can occur 
with the genetic modification of animal genomes, it would appear upon current review of 
known or suspected hazards that transgenic animals should not present significant food 
safety concerns. At least in mammals it should be emphasized that a normal healthy and 
productive animal is in effect an indication that food from that animal should generally be 
considered safe. The Consultation also considered that exact gene products that may be the 
result of transgenic modification should be fully characterized as either an existing substance 
or one which may be new or unique to the particular animal species. Assessment of the safety 
of products obtained from genetic manipulation in foods can be conducted in the same 
manner as is performed for other animal drugs and food additives. 
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Trade 
Trade in safe animal products, produced with the aid of biotechnology, should not be 
subject to any increased barriers compared to trade in their "traditional" counterparts. 
Although countries have the right to take national measures necessary to protect public 
health, or animal health and welfare, and their environment, there is a growing consensus that 
such measures should be applied only to the extent necessary to protect human and animal 
health, and that these measures should be based on sound scientific principles. The objective 
is the development of a freer trading environment which is now recognized as an essential 
requirement for economic and social developments on a global level. 
Benefits for sustainable agriculture and nutrition 
Biotechnology in animal production can have potential net benefits for agriculture and its 
sustainable development and very importantly, for nutrition. Traditional selection and 
breeding has accomplished much in these areas, but biotechnology offers new opportunities 
to reduce dependence on chemicals used in animal production, and also perhaps, to reduce 
methane production by increasing conversion efficiencies. Consumer demands, especially in 
developed countries, are lending towards the need for a more diversified food supply and 
products which are lower in fat and other components. Lean meat, low-fat milk or 
cholesterol-reduced eggs are all achievable goals through biotechnology. Regional and 
national considerations which need to be recognized include: climate; type of agriculture; 
food patterns and habits; level of development including the degree of infrastructure such as 
laws and regulations, inspection and control systems, research and development, 
agricultural extension services; and social consideration and consumers' opinions. 
Each of these considerations have global and uniform validity, providing a base for a 
global approach. 
Climate, ranging from temperate to tropical, the type of agriculture, ranging from 
subsistence to intensely industrialized, and national food patterns and habits, will all tend to 
dictate which biotechnologies will be used in animal production, but not whether 
biotechnologies should be used or not. In fact, mutual recognition of the needs of other 
countries in their use of biotechnology in relation to their national or regional conditions will 
benefit the exchange of research information and information on the practical application of 
biotechnology; benefit trade in products, and provide an enhanced degree of consumer 
acceptance as consumers see applications which are relevant to their situations. 
Biotechnology in developing countries vis-à-vis industrialized ones 
Questions have been raised about the relative impact of the use of biotechnology in 
developing countries vis-à-vis industrialized ones. These questions relate to the proprietary 
ownership of many biotechnological processes and to the possibility that the technology gap 
between rich and poor countries will be further widened by the introduction of 
biotechnology. The differing degrees of infrastructure of developing countries also poses an 
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additional restraint of their ability to regulate the use of biotechnology. FAO is aware of these 
potential problems and is providing advice and assistance to developing countries, especially 
in the area of livestock production where these countries can benefit greatly from the use of 
new technologies. FAO also provides advice and assistance in establishing efficient, 
integrated food control programme, including elements of food legislation, standardization, 
inspection, analysis, and the management of such programmes. This work can only be 
enhanced by the development of a global approach to the regulatory aspects of biotechnology 
in animal production, which can then be applied specifically at the national level. 
Social considerations and consumers' opinions 
Social considerations and consumer's opinions have sometimes been seen as obstacles to 
global approaches in the acceptability of new processes for food production and 
manufacturing. A careful analysis of the situation reveals that this is not always the case. For 
example, the development of a major sector of the food industry, low-calorie foods, has been 
reliant on the judicious use of food additives despite concerns expressed by some specialized 
consumer organizations about the use of additives in general. In this case, consumer 
acceptance has been based on the confidence which the true consumer, the purchaser, has in 
the regulatory authorities concerned, and the desire to have access to these types of products. 
In the case of biotechnology applied to animal production, it is indeed possible that similar 
consumer acceptance can be found. 
Factors such as climate and the type of agriculture will dictate many of the uses of 
biotechnology in animal production. The prevalence of diseases or insect pests will be one 
important factor, as will the price and availability of feed for the animals. Each local 
agricultural environment will have its own problems and its own means of overcoming them. 
Farmers and animal health specialists in all countries should have a wide range of 
technologies available for use, from traditional cross-breeding to biotechnologically 
produced vaccines and aids to production. 
Global approach to regulation and acceptability of biotechnology 
Elements of these regional and national considerations can be brought together to form a 
global approach to regulation and acceptability of biotechnology in animal production. This 
global regulation should be related to regulation of the products produced through its use and 
should be based on the definable differences between these products and their normal 
counterpart. Regulation of the processes and techniques used will develop in the light of 
national conditions. 
Alternative narrow approaches will not work. Regulations aimed at rigidly restricting the 
application of biotechnology in animal production, simply because the technology is new or 
is not well understood, are not valid and will impede research and development in those parts 
of the world where unnecessarily strict controls are introduced. The assessment of safety, 
both to human and animal health and the environment, is a legitimate concern for 
governments and a legitimate object of regulation. It must however be based in the scientific 
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evaluation of the risks entailed in the use of biotechnology, in the same way that risks arising 
from the use of food additives or agricultural and veterinary chemicals are evaluated. Public 
concerns, based primarily on the lack of knowledge or lack of understanding of the process, 
cannot be the basis for decision making at the global level. Structural impediments in the 
form of food laws and regulations, should not confuse the scientific assessment of food 
safety with concerns for animal welfare or consumers' perceptions. 
The FAO/WHO Codex Alimentarius Commission has initiated its consideration of the 
implications of biotechnology in the development of international standards for foods. 
Among the Commission's responses to this paper was the request to convene the Expert 
Consultation referred to above. The work of FAO, and in particular the FAO/WHO Codex 
Alimentarius Commission, will provide a focal point for governments, producers, industry 
and consumers, to work together in creating international rules for the acceptability of the use 
of biotechnology in animal production. 
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Important goals of animal production are to increase nutrient use 
for lean tissue growth and reduce nutrient use for body fat deposition, 
with the overall result of increasing productive efficiency (gain per unit 
of feed). The excellent presentations in this session reviewed recent 
developments in biotechnology which have potential to allow for 
unprecedented gains in the productive efficiency of farm 
animals. These technologies also give us insight into the biology of 
growth in domestic animals and aid in our understanding of how 
animals regulate the use of nutrients for productive functions. For this 
reason, these technologies are frequently referred to as nutrient 
partitioning agents or metabolism modifiers. 
Presentations in this session focused on the somatotropin axis. This 
axis is clearly an important biological system in the regulation of 
nutrient use by animals, and manipulation of different regulatory 
elements of this axis offers the potential to improve animal efficiency. 
The changes which occur when the somatotropin axis is altered include 
an increase in the rate of lean accretion and a reduction in the rate of 
fat accretion. Depending on the magnitude of these reciprocal changes 
in lean and fat accretion, one can also observe alterations in average 
daily gain and feed intake. Overall, the net result of these changes is an 
unprecedented improvement in productive efficiency, especially of lean 
tissue. 
One way to alter the somatotropin axis is to directly administer 
somatotropin (ST) or growth hormone-releasing factor (GRF). 
Animal responses to exogenous ST and GRF, and factors affecting these 
responses were reviewed by McBride and Moseley for ruminants and by 
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Bonneau for swine and poultry. A second approach to alter the 
somatotropin axis is by immunomodulation. This is a relatively new 
approach and the possibilities and limitations were reviewed by Pell 
and co-workers. In general, this approach involves modification of an 
animal's immune system to produce long term changes in elements of 
the somatotropin axis. A third approach is to use advanced breeding 
technologies and gene transfer to improve the productive efficiency 
of animals; Smith and Brascamp reviewed the present status of this 
approach, including an evaluation of the specific techniques available 
to produce transgenic animals. 
While the potential for commercial use of these technologies is of 
immediate interest, their use in understanding the regulation of 
nutrient partitioning will likely be of greater importance in the 
long term. Indeed, throughout this session, authors related results to 
biological implications and concepts. While results to date do lead to 
important advances in knowledge, they have also highlighted our lack 
of understanding in some areas. For example, the dramatic 
responses in productive efficiency observed with use of exogenous ST in 
pigs clearly demonstrates that the components of the somatotropin axis 
which are downstream from ST have not yet been maximized. Yet 
responses in lean and fat accretion to ST treatment are quantitatively 
less in ruminants and negligible in poultry. There could be a 
nutritional explanation for the less dramatic response in ruminants 
(post-ruminal supply of amino acids) but that would not explain the 
lack of effect in poultry. Also, regarding immunomodulation of 
productive function, we know very little about the immune system of 
farm species and how it can be regulated with consistency and lack of 
variability between animals. Similarly, in the exciting area of gene 
manipulation and transfer in general, we still must identify the specific 
genes which are most appropriate to transfer and develop the 
technology to confidently regulate their site of insertion and tissue 
expression. 
In summary, there are technologies available to significantly 
improve animal performance and quality. Also, we have gleaned a 
tremendous amount of important basic information on the growth 
biology of farm animals through the development of these technologies. 
In the future, we will continue to make major strides through 
fundamental research and to convert this knowledge into applied 
technology for commercial use by the producer and to provide 
increasingly better quality animal products for the consumer. 
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GENETIC IMPACT BY ADVANCED BREEDING 
TECHNOLOGIES AND GENE TRANSFER 
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Basic Animal Science Research, Merck Sharp and Dohme Research Laboratories, 
PO Box 2000, Rahway NJ. 07065, U.S.A. and 
Department of Animal Breeding, Wageningen Agricultural University, PO Box 338, 
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Summary 
This paper reviews the prospects for enhancing animal breeding through cloning, 
selection by genetic markers, and transgenic animals, with special attention to genetic 
engineering. It is concluded that cloning has relatively little influence on the rate of genetic 
gain in nucleus herds but it could shorten the time interval between nucleus and commercial 
herds. Genetic markers in a selection program may increase the annual rate of genetic change 
as much as 30%. The contribution of transgenetics to animal improvement can be enhanced 
with cloning. To achieve continuing genetic improvement, one wishes to generate many 
animals identical with respect to the transgene but possessing the full genetic variation 
present in the stock. 
In producing transgenic animals, the relative advantages of microinjection into the zygote, 
or of using embryonic stem cell and primordial germ cells as methods to introduce foreign 
DNA into the germ-line of animals are reviewed. Examples of genes which control growth 
and genes with potential for conferring disease resistance in poultry are briefly discussed. 
The advantage of selecting particular promoters to allow tissue specific or external control of 
expression of transgenes is addressed. Finally, a possible complication associated with 
genetic imprinting in transgenic animals is considered. 
Keywords : Meat production, gene transfer, advanced breeding 
Introduction 
Quantitative genetics as an application of biotechnology in the past has contributed to 
improvement in animal production. Now application of new biotechnologies offer additional 
major improvements in livestock which could not be accomplished through traditional 
breeding methods. We wish to describe three new technologies; production of genetically 
identical animals by cloning (Bondioli et al., 1990), marker assisted selection (Stam, 1986; 
Lande & Thompson, 1990), and genetic engineering (Palmiter et al., 1982). These techniques 
will not replace present selection and improvement strategies of livestock; they will be 
incorporated into traditional breeding programs and some of the results will be additive. 
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Genetic engineering may be the most revolutionary of the three technologies because it 
offers to incorporate into the genome traits which do not exist in the base population and 
make subtle changes in other traits. Genetic engineering of animals has become a reality 
during the last 20 years through the isolation of specific genes of known function, and 
through our understanding of the role of regulatory elements that control expression of these 
genes. Until recently, the most common method of introduction of additional normal or 
modified genes into the germ-line has been by microinjection into the male pronucleus of the 
zygote. More recently, two alternative methods have been developed where instead of the 
zygote, embryonic stem (ES) cells or primordial germ cells are targeted. Now that the 
technology to produce transgenic animals has become routine in research institutions around 
the world, the potential practical impact on the breeding of livestock is revolutionary. 
However, we are currently constrained by the small number of genes that are known to be 
associated with specific traits and the lack of availability of efficient inducible promoters that 
allow us to activate these transgenes in a well controlled manner. Once we have this 
knowledge, the sorts of beneficial changes that can be introduced into domestic animals is 
limited only by our imagination. 
The purpose of this paper is to briefly outline new technologies and discuss how cloning, 
genetic markers and genetic engineering may contribute to selection and improvement 
programs. 
Current Breeding Programs 
Current breeding programs in farm animals amount to the choice (selection) of the best 
parents to produce the next generation. This selection process is generally continuous, and 
selection decisions repeatedly are taken for subsequent batches of potential parents tested. 
Tests may include measurements on the potential parents themselves, sibs or progeny. At 
present, measurements generally concern performance traits like weight, body composition, 
fertility or scores of quality. Which potential parents are best is defined in a breeding goal, 
which generally specifies the effect of genetic changes in performance traits on overall 
economic merit of animals, herds or sections (Smith et al., 1986). 
Two features of breeding programs should be pointed out in the context of the present 
paper. The first is that breeding programs are pyramidal in structure. The top of the pyramid 
is formed by breeding herds (nucleus herds) at which the actual selection and improvement 
takes place. The base of the pyramid consists of commercial herds using genetic material 
originating from the nucleus. Generally, multiplication levels exist to multiply the improved 
genetic stock, often by crossing different strains from the nucleus level. The organization of 
the pyramid influences the genetic lag between nucleus and base in the pyramid 
(Bichard,1971). Genetic improvement may be enhanced by diminishing this lag and by 
improving the efficiency of genetic change in the nucleus. This underscores another feature, 
essential for the animals in the nucleus; the existence of genetic variation. Without genetic 
variation, further improvement by selection is not possible. Smith (1984) summarized results 
of selection experiments and commercial selection programs in different species. He showed 
that one percent genetic improvement in overall economic merit seems a realistic figure for 
most farm animal species. 
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Implications of Advanced Techniques 
Shorten the time lag 
Cloning offers to reduce the time interval required for multiplication of animals from 
nucleus herds for use in commercial herds. Artificial insemination is a classic example of 
this. The cost effectiveness of cloning of embryos (Bondioli et at., 1990) together with 
embryo transfer varies among species. Cloning and embryo transfer in milk and meat 
production may prove useful only when they offer very superior stock, while there are more 
possible applications in dairy cattle. Sexing the embryos improves the usefulness of cloning 
in all species. Another point is that cloning would facilitate selection for special markets, 
because in principle only one embryo is needed meeting the special requirements. 
New Selection Criteria 
/ Presently selection decisions are based on performance traits. New selection criteria will 
arise based on physiological processes,regulation at the DNA-level of factors affecting 
performance traits, or because variation of coding genes or regulatory elements becomes 
known and exploitable. The use of genetic markers (Beekman & Soller, 1983) is a special 
case of the latter where DNA regulatory elements are not known, but polymorphic 
DNA-sequences appear to be associated with variation in performance. There are several 
suggestions for a large numbers of genetic markers (Jeffreys et at., 1985; Georges et al., 
1990) and international programs have been initiated directed at genome maps for various 
species (e.g. for pigs Haley et al., 1990). Application of these new selection criteria looks 
very promising in principle for at least two reasons. First, while measurements of 
performance traits have normally reflected the joint effect of genetics and environment, some 
genetic markers may be free of environmental effects. Secondly, they may be measured on 
young animals and in both sexes. Some examples can be found in model approaches of 
Stam(1986) and Lande & Thompson (1990)allowing some 30% increase in rate of annual 
genetic change by the application of genetic markers. 
Genetic Engineering 
Smith et al (1987) and Kanis (1989) discussed the possibilities of transgenics in breeding 
programs. We wish to stress two aspects. In present breeding programs for nucleus stock, 
genetic variation is a prerequisite. This variation promises annual genetic improvements 
approaching 1% in overall economic merit. Based on expected time of development and 
testing of transgenic animals, Smith et al (1987)concluded that a founder transgenic animal 
has to be some 5 to 10% superior to competing non-transgenic parents. This implies that a 
transgene has to be introduced in a nucleus strain without loss of the existing genetic 
variation. Starting with one founder sire, the transgene can be incorporated by back crossing 
of transgenic animals on superior non-transgenic stock representing the required array of 
genetic variation. Of course, the transgene has to be carried over to each new generation. The 
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original stock is hemizygous, one generation is needed to produce homozygous transgenic 
stock, and this along with the backcrossing requires several years. Smith et al (1987) 
suggested that one should mate transgenic parents at an early stage of the program to identify 
potential unwanted side effects. 
For commercial herds, transgenic animals probably must be hemizygous or homozygous 
for the transgene. Otherwise, the genetic variation at commercial level may impair sound 
management and marketing. In cross breeding systems, which dominate meat production, 
this implies that at least one of the parental stocks of commercial animals has to be 
homozygous. Where parental stock is crossbred, which is common in pigs, both grand 
parental stocks have to be homozygous. 
The back-crossing procedure is not needed if techniques become available to produce 
various individuals identical with respect to the transgene but exhibiting the full genetic 
variation for further improvement. 
Methods of Producing Transgenic Animals 
Pronuclear injection 
The potential offered by gene transfer was most dramatically illustrated by the "super 
mouse" in which high level expression of rat growth hormone (GH) caused a major increase 
in growth (Palmiter et al., 1982). In this particular example, rather than the natural regulatory 
regions being used to control expression of the growth hormone gene Palmiter used the 
mouse metallothionein (MT)promoter fused to the GH structural gene. This fusion gene 
allowed expression to occur not just in the pituitary gland but in several organs and tissues of 
the mouse. Another advantage of the MT promoter was that basal expression could be further 
increased by dietary supplementation with zinc or cadmium. 
To produce the "super mouse" the MT-GH fusion gene was injected into the pronucleus of 
the zygote and the zygote transferred to a surrogate mother to allow development to term. 
The process of microinjection is very effective in the mouse. In our laboratory, 
approximately 50% of eggs injected produce progeny containing the transgene; about half 
the mice express the transgene. 
The disadvantage of microinjection of DNA into the zygote is that there is no control of 
the site of integration or of the number of copies of a transgene that integrate into the genome 
of the host. In general multiple copies are inserted in a head to tail array. The result is an 
inherent variation in the degree of expression across the different transgenic lineages. 
However, this is not necessarily a problem if high level expression of a transgene is required. 
Microinjection of DNA into a pronucleus also has been used successfully to produce 
transgenic pigs. Problems of visualizing the pronuclei because of opacity of the cytoplasm of 
pig ova was overcome by centrifugation (Wall et al., 1985). However, the efficiency of 
transferring genes into the germ-line of pigs is still low and varies from 0.31 to 1.73% (Pursel 
et al., 1990). Although a dramatic depression in backfat thickness was evident in MT-GH 
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transgenic pigs, unfortunately the enhanced growth rate typically observed in transgenic 
mice was not observed. There are a number of factors that appear to be relevant including the 
dietary requirements, appetite depression, and health problems associated with excess GH 
production in pigs (Pursel et al., 1990). The health problems and impairment of reproductive 
capacity are particularly severe in some animals and it must be concluded that uncontrolled 
overproduction of GH in pigs is unlikely to produce a superior pig. A similar conclusion can 
be made from studies in transgenic sheep (Rexroad et al., 1989). 
Attempts have been made to express GH in a more controlled manner by using inducible 
promoters having very low basal activity such as the phosphoenolpyruvate carboxykinase 
(PEPCK) promoter. While PEPCK-GH fusion genes were useful in producing large mice and 
the promoter could be regulated by alteration of dietary carbohydrate and protein, the results 
in transgenic pigs was not ideal. Apart from a delayed onset of pathology, the performance 
mimicked that of the MT-GH transgenic pigs; most disappointingly, in contrast to the 
PEPCK-GH mouse there was no significant regulation afforded by manipulating the diet 
(Pinkert et al., 1990). 
The results described above all indicate that continued overproduction of GH is 
detrimental to the animal. However, pigs injected with GH at specific periods throughout 
their growth phase remain healthy and have improved production traits (Etherton et al., 
1986); therefore, it seems likely that effective external control of expression of the GH 
transgene is critical. In this regard, the results of experiments in which the bovine prolactin 
promoter has been used to direct transcription of the bovine GH gene in transgenic pigs are 
particularly encouraging (Polge et al., 1989). Basal activity of the promoter is low so that 
plasma levels of GH in the uninduced state are within the normal range of endogenous 
prolactin. A pulsatile secretion pattern of GH release can be induced by single injections of 
TRH. Most importantly, the transgenic pigs do not have the pathology typical of MT-GH and 
PEPCK-GH transgenic pigs. A recent report describing the use of a sheep MT rather than 
mouse MT promoter is also encouraging since this promoter is zinc inducible but has low 
basal activity (Shanahan et al., 1989). 
An alternative approach to external control of gene expression is to use promoters which 
are controlled developmentally such as the alpha-fetoprotein and albumin promoters. The 
former is active in the liver only during early development, whereas the latter is active later 
when the alpha-fetoprotein promoter is developmentally switched off. Thus genes providing 
a growth advantage when overexpressed at a particular stage of development can be 
regulated by constructing the appropriate fusion gene. The DNA sequences necessary for 
skeletal muscle specific expression in vivo have recently been described by Chen et al 
(1990). Fusion genes in which these sequences are used as the promoter allows the 
expression of growth promoting genes to be targeted to skeletal muscle growth. Specific 
transgenes selected for improving production traits through developmentally or tissue 
specific expression have not been defined. However, identification of these genes and the use 
of very selective promoters will allow the generation of new genetic lines of livestock which 
lack the pathology caused by uncontrolled expression of transgenes. 
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Embryonic Stern Cells 
The limitations imposed by microinjection; ie. the lack of control of the number of 
integrations and the site of integration can be avoided by using homologous recombination 
of DNA fragments into embryonic stem (ES) cells. ES cells are pluripotential cells isolated 
from the inner cell mass of blastocysts at the pre-implantation stage. The establishment of ES 
cell lines and their maintenance is well documented in the mouse (Robertson, 1987) and in 
the hamster (Doetschman et al., 1988). A challenge for reproductive biologists is the 
development of similar cell lines from livestock. To our knowledge only in the pig have ES 
cells been maintained through serial cultures (Piedrahita et al., 1988). 
The advantage of ES cell lines for production of transgenic animals is that by homologous 
recombination genetic information can be altered in a controlled manner. For example, genes 
can be inactivated, replaced or mutated, or regulatory regions can be altered. The changes are 
introduced by transfecting, microinjecting, or infecting ES cells with DNA constructs having 
high homology with the chromosomal sequences to be modified. By specific selection 
techniques and by cloning, ES cells which have been modified by homologous 
recombination are isolated and then injected into blastocysts to produce chimeric offspring. 
Some of the offspring will be germ-line chimeras. 
Once ES cell lines have been established from the embryos of economically important 
livestock and altered by homologous recombination they can be preserved indefinitely to be 
used as a resource to provide a stock of genetically identical animals. Importantly, as new 
discoveries are made the cells can be further modified to introduce additional desirable traits. 
ES cells can also be used for genetic selection in vitro by selection of lines having desired 
linkage patterns. 
Primordial Germ Cells 
The production of transgenic chickens is more difficult than the production of other 
transgenic animals because the early embryo is not readily accessible. When the fertilized 
egg is laid it consists of approximately 50,000 cells and microinjection of either DNA or ES 
cells to produce germ-line chimeras is very inefficient because only about 200 of the 50,000 
cells in the egg are germ cells. The conventional approach is to use a retrovirus to deliver the 
transgene with the objective to infect every cell in the embryo. Although the efficiency of this 
approach is low it has been used successfully (Salter et al., 1986; Bosselman et al., 1989; 
Chen et al., 1990). Improved growth and acceleration of sexual development was observed 
following high level expression of bovine GH (Chen et al., 1990). Using similar methods 
transgenic chickens expressing the env gene have shown resistance to infection by avian 
leucosis virus (Salter & Crittenden, 1989; Chen et al., 1990). More recently studies with the 
Mx gene suggest that transgenic chickens expressing Mx would be resistant to avian 
influenza (Garber et al., 1990). 
Although the early chicken embryo is not readily accessible the primordial germ cells 
themselves present a potential target for gene insertion. On day 1, when the fertilized egg is 
laid the primordial germ cells are located extra-embryonically at the germinal crescent. 
Between day 2 and 3, these cells migrate through the vasculature to settle in the gonadal 
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ridge. It is possible to isolate these cells either by dissection from the germinal crescent or 
from the blood. Indeed, it has been shown that primordial germ cells from one embryo can 
be introduced into a surrogate embryo between days 2 - 3 and that these cells populate the 
gonadal ridge to produce germ-line chimeras (Wentworth, 1989; Simkiss et al., 1989). 
Clearly, once primordial germ cells can be maintained and passaged in a manner similar to 
that described for ES cells the establishment of new lines of transgenic poultry will become 
routine. 
Consequences of Imprinting of Transgenes 
Transgene inserts are prone to methylation imprinting such that paternally transmitted 
transgenes are undermethylated whereas maternal transmissions are hypermethylated 
(Surani et al., 1990). Because DNA methylation can control which genes are expressed, 
allelic differences in epigenetic modifications can affect expression of the transgenes. In 
most cases methylation patterns are reversible when transmitted alternately through the male 
and female germ line; although an example has been reported where transmission through 
the female line caused irreversible hypermethylation and the gene was only expressed when 
it was repeatedly transmitted through the paternal germ line (Hadchouel et al., 1987). 
It is curious that there is a higher incidence of imprinting of transgenes (ca. 20%) than 
would be anticipated if one considered random integration into the mouse genome where 
only about 10% is subject to imprinting (Surani et al., 1988; Cattanach, 1986). There is 
evidence to suggest that transgenes can be imprinted even when they integrate outside the 
imprinted domains defined by genetic studies. It is possible that transgenes act as insertional 
mutations which perturb chromatin structure during development; similar perturbations 
might also occur in DNA deletion experiments (Surani et al., 1990). Thus a priori it is 
difficult to predict a specific phenotype even when a gene of known function is modified in 
a controlled manner. 
Observations have been made in mice showing that the expression of transgenes can also 
be affected by strain differences. These differences are thought to be regulated by 
strain-specific modifier genes involved in DNA methylation. Cumulative DNA methylation 
differences have also been observed from one generation to the next (Surani et al., 1990). 
How these observations might extrapolate to transgenic livestock is unknown. However, 
imprinting is an important factor to be considered, particularly in situations where one 
wishes to maintain a stable phenotype. 
Discussion 
Although ultimately the power of controlled genetic engineering of livestock will 
revolutionize the industry there remain a number of barriers to overcome. We do not have a 
sufficient knowledge of the role of specific genes which control performance in domestic 
farm animals. We also lack understanding of how specific genes are normally regulated. 
Furthermore, in situations where we would choose to regulate transgene expression 
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externally, as is apparently the case with GH, we are only beginning to identify inducible 
promoters having low basal activity in vivo. 
There are technical problems associated with the reproductive biology of farm animals. 
The recovery of eggs for microinjection and conditions for survival of pig, cattle and sheep 
eggs in vitro must be optimized. This becomes a complex issue when one considers the 
genetic diversity of commercially important livestock. The long gestation times and the long 
gestation intervals of cattle, sheep and pigs, and a relatively small litter size limits the rate at 
which research can progress. 
The efficiency of producing transgenic farm animals is very low, and the costs of 
maintaining a large animal research facility are enormous. There is also the hurdle of 
obtaining permission to allow experimental transgenic food animals to enter the food chain. 
Clearly, economics are also a major problem in promoting transgenic research on large and 
expensive animals. 
With the present techniques of producing transgenic animals, the transgene is 
incorporated randomly into the genome, or in case of ES cells, directly in one particular stem 
cell line. The controlled manipulation of genetic traits through ES cell technology can be 
used to compliment traditional quantitative genetic approaches. However, it is not yet 
feasible to routinely derive an ES-line for, say, 100 founder breeding animals. In the setting 
described here that is a serious problem. If with improved techniques several outstanding 
founder animals can be produced with the transgene at a specific site in the genome, the 
potential of inclusion in a breeding program improves considerably. The back-crossing 
procedure is no longer needed then and the creation of two strains producing crossbred stock 
homozygous for the transgene becomes feasible. 
Genetic engineering of livestock is clearly still in its infancy. The most likely outcome of 
the explosion of knowledge in molecular genetics is that both the traditional and 
contemporary genetic approaches will complement each other in producing livestock with 
traits of enhanced growth performance and disease resistance. In particular, the current 
projects under way to map the pig genome will provide information of enormous value for 
defining specific traits at the DNA level. It should be possible to extrapolate this information 
to other species with a high level of confidence. By applying this knowledge it will be 
possible to modify the genome by transgenic means in a very predictable manner. 
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Summary 
The immunological manipulation of hormones of the somatotropin axis has been 
described. The activity of growth hormone-inhibiting hormones can be reduced by 
autoimmunization, leading to the production of polyclonal antibodies which neutralize 
hormone activity in much the same way that vaccination against protein antigens is used to 
convey disease resistance. Alternatively, certain monoclonal antibodies to protein hormones 
actually increase their activity; this phenomenon can be extended to the production of 
endogenous polyclonal antibodies of restricted specificity which recognize peptide regions 
of the hormone (equivalent to those for the monoclonal antibody) and result in increased 
activity of hormones of the growth hormone axis. Lastly, the use of antibodies as hormone 
(or protein) mimics is described, in which anti-antibodies (termed anti-idiotypes) behave as 
original hormone. 
Keywords: Meat production, immunomodulation, somatotropin axis. 
Introduction 
During recent years, it has become clear that exogenous administration of growth 
hormone (GH) can improve animal performance. GH will increase milk yield in dairy cows 
(e.g. Bauman et al., 1989; Phipps et al., 1990) and will stimulate greater lean: fat ratios and 
also rates of daily gain in meat-producing animals (e.g. Boyd & Bauman, 1989; Campbell et 
al., 1988; Pell & Bates, 1990; Pell et al., 1990). The reduced fat content of carcasses and the 
decreased urinary nitrogen output (van Weerden and Verstegen, 1989) of GH-treated 
animals is of benefit to both the consumer and the environment. However, exogenous 
treatment with GH involves regular administration of hormone, either as injections or as 
implants and their effects are relatively short-lived. Whilst this might be a versatile 
advantage for the strategic use of GH, for example in dairy animals, it is not as suitable for 
meat-producing animals which are not maintained for reproductive purposes. 
Immunological modification of an animal's existing hormonal repertoire, producing similar 
effects to those of exogenous GH, offers an alternative approach. Such immunizations have 
the additional advantage of requiring only minute quantities of material compared to the 
considerable amounts needed for simple hormone treatment. 
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Somatostatin Growth hormone-releasing hormone 
Local IGF-1 synthesis 
TARGET TISSUES f 
Autocrine/paracrine action 
Figure 1. Diagrammatic summary of the somatotropin axis 
A schematic summary of the somatotropin axis is presented in Figure 1 and it is clear 
from this that several sites for potential immunological manipulation exist. Basically, 
hormones which stimulate GH activity may be amplified or those which inhibit GH action 
may be suppressed. Therefore, to try and amplify GH action the amount or activity of growth 
hormone-releasing hormone, GH or IGF-1 (insulin-like growth factor-1) must apparently be 
increased or those of somatostatin decreased. This simple approach does not take into 
account negative feedback mechanisms which counterregulate the somatotropin axis and 
which may confound long term effects. 
Alternative approaches for immunomodulation 
Neutralization of activity 
The simplest modification of hormone activity is to raise polyclonal antibodies against 
that hormone in the same way that injection of antigen is used to convey disease resistance 
in animals and man. The mixture of antibodies which is produced will bind to multiple sites 
on the hormone and inhibit activity, presumably by preventing access of binding sites to 
hormone receptors and by facilitating hormone destruction via the immune system. This 
straightforward approach is, of course, well-established in the field of animal health. 
52 
THE TECHNOLOGIES IMMUNOMODULATION 
Potentiation of activity 
Using hypopituitary animal models, it has been shown that certain monoclonal antibodies 
(MAbs) raised against both human (h) and bovine (b) GH could increase the activity of 
exogenous homologous GH's; complexes of GH and MAb induced further stimulation of 
weight gain and sulphate incorporation into cartilage when compared to the increases 
induced by GH alone (Aston et al., 1987; Holder et al., 1985). The mechanism of action of 
this phenomenon is not yet fully elucidated (schematically represented in Figure 2) but the 
specifity of antibody binding to certain epitopes of GH must be critical. However, the 
molecular topography of sites of binding for these panels of MAb's has, so far, remained 
undefined, although epitopes have been identified for other panels (Cunningham et al., 
1990; Mazza et al., 1990; Roguin et al., 1990). The use of antisera raised against synthetic 
peptides which cross-react with native GH allows identification of sequence regions of GH 
which are associated with enhancement of activity. For instance, peptide regions of GH can 
be selected according to their hydrophilicity and the secondary structure of GH so that 
peptides with antigenic potential are predicted. A systematic approach for the mapping of 
topographical sites involved in hormone enhancement can be made using the methods of 
Geysen et al. (1984) in which hundreds of peptides can be synthesised and binding assays 
performed on microtitre plates. ' 
The identification of sequence regions of GH which are involved with enhancement of 
activity is of crucial importance as these peptides can then be used for the development of 
growth-enhancing vaccines. Thus, animals could be immunized with small amounts of 
synthetic peptide, inducing the production of endogenous polyclonal antibody of restricted 
specificity (defined by the peptide design) which would bind to a specific region of GH, 
enhancing its activity and mimicking the potentiation previously observed using MAb 
enhancement. It is important to note that MAb's will recognize conformational determinants 
which can involve discontinuous regions of amino acid sequences whereas potentiation 
using antisera raised against synthetic peptides involves linear sequences. Thus, it is 
necessary that the peptide in isolation must be administered so that it retains the 
three-dimensional structure of the corresponding region of the native GH. 
The mechanism of action of MAb- and presumably of peptide antiserum- mediated 
enhancement remains unresolved; several theories exist and have been reviewed by Aston et 
al. (1989); the major propositions are considered here. Binding of GH to enhancing 
antibodies in blood may simply prolong the half-life of GH by acting as a reservoir or 
slow-release system and protecting GH from degradation. Receptor processing and 
degradation of GH-receptor complexes may be inhibited in the presence of enhancing 
antibodies, resulting in decreased receptor turnover and an increased intracellular signal. 
The binding of antibody may induce conformational changes in GH itself, causing increased 
affinity of hormone for receptors. Several different receptor subtypes exist for GH (Barnard 
et al., 1985) and anti-hormone antibodies may inhibit binding to one type but not another 
(Ivanyi, 1982; Aston et al., 1986; Thomas et al., 1987). Thus enhancement could be due to 
restriction of GH binding to certain receptor subtypes, therefore increasing availability to 
others. 
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Figure 2. Interaction of (a) GH with receptor (R), (b) GH with MAb and (c) anti-idiotype with 
GH receptor. 
Antibodies as protein mimics 
In 1974, Jerne proposed that regulation of the immune system involved a network of 
interacting antibodies. In this system any new antibody (Abi) produced to a novel antigen 
would itself be novel (and hence 'foreign') to the animal producing it, leading to the 
production of anti-antibodies (Ab2). Within these antibody populations there exists a subset 
of antibodies which are described as the 'internal image' of the original antigen because Ab2 
binds to Abi at the same position as the original antigen. Since Abi is referred to as the 
idiotypic response, these internal images (Ab2) are referred to as anti-idiotypes. 
Anti-idiotypes can be produced in a deliberate fashion using the approach described in 
Figure 2. Such anti-idiotypes have been produced for a number of hormones, including 
insulin (Sege and Petersen, 1978), ß-adrenergic compounds (Schreiber et al., 1980), 
acetylcholine (Wasserman et al., 1982), TSH (Farid et al., 1982) and GH (Gardner et al., 
1990). In many cases these antibodies are also capable of inducing the biological response 
normally attributed to the respective hormone whilst in other cases they may serve as 
antagonists. 
Anti-idiotypes to GH have obvious application to animal production systems as 
alternative non-hormonal techniques for the manipulation of carcass composition. 
Identification in monoclonal form of the idiotypes (Abi) which induce the formation of 
hormone mimics (Ab2) would allow them to be used to immunize animals in order to induce 
an endogenous production of Ab2, the GH image. The monoclonal anti-idiotypic antibodies 
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should mimic single epitopes on the GH molecule and will allow several questions to be 
addressed: how many epitopes of GH are involved in binding to GH receptors and do 
mimics of different epitopes on GH bind to specific receptor populations in different tissues? 
In addition, it is important to discover whether the different subsets of GH receptors bind to 
different epitopes on the GH molecule and whether they induce different metabolic 
responses. Studies attempting to resolve these questions have involved the concept of 
bioactive fragments of GH but anti-idiotypic mimics have a distinct advantage over 
fragments; they essentially resemble the shape rather than the primary amino acid sequence 
of the epitope on GH which they mimic. They are thus in the appropriate physical 
conformation which, as mentioned earlier, is difficult to achieve for short synthetic or 
cleaved peptides. An additional advantage is that these antibodies may be mimics of 
epitopes which involve amino acid residues held in close proximity to one other but derived 
from different parts of the polypeptide chain (discontinuous epitopes). The 
three-dimensional structure of porcine GH was recently elucidated by using X-ray 
diffraction (Abdel-Meguid et al., 1987) and it seems likely that such epitopes may well be 
involved in binding to the GH receptor. The primary amino acid structure of the GH receptor 
has also been deduced recently using recombinant DNA techniques (Leung et al., 1987) and 
with eventual detail of its three-dimensional structure, proposed sites of interaction with GH 
should be possible. Even though this discussion has largely been confined to the 
consideration of GH mimics, the anti-idiotypic approach to improvement of animal 
production is versatile as any protein can be mimicked, for example GH receptors, binding 
proteins or even enhancing antibodies. 
Evidence for immunomodulation of the somatotropin axis 
Neutralization 
Immunoneutralization of the growth hormone inhibiting factor (SRIF), somatostatin, was 
first shown by Spencer & Williamson (1981) to have a dramatic effect upon the growth rate 
of St. Kilda lambs. A 76% improvement was observed compared with globulin-immunized 
controls. There was no alteration in the proportions of muscle, bone or fat suggesting that 
this improvement was not exerted simply via GH. Despite the sometimes dramatic rise in 
circulating GH concentrations induced by paseive immunizations (infusion of antibodies), 
there are only marginal changes after active immunizations, even when high titres of 
anti-SRIF antibodies are detected (Spencer et al., 1983). Other mechanisms have been 
proposed primarily involving an effect on gut function, possibly mediated by the gastrin 
family, which include changed rate of passage and improved digestibility of nutrients 
(Fadlalla et al., 1983; Rodriguez et al., 1988). Since the early encouraging experiments, the 
positive results have been far less dramatic and are matched by similar numbers of reports 
of lack of efficacy as well as an erratic pattern of associated changes in IGF-1 concentrations 
etc. Even in recent reports no clear consensus has emerged with disappointing results in 
cattle (Trout & Schambacher, 1990) and sheep (Hoskinson et al., 1988) being countered by 
improvements in a range of parameters observed by Sun et al. (1990a). 
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The use of severe adjuvanting protocols has been shown to depress growth (Klasing et al., 
1987) so the invariant use of Freund's Complete adjuvant in these growth experiments might 
have led to problems. The difficulty of consistently recording improvement in some 
ruminant growth parameters by simple administration of GH itself suggests that a more 
appropriate model is needed, such as lactation in small ruminants or growth in pigs. 
However, even here contradictory reports exist with both nil effects (Deligeorgis et al., 
1988) and positive findings (Sun et al., 1990b) in lactating sheep. Published data from pigs 
have not yet illustrated the potential of this approach in a single unified protocol. 
From the confusion of available data and also the tendency for negative results to remain 
unreported, the value of SRIF immunization remains, at present, equivocal. In any case, 
evidence suggests that the somatotropin axis is not the target for effects of SRIF 
neutralization. No other component of this axis is appropriate for immunoneutralization to 
improve growth or body composition. 
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Figure 3. GH release in response to GRF and anti-GRF antisera. 
Enhancement 
The monoclonal antibody enhancement of GH activity is well established for 
hypopituitary animals which can, therefore, only be stimulated using exogenous hormone. 
Of key importance is the demonstration that the activity of endogenous hormone in normal 
farm animals can be increased and preferably by antibodies produced by the animal itself 
(active instead of passive immunization). The following describes available information to 
date. 
Growth hormone-releasing factor (called GRF, somatocrinin or GHRF) is a single 
polypeptide chain of 40 or 44 amino acids and is thus about one-fifth of the size of GH. 
Using short conjugated polypeptide sequences derived from human GRF, we immunized 
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sheep using Freund's adjuvant. The anti-hGRF antibodies were purified by ammonium 
sulphate precipitation and hydroxy apatite chromatography. On the basis of tests in vitro, 
three different antisera were selected for direct infusion into three groups of five sheep. Each 
sheep received, at different times: antibodies only, hGRF or hGRF complexed to each of the 
antibodies. Levels of circulating GH were measured 60 min before and 240 min after the 
treatment. The results are summarised in Figure 3. As there were no significant differences 
in the pre-treatment GH levels, the area under the plasma GH curve from treatment to 240 
min has been treated as a measure of GH release capability. The GRF alone produced similar 
responses in all three groups. This was significantly reduced in those animals receiving GRF 
plus anti 1-14 antibodies. These antibodies and those directed against GRF 31-44 when 
administered alone had no effect on GH concentrations. In contrast, the preparation from 
anti 35-44 antisera given alone equalled the GH release stimulated by GRF alone. The 
potency of this particular antiserum was further emphasised by the significant increase in 
GH levels over antibodies or GRF alone (P and P, respectively) when the complex of 
antibodies plus GRF was administered. This effect could be seen over the entire 240 min 
period. Similar additional and significant increases as a result of the 31-44 plus GRF 
complex could be seen over the 60 min post-treatment (not shown), but these were not 
sustained. Whether the apparent enhancement effect observed here with antibodies and GRF 
is the same phemonomon as that with GH remains speculative but does indicate that the 
principle may have wide application within the management of the growth and development 
of farm animals. Equally, it may not be confined to hormones of the somatotropin axis. 
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Monoclonal antibody-induced increases in the diabetogenic action of GH were 
demonstrated for both exogenous and endogenous hormone in lambs (Pell et al., 1989b). 
Plasma glucose concentrations during insulin tolerance tests are given in Figure 4. After 40 
min, insulin induced a decrease in glucose concentrations of 1.6 to 2.0 mmol/1 for all groups 
of lambs during the pre-treatment period. As expected, treatment with GH alone inhibited 
the insulin-induced fall in glucose concentrations (P). This also occurred in sheep treated 
with MAb alone (P) implying potentiation of endogenous GH. The fall in glucose 
concentrations was further inhibited in lambs treated with the MAb-GH complex thus 
confirming earlier observations of MAb-enhancement in rodents. 
Table 1. Lipid metabolism in vitro (mol/2h/g wet weight) for samples of subcutaneous fat from lambs 
passively immunized against a peptide region of bGH. 
Treatment Lipogenesis Lipid Lipolysis 
group oxidation 
Control Ig 
Anti-peptide Ig 
GH + control Ig 
GH + anti-peptide Ig 
S.E. (n=6) 
Significance 
45.2a 
32.3ab 
18.3c 
1 9 7 b.c 
4.7 
0.01 
2.69a 
1.81b 
l . l l b ' c 
1.01° 
0.25 
0.001 
5.79 
6.03 
6.93 
7.36 
0.94 
NS 
GH activity has also been increased by passive immunization of lambs (Pell et al., 
1989a). Antibodies were raised in sheep against a synthetic peptide region equivalent to 
amino acids 134 to 154 of bGH and these were concentrated by sodium sulphate 
precipitation. This preparation, when complexed to GH, enhanced sulphate uptake into 
costal cartilage of Snell dwarf mice by approximately two-fold when compared to 
stimulation by GH alone. Lambs were treated for 16 days with either control antibody, bGH, 
anti-peptide antibody or GH pre-complexed to anti-peptide antibody. At slaughter, samples 
of subcutaneous fat were removed for the determination of rates of lipogenesis, lipolysis and 
lipid oxidation in vitro. As shown in Table 1, both GH and anti-peptide antibody inhibited 
rates of lipogenesis and lipid oxidation. The animals treated with the GH antibody complex 
did not exhibit further changes in lipid than those for GH alone but it is possible that the dose 
of GH used (10 mg per lamb every other day) stimulated maximal changes. 
Antibodies to a similar region of bGH potentiated the galactopoietic action of GH 
(Figure 5). Lactating ewes were treated for 21 days with GH and anti-peptide antibodies 
using a similar experimental design to that for the lambs. Both exogenous GH and 
anti-peptide antibody increased milk yield significantly. This, and the previous experiment 
demonstrate that antibodies raised against specific sequences of bGH can potentiate both 
exogenous and endogenous GH when the antibodies are administered passively and for 
short periods of time. 
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Figure 5. Milk yield response of ewes treated with bGH and passively immunized against a 
peptide region of bGH. 
To further the investigation of the capacity of endogenous antibodies to enhance GH, 
whilst retaining the sensitivity of a traditional GH bioactivity model, experiments were 
performed in hypophysectomized rats (James & Cottingham, 1989). Once good levels of 
anti-hormone antibodies had been detected in response to various porcine (p) GH peptide 
fragment immunizations, the rats were dosed daily with 50 g recombinant pGH. Resultant 
growth rates were compared, in the same experiment, to those of hypophysectomized rats 
which had received adjuvant but no antigen and were similarly dosed with pGH. These latter 
groups also received a GH-potentiating monoclonal or passive immunizations of 
anti-peptide antibodies raised in sheep; control rats were treated with pGH in placebo 
vehicle. As shown in Figure 6 the passive procedures with the monoclonal and the sheep 
antibodies significantly potentiated GH. In the case of active immunization with pGH 
fragment 122-138Cys, the endogenous antibodies were able to exert a very effective 
potentiation of administered pGH. Despite a similar range of titres, the 175-189 fragment 
was not able to exert a similar effect, though no inhibition was observed either. 
Table 2. Carcass composition of lambs actively vaccinated with peptide 133-153 and treated 
with exogenous GH. 
Weight 
Water 
Protein 
Fat 
Ash 
C 
23.91 
10.67 
3.39 
8.56 
1.16 
GH 
23.68 
11.55 
3.81 
6.96 
1.44 
AP 
25.16 
12.24 
3.73 
8.33 
1.17 
GH+AP 
24.94 
12.35 
3.88 
7.93 
1.29 
SED 
0.85 
0.41 
0.14 
0.59 
0.16 
Main effects 
GH AP 
NS 
0.094 
.. 
NS 
0.093 NS 
C, control; GH, 0.10 mg/kg/day; AP, active vaccination with peptide; * = P< 0.05; ** = P>0.01; 
" * = P>0.001 
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Lambs actively vaccinated with the bGH peptide corresponding to amino acids 133-153 
have also provided encouraging data. Lambs were immunized with bGH peptide or 
ovalbumin and were treated with exogenous GH or vehicle for 10 weeks; carcass weight and 
composition are given in Table 2. GH alone induced an increase in carcass protein content 
and tended to increase water and ash accumulation; these increases were offset by a 
considerable decrease in carcass fat accumulation so that carcass weight was unchanged. 
Peptide immunized- lambs exhibited a significant increase in carcass weight which 
consisted of water and protein; little effect was observed on carcass fat content. Actively 
vaccinated lambs treated with additional GH did not have any further improvement in 
carcass weight or quality. 
These encouraging results indicate that there is potential benefit from 
endogenously-derived antibodies to potentiate GH activity but this is no substitute for 
definitive experiments in target species; no such work has been published. However, 
preliminary positive observations exist. In the course of investigations on the use of different 
adjuvants, the levels of anti-hormone antibodies raised in response to peptide immunizations 
were positively and significantly correlated with the growth rate of the animals during the 
period that the antibody titres were elevated (Figure 7). 
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Figure 6. Cumulative weight gain in hypophysectomized rats actively or passively immunized 
against peptide regions of pGH or treated with MAb, and administered exogenous 
pGH. 
Even though IGF-1 is known to mediate many of the anabolic actions of GH, little 
research has been published on the immunological manipulation of IGF-1 activity. Several 
groups have raised MAbs to IGF-1 (Morrell et al., 1989; Cascieri et al., 1990; Tamura et al., 
1990). In general, these inhibit the actions of IGF-1 in vivo, implying that they bind to 
epitopes on or near the receptor-binding region. IGF-1 epitopes which recognize both 
monoclonal and polyclonal antibodies have also been identified recently. 
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Anti-idiotypes 
Anti-idiotypes to GH have been produced and shown to bind to GH receptors in sheep 
and rat liver and rat adipocytes. They did not however disrupt prolactin binding to the liver 
(Figure 8), indicating a high degree of specificity for GH receptors; when given to 
hypophysectomized rats for 3 days, they also increased body weight gain (Figure 9) 
although somewhat surprisingly, they failed to stimulate serum concentrations of IGF-1 
(Gardner et al., 1990). These results were produced using polyclonal antisera and therefore 
a mixture of antibodies, probably mimicking a number of epitopes on the GH molecule. The 
production of monoclonal anti-idiotypic antibodies which should mimic single epitopes on 
the GH molecule would appear to present a much better prospect for producing consistent 
effects. 
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Figure 7. Correlation of growth rate and antibody titre in pigs actively immunized against a 
peptide region of pGH. 
As discussed earlier, the production of antibodies to GH has provided evidence that 
different forms of GH receptor may exist in different tissues. The studies of Barnard et al. 
(1985) and Thomas et al. (1987) demonstrated that monoclonal antibodies bound to GH 
restrict its ability to interact with GH receptors in some tissues but not others. Recent studies 
by Elbashier et al. (1990) involving a panel of monoclonal anti-idiotypic antibodies to hGH 
showed divergent effects in different receptor-binding systems. Several of these antibodies 
inhibited GH binding to rat liver, enhanced binding to the human GH serum-binding protein 
whilst having no effect on GH binding to rabbit liver. This is possibly the most direct 
evidence to date to suggest that different epitopes of GH are involved in binding to different 
receptor populations. 
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Conclusions 
The exciting and relatively new field of immunological manipulation of hormone 
concentration or activity has been reviewed in this article. Several approaches exist and have 
been described; each has particular disadvantages and merits. Generally, modification of an 
animal's immune system should produce long-term rather than temporary changes of 
GH/IGF-1 status and is therefore of benefit where permanent responses are needed, such as 
for the rapid growth of a lean carcass. 
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THE EFFECTS OF EXOGENOUS GROWTH 
HORMONE-RELEASING FACTOR OR SOMATOTROPIN 
ADMINISTRATION ON GROWTH PERFORMANCE, CARCASS 
CHARACTERISTICS, MEAT QUALITY AND REPRODUCTIVE 
FUNCTION IN POULTRY AND PIGS 
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Station de Recherches Porcines, INRA, St Gilles, 35590 L'Hermitage, France 
Summary 
The present paper reviews the experimental data concerning the effects of exogenous 
Growth Hormone-Releasing Factor (GRF) or somatotropin (ST) administration in pigs and 
poultry. / 
Although somatotropin seems to be more or less involved in the regulation of growth in 
birds, exogenous administration of GRF or somatotropin has only transient (or, most often, 
no effect at all) on growth performance and carcass characteristics of chickens. 
In ad libitum fed pigs administered porcine somatotropin (pST) during the finishing 
period, daily feed intake is reduced (2-22%), growth is generally accelerated (up to 47%) and 
feed efficiency is dramatically improved (3-38%), in connection with a sharp reduction in fat 
deposition (7-44%). Lean content of the carcass is augmented (2-23%). Due to the increased 
weight of some organs (liver, heart, etc.), dressing percentage is reduced (1-4%). 
Administration of GRF or of a GRF analog have qualitatively the same effects as pST. 
Main factors of variation of pST effect on performance and carcass characteristics of pigs 
include: 1) Dose ofpST. Daily feed intake and fat deposition decline linearly with increasing 
pST doses while the response of feed efficiency, growth rate and lean deposition is quadratic. 
2) Form of administration. Sustained release of pST seems to be less efficient than daily 
injection. 3) Age and weight. The effects of pST are similar, both qualitatively and 
quantitatively, during the growing period or in heavy pigs than during the finishing period. 
4) Genotype, sex and castration. The effects of pST are negatively related to the animal's 
potential for lean tissue growth. 
The effect of pST on the percentage of the various muscle fibre types is unclear. However, 
an increase in their size is most often noticed. Data indicate pST effects on muscular 
characteristics may vary widely according to muscles. Physical and sensory properties of 
meat are generally unaffected or only slightly altered by pST treatment. Besides pST effects 
on muscle and fat composition, the most consistent changes concern elevated ultimate pH 
measurements, increased shear force values and decreased tenderness. Consumer acceptance 
of fresh pork or processed products does not seem to be impaired by pST treatment. 
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The impact of pST treatment on the onset of puberty is not clear. However, there is 
convincing evidence that any possible adverse reproductive change associated with chronic 
administration of pST to prepubertal gilts is transient. Administration of pST during 
gestation has no effect on litter. The impact of pST treatment on milk production by lactating 
sows is still controversial. 
Keywords: GRF, GH, poultry, pigs, growth, carcass characteristics. 
Introduction 
The aim of the present article is to review the experimental data concerning the effects of 
exogenous administration of GRF (Growth Hormone-Releasing Factor) or ST 
(Somatotropin) on performance, carcass characteristics, meat quality and reproductive 
function in pigs and poultry. 
The paper is organised into the following sessions: the effect of exogenous administration 
of ST or GRF on performance in poultry; the main effects of exogenous porcine 
somatotropin ((r-)pST) or GRF administration on growth performance and carcass 
composition in ad libitum fed pigs; the main factors of variation of performance response to 
rpST administration; meat quality in rpST treated animals; the impact of rpST administration 
on reproductive function. 
The effects of exogenous ST administration on growth performance and 
carcass characteristics in poultry 
As in mammalian species, ST seems to be involved in the regulation of growth in poultry. 
ST has lipolytic and antilipogenic effects in birds (John et al., 1973 ; Foltzer et al., 1975 ; 
Foltzer & Miahle, 1976 ; Harvey et al., 1977 ; Campbell & Scanes, 1986). Administration of 
ST antisera (Scanes et al., 1977) or hypophysectomy (Nalbandov & Card, 1943 ; King, 1969 
; Scanes et al., 1986) results in a reduction of growth rate. However the effects of 
hypophysectomy are only partially reversed by chicken or mammalian ST administration 
whereas growth is fully restored by exogenous T3 injection (Marsh et al., 1984 ; Scanes et 
al., 1986). Moreover, there is no evidence for a positive relationship between growth 
potential and chicken somatotropin (cST) secretion. Dwarf chicks exhibit higher circulating 
cST levels than their normal counterparts (Harvey et al., 1984 ; Lilburn et al., 1986 ; 
Huybrechts et al., 1987). Similarly, blood cST levels are higher in slow growing than in fast 
growing strains (Burke & Marks, 1982 ; Stewart & Washburn, 1983 ; Lilburn et al., 1986 ; 
Goddard et al., 1988). However IGF-I levels are higher in normal than in dwarf chickens 
(Huybrechts et al., 1987), in connection with a higher number of hepatic cST receptors 
(Leung et al., 1987 ; Kuhn et al., 1989). 
Immunoneutralization of somatostatin has been shown to increase growth rate and 
decrease abdominal fat in chickens (Spencer et al., 1986 ; Buonomo et al., 1987). However, 
since neither cST nor IGF-I levels were elevated in immunized birds, the benefits gained 
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from somatostatin immunoneutralization may be exerted through mechanisms unrelated to 
the somatotropic axis. 
Effects of mammalian ST 
In early studies, relatively impure preparations of ovine (oST) or bovine (bST) 
somatotropin did not stimulate growth in chickens (Eaton et al., 1955 ; Libby et al., 1955 ; 
Glick, 1960). More pure bST or oST preparations or recombinant bST (r-bST) have no effect 
on growth rate in normal chickens (Tojo et al., 1979 ; Scanes et al., 1975,1984 ; Marsh et al, 
1984). However, increased growth rate has been reported in chickens treated between 6 and 
12 weeks of age with a tryptic digest of bST (Myers & Peterson, 1974) or in chick embryos 
treated with a bST preparation (Hsieh et al., 1952). Administration of r-bST at very high 
doses (0.5 or 2.5 mg/kg BW per day) in female broiler chicks between 4 and 6 weeks of age 
increased growth rate and feed intake during the first week of treatment (Buonomo & Baile, 
1988). However, r-bST had no effect on performance during the second week, while high 
antibody titres appeared in blood. No significant effect of r-bST treatment was observed on 
carcass characteristics at the end of the two week period. , 
Effects of cST 
Purified or semipurified preparations of cST administered for short periods (4-9 days) 
have a stimulatory effect on growth of young chickens (Tojo et al., 1979 ; Scanes et al., 
1986). Leung et al. (1986), observed a transient stimulation of body growth in 4 week old 
cockerels administered 5, 10 or 50 ug pituitary-derived cST (p-cST) per day for 2 weeks. 
However, differences between treated and control birds were not significant at the end of 
treatment. Continuous infusion of p-cST (20 ug/kg BW per day) in 2-5 week old pullets had 
no effect on feed intake, body weight gain, feed efficiency or carcass composition (Cravener 
et al., 1989). Above approaches of ST effect on chicken growth may be considered as 
sub-optimal, since doses and(or) durations of treatment were limited, due to the scarcity of 
adequate quantities of pure cST. With the availability of recombinant cST (r-cST ; Souza et 
al., 1983), which exhibits distinct growth promoting activity in the hypophysectomized rat 
(Souza et al., 1984 ; Burke et al., 1987 ; Peebles et al., 1988), it was possible to investigate 
the effect of ST administration on performance in chicken over longer periods of treatment. 
Thrice daily (Burke et al., 1987) or twice daily (Peebles et al., 1988) administration of high 
doses of r-cST (50,250 or 1500 ug/kg B W per day) had no stimulatory effect on performance 
of young chickens. Liou et al. (1986), found that the combination of exogenous r-cST and 
dietary thyroid hormones depressed growth rate of broiler chickens between 21 and 42 days 
of age. Protein and ash content of the carcass as well as nitrogen retention were not affected 
by exogenous r-cST administration (Burke et al., 1987). Dressing percentage has been 
reported to be lower in p-cST treated birds (Cravener et al., 1989). 
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Effects ofGRF 
GRF has been shown to stimulate cST secretion both in vitro and in vivo, and to potentiate 
cST response to TRH in chickens (Leung & Taylor, 1983 ; Harvey et al., 1984 ; Leung et al., 
1985 ; Harvey & Scanes, 1985) and turkeys (Proudman, 1984). Exogenous administration of 
GRF doses known to vastly stimulate cST secretion, has transient (Leung et al., 1986) or no 
effect (Buonomo & Baile, 1984, 1986) on body weight gain and feed efficiency in broiler 
chickens. 
Conclusion 
In a recent review, Johnson (1989) discussed the possible reasons for the failure of growth 
hormone to improve performance in poultry: 
- broiler chickens exhibit very rapid early growth at a time when endogenous production 
of cST is very high (Burke & Marks, 1982 ; Vasilatos-Younken & Leach, 1986 ; 
Vasilatos-Younken & Zarkower, 1987). Thus, exogenous ST may negate the growth 
promoting activity of endogenous cST secretion in young chickens, 
- broiler chickens have a unique pattern of somatotropin secretion, with a high pulse 
amplitude and a more rapid pulse frequency than in other species (Johnson et al., 1987 ; 
Vasilatos-Younken & Zarkower, 1987). Vasilatos-Younken et al., (1988) demonstrated that 
pulsatile administration of p-cST improved performance of 8-11 week old pullets, whereas 
continuous infusion did not. Therefore, the pattern of administration of cST may be 
important in obtaining positive responses to the hormone. However, this experiment should 
be repeated in younger birds. 
The effects of exogenous pST or GRF administration on growth 
performance and carcass characteristics in swine 
Effects of porcine somatotropin (pST) 
In the first attempts to investigate the effects of exogenous pST administration on pig 
growth performance, imperfectly purified pituitary extracts were used (Turman & Andrews, 
1955 ; Henricson & Ullberg, 1960 ; Lind et al., 1968 ; Machlin, 1972). During the 1980's, 
progress in preparative biochemistry provided improved pituitary preparations. At the same 
time, GRF was discovered and synthesized and recombinant pST became available, having 
the same biological and zootechnical effects as native pituitary pST (Ivy et al., 1986, Evock 
et al., 1988). 
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Table 1. The effects of pST administration on growth performance and carcass characteristics of 
ad libitum-fed finishing pigs. 
Breed 
LWxDU 
LWxLR 
DU 
LWxLR 
PP 
LWxLR 
HAxLW 
LW 
PP 
LW 
LWxDU 
MS 
LWxPPxMS 
PP 
LRxLW 
"Sex" 
C&F 
C 
C&F 
E&F 
C&F 
C&F 
C 
C 
F 
C 
F 
F 
F 
F 
Daily 
dose 
2mg* 
2mg 
30 ug/kg 
3 m g 
3 m g 
4 m g 
4 m g 
4 m g " 
4 m g " 
4 m g " 
50 ug/kg 
5 m g 
5mg 
5 m g 
5 m g 
60 ug/kg 
60 ug/kg 
70 ug/kg 
70 ug/kg 
70 ug/kg 
6mg 
6 m g 
6 m g 
100 ug/kg 
DFI 
-10 
-14 
-22 
-9 
-8 
-4 
-4 
-5 
-7 
-13 
-12 
-3 
-2 
-10 
-17 
-7 
-10 
ADG 
+ 17 
+9 
+11 
+5 
+13 
+29 
+4 
+6 
+3 
-9 
-5 
+1 
+ 19 
+7 
+ 11 
+ 18 
+ 14 
+43 
+ 18 
+31 
+47 
FCR 
-23 
-21 
-19 
-25 
-19 
-29 
-7 
-10 
-8 
-11 
-24 
-24 
-12 
-3 
-20 
-15 
-20 
-22 
-17 
-38 
-29 
-31 
-41 
Fat LEA 
thickness 
-11 
-38 
-36 
-21 
-13 
-7 
-23 
-37 
-37 
-19 
-41 
-44 
-36 
-31 
+21 
+11 
+ 16 
-3 
+7 
+25 
+6 
DP 
-3 
-3 
-4 
-2 
-1 
Lean 
+26 
+9 
+12 
+7 
+4 
+2 
,
 +6 
+9 
+ 12 
+ 14 
+ 19 
+33 
+ 11 
+3 
Ref. 
% 
1 
2 
3 
4 
5 
6 
7 
8 
8 
8 
9 
10 
10 
11 
11 
12 
13 
14 
15 
16 
17 
17 
17 
18 
Data expressed as % changes of treated vs control pigs 
DFI: Daily Feed Intake ; ADG: Average Daily Gain ; FCR: Feed Conversion Ratio ; LEA: Loin Eye 
Area ; DP: Dressing Percentage 
Breed : DU = Duroc ; HA = Hampshire ; LR = Landrace ; LW = Large-White ; MS = Meishan ; PP = 
Retrain 
"Sex": E = entire males ; C = castrated males ; F = females 
* as an implant ; *" as twice weekly injections of 14 mg 
From 1: Knight et al„ 1988;2: Azainetal., 1989;3: Ethertonetal., 1986;4: Bechtel etal . , 1988; 
5: Baile et al., 1990 ; 6: Skaggs et al.. 1989c ; 7: Goodband et al., 1988 ; 8: Kanis et al., 1990 ; 9: 
Smith et al., 1987 ; 10: Nossaman et al., 1989 ; 11 : Fowler & Kanis, 1988 ; 12: Trenkle, 1988 ; 13: 
Jones et al., 1989 ; 14: Bark et al., 1989 ; 15: Bryan et al., 1989a ; 16: Etherton et al., 1987 ; 17: 
Bonneau et al., 1990a ; 18: Campbell & Tavemer, 1988 
Unless otherwise stated, the results presented in this paper were obtained with daily 
injections of the hormones. Relatively few published data are available concerning the 
efficacy of prolonged release pST implants (Knight et al., 1988, 1989, 1990 ; Baile et al., 
1989; Becker et al., 1989). 
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A selection of results relating to the influence of exogenous pST administration on growth 
performance and carcass characteristics of finishing ad libitum-fed pigs are presented in 
Table 1. Despite a significant reduction of daily feed intake, pST treated pigs grow faster 
with a dramatically improved feed efficiency. Fat percentage in the carcass is sharply reduced 
with a concomitant increase in muscle proportion. More generally, pST enhances the 
development of all protein rich tissues (muscle, skin and bone) to the detriment of fat 
(Bonneau et al., 1989 ; Bark et al., 1990 ; Caperna et al., 1990 ; Thiel et al., 1990b). 
Dressing percentage falls 1-4% after pST administration. Part of the decrease is due to the 
increased size of some organs. The weights of liver, heart and kidney are augmented 4-30%, 
2-22% and 15-52%, respectively (Grebner et al., 1987 ; Bechtel et al., 1988 ; Evock et al., 
1988 ; Kanis et al., 1988b ; Trenkle, 1988 ; Bonneau et al., 1989 ; Bryan et al., 1989a). 
Preliminary results (Bidanel et al., unpublished) suggest that increased weight of blood and 
intestinal content at slaughter may also account for some part of the decline in dressing% in 
pST-treated animals. 
Effects of GRF 
Daily or three times daily injection of GRF or GRF analog increases blood pST levels, in 
a dose related manner, throughout the entire period of administration, with no desensitization 
of the somatotroph cells (Dubreuil et al., 1990a, 1990b). The effects of exogenous GRF or 
GRF analog administration are qualitatively similar to those obtained with pST (Table 2). 
Table 2. The effects of GRF administration on growth performance and carcass characteristics of 
ad libitum-fed finishing pigs. 
GRF 
type 
GRF 1-44 
GRF 1-44 
GRF 1-44 
GRF 1-29 
analog 
analog 
analog 
analog 
Daily 
dose* 
30 
20 
40 
15 
5 
10 
20 
10 
Number 
inject, 
per day 
1 
2 
2 
2 
3 
3 
3 
1 
DFI 
-6 
-8 
-2 
-8 
-6 
-21 
-10 
ADG 
+6 
+8 
+ 14 
0 
+3 
+ 12 
+7 
-1 
FCR 
-9 
-13 
-19 
-17 
-11 
-16 
-26 
-11 
Fat LEA 
thickness 
-12 
-22 
-21 
-7 
-24 
-32 
-16 
+ 13 
+11 
+ 12 
+6 
+2 
+4 
+ 13 
+10 
DP 
-2 
-1 
-3 
-2 
-1 
Lean 
+3 
+5 
+6 
+5 
Ref. 
% 
1 
2 
2 
3 
4 
4 
4 
4 
Data expressed as % changes of treated vs control pigs 
* ug/kg/d 
DFI: Daily Feed Intake ; ADG: Average Daily Gain ; FCR: Feed Conversion Ratio ; LEA: Loin Eye 
Area ; DP: Dressing Percentage From 1 : Etherton et al., 1986 ; 2: Johnson et al., 1989 ; 3: Dubreuil 
et al., 1990c ; 4: Dubreuil et al., 1990b 
However, the improvement in performance is significantly lower with GRF than with pST 
injected at the same dose (Etherton et al., 1986 ; Johnson et al., 1989). As does pST, GRF or 
GRF analog accelerate the development of some organs (Dubreuil et al., 1990b) and of all 
protein rich tissues (muscle, skin, bone) to the detriment of fat (Pommier at al., 1990). 
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Conclusion 
Exogenous pST or GRF administrations dramatically improve both rate and efficiency of 
lean tissue growth to the detriment of fat deposition. The fact that somatotropic hormones are 
a limiting factor for performance in pigs may be related to the observation that endogenous 
blood pST has fallen to low levels during the growing and finishing periods, compared to the 
neonatal period (Klindt & Stone, 1984 ; Scanes et al., 1987 ; Louveau et al., 1990). 
Factors of variation of performance response to pST administration 
Among the various factors of variation of performance response to pST administration, 
nutrition certainly plays a key role. However, this will not be developed in the present paper, 
as the effects of pST administration on nutritional requirements are reviewed elsewhere (Van 
Vlissingen et al., 1990b). Factors reviewed include those related to pST (dose, form and 
schedule of administration) and animal (age and weight, genotype, sex and castration). 
Possible interaction of pST with B-agonist will also be considered. 
Dose, form and schedule of administration 
The dose of injected pST is either constant (expressed as mg per day) or adapted to the 
increasing weight of the animal (expressed as ug per kg live weight per day). The dose 
providing maximum effect is not the same for the various performance criteria (Figure 1). 
Feed intake declines linearly with increasing doses while feed efficiency is not further 
improved beyond 80-100 ug/kg per day or 6 mg per day. Therefore, growth rate response to 
increasing pST doses is quadratic. The dose at which maximum growth rate is obtained may 
vary according to experimental conditions from 3 mg per day (Darden et al., 1990 ; Fitzner 
at al., 1990) to 60-70 ug/kg per day or 6 mg per day (Boyd et al., 1986 ; Evock et al., 1988 ; 
Mc Laren et al., 1987). Carcass fat content is reduced linearly, whereas carcass lean content 
is increased quadratically with increasing pST doses (Boyd et al., 1986 ; McNamara et al., 
1990 ; Yen et al., 1990). However, Thiel et al. (1990b) observed a linear increase in muscle 
content with pST doses ranging from 50 to 200 ug/kg per day. 
Little information is available concerning the comparison of daily injection vs continuous 
release of pST. However, the preliminary observations of Knight et al. (1988) are consistent 
with a lower efficacy of continuous release versus daily bolus injection of pST. 
Van Vlissingen et al. (1990a) found only minor differences for the effects on performance 
and carcass quality between three schedules of pST administration: constant (4 mg/d), 
increasing (from 2 up to 6 mg /d), decreasing (from 6 down to 2 mg /d). As could have been 
expected, the improvements in growth rate and loin eye muscle area are higher with 
continuous daily injections than with daily injections during alternate weeks (Bryan et al., 
1990b). 
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Feed Conversion Ratio 
1 
pST dose 
9 
pST dose 
Figure 1. The effect of pST dose on performance and carcass characteristics of pigs (data expressed 
as % changes of treated vs control pigs. From 1 : Boyd et al., 1986 ; 2: Evock et al., 1988 ; 3' 
Rebhun & Etherton. 1985 ; 4: Mc Laren et al., 1987 and Grebner et al., 1987 ; 5: Demeyer et al., 
1988 ; 6: Darden et al., 1990 and Baldwin et al., 1990 ; 7: Fitzner étal., 1990 ; 8: Mc Laren étal 
1990). 
Age and weight 
The finishing period, during which muscle growth rate is still steady whereas adipose 
tissue development accelerates, is usually considered as the best time for pST administration 
to pigs. 
However, pST treatment during the growing period (25-30 to 50-60 kg live weight) has 
similar effects as in older pigs. Daily administration of 100 ug/kg per day enhances protein 
retention by 35-50% and reduces fat accretion by 26-32% (Campbell et al., 1988a). 
According to Campbell et al. (1989b), animals treated with pST during the growing period 
also exhibit improved performance, except for fat accretion, during the finishing period, long 
after the end of treatment. Such carryover effect of pST is however controversial (Smith et 
al., 1989). 
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The repartitioning effect of pST is also observed in animals treated beyond 100 kg live 
weight. The changes in performance are similar (Jones et al., 1989 ; Crenshaw et al., 1990 ; 
Shoup et al., 1990) or higher (Kanis et al., 1990) than in pigs treated during the finishing 
period. 
Genotype 
In all genotypes of pigs so far studied, performance responds favourably to pST treatment. 
In genotypes differing only slightly for their growth performance and carcass characteristics, 
no interaction between pST treatment and genotype is observed (Bark et al., 1990 ; Shoup et 
al., 1990). The effects of pST on performance are similar in lines of pigs selected for either 
leanness or fatness (Campbell & Taverner, 1988 ; Bark et al., 1989). Pigs from the 3 
halothane sensitivity groups (NN: Normal/Normal ; Ns: Normal/sensitive ; ss: 
sensitive/sensitive) also respond similarly to pST treatment, although the improvement in 
feed efficiency is lower in ss than in NN pigs (Skaggs et al., 1989a, 1989b). 
On the other hand, genotype x treatment interactions are clearly demonstrated when the 
effects of pST administration are compared in obese versus lean (Yen et al., 1990), obese 
versus double-muscled (Bonneau et al., 1990a) or conventional versus double-muscled pigs 
(Kanis et al., 1990). The improvement in performance is particularly impressive in the slow 
growing-fat Chinese pigs, as pure breed or crossbred with conventional pigs (Fung & Qi, 
1988 ; McLoughlin et al., 1989 ; van der Steen et al., 1989 ; Bonneau et al., 1990a, Prunier 
et al., 1990). In very lean breeds, such as Pietrain or Belgian Landrace, subcutaneous fat 
almost disappears while muscle percentage in the carcass is only slightly increased (Demeyer 
et al., 1988 ; Bonneau et al., 1990a ; Kanis et al., 1990). Overall, it can be considered that the 
relative improvement in performance due to pST treatment is in inverse proportion to the 
animal's potential for lean meat growth. However, pST effect is still significant in the leanest 
breeds (Kanis et al., 1990 ; Bonneau et al., 1990a). 
Sex and castration 
The repartitioning effect of a high dose of pST (100 ug per kg per day) is more 
pronounced in castrated males than in females and in females than in entire males (Campbell 
et al., 1989a), so that differences in performance between "sexes" are narrowed with pST 
treatment. With lower pST doses (3 or 4 mg per day), castrates also exhibit higher responses 
to pST, but the superiority of female carcass composition is still apparent in treated animals 
(Bonneau et al., 1989 ; Kanis et al, 1990). 
Interaction withß-agonists 
Provided that nutritional conditions are satisfactory, the repartitioning effects of pST and 
ß-agonists seem to be additive in swine (Anderson et al., 1989 ; Jones et al., 1989). 
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Meat quality in pST-treated pigs 
The effect of pST on muscle and fat composition will not be discussed in this paper as 
these aspects are covered elsewhere (Beermann et al., 1990). However, we will consider the 
effects of pST administration on muscle fibres as well as on physical and sensory 
characteristics of pork meat. 
Muscle fibre types 
The effect of pST treatment on the percentage and size of the various fibre types is still 
controversial. In the longissimus dorsi or semitendinosus muscles, pST treatment increases 
the size of fibre types (Beerman et al., 1987 ; Solomon et al., 1988,1990 ; Lefaucheur et al., 
unpublished results). However, in the same muscle, Whipple et al. (1989) did not find any 
difference in fibre size. The percentage of the various fibre types in longissimus dorsi may be 
unaffected (Solomon et al., 1988 ; Lefaucheur et al., unpublished results) or altered towards 
a higher (Whipple et al., 1989) or lower (Solomon et al., 1990) percentage of white fibres. In 
another predominantly white muscle (semimembranosus), neither fibre percentage nor fibre 
size are significantly affected by pST treatment (Whipple et al., 1989). In the predominantly 
red semi spinalis muscle, the percentage of type ÜB fibres and the size of all fibre types are 
increased by pST administration ; lactate dehydrogenase activity is augmented while citrate 
synthase and ß-hydroxy-acyl-CoA-dehydrogenase activities are reduced by pST treatment 
(Lefaucheur et al., unpublished results). In summary, pST seems to increase fibre size with a 
still controversial effect on the percentage of the various fibre types in predominantly white 
muscles. The metabolism of predominantly red muscles is altered towards a reduction of 
oxidative and an elevation in glycolytic pathways, in association with the increased 
percentage of the mostly glycolytic type IIB fibres. That pST effects may vary according to 
muscle type is further demonstrated by the observations of Evock et al. (1990): pST 
increased RNA content and RNA/DNA ratio in longissimus dorsi whereas DNA 
concentration was increased in semi membranosus muscle. 
Physical characteristics 
Treatment with pST generally has no significant effect on muscle pH fall after slaughter 
(Bonneau et al., 1989 ; Ender et al., 1989 ; Hagen et al., 1990a ; Lefaucheur et al., 
unpublished results)). However, elevated pH measurements 45 minutes or 24 hours after 
slaughter have been reported (Demeyer et al., 1988 ; Skaggs et al., 1989a ; Mourot et al., 
1990). Similarly, a tendency for higher pH measurements has been noticed in pigs treated 
with a GRF analog (Pommier et al., 1990). 
Shear force, drip and cooking losses, and reflectance of meat are generally not 
significantly affected by pST treatment (Beerman et al., 1988 ; Demeyer et al., 1988 ; Kanis 
et al., 1988c ; Prusa, 1988 ; Ender et al., 1989 ; Gardner et al., 1990 ; Williams et al., 1990 ; 
Mourot et al., 1990). However, Novakofski (1987) and Williams et al. (1990) observed a 
greater shear force value in muscles of pST treated pigs. In some cases meat colour has been 
reported to be negatively (Kanis et al., 1988c) or positively affected (Demeyer et al., 1988). 
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Sensory properties 
Sensory characteristics of pig meat, as assessed by laboratory panels, are generally 
unaffected by pST treatment (Novakofski, 1987 ; Beerman et al., 1988 ; Demeyer et al., 1988 
; Kanis et al., 1988c ; Prusa, 1988 ; Thiel et al., 1990a ; Hagen et al., 1990a ; Williams et al., 
1990). However, significant reductions in tenderness (Evock et al., 1988 ; Beermann et al., 
1988 ; Prusa, 1988 ; Boles et al., 1990 ; Thiel et al., 1990a ; Williams et al., 1990), juiciness 
(Beermann et al., 1988) or flavour (Prusa, 1988) have been reported. The decreased 
tenderness could be related to the increased collagen deposition (Caperna et al., 1990); 
however collagen as % of total proteins as well as soluble collagen as % of total collagen are 
unaffected by pST treatment. Such deleterious effects of pST treatment on sensory quality of 
meat are mostly observed with high pST doses and often reported as of little practical 
significance. 
Prusa et al. (1990), using a large consumer panel, reported a positive consumer acceptance 
of meat from pST treated animals. Degree of liking, tenderness, juiciness and flavour were 
slightly, but significantly, higher in meat from pST treated than from control animals. 
Processing characteristics of meat does not seem to be affected by pST treatment as well 
as sensory quality of frankfurters (Reagan et al., 1990) or cooked hams (Kuecker et al., 1990) 
manufactured from pST meat. 
The effect of pST administration on reproductive function 
PST and development of ovarian activity 
The dramatic reduction in adipose tissue development as well as endocrine changes 
triggered by pST treatment may have some consequences on reproductive function (Aherne 
& Kirkwood, 1985 ; Kirkwood et al., 1989). The normal schedule of cytoplasmic maturation 
of oocytes is accelerated by pST (Hagen & Graboski, 1990). Progesterone secretion by 
ovarian follicles is modified (Bryan et al, 1988,1989a, 1989b), although Spicer et al. (1990) 
did not find any effect on progesterone content of follicular fluid. Number of hCG binding 
sites are reduced in granulosa cells (Spicer et al., 1990) and increased in luteal tissue 
(Kirkwood et al., 1990b). Ovarian response to PMSG/hCG stimulation is altered and the 
amplitude of estrogen-induced LH peak is reduced (Kirkwood et al., 1989a, 1990a). 
The effect of pST treatment on puberty attainment in gilts is not clear. Some authors 
observe that less treated gilts reach puberty and at an older age than control (Bryan et al., 
1989a). On the other hand, others do not obtain any significant effect on age at puberty, or 
percentage cyclic gilts at the end of treatment, even with high pST doses (Andres et al., 1989 
; Prunier et al., 1990 ; Bidanel et al., 1990 ; Kirkwood et al., 1989b). Genital tract 
development of prepubertal gilts is mostly unaffected by pST treatment (Bryan et al., 1988, 
1989b, 1990b ;Terlouw et al., 1989; Prunier et al., 1990). However, Hagen et al. (1990b) and 
Bryan et al. (1990b) observed a significant increase in uterus weight and length in gilts 
receiving 5 mg pST per day for 20 or 40 days. 
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Sexual activity seems to return to normal very rapidly after the end of pST treatment. The 
response to boar stimulation is similar or even better in pST treated than in control gilts (Day 
et al., 1988 ; Bryan et al., 1990). Moreover, duration of oestrous cycles, ovulation rate, 
percentage pregnant females and embryo survival are not significantly affected by pST 
treatment (Day et al., 1988 ; Andres et al, 1989, 1990 ; Kirkwood et al., 1989b, 1989c). In 
summary, any possible reproductive change associated with chronic administration of 
exogenous pST to prepubertal gilts seems to be transient. 
Little information is available concerning the effect of exogenous pST administration on 
male sexual development. Hagen et al. (1990a) observed no effect of pST on the 
development of the male genital tract. 
PST administration to pregnant or lactating sows 
Exogenous pST administration to sows during the last 2 or 3 weeks of gestation has no 
significant effect on birth and weaning weight of piglets or on their survival rate (Kveragas 
et al., 1986 ; Baile et al., 1989). However, Kveragas et al. (1986) noticed that body glycogen 
and lipid contents at birth as well as fasting blood glucose profiles were higher in piglets born 
from pST treated than from control sows. 
According to Harkins et al. (1989), exogenous pST administration during lactation 
induces a large increase in milk production, with no alteration in milk composition. Piglets 
suckling a pST treated sow weigh 6% more at weaning. The increase in milk production and 
concomitant decline of daily feed intake are responsible for larger body weight and fat losses 
in treated sows. Other authors do not confirm the stimulating effect of pST treatment on milk 
production in sows. However, their experimental conditions were not favourable for the 
observation of a positive effect, either because of harsh environmental conditions (Cromwell 
et al., 1989a) or due to infrequent pST injections (Cromwell et al., 1989b, Crenshaw et al., 
1989). 
Conclusion 
Exogenous administration of somatotropic hormones does not seem to have any 
significant impact on growth performance and carcass characteristics of young broiler 
chickens whereas it dramatically improves both rate and efficiency of lean deposition and 
inhibits lipid deposition in swine. Therefore, the use of GRF or recombinant pST could 
sharply reduce feeding costs and improve carcass quality in pig production. The impact of 
pST treatment on meat quality seems to be limited. Deleterious effects (if any) on the onset 
of reproductive function are transient and quickly reversed after the end of treatment. 
Therefore, provided that proper delivery systems can be developed, exogenous 
administration of somatotropic hormones to swine seems to be a very promising technique, 
leading to the production of a cheaper product, better fit to the lean meat consumer demand. 
However, public perception of the acceptability of meat from such animals might be a 
limitation to its development. 
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Summary 
Somatotropin treatment of sheep and cattle increases body weight gain by 8-10% and feed 
conversion by a comparable amount. However, this is often accompanied by an increase in 
non-carcass components and the carcass weight may not necessarily be significantly 
increased. Yet, somatotropin still imparts a repartitioning of carcass components to more 
protein and less fat. The regional sites where repartitioning takes place are predominantly in 
the hindquarter and the subcutaneous fat depots. The improvements in feed conversion 
efficiency are driven by the components of gain as opposed to any real change in the 
biological conversion processes. 
Administration of exogenous somatotropin presents a management tool to enhance 
growth performance and improve carcass composition which is consistent with the desires of 
the producer and consumer. A key to the successful implementation of this technology will 
be the identification of a long term delivery system for somatotropin which is efficacious, 
easily administered and cost effective. 
Keywords: somatotropin, growth, carcass composition, protein turnover 
Introduction 
In domestic livestock production, new technologies to dramatically improve lean carcass 
yield, improve efficiency of feed utilization and increase the rate of daily gain are available. 
Agents which affect these characteristics, coined repartitioning agents, are exemplified by 
ß-agonists and somatotropins. Neither of these compounds have yet been cleared for 
commercial use. Considerable information is available in swine on the anabolic responses to 
somatotropin administration. However, the data on the influence of somatotropin on growth 
in ruminants is only now beginning to accumulate. 
A number of experiments have been published on the influence of exogenous 
somatotropin on average daily gain and feed conversion efficiency but very few of these long 
term studies have reported organ development and carcass composition data. Many short 
term trials have reported increases in nitrogen retention in response to somatotropin 
administration (Wheatley et al., 1966; Moseley et al., 1982; Crooker et al., 1990) but these 
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trials did not define the site of the increased nitrogen and/or protein accretion. By inference, 
it is often assumed that relatively short term growth trials (three weeks or less) reflect the 
long term (several months) growth response. However, the location and magnitude of 
enhanced protein accretion may be drastically altered depending upon the length of 
somatotropin administration in relation to the animal's age and development. This is 
particularly important with respect to protein synthesis since skeletal muscle, liver and the 
intestines can account for 12-32%, 11-25% and 15-33%, respectively, of whole body protein 
synthesis, depending upon the age of the animal (Reeds, 1989). Therefore, the purpose of this 
review is to summarise the long term growth trials with sheep and cattle in which exogenous 
treatment with somatotropin was applied, and to develop a hypothesis as to the action of 
somatotropin on the components of growth. 
Performance trials 
The increase in average daily gain (ADG) induced by somatotropin treatment varies 
considerably across species and sex (Table 1). These differences undoubtedly reflect 
differences in experimental design, dose of somatotropin, duration of administration, breed 
of animal and dietary regimen. McShane et al. (1989) found that under controlled intake 
regimen, higher energy diets induced a greater absolute gain and somatotropin increased 
ADG by 8-10% over controls, depending upon diet. The largest increases in ADG in 
response to somatotropin treatment have been reported for very young (one week of age) 
Holstein bull calves (18%, Groenewegen et al., 1990), for dairy heifers (24%, Grings et al., 
1990) and for Belgian White Blue heifers (23.5%, Fabry et al., 1987). On a percentage basis, 
it appears that in both sheep and cattle, the largest responses in ADG occur in younger 
animals. This is not surprising given the proposed actions of somatotropin and IGF-1 on 
muscle protein synthesis and cartilage development (Green et al., 1985) and the capacity for 
muscle and skeletal development in the young animal. The average increase in ADG for these 
trials, in cattle and sheep, is approximately 10%, which is somewhat below the response 
observed for somatotropin treated swine (Chung et al., 1985; Campbell et al., 1988). 
Sheep and cattle have tended to respond to treatment with somatotropin by small changes 
either upward or downward in dry matter intake (DMI). In finishing beef steers, Moseley et 
al., (1990) reported a linear decrease in feed intake (-6% to -16.7%) with increasing doses of 
somatotropin. Similarly, Wagner et al. (1988) reported a -7.8% decrease in DMI in finishing 
beef steers treated with somatotropin. The data in swine shows marked decreases in DMI in 
response to somatotropin (Etherton, 1989). A hypothesis to explain this depression in DMI, 
might be that the abundance of nutrients from mobilized fat stores cannot be utilized by the 
growing tissues at a rate fast enough to reduce circulating nutrient concentrations, therefore, 
the animal responds by reducing DMI to bring the body to homeorhesis. On the other hand, 
in young growing cattle and sheep treated with somatotropin, it would be expected that the 
protein and energy requirements cannot be met by mobilization of energy reserves, therefore 
DMI may be increased to help support the stimulated metabolic response to somatotropin. An 
alternative reason for the increase in DMI in young, growing animals is noted by 
Groenewegen et al. (1990) who reported a significant increase (21%) in DMI with a pelleted 
starter/grower diet fed to bull calves (one to 14 weeks of age). This response may simply 
have reflected an increase in digestive tract volume since the reticulorumen, small intestine 
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and large intestine weights were 24, 28 and 19% larger, respectively, for the 
somatotropin-treated bull calves. On average, the proportional increase in gut was 3-fold 
greater than the increase in carcass accretion (Groenewegen et al., 1990). Others have 
reported significant increases (14.3%) in the weight of the small intestine of 
somatotropin-treated cattle even under short term treatment conditions (Eisemann et al., 
1989b). When expressed on a unit empty body weight basis, small intestine weight was also 
significantly greater in somatotropin- treated cattle (9.2%) (Eisemann et al., 1989b), again 
inferring that gut development was disproportionate to whole body growth. However, these 
observations do not necessarily imply a direct causal relationship for enhanced capacity for 
intake. 
Table 1. Growth response to somatotropin in treated cattle and sheepa b 
Initial 
ADG DM I F/G Wt. Age Dur. Dose Reference 
(kg) (mo) (wk) (mg/kg/d) 
Cattle 
steers 
steers 
steers 
steers 
steers 
steers 
heifers 
heifers 
heifers 
heifers 
heifers 
heifers 
heifers 
bull calves 
bull calves 
Sheep 
wether 
wether 
wether 
ewes 
& wethers 
ewe 
ram lambs 
15 
10 
6 
7.9 
-7.0 
-37.7 
10 
9 
8 
24.0 
8 
10 
23.5 
18 
7.1 
4 
20 
12.3 
17 
22 
1 
2 
-7.8 
3 
-6 
-13.1 
-16.7 
-
6 
-
— 
-
-
1.5 
21 
0 
-4 
-
-
-
6 
<1 
-12 
-18 
-4 
-11.6 
-6.3 
34.4 
--
-2 
-8 
-
-8 
-10 
-20.3 
0 
-5.3 
-7 
-14 
-19.6 
-22.4 
-14 
<1 
231 
336 
237 
393 
393 
393 
89 
92 
180 
295 
228 
229 
439 
45 
45 
28 
40 
25.5 
25.5 
17 
17 
8 
-
9 
-
-
-
2 
4 
8 
-
7 
7 
-
0.25 
0.75 
— 
-
-
— 
2 
2 
16 
20 
22 
17 
19 
22 
12 
21 
16 
21 
21 
32 
18 
13 
15 
8 
15 
6 
6-8 
12 
4 
0.08 
0.20 
0.04 
0.033 
0.10 
0.30 
0.11 
0.60 
0.10 
0.14 
0.09 
0.09 
0.05 
0.10 
0.08 
0,25 
0.37 
0.20 
0.16 
0.10 
.1-.2 
Early et al., 1990g 
Wagneretal., 1988 
Enrightetal., 1990 
Moseleyetal., 1990 
Moseleyetal, 1990 
Moseleyetal., 1990 
Brumby, 1959 
Sandles and Peel, 1987 
Sejrsen et al., 1986 
Gringsetal., 1990 
McShaneetal., 1989 
McShaneetal., 1989 
Fabry e ta t , 1987 
Groenewegen et al., 1990 
Maltinetal., 1990 
Muiretal., 1983 
Wagner and Veenhuizen, 1978 
Wise et ai., 1990 
Beermanetal., 1990 
Johnsson étal. , 1985 
Rosemberg et al., 1989 
a
 Responses in ADG, DMI and F/G are all based upon a percentage response compared to 
controls. 
b
 The values reported do not necessarily imply statistically significant responses. 
The most consistent response in both cattle and sheep is that of a statistically significant 
improvement in the feed/gain (F/G) conversion rate (Table 1). The majority of long term 
trials under both ad libitum and restricted intake regimes showed a 4-22% (=9%) 
improvement in feed/gain ratio. The observed improvement in (F/G) by 9% coupled with an 
average increase of 10% in ADG certainly suggests a performance advantage with 
somatotropin treatment. However, Moseley et al. (1990) reported that steers administered a 
high dose of somatotropin (300 g rbST/kg/d) responded with a 16.7% reduction in feed 
intake and a 37.7% slower ADG which resulted in a 34.4% poorer F/G ratio than controls. 
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Yet the carcass composition characteristics of these steers reflected the repartitioning effects 
of somatotropin with a reduction in carcass fat and an increase in carcass protein. It is 
apparent that the location and chemical components of the enhanced tissue accretions to 
somatotropin treatment need to be assessed before the performance responses are deemed 
beneficial. 
Three studies have examined the interaction of somatotropin with other growth promoting 
agents. Steers which received somatotropin plus oestradiol via a Compudose implant 
(Wagner et al., 1988; Enright et al., 1990) and bull calves which received somatotropin plus 
the ß-agonist Clenbuterol. Maltin et al., (1990) responded with an additive effect for F/G and 
ADG. An interpretation is that the growth promoting effects of somatotropin operate through 
mechanisms different than either estradiol or the ß-agonists such that a combination of these 
agents produced greater responses than either agent alone. 
This review focuses on somatotropin and does not cover growth hormone-releasing factor 
(GRF) (See Enright, 1989). However, two studies with young growing sheep reported that 
GRF administered either 2 or 4 times daily produced improvements in ADG and F/G similar 
to that produced by administration of ovine somatotropin (Beermann et al., 1990; Wise et al., 
1988). As sources of GRF become more readily available to the research community, the data 
on GRF as a growth promoting agent will begin to increase. Recent data in pigs substantiates 
that GRF administered at an appropriate dose and frequency can markedly improve growth 
rate and efficiency of growth and lean carcass yield (Dubreuil et al., 1990; Pommier et al, 
1990). Clearly, GRF represents an alternative to somatotropin as a means to improve growth 
performance in domestic livestock. 
Components of gain 
Organ development 
The number of published long term growth trials in cattle and sheep using somatotropin 
treatment in which ADG was increased and full carcass composition was compiled are few 
in number (Early et al., 1990a; Groenewegen et al., 1990; Sandles and Peel, 1987 and 
Johnsson et al., 1985). Within these studies, some striking similarities appear, with the 
exception of the Sandles and Peel (1987) study, which used a bigger dose of somatotropin 
than the other studies. Carcass weight accretion was increased by 6.2-9.9% whereas 
non-carcass weight accretion was disproportionately increased (Table 2). The calculations 
for the Groenewegen et al. (1990) and Johnsson et al. (1985) data would include differences 
in gut fill but in each case specific organs and other non-carcass tissue components were 
increased in weight disproportionately to carcass weight accretion. In sheep, Johnsson et al. 
(1985) reported significant increases in the weight of the skin (minus the fleece; 46%) and 
pluck (trachea, lung, heart, liver, spleen; 27%) over those of control animals. These values 
represent a 2.5 to 4-fold increase compared to the relative increase in the carcass component. 
Similarly, in bull calves, Groenewegen et al. (1990) found a 1.6-fold increase in lungs and 
liver weight and a 3-fold increase in the gut weight compared to the relative increase in the 
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carcass component. Early et al. (1990a) also reported large increases in the weight of the 
liver, kidneys and lungs plus trachea in somatotropin-treated steers. 
In another study in sheep, somatotropin or GRF treatments induced significant increases 
in weight of several non-carcass components such as pelt, liver, head and feet (Wise et al., 
1988). Disproportionate increases, due to ST, in liver weight compared to carcass weight is 
commonly found across trials (Table 3). Liver growth was increased 1.6 to 2.6 fold compared 
to carcass growth. The organs undergo the greatest growth (liver, kidneys, lungs) represent 
such a small component of total weight gain that a relatively small decrease in dressing 
percentage is observed (Table 2). However, the important question is whether alteration of 
organ growth has influenced organ function. Early et al. (1990a) examined blood chemistry 
profiles of somatotropin-treated steers and found the majority of compounds examined (Ca, 
P, Na, K, CI, total protein, albumin, alkaline-phosphatase, glutamate oxaloacetate 
transaminase, creatinine kinase and glucose) were unaltered by somatotropin treatment. 
However, serum urea nitrogen, creatinine, total bilirubin, conjugated bilirubin and 
glutamate-pyruvate transaminase were lower in somatotropin-treated steers but these values 
remained within the range of normal physiological concentrations for the cattle (Duncan and 
Prasse, 1986). The changes in serum urea nitrogen and cholesterol will be discussed in 
context with carcass component changes. The lower total and conjugated bilirubin 
concentrations likely reflect the larger liver since the liver is the site of clearance of these 
break-down products of haemoglobin. 
Table 2. Comparison of weight gain responses in long term trials with somatotropin or saline 
treated ruminants01 
Cattle 
steers 
steers 
heifers 1 
bull calves 
Sheep 
ewe lambs 
wether lambs 
ram lambs 
Carcass 
accretion15 
6.2 
6.6 
6.3 
7.9 
11.0 
3.7 
0 
Non-
carcass 
accretion 
29.6 
0 
11.8 
80.5° 
30.0C 
3.7 
1.4 
Dressing 
% 
-3.7 
+0.6 
0 
-3.3 
-5.8 
0 
-2 
Reference0 
Early et al., 1990b 
Enrightetal., 1990 
Sandles and Peel, 1987 
Groenewegen et aï. 1990 
Johnssonet al., 1985 
Muiretal., 1983 
Rosemberg étal . , 1989 
a
 Responses are all based upon a percentage response compared to controls. 
b
 The initial carcass weight was calculated assuming the dressing percentage of controls 
applied to both treatment groups at treatment initiation. 
cPart of this non-carcass accretion would include differences in gut fill. 
d
 Responses do not necessarily imply statistically significant responses. 
Data on the influence of somatotropin on kidney function are quite scarce. Wheatley et al. 
(1966) found reduced water intake and urinary sodium excretion during somatotropin 
treatment of sheep. Also, Parving et al. (1978) found short term treatment of humans with 
human somatotropin resulted in increased renal plasma flow and glomerular filtration rate. In 
two short term studies with humans, somatotropin had no influence on kidney size 
(Christiansen et al., 1981; Parving et al., 1978). Since somatotropin did not substantially alter 
blood chemistry profiles of treated steers, it is unlikely that homeostasis was impaired. 
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Of interest is the influence of somatotropin treatment on immune function of animals. In 
the study of Groenewegen et al. (1990), the thymus weight of the somatotropin treated calves 
was almost 2-fold greater than that of controls, which represented 12 times the relative 
increase induced in the carcass by ST. B.W. McBride, R.J. Early and R.O. Ball (unpublished) 
also recorded a 2-fold increase in the weight of mesenteric lymph nodes in somatotropin 
steers (same study as Early et al., 1990a,b,c). Interestingly, similar observations have been 
made for somatotropin-deficient animals (Berczi, 1986). In monogastric animals, Kelley 
(1989) reviewed the influence of somatotropin on lymphocytes and macrophages and 
reported that somatotropin regenerated a number of T-cell dependent immune responses in 
somatotropin deficient animals. Furthermore, somatotropin has been shown to activate the 
oxygen free radical burst in macrophages both in vivo and in vitro (Edwards et al., 1988). 
Burton et al. (1990a,b) have shown that long term somatotropin treatment of lactating dairy 
cattle increases peripheral T-lymphocyte proliferative response to mitogen and enhances the 
concentration of blood IgG2 levels. This, coupled with observations that somatotropin 
increases interleukin-1 production by macrophages (I. Politis, X. Zhao, B.W. McBride, and 
J.H. Burton, unpublished), suggests that somatotropin does not hinder immune function but 
rather, it may induce characteristics of both cell-mediated and humoral immunity. 
Table 3. Liver development in somatotropin versus saline treated ruminants. 
Cattle 
steers 
heifers 
bull calves 
Sheep 
wethers 
Liver weight 
(% gaina) 
15.4 
26° 
13 
9.6 
Fold Reference 
increase 
above carcass 
% gainb 
2.5 
1.6 
1.6 
2.6 
Early et al„ 1990b 
Sandles and Peel, 1987 
Groenewegen et al., 1990 
Muiretal., 1983 
"Percentage increase versus control. 
bAn estimate of disproportionate gain compared to the carcass development calculated as 
the percentage increase in liver weight divided by the percentage increase in carcass gain 
of rbST treated versus control animals. 
cNon-significant increase in liver weight in somatotropin-treated heifers. All other reported 
differences were statistically significant. 
Carcass Composition 
Table 4 summarises 5 published long-term somatotropin growth trials that conducted full 
carcass chemical analysis (as opposed to rib section analysis or carcass dissection). The most 
dramatic effect of somatotropin treatment on carcass composition is a reduction in carcass fat 
by 10.7-17.5% (=13.1%). The carcass composition parallels the observations that 
somatotropin treated steers have lower circulating concentrations of cholesterol (Early et al., 
1990a) which has been correlated with lower fat containing carcasses (Wheeler et al., 1987). 
As expected, protein and water content increase to the same degree (+2.3% on average). This 
agrees with many observations that somatotropin decreases serum urea nitrogen in growing 
ruminants (Early et al., 1990a; Eisemann et al., 1989a; Davis et al., 1969). Ash content 
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increases by 6.2% in response to somatotropin treatment. Chemical composition of the 
9-10-llth rib section from finishing steers showed significant linear relationships with 
recombinantly-derived bovine somatotropin (rbST) dose (Moseley et al., 1990). Percent fat 
was reduced 13.4, 21.2 and 54.4%, percent protein increased 10.6, 13.6 and 39.4% and per 
cent water increased 10.2, 15.2 and 39.9% in steers receiving 33, 100 and 200 g rbST/kg/d, 
respectively compared with control steers. As in dairy cattle (Bauman and McCutcheon, 
1986), somatotropin acts as a repartitioning agent in beef cattle. Many of the studies report 
that it took 30-45 days of somatotropin treatment before weight gains began to diverge 
between treated and control cattle. However, repartitioning of the carcass muscle and fat 
compartments probably begins immediately upon initiation of somatotropin treatment. 
Table 4. Influence of somatotropin treatment on carcass chemical composition of ruminantsa,b 
% Change 
Cattle 
steers 
heifers 
bull calves 
Sheep 
wethers 
ram lambs 
protein 
1.9 
0.5 
1.9 
4.5 
2.7 
fat 
-11.0 
-17.5 
-14.3 
-12.0 
-10.7 
ash 
7.8 
5.6 
2.6 
8.6 
water 
1.9 
0.9 
4.7 
1.8 
2.2 
Reference 
Early et al., 1990b 
Sandles and Peel, 1987 
Groenewegen et al., 1990 
Muiretal., 1983 
Rosemberg et al., 1989 
aLong term trials where values represent percent changes relative to control data. 
'Values do not necessarily imply statistically significant differences. 
The data presented in Tables 5 and 6 depict the geographic sites at which somatotropin 
acts. Early et al. (1990b) showed that somatotropin treatment of steers induced the greatest 
proportional effects on dissectible lean and fat in the hip, loin and flank area. Surprisingly, 
the greatest effect on bone was in the ribs, chuck, brisket, plate and shank (Table 5). In most 
instances, the lean:fat ratio was increased in somatotropin-treated steers (Early et al., 1990b) 
again depicting the reciprocal action of somatotropin on protein/lean vs fat components of 
the carcass. 
The geographic sites of action of somatotropin on fat development in the carcass are 
shown in Table 6. The majority of the difference in fat deposition occurred in the 
subcutaneous deposits in the hip and loin (-20.4%). Very similar observations by 
Butler-Hogg and Johnsson (1987) were reported for Iamb carcasses where the sites at which 
somatotropin acts on fat accretion were subcutaneous depots of the hindquarter. 
.The mechanisms by which somatotropin affects growth have been extensively covered by 
Hart and Johnston (1986) and McBride et al. (1988), and the subsequent actions of IGF-1 on 
growth have been discussed by Steele and Elsasser (1989). Somatotropin, per se, is lipolytic 
(Hart et al., 1984) and also increases adipose tissue sensitivity to lipolytic agents, such as 
epinephrine (McCutcheon and Bauman, 1986). Somatotropin also appears to decrease fatty 
acid synthesis in adipose tissue via an insulin antagonism (Vernon, 1982; Etherton et al., 
1987). Some of the cell associated activities mediated by IGF-1, as summarised by Steele and 
Elsasser (1989), include increased sulfate incorporation, and increased mRNA and DNA 
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synthesis in chondrocytes. Presumably, those cartilage related events help explain the 
augmented bone growth in somatotropin-treated animals. 
Table 5. Average daily gains of bone, lean and fat from steers treated with rbST0,13 
% Change 
total 
carcass 
hip and 
loin 
flank ribs, chuck 
brisket, plate 
shank 
Weight 
Bone 
Lean 
Total fat 
7.8 
16.7 
25.0 
-11.0 
3.4 
3.9 
32.8 
-15.4 
36. f 
200.f 
<1 
9.0 
18.0 
12.0 
-10.2 
aAdapted from Early, McBride & Ball, 1990b. Values are expressed relative to controls. 
b
 Values do not necessarily imply statistically significant responses. 
Table 6. Fat distribution in the carcass of steers treated with rbST0,0 
% Change 
Subcutaneous 
Intermuscular 
total 
carcass 
-14.2 
-7.9 
hip and 
loin 
-20.4 
-7.5 
flank, ribs 
chuck, brisket 
plate, shank 
-9.0 
-7.2 
aAdpated from Early, McBride and Ball, 1990b. Values are expressed relative to controls. 
b
 Values do not necessarily imply statistically significant responses. 
A total of three studies have been published to date regarding the influence of 
somatotropin treatment on protein synthesis in cattle and sheep (Table 7). The work of 
Eisemann et al. (1989) was relatively short term in nature but produced rather similar 
responses in skeletal muscle to those of Pell and Bates (1987) and Early et al., (1990c). In the 
semitendinosus muscle, a skeletal muscle that is classified as having primarily white fibres, 
somatotropin did not significantly alter the fractional rate of protein synthesis in any of the 
three studies. In contrast, somatotropin increased the fractional rate of protein synthesis in a 
variety of skeletal muscle groups dominated by red fibres (Pell and Bates, 1987; Eisemann et 
al., 1989). The numeric increase in each of the three studies was very close. In the organs 
studied, the fractional rate of protein synthesis was not altered. However, when the absolute 
rate of protein synthesis and degradation was considered (g/d; Table 8), somatotropin 
increased both protein synthesis and protein degradation in the liver (Early et al., 1990c). 
Eisemann et al. (1989) found somatotropin altered the absolute rate (g/d) of protein synthesis 
in skeletal muscle and the small intestine. The duration of somatotropin treatment and the 
stage of growth of the steers in each of these trials varied and discussion of each may help to 
clarify the different responses (Table 8). The fractional rate determinations of Early et al. 
(1990c) were made at the termination of a 112-day growth trial, during which the rate of 
growth induced by somatotropin decreased over time. The fractional rate determinations 
were applied to tissue protein density (at slaughter) to 
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Table 7. Maximal fractional synthetic rate in somatotropin-treated ruminants0 
% Change 
Skeletal 
muscle 
a white a red 
fibres'3 fibres 
heart liver kidney Small 
intestine 
Reference 
Cattle 
steers 
steers 
Sheep 
wethers 
2.2 
26.7 
6 
20.1 
28.9 
30 
8.1 
~ 
-1.4 
11.5 
-0.7 
-
— 
-1.6 
20.3 
Early et al., 1990c 
Eisemann et al., 1989 
Pell and Bates, 1987 
a
 Values are expressed relative to controls and do not necessarily imply statistically significant 
differences. 
b
 Semitendinosus muscle 
Table 8. Comparison of maximum protein synthesis rate change (PS) (g/d) and degradation 
rate (PD)(g/d) of various tissues from control vs. somatotropin-treated steers0. ,, 
Early et al. 
1990c 
Eisemann et al. 
1989 
Skeleta 
Heart 
Liver 
Kidney 
muscle 
Small intestine 
PS 
PD 
PS 
PD 
PS 
PD 
PS 
PD 
PS 
PD 
10.8 
11.6 
11.9 
11.0 
57.4 
56.4 
15.6 
15.6 
5.8 
5.8 
27.7 
19.4 
46.2 
a
 Values are expressed relative to controls. Responses do not necessarily imply statistically 
significant responses. 
calculate the absolute rate of protein synthesis (g/d). The protein degradation values were 
determined from the difference of measured accretion (over the whole growth period) and 
protein synthesis. The underlying assumption under such calculations implies that the 
fractional protein synthesis value determined at slaughter is representative of protein 
synthesis throughout growth. This clearly cannot be the case given the differential growth 
pattern exhibited by these animals. (Early et al., 1990a). The kinetic values more closely 
depict the conditions at slaughter and suggest that at the termination of growth, in animals 
aged 11-12 months, somatotropin altered the absolute rate (g/d) of protein synthesis and 
degradation by approximately the same degree (Early et al., 1990c). The study of Eisemann 
et al. (1989b) gives a snapshot in time during the early phases of growth with somatotropin 
treatment. Somatotropin significantly increased the absolute rate of protein synthesis in 
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skeletal muscle and the small intestine whereas liver growth was probably altered by 
decreased protein degradation (Eisemann et al., 1989b). The Eisemann et al. (1989b) study 
also suggests that the augmented protein synthesis exhibited in various tissues likely reflects 
transcriptional induction as opposed to translational augmentation since protein synthesis per 
g of both RNA and DNA was unaltered. This would agree with the cell-associated events 
ascribed to IGF-I as summarised by Steele and Elsasser (1989). 
The improvement in the feed:gain ratio exhibited by growing animals treated with 
somatotropin likely reflects the repartitioning of components of gain, namely, a reduction in 
fat deposition in conjunction with an increase in protein, water and ash accretion. This agrees 
with the measurement made by Groenewegen et al. (1990) who found that the efficiency of 
protein, fat and ash accretion was unaltered by somatotropin treatment. Furthermore, total 
oxygen consumption (otherwise expressed as heat production; HP) per unit of tissue weight 
was unaltered in tissues (skeletal muscle, liver, kidney, intestine and brain) of somatotropin-
treated steers (Early et al., 1990c). Therefore, the improved efficiency of gain (or retained 
energy; RE) per se must be driven by the components of gain (i.e. ME = HP + RE) which are 
altered by repartitioning caloric input into proportionally more protein within both the 
carcass and non-carcass components (Early et al., 1990b). 
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SAFETY, WELFARE AND REQUIREMENTS OF THE TARGET 
ANIMAL 
* Animal safety and welfare 
* Thermal balance 
* Nutrient requirements of pigs 
* Disease resistance 
IMPACT ON TARGET ANIMAL SESSION CONCLUSION 
SUMMARISED AND ADOPTED CONCLUSIONS 
FROM PAPERS AND DISCUSSION 
ON 
SAFETY, WELFARE AND REQUIREMENTS OF 
THE TARGET ANIMAL 
Chairman: 
R. Dantzer Institut National de la Santé et de la Recherche 
Médicale - France. 
Discussion moderator: 
N.C. Steele United States Department of Agriculture, 
Livestock and Poultry Science Institute - USA 
• As pointed out by Dr. Mussmann in his introduction to the session, the 
use of somatotropin (ST) holds much promise in animal 
production, including reduction of animal waste. However, it is 
strongly opposed to by those who favour organic, i.e. natural, farming 
and claim that administration of ST increases the level of stress farm 
animals are exposed to in intensive husbandry systems. 
• The way biotechnology can impact on welfare of farm animals was 
discussed by Prof. Ingvar Ekesbo. Although biotechnology can have a 
positive influence on health and welfare, for example when it aims at 
enhancing resistance to pathogens by genomic manipulations, it has 
potential risks for the well-being of animals. These risks must not lead 
to the ban of biotechnology but to a careful and objective 
assessment of its consequences on health and welfare. 
• The next three papers addressed whether the use of ST can interfere 
with health of target animals. Since ST increases heat production 
and decreases the amount of subcutaneous fat, it has been speculated 
that ST-treated animal might be more susceptible to thermal stress. 
This possibility was examined by Ann Becker who reported the results 
of a series of experiments carried out at the University of Missouri at 
Columbia on dairy cows and finishing hogs exposed to cold and heat 
stress. The administration of exogenous ST did not have any 
detrimental effect on performance or thermal balance of 
animals exposed to heat or to cold. In addition, the increase in 
production performance due to ST treatment was maintained in both 
extreme environments. 
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Martje Fentener van Vlissingen summarised the evidence pointing to a 
modification by pST treatment of protein requirements for maximal 
growth rate and optimal dietary protein utilization. Because of 
improved protein utilization, it does not appear necessary to 
drastically revise the animo acid composition of the diet fed to 
pST-treated animals. However, if the full benefit of the pST treatment is 
to be obtained, both protein requirements and mineral requirements 
must be better defined in view of the reduced food intake displayed by 
pST-treated animals. 
Based on à survey of the existing literature, James Roth emphasized 
the fact that ST treatment at doses anticipated to be used in food 
producing animals is not associated with any important 
detrimental effect on animal health. However, few published 
studies appear to have been specifically designed to examine the 
possible negative influence of ST on specific components of health. As 
far as immune function is concerned, the general opinion is that ST 
does not impair immune function but, on the contrary, is capable of 
enhancing a wide variety of immune responses. He presented 
data obtained in his own laboratory at Iowa State University 
suggesting that repeated injections ofpST have no negative influence 
on immunocompetence and overall health. 
In the discussion, the chairman, Robert Dantzer, pointed out that 
welfare must be dissociated from production performance and 
physical health, even if its assessment includes these two aspects. The 
concern for welfare reflects the fact that farm animals have a mental 
life the quality of which can be altered by the way they are kept. 
Objective methods have been developed to assess welfare and they need 
to be used if there is an authentic concern for welfare of farm animals 
in relation to biotechnology. Norman Steele asked for a clear separation 
between the issue of animal rights and the issue of animal welfare to 
clarify the debate about what is acceptable from the viewpoint of the 
animal. The meaning and generality of the data presented at the 
session were discussed. 
In conclusion, there is an agreement on the fact that the administration 
of ST at doses anticipated to be used in food producing animals has no 
gross detrimental effects on physical health of the target 
animal. However, safety does not imply that ST has no impact on 
animal welfare and a fortiori that biotechnology is safe in this respect. 
The public concern for animal welfare still needs to be 
responded to in an appropriate manner. 
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BIOTECHNOLOGY FOR CONTROL OF GROWTH AND 
PRODUCT QUALITY IN MEAT PRODUCTION. IMPLICATIONS 
AND ACCEPTABILITY FOR ANIMAL SAFETY, HEALTH AND 
WELFARE 
Ingvar Ekesbo 
Dept of Animal Hygiene, Vet.Med. Faculty, Swed. Univ.of Agr. Sciences, Skara, 
Sweden. 
Summary 
The definition of biotechnology in conjunction with this paper comprises a broad 
spectrum of manipulations in animals including utilization of phenomena such as 
immunological tolerance, manipulations of receptors by monoclonal antibodies or other 
means, or the injections of engineered proteins or peptides produced by recombinant DNA 
technologies. It does not include manipulations like artificial insemination, egg or embryo 
transplantations. The paper is restricted to animals kept for farming purposes. 
Developments in biotechnology may lead to genetic manipulation of farm animals that 
would not serve their health and welfare but one may also visualise manipulations that would 
improve their health and welfare. It is important that basic species-specific biological 
characteristics will not be changed through chemical or other supplies nor through genetic 
manipulation so that the single animal or its offspring can be caused suffering. 
Animals resulting from manipulated embryos and the offspring of such animals should be 
carefully monitored with respect to untoward effects of the genetic material that has been 
introduced before being allowed for farming purposes. Whenever an untoward effect is 
found, the animal and its offspring must not be allowed for farming purposes. 
The animals used at present for farming purposes should be preserved in populations of 
large enough effective size and otherwise in a way that makes it possible to again start 
breeding a variety that may not have been bred for several years, should this be judged 
desirable. 
The Council of Europe's Convention for the protection of animals kept for farming 
purposes is proposed to be completed with rules which increase the protection for such 
animals by indicating limitations in man's right to manipulate animals kept for farming 
purposes. Three such rules are proposed. 
A clear distinction must be made between experimental animals and animals kept for 
farming purposes. The proposed rules have reference to animals kept for farming purposes. 
They do not intend to stop objective, scientific research in the areas where important progress 
can be made without jeopardising the health or welfare of animals or man. It is of the utmost 
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importance, however, that financial considerations are not permitted to preclude the 
application of ethical norms. 
Keywords: Biotechnology, meat animals, safety, health, welfare. 
Introduction 
The definition of biotechnology in this connection comprises a broad spectrum of 
manipulations in animals including utilization of phenomena such as immunological 
tolerance, manipulations of receptors by monoclonal antibodies or other means, or the 
injections of engineered proteins or peptides produced by recombinant DNA technologies. It 
does not include manipulations like artificial insemination, egg or embryo transplantations. 
The paper is restricted to animals kept for farming purposes. 
In principle, DNA could be manipulated in somatic cells, gametes or very early embryos. 
The consequences for animal welfare would, as far as one can see today, be essentially the 
same whether gametes or a very early embryo or fertilized egg were manipulated (Berg, 
1989). 
Introduction of genetic material (genetic manipulation) in somatic cells is of consequence 
only for the animal or animals that carry the manipulated cells. The genes that may have been 
introduced will not be present in gametes and therefore not transferred to new generations. 
Therefore, genetic manipulation of somatic cells, although it may pose risks for the 
individual animals is of no consequence for other animals. 
Genetic manipulation of the fertilized egg or early embryo has more far-reaching 
consequences and also much greater potential with regard to commercial utilization (Berg, 
1989). 
General consequences and risks of genetic manipulation of the fertilized 
egg or early embryo 
There are several examples of successful integration of an exogenous gene into the 
genome of an early embryo, resulting in a transgenic animal (e.g. Pursel et al., 1989; Rexroad 
et al., 1989; Bondioli et al., 1990). Transmission of the integrated exogenous gene, the 
transgene, through several generations in a functioning state has been demonstrated for 
several genes, particularly in the mouse (e.g. Palmiter et al., 1982). This is true for example 
for genes coding for human haemoglobin chains which are easily distinguishable from 
mouse haemoglobin (Berg, 1989). Successful genetic manipulation of animals kept for 
farming purposes is feasible and has been performed, e.g. for pig, cattle, sheep and chicken 
(Rexroad et al , 1989; Bondioli, 1990; Chen et al., 1990). 
When a maximum of success is achieved in attempting to integrate exogenous genes into 
an early embryo, the foreign gene will be integrated in a stable manner in the genome and be 
present in most, if not all of the cells of the animals resulting from the manipulated embryo, 
and transferred to new generations in a stable and functioning state. Thus, a permanent 
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change has been made in the genetic material that may be transferred to innumerable new 
generations. The segregation of chromosomes at meiosis and the naturally occurring 
phenomenon of meiotic recombination will cause the exogenous gene to occur in a vast 
number of combinations with other genes. The consequences of having the exogenous gene 
in a countless number of combinations with other genes several generations in the future do 
not seem to be entirely predictable (Berg, 1989). Therefore, the risk of untoward effects must 
be carefully evaluated in enough generations (Pursel et al., 1989). Animals who, during such 
scientific evaluations have exhibited any untoward consequences, or their offspring, must 
not be allowed to use for farming purposes. 
The introduction of an exogenous gene or gene construct into an early embryo may cause 
integration into an area of the genome where the foreign DNA may lead to untoward 
consequences (Pinkert, 1987; Rexroad and Pursel, 1988; Pursel et al., 1989). Illegitimate 
integration of exogenous genetic material is apparently not just a theoretical possibility 
(Berg, 1989). It makes it necessary to monitor carefully the animals resulting from the 
manipulated embryos, and their offspring. Such monitoring would be advisable even when 
methods for safe and legitimate integration into the genome become available. 
Such uncertainties and risks seem to be the main reasons why genetic manipulation of the 
human embryo, even for the purpose of curing recessive disease, is rejected b ƒ most medical 
geneticists and other experts in human medicine. Concern with respect to activation of 
oncogenes has been voiced also in connection with manipulation of somatic cells and this is 
probably the main reason why the attitude of several influential research bodies is that 
therapy in man by genetic manipulation of somatic cells should only be attempted in very 
serious disorders where no other effective treatment seems available (Berg, 1989). 
In view of the particular responsibility that man must have for animals that for thousands 
of years have been kept for farming purposes, it could be argued that one should be almost as 
restrictive with respect to genetic manipulation of such animals as one with respect to man. 
However, there is also argued that animals are farmed because of their usefulness to man and 
because man has literally been dependant on them for survival (Berg, 1989). There is no 
realistic possibility for man to stop keeping animals for farming purposes. Accordingly, it 
seems permissible and reasonable that even some genetic changes may be made to improve 
the usefulness of these animals. There must, however, be strict animal health and welfare 
limits to quality and quantity of genetic changes that man may cause in animals kept for 
farming purposes. Therefore ethical rules are necessary. 
Improvement of production efficiency in farm animals by genetic 
manipulation. Problems and possibilities 
Some years ago, great publicity was given to experiments in which several copies of the 
gene for the human growth hormone had been introduced into mouse embryos (Palmiter et 
al., 1982). This caused the mice that were later born to develop into "giant mice", showing 
that animals with greater body mass may be produced by integrating several copies of the 
gene for growth hormone into animal embryos. The question is if such methods could be 
used in farm animals for increasing production efficiency. 
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When considering animals for meat production changes in quantity or quality of muscle 
tissues may and may not have untoward effects. Such effects could put the animal's welfare 
in jeopardy. Thus, it may not be taken for granted that a significant increase in body mass and 
particularly muscle mass will be accompanied by adequate changes in the body's support 
system, the skeleton. It would be more than just a hypothetical danger that legs and spine will 
not be adequate to support a greatly increased body weight. This could cause malfunction of 
the skeleton, give rise to locomotor and other behavioural aberrations resulting in injuries, 
diseases and suffering to the animal. 
In the same way increases in milk production by genetic manipulation could lead to risks 
for increased udder injuries and diseases. Already now udder injuries and diseases have been 
increasing parallel with the increase in milk production. Considerable efforts are made to 
prevent these disease problems by genetic measures for preventing such diseases e.g. by 
improving udder forms (Lindhé, 1986; Lindhé et al., 1990). Therefore, genetic manipulation 
in order to increase milk yield must take udder anatomy into consideration. This does not 
mean that other risks should not be taken into account, e.g. tendency to get mastitis. 
Likewise improvement of the yield or quality of wool by genetic manipulation of sheep 
embryos may include risks. The wish to change wool quantity or quality would have to be 
weighed against risks for e.g. negative effects on the thermoregulation of the animal. 
In all the above cases the danger of illegitime integration into the genome would exist. 
Therefore it would be necessary to carefully control the manipulated animals and their 
offspring with respect to incidence of different disorders before such animals will be allowed 
to be kept for farming purposes. 
There are apparently detrimental effects on the health of transgenic animals (Pinkert, 
1987; Rexroad and Pursel, 1988; Pursel et al., 1989, 1990). The problems seem to be 
anatomical as well as physiological. Altered endocrine profiles, metabolism changes, altered 
thermoregulation and libido, lowered fertility, increased susceptibility against infections, 
lameness, arthritis are reported (e.g. Pinkert et al., 1990). 
Three requisites must be fulfilled before any animal, which is a result of genetic 
manipulation has to be allowed to be used for farming purposes, i.e. is allowed to leave the 
limited sphere of research and enter the sphere of animal husbandry. The first is that it must 
have been fully proved that exact that manipulation, which was intended to be done, really 
has occurred, is stable and that no integration has occurred into any other area of the genome 
than where it was meant to be located. The second requisite is that there must be secure and 
reliable screening methods available which make it possible to find and define each 
manipulated animal in a population, e.g. in a commercial cattle, swine, sheep or poultry herd. 
This is necessary for making follow up control investigations on manipulated animals which 
are released into commercial herds. The third is that it should have been shown that the 
manipulated genome when introduced in a breeding system which permits recombination of 
genes does not result in detrimental effects in the next generations. 
Attempts to improve the economical yield of keeping animals for farming purposes by 
genetic manipulation would most likely comprise a very large number of animals, perhaps 
most animals of a given species in a region. Great gains could result if such experiments were 
successful and had no untoward effects. It could, however, be economically disastrous if an 
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unforeseen negative effect or purported negative effect scared people away from using either 
the meat or the milk from manipulated animals. Even an unfounded rumour that the 
manipulated animals frequently had virus-induced tumours could cause serious problems 
(Berg, 1989). Thus, it complicates the issue that not only must the real risks be considered, 
but also the effect of purported risks and claims made by eloquent groups who want 
essentially all DNA work to be forbidden. 
However, neither the assumed or supposed risks nor the scare without a basis in reality 
should be permitted to stop objective, scientific research in the areas where important 
progress can be made without jeopardising the welfare of animals or man. It is of the utmost 
importance, however, that financial considerations are not permitted to preclude the 
application of ethical norms. 
Need for preserving existing genetic material 
We are apparently just in the beginning of a period of intense research and research 
progress in genetic manipulations. In such a situation it is of great importance that 
agreements are arrived at that animals used at present for farming purposes should be 
preserved. And they must be preserved in populations of large enough effective size and 
otherwise in a way that makes it possible to again start breeding a variety that may not have 
been bred for several years, should this be judged desirable. 
Improvement of the animal health by genetic manipulations 
Several diseases in man and in animals have environmental, nutritional as well as genetic 
components to their etiology. An outstanding example in man is early atherosclerosis where 
it seems clear that in most cases, unfavourable environmental or nutritional conditions cause 
disease preferentially in those who are genetically predisposed (Berg, 1989). Another 
example is malignant hyperthermia, an inherited skeletal muscle disorder characterised by a 
profoundly accelerated muscle metabolism, contractures, hyperthermia, and tachycardia, and 
which is one of the main causes of death due to anaesthesia. This disorder is very similar to 
porcine malignant hyperthermia (Ludvigsen, 1957; MacLennan et al., 1990; McCarthy et al., 
1990). 
The chromosomal localisation for more and more hereditary diseases may be possible to 
map (Lalley et al., 1989) Animals may differ genetically with respect to resistance towards 
negative environmental.infectious or nutritional influences and it would be useful if 
integration of exogenous genes or gene constructs into the genome of susceptible breeds 
would improve their health and welfare as well as reducing the need to give animals 
antibiotics. There are examples of by genetic manipulation obtained enhanced resistance 
against e.g. infection by Salmonella strains in mice (Edwards et al., 1989) or leucosis virus 
in poultry (Salter & Crittenden, 1989). 
Any genetic manipulation aimed at improving the animals' health would seem highly 
commendable. However, each time the desired changes might be obtained by traditional 
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breeding experiments, this procedure would be preferable because it does not carry with it 
the risks of uncertainties caused by integrating exogenous genes or gene constructs into the 
genome. 
Administration of substances for stimulation of growth or other production 
traits. 
A review of the literature indicates a great variation in responses of farm animals to 
substances given in order to stimulate growth or other production traits (e.g. Machlin, 1972; 
Bryan et al., 1987; Eppard et al., 1987; Evock, 1988; Kievits, 1988; Kronfeld, 1988; Kelley, 
1989; Evock, 1990; Dau & Bane, 1990) Such substances are engineered proteins or peptides 
produced by recombinant DNA technologies. 
This great biological variation indicates risks if the handling and utilization of these 
substances are not taking into account all factors in the animal and its environment which 
may interfere with the substance administered. 
However, potential adverse effects of substances like bST, pST etc. and methods to 
prevent such effects seem to have received much less attention than the efficacy of such 
substances (Kronfeld, 1988; Sejrsen et al., 1989). 
One problem is apparently that there until now have been lack of funds for research 
regarding the risks. More economical resources have for natural reasons been allocated to 
investigate the possibilities to utilize such substances. The problem is that the risk research 
must be mainly supported by public funds whereas the possibility research is mainly 
commercially supported. 
New technique and new methods were introduced in the farm animal environment from 
the 1950's. At the same time a great increase in the animal production took place (Ekesbo, 
1973, 1990). As a not foreseen result there were changes in the disease panoramas for the 
species concerned. The change was characterised by an increase of what are often called man 
made diseases, environmentally evoked diseases or production diseases (Ekesbo, 1976). The 
main reasons for these increases of diseases were changes in relationship between the animal 
and its environment, it may be mastitis, ketosis or hoof problems in cattle (Ekesbo, 1966; 
Bakken, 1981), MMA (Bäckström, 1973; Bogner et al., 1978) pleuritis, pneumonia or PSE 
in pigs (Rülcker, 1968; Lindqvist, 1974), feather, skin or claw damages or salpingitis in egg 
laying hens (Svedberg, 1976, 1988). In order to prevent these diseases it has been necessary 
to perform epidemiological studies showing the associations between these diseases and risk 
factors in the environment, in the management and in the animals (e.g. Ekesbo, 1966; 
Bakken, 1981; Bendixen et al., 1988a, 1988b). The associations do not explain the causal 
connections. In order to explain causal connections epidemiological methods must be 
combined with microbiological, physiological, clinical, ethological and other methods (e.g. 
Algers 1982a, 1882b; Ekesbo, 1979; Jensen, 1983; Algers et al., 1984; Plym Forshell, 1986; 
Plym Forshell & Ekesbo, 1990). However, when the causal risk factors are defined, it was 
and is possible to change the environment and adapt it to the animals (Ekesbo, 1988b). In the 
meantime, however, much animal suffering and economical losses for farmers have 
occurred. 
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In order to prevent such animal health and welfare and economical problems, Sweden and 
Switzerland have introduced a system for testing new technique from animal health and 
welfare point of view. The Netherlands are to do the same from 1993 (Steiger, 1990). 
It seems even more reasonable to introduce a mandatory testing system from animal 
health and welfare point of view for substances aiming at stimulation of growth or other 
production traits. In this connection it is necessary to remind of the fact that quite contrary to 
what sometimes is claimed (e.g. McClary et al., 1990) production level is no measure of 
animal health (Ekesbo, 1966, 1988b) but must be taken into consideration when evaluating 
the effect of different factors on the animals health and welfare (Ekesbo, 1988b).No 
substance should be allowed to be purchased for use on farm animals before independent 
scientific research has shown that the substance has no detrimental effects on stress, immune 
competence, disease resistance, reproductive performance and other for the health and 
welfare essential biological functions of the species in question. Assessment of the 
substances could be conducted like it is done in many countries for drugs combined with 
methods for testing impact on animal health and welfare by environmental factors (Ekesbo, 
1984, 1988a, 1988b;). If such precautions will not be taken we might come into principally 
similar problems as when during the 1950's antibiotics were introduced. In the beginning 
these substances were used with very little restrictions not only for disease treatment but also 
for disease prevention and also as so called growth promotors in feed for animals which all 
created resistance problems. Introduction and use of somatotropin in commercial herds 
before all health and welfare aspects are fundamentally scientifically investigated and 
defined could create and cause other problems than the ones mentioned for the antibiotics but 
not less difficult to solve. 
A proposal for ethical rules indicating limitations in man's right to 
manipulate animals kept for farming purposes 
Between 1971 and 1975 a European Convention for the protection of animals kept for 
farming purposes was elaborated by an ad hoc committee comprising delegations from most 
of the member states of the Council of Europe. The convention was opened for signature in 
1976 and came into force on the 10th September 1978. Until 1990,17 countries have ratified 
the convention. They are: Belgium, Cyprus, Denmark, Finland, France, Germany, Iceland, 
Ireland, Italy, Greece, Luxembourg, The Netherlands, Norway, Portugal, Spain, Sweden, 
Switzerland and the United Kingdom. Also EEC as an overnational organisation has ratified 
the convention. 
According to article 8 - 13 in the convention (Council of Europe, 1976) a Standing 
Committee in the Council of Europe shall elaborate detailed rules for animal husbandry from 
animal welfare point of view for each species. This Committee was established in 1979. 
These rules have to be transformed into binding rules via law or otherwise administrative 
praxis in those member countries which have ratified the convention within 12 months after 
the adoption of the committee. EEC must adapt its common rules according to at least the 
standards of the rules adopted by the Standing Committee. Until now such rules are 
elaborated and adopted by the Committee for cattle, swine, egg laying hens and fur animals. 
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In the Standing Committee all nations which have ratified the Convention have full 
membership, are "contracting parties". Ratification in most countries means a decision by the 
national parliament. Countries which have not ratified the Convention have status as 
observers. Several countries have observer status, e.g. Austria, Finland, Turkey, and others. 
Outside Europe Australia, U.S.A. and Thailand have observer status. The committee also 
have delegations with status as "experts". To this group belongs the European Confederation 
of Agriculture, the World Society for the protection of Animals, The Society for Veterinary 
Ethology and The Federation of Veterinarians of the EEC. 
The convention comprises 18 articles. In its first article it says "This Convention shall 
apply to the keeping, care and housing of animals, and in particular to animals in modern 
intensive stock-farming system. For the purposes of this Convention "animals" shall mean 
animals bred or kept for the production of food, wool, skin or fur or for other farming 
purposes..". Article 3 says "Animals shall be housed and provided with food, water and care 
in a manner which - having regard to their species and to their degree of development, 
adaption and domestication - is appropriate to their physiological and ethological needs in 
accordance with established experience and scientific knowledge." 
There are different opinions among experts in law if the convention is covering the current 
situation of biotechnology in animal husbandry. It seems therefore advisable to include in the 
convention some basic rules that indicate limitations in man's right to manipulate animals 
kept for farming purposes. Such rules shall not limit the possibility to do research in 
biotechnology. 
The rules regarding biotechnology could be formulated according to the following: 
* Animals produced as a result of genetic manipulation procedures shall not be kept for farming 
purposes unless it through scientific evidence is shown that their health and welfare will not 
suffer. 
* No substance shall be administered to an animal kept for farming purposes unless it has been 
demonstrated by scientific studies of animal welfare that the ultimate effect of the substances 
is not detrimental to the health and welfare of the animal. 
* The animals used at present for farming purposes should be preserved in a way that makes it 
possible to again start breeding a variety that may not have been bred for several years, should 
this be judged desirable. 
Final comments 
Man has always had ethical rules, written or unwritten, for animal husbandry. In our time 
with rapid scientific achievements international agreement on ethical rules are necessary for 
the protection of the animals, the farmers and the society. 
Besides the references given this paper is partly based on discussions which during the 
latest years have taken place in The Council of Europe's Standing Committee for Farm 
Animal Welfare. 
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EFFECT OF EXOGENOUS SOMATOTROPINS ON THERMAL 
BALANCE AND CONSEQUENCES IN THERMALLY STRESSFUL 
ENVIRONMENTS 
B. A. Becker, H. D. Johnson, C. D. Knight, R. J. Collier, W. Manalu and C. A. Baile 
USDA-Agricultural Research Service and Animal Sciences Department, 
University of Missouri, Columbia, MO, USA and Monsanto Co., St. Louis, MO, USA 
Summary 
Recombinantly-produced somatotropins, both bovine and porcine, have been shown to 
alter energy metabolism and body composition. Such alterations have been hypothesized to 
make the animals more vulnerable to environmental extremes. A series of experiments has 
been conducted with lactating dairy cows and finishing hogs under simulated cycling hot 
and cold environmental conditions at the Samuel Brody Climatology Laboratory to test this 
hypothesis. In both lactating dairy cows and finishing hogs treated with somatotropin, 
changes in heat production were demonstrated; however, the animals were able to cope with 
such changes and no thermal imbalance occurred. Physiological changes occurred due to 
both environment and hormone treatments, yet no interaction between these two effects 
interfered with the benefits of somatotropin treatment obtained in performance in both 
species under hot and cold conditions. 
Keywords: somatotropin, lactating cows, finishing hogs, thermal environment, thermal balance, 
performance 
Introduction 
Various researchers have hypothesized that when exposed to thermally stressful 
environments animals treated with somatotropin would not be able to maintain enhanced 
performance found under thermoneutral conditions (Curtis, 1989; Verstegen et al., 1989). 
Further, it was projected that the physiological alterations associated with somatotropin 
supplementations would override the thermoregulatory mechanisms associated with 
additional thermal load, and that the effects of thermal stress would be detrimental to 
performance. Accompanying this effect on performance would be a reduction in quantity 
and quality of product and efficiency of energy utilization. To test this hypothesis, a series of 
studies was conducted to determine the effect of somatotropins, both bovine and porcine, on 
the performance, physiology and thermal balance of lactating dairy cows and finishing hogs 
in hot and cold environments. 
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Studies conducted at the Samuel Brody Climatology Laboratory 
In a series of experiments conducted at the Samuel Brody Climatology Laboratory 
located in the Animal Science Research Center at the University of Missouri, Columbia, 
MO, USA, lactating dairy cows and finishing hogs were exposed to various cold and hot 
environmental conditions that typify extreme winter and summer conditions in Missouri 
(Table 1). In the cold experiment for lactating dairy cows, an addition of wind and water 
spray was applied during the light cycle of the photoperiod to increase the effective cold 
temperature. 
Table 1. Environmental conditions simulating extreme summer and winter weather in Missouri. 
Animals 
Dairy 
Swine 
Condition 
Hot 
Cold 
TN1 
Hot 
Cold 
TN' 
'TN = thermoneutral 
Temperature 
(C) 
24 to 35 
-5 to 5 
18 to 22 
27 to 35 
5 to 15 
18 to 25 
Relative humidity 
(%) 
55 to 65 
50 to 55 
50 to 64 
40 to 70 
50 to 70 
50 to 55 
Lactating dairy cows in hot and cold environments 
Two groups of 12 lactating Holstein cows, 90 to 150 days postpartum with milk 
production of 25 kg/d or greater, were used in each of the hot and cold studies. Half were 
injected i.m. daily with 25 mg of bovine somatotropin (rbST; methionyl bovine 
somatotropin, Monsanto Company, St. Louis, MO) while the remaining cows were injected 
with a control vehicle of sodium bicarbonate. Cows were maintained in respective 
environments for 10 days. Cows were milked twice daily, and milk yield and milk 
composition were determined. Diet available ad libitum consisted of corn silage and alfalfa 
hay. To assess thermal balance, heat production and evaporative heat loss were measured by 
indirect calorimetry and capsule method, respectively. Gross energy intake and milk energy 
secretion were also measured. Rectal temperatures and respiratory rates were measured and 
used as indicators of thermal balance. 
Finishing hogs in a hot environment 
Forty crossbred finishing hogs (20 barrows and 20 gilts) averaging 77 kg were used in 
the first heat study. Hogs were individually penned and fed an 18% corn soybean ration ad 
libitum. Six percent soy oil was added to increase the energy content to 3.6 Mcal/kg. Half of 
the hogs were administered a single 100 mg porcine somatotropin (rpST) prolonged release 
implant (Monsanto Company, St. Louis, MO, USA) on day 0, while the remaining hogs 
(control) received a placebo implant. Body weights and feed consumption were determined 
weekly. Rectal temperatures and respiratory rates were taken to assess thermal status. When 
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final weight was reached, hogs were slaughtered and carcass measurements and quality were 
determined. 
A second study was conducted in a hot environment using 24 barrows. Protocol, diet and 
rpST administration were similar to the first study. In addition, heat production was 
determined by indirect calorimetry. When hogs were slaughtered, one-half of the carcass and 
empty viscera was processed for body composition determination by chemical proximate 
analyses. Heat production was calculated from the metabolizable energy intake and the 
energy retained in the fat and protein of the carcass. 
Finishing hogs in a cold environment 
Twenty-four finishing hogs were exposed to a cold environment using similar protocol 
and implant procedure as in the previous two studies. Besides difference in environment, the 
only other change in protocol was the diet. Hogs were fed a 12% crude protein corn-soybean 
meal diet with energy content of 3.28 Mcal/kg. 
Performance of animals supplemented with somatotropins in hot 
environments 
Lactating dairy cows and finishing hogs under hot environments responded to the 
administration of somatotropins with enhanced performances over the nontreated animals 
(Table 2). For lactating dairy cows, milk yield increased 31 and 35% over the yields of 
nontreated cows in the thermoneutral and hot environments, respectively. The response to 
somatotropin treatment was slightly greater in the hot environment than in the thermoneutral 
environment. Milk fat increased due to rbST, but rbST or environment did not affect milk 
protein. Cows treated with rbST had greater feed intake and efficiency regardless of 
environment. 
Table 2. Performance of lactating dairy cows and finishing hogs in hot environments. 
Parameter 
Dairy cows 
Feed intake (kg/d) 
Milk yield (kg/d) 
Milk fat (%) 
Milk protein (%) 
Hogs 
Sain (kg/d) 
Feed intake (kg/d) 
Feed/gain ratio 
Final weight (kg) 
TN 
Control 
30.8 
24.9 
2.6 
2.9 
1.0 
3.4 
3.4 
106.5 
bST/pST 
36.6 
32.6 
2.9 
3.0 
1.0 
3.0 
2.9 
107.9 
Control 
24.1 
20.9 
2.6 
2.8 
.8 
2.7 
3.5 
101.3 
Hot 
bST/pST 
28.8 
28.3 
3.0 
3.0 
.8 
2.4 
3.0 
102.3 
Effect' 
B.H 
B.H 
B 
H 
P.H 
P 
H 
'B or P » significant effects of bST or pST (P<.01) 
1H = significant effects of the hot environment (P<.01 ) 
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Somatotropin treatment increased the efficiency of energy utilization for milk production 
such that milk energy secreted required less energy (5.7, 4.6, 5.2, and 4.1 Meal feed/Meal 
milk for TN-control, TN-rbST, H-control, and H-rbST, respectively). No significant change 
in body weights was found due to rbST treatment. 
Finishing hogs in the hot environment gained at a slower rate than those in the 
thermoneutral environment. Both rpST-treated and control hogs gained at similar rates in 
respective environments. However, rpST-treated hogs ate 13% less feed than the control 
hogs in both environments, resulting in 15% greater feed efficiency. 
Finishing hogs in the hot environment had 4% lower final body weight; however, no 
differences in hot carcass weight or dressing percentage were found due to environment or 
rpST. Hogs in the hot environment treated with rpST had reduced 10th rib backfat and leaf 
fat, with the interaction of environment and hormone having a further significant reduction 
only on leaf fat (P<.02). Loin muscle size and scoring for muscle, colour, marbling and 
firmness were not affected either by environment or rpST. 
Performance of animals supplemented with somatotropins in cold 
environments 
Lactating dairy cows and finishing hogs responded to the administration of somatotropins 
while in cold environments (Table 3). Overall milk yield was higher in rbST-treated cows in 
both thermoneutral and cold environments. Cows treated with rbST produced 16.3 and 
17.4% more milk than the control cows in thermoneutral and cold conditions, respectively. 
These increases were considerably less than those found in the heat study. Milk fat was not 
affected by environment or rbST, while milk protein was slightly increased by the cold 
environment. 
Table 3. Milk yield and composition of lactating dairy cows and 
performance of finishing hogs in cold environments. 
Parameter 
Dairy cows 
Feed intake 
Milk yield (kg/d) 
Milk fat (%) 
Milk protein (%) 
Hogs 
Gain (kg/d) 
Feed intake (kg/d) 
Feed/gain ratio 
Final weight (kg) 
Control 
36.2 
28.8 
37 
3.0 
.8 
3.6 
4.2 
113.1 
TN 
bST/pST 
39.1 
33.5 
3.7 
3.1 
1.0 
3.5 
3.5 
115.7 
Contro 
36.1 
31.0 
3.5 
3.4 
.7 
3.9 
5.3 
108.2 
Cold 
bST/pST 
38.4 
36.4 
3.4 
3.5 
7 
3.4 
4,6 
111.0 
Effect1 
B,C 
C 
C 
P.C 
C 
B or P = significant effects of bST or pST (P<.01) 
C = significant effects of the cold environments (P<.01) 
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Finishing hogs in the cold environment gained at a slower rate than those in the 
thermoneutral environment, and this rate was not affected by rpST. Control and rpST-treated 
hogs overall had similar feed intakes; however, rpST-treated hogs had lower feed intake 
during the first several weeks. Feed intake was lower in rpST hogs in the cold, but again, the 
differences tended to diminish in the last weeks of the study. Despite the increased feed 
intakes in the rpST hogs toward the end of the study, feed/gain ratios were 16 and 13% 
greater than those in control hogs in thermoneutral and cold conditions, respectively. 
Finishing hogs in the cold environment had a 5% lower final body weight and tended to 
have lower hot carcass weights than those in thermoneutral environments. There were no 
differences in dressing percentage, 10th rib back fat, loin muscle size, leaf fat and muscle 
scoring due to either rpST or cold conditions. 
Assessment of thermal balance of animals supplemented 
somatotropins in hot environments 
with 
Based on rectal temperatures and respiratory rates, which are indices of thermal stress, 
lactating cows and finishing hogs treated with somatotropins did not experience significant 
thermal imbalance. In the hot environments, rectal temperatures and respiratory rates were 
significantly increased; however, no significant increase in these parameters was due to 
either rbST or rpST. Lactating cows treated with rbST had greater energy intake than 
controls; this increase occurred in hot environments where energy intake decreased in all 
cows (Table 4). Energy output in the milk, accompanying the increase in milk yield, was 
greater in rbST-treated cows in both thermoneutral and hot conditions, although overall milk 
energy was less in the hot environment. Cows treated with rbST had higher heat production 
but also had a higher evaporative heat loss. This higher evaporative heat 
Table 4. Assessment of thermal balance of lactating dairy cows in a hot environment. 
TN Hot 
Parameter Control bST/pST Control bST/pST Effect' 
Rectal temperature 
(C) 
Respiratory rate 
(/min) 
Energy intake 
(Mcal/d) 
Heat production 
(Mcal/d) 
Milk energy 
(Mcal/d) 
TEVHL2 
(Mcal/d) 
38.2 
43.2 
83.9 
30.6 
15.0 
9.2 
38.5 
51.2 
94.6 
36.4 
21.0 
12.4 
39.7 
86.3 
65.0 
30.3 
12.7 
13.7 
39.9 
91.4 
76.1 
38.0 
18.8 
17.1 
H 
H 
B,H 
B 
B,H 
B,H 
1B = significant effects of bST (P<. 01 ) 
'H = significant effects of hot environment (P<.01) 
2TEVHL = total evaporative skin and respiratory heat loss 
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loss explains how the rbST-treated cows, despite higher heat production, can maintain 
thermal balance regardless of environment and sustain efficient milk production. 
Heat production of finishing hogs treated with rpST was similar when measured by 
indirect calorimetry during the peak of the cycled temperatures (data not shown), and when 
estimated from proximate analysis of the carcass in both thermoneutral and hot 
environments (Table 5). In contrast to the dairy cow, energy intake in the finishing hog was 
significantly reduced by rpST. When heat production was compared to metabolized energy 
intake, the rpST-treated hogs had a higher percentage of metabolizable energy being 
converted to heat in both environments. Energy retained was a combination protein and fat 
deposition. Protein deposition rates were increased significantly, but fat deposition rates 
were decreased even more dramatically. As a result, total energy retained was less in the 
rpST-treated hog (Figure 1). 
Table 5. Assessment of thermal balance of finishing hogs in a hot environment. 
Parameter 
Rectal temperature 
(C) 
Respiratory rate 
(/min) 
MetabolizableT9450 
energy intake 
(kcal/d) 
Energy retained 
as protein 
(kcal/d) 
Energy retained 
as fat (kcal/d) 
Heat production 
(kcal/d) 
Moisture in 
carcass (g/d) 
Control 
39.3 
36.9 
8365 
331 
4425 
4693 
145 
TN 
bST/pST 
39.5 
39.7 
7875 
599 
3175 
4591 
322 
Control 
39.6 
69.1 
5950 
385 
3015 
4474 
169 
Hot 
bST/pST 
39.7 
77.3 
P.H 
481 
1249 
4220 
301 
Effect' 
H 
H 
P 
P,H 
P 
'P= significant effects of pST(P<.01) 
'H = significant effects of hot environment (P<01) 
Despite the increased percentage of metabolizable energy converted to heat production, 
there were no significant differences in rectal temperatures and respiratory rates due to rpST. 
The rpST-treated hogs contained significantly greater amounts of moisture, which acts as a 
"heat sink" that could greatly enhance the ability of rpST-treated hogs to tolerate the 
additional heat load. The mechanism by which that much water was retained in rpST-treated 
hogs is not known, but we are pursuing the hypothesis that sodium retention may increase in 
rpST-treated hogs. 
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I I Protein deposition 
E223 Fat deposition 
• • Heat production 
C pST 
COLD 
Figure 1. Assessment of heat production and fat and protein deposition relative to metabolizable 
energy intake in pST-treated finishing hogs under hot and cold environmental conditions. 
A clearer assessment of thermal balance based on percent of metabolizable energy intake 
is shown in Figure 1 and suggests thatrpST-treated hogs partition energy differently than the 
control hogs. These data support the concept that rpST is a "partitioning agent" as 
demonstrated by nutritional and physiological data. 
Assessment of thermal balance 
somatotropins in cold environments 
of animals supplemented with 
As in the hot environments, lactating cows treated with somatotropins did not have 
significantly different rectal temperatures and respiratory rates from the control cows in 
either the thermoneutral or cold environment. Finishing hogs treated with rpST had slightly 
higher rectal temperatures in both thermoneutral and cold environments; however, no 
significant differences in respiratory rates were found. Neither of the species treated with 
somatotropins demonstrated greater susceptibility to cold than the nontreated animals. In 
both species in the cold environments, rectal temperatures and respiratory rates were lower 
(Tables 6 and 7). Energy intake in the lactating dairy cows was slightly, but not significantly, 
higher than in the hot study. Energy output in the milk and heat production were higher in 
the rbST-treated cows than in the control cows in both thermoneutral and cold environments 
(Table 6). Total evaporative heat loss was higher in the rbST-treated cows in thermoneutral 
but lower than the control cows in the cold. Overall, cold reduced total evaporative heat loss 
by over 50% and appears to be a major method of heat conservation by dairy cows in cold 
environments. 
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38.5 
52.7 
96.8 
31.9 
21.0 
11.7 
38.6 
57.4 
104.6 
37.6 
23.9 
12.5 
38.3 
27.3 
100.5 
32.1 
20.3 
5.1 
38.3 
24.9 
105.3 
35.2 
25.4 
4.8 
C 
C 
B 
B 
B,C 
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Table 6. Assessment of thermal balance in lactating dairy cows in a cold environment. 
TN Cold 
Parameter Control bST/pST Control bST/pST Effect1 
Rectal temperature 
(C) 
Respiratory rate 
(/min) 
Energy intake 
(Mcal/d) 
Heat production 
(Mcal/d) 
Milk energy 
(Mcal/d) 
TEVHL2 
(Mcal/d) 
1B = significant effects of bST (P<.01 ) 
'C = significant effects of cold environment (P<.01) 
2TEVHL = total evaporative skin and respiratory heat loss 
Finishing hogs treated with rpST in the cold environment had higher net heat production 
than hogs in thermoneutral (10.3 versus 7.2 kcal/kg.75/hr) when measured by indirect 
calorimetry at the end of the trough of the cycle. Net heat production as estimated by 
proximate analyses was not different (Table 7). The higher heat production at the trough of 
the cold cycle in the live animal suggests that, in the cold, hogs may let heat production and 
rectal temperature rise and fall with the daily temperature-humidity cycle while maintaining 
a constant overall heat production. In contrast to the studies in the hot environment, feed 
intake, regardless of treatment or environment, was not significantly different. If heat 
production and energy retained were evaluated as a percentage of metabolizable energy 
intake, heat production was only slightly higher in the rpST-treated hog in either 
environment (Figure 1); however, energy retained as protein was greater in rpST-treated 
hogs but to a lesser degree in hogs in the cold environment. Energy retained as fat was less 
in the rpST-treated hog than in the control but was similar among the treated hogs in each 
environment. This lower fat content was hypothesized to make the rpST-treated hog more 
vulnerable to cold stress (Curtis, 1989); however, the slight increase in heat production 
appeared to enable the rpST-treated hog in a cold environment to maintain homeothermy. 
Rectal temperatures were slightly higher (P<.04) in treated than in control hogs in both 
thermoneutral and cold environments. As was observed in rpST-treated hogs in the hot 
environment, rpST-treated hogs in the cold environment had significantly higher moisture 
content; however, this amount was reduced in the cold animal. The implication of this in 
cold tolerance is not understood. 
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Table 7. Assessment of thermal balance of finishing hogs in a cold environment. 
Parameter 
Rectal temperature 
(C) 
Respiratory rate 
(/min) 
Metabolizable 
energy intake 
(kcal/d) 
Energy retained as 
protein (kcal/d) 
Energy retained as 
fat (kcal/d) 
Heat production 
(kcal/d) 
Moisture in carcass 
Control 
39.3 
36.6 
11775 
671 
3335 
7769 
362 
TN 
1 bST/pST 
39.6 
37.0 
11546 
759 
2779 
8007 
476 
Cold 
Control 
39.1 
27.9 
12890 
361 
4020 
8509 
187 
bST/pST 
39.2 
25.9 
11086 
520 
2200 
8366 
331 
Effect1 
P.C 
C 
P.C 
p 
P.C 
]P = significant effects of pST (P<.01) 
]C = significant effect due to cold environment (P<.01) 
Conclusion 
The administration of exogenous somatotropins does not have a detrimental effect on 
performance or thermal balance in lactating dairy cows and finishing hogs in hot or cold 
environments. Somatotropins increased the efficiency of production in both species; and this 
efficiency was maintained, although not always to as great an extent, in hot and cold 
environments. Energy utilization appeared to be different in animals treated with 
somatotropins, but this difference was not detrimental to thermal balance. In both hot and 
cold environments, somatotropin-treated animals maintained homeothermy, with no costly 
loss in performance and production. 
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Summary 
Growth rate and composition are modified when pST is administered to growing pigs. 
The accretion rate of protein and minerals is enhanced, and heat production is increased. 
Nutrient requirements cannot be simply predicted by the application of factorial models, as 
derived from nutrient requirement estimations in normal, untreated animals. Utilization of 
nutrients appears to be more efficient in pST-treated pigs. In addition, proçein accretion 
seems to depend less on dietary energy supply, leading to an enhanced protein accretion rate 
combined with a low fat accretion rate. Since feed intake is commonly reduced by 
pST-administration, diet composition needs to be adapted in order to provide the required 
daily nutrient supply. It is concluded that the effect of pST is expressed in combination with 
all practical feeds or feeding strategies. If the full benefit of the pST-effect is to be obtained, 
dietary nutrients must meet animal requirements. Animal wastes, and thus environmental 
pollution by excess of animal wastes, can be reduced if the diet is carefully balanced and if 
supply of individual amino acids and minerals is not excessive. 
Keywords: pST, nutrient requirements, pigs. 
Introduction 
When pST (either pituitary-derived or produced by recombinant-DNA technology, Evock 
et al., 1988) is administered to growing pigs, nutrient utilisation is influenced in various 
ways. Protein metabolism is enhanced, resulting in an increased net protein accretion rate. 
The growth of body adipose tissues, as this occurs normally, is diminished distinctly. Energy 
retention is decreased and heat production is enhanced. Retention of dietary minerals is 
increased. Voluntary feed intake is decreased, so that under ad libitum feeding conditions 
composition of growth is influenced rather than average daily gain, which is clearly 
enhanced under restricted feeding conditions. Most effects of pST-administration are clearly 
dose-dependent, but expression of pST-effects is also related to genotype, age and gender of 
the animal. Since practical application of pST will probably concentrate on finishing pigs 
(50 - 100 kg, possibly extended to a slaughter weight of 140 kg) the assessment of nutrient 
requirements during this growth period should receive most attention. The effects of pST are 
generally expressed on any practical feed and feeding schedule. Nutrient requirements, 
defined as nutrient supply corresponding to maximal production or efficiency, do not 
necessarily correspond to an economic optimum, when the cost of feed is considered. 
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Although endocrine mechanisms and target tissue effects are being progressively elucidated, 
these will not be covered in this paper. 
Requirements of dietary protein and amino acids 
The estimation of protein/amino acid requirements provides specific difficulties. Many of 
the published studies were not designed to estimate requirements of protein or specific 
amino acids. Maximum response can be truncated because other essential nutrients are 
limiting the growth and protein accretion. A positive control group, exceeding requirements, 
should be included in order to define the maximum response level in each study. Specifically 
this second issue imposes problems in the interpretation of data on pST-treated pigs, because 
the maximum response level to increasing of dietary protein supply has not been fully 
established, yet. Several authors have explored the dose-response relationship between 
dietary protein and protein accretion in pST-treated pigs. Campbell et al. (1989b, 1990) fed 
increasing levels of dietary protein (8.3 - 23.8%) at a fixed feeding level of 1.85 
kg/animal/day to fast growing boars (30 to 60 kg). Protein deposition in terms of maximum 
protein accretion plateau at 173 g/d in pST-treated animals and was obtained with 383 g of 
dietary protein per day. Protein accretion in placebo-treated control animals was 144 g/d as 
a maximum, that was reached when feeding 326 g of dietary protein per day. At low dietary 
protein levels, the expression of pST-effect was inhibited, as was also reported by Caperna 
et al. (1989b), Beermann et al. (1990), Darden et al. (1990), and Smith et al. (1989). 
The required dietary content of lysine (the first limiting essential amino acid in practical 
diets) was estimated to be 1.00 - 1.16 % by Andres & Cline (1989) (Table 1). Higher 
inclusion levels were compensated for by decreased voluntary feed intake by the animals 
tested (crossbred barrows, 55 - 82 kg). Boyd et al. (1989), using a factorial approach and 
adopted normal efficiency parameters, calculated a lysine requirement of 35.8 g/d in 
pST-treated pigs with a protein accretion of 260-280 g/d. Untreated pigs, retaining 130 g of 
protein per day, would need 20.5 g of lysine per day. Campbell et al. (1989d) also reported 
on lysine requirements in pST-treated pigs growing from 60 to 90 kg. For control animals, 
20.1 g of lysine per day (0.88 % of the diet) resulted in a maximal protein accretion of 118 
g protein, whereas pST-treated animals required 28.4 g of lysine (1.31 % of the diet) for a 
maximal daily protein accretion rate of 216 g. Goodband et al. (1990), testing dietary lysine 
contents of 0.6 -1.4 % in a 17.8 % crude protein diet, observed optimalisation of daily gain 
at 1.19 % lysine and minimal feed conversion efficiency at 0.98 % lysine in the diet of 
finishing swine. Krick et al. (1990) estimated requirement of dietary lysine to be 23 to 24 g/d 
in pST-treated growing pigs (20 - 60 kg). Krick et al. (1990a) considered lysine requirements 
for pST-treated genetically fast-growing pigs (55 -100 kg) to be marginally increased by 4.5 
g/d over placebo-treated controls (requiring 31 g of lysine per day). 
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Table 1. Summary of dietary lysine requirements in pST-treated finishing pigs. 
estimated lysine req. 
growth control/ reference 
phase treated 
(kg-kg) % of diet g/d 
55-82 
50-100 
60-90 
60-100 
55-100 
T 
C 
c 
T 
T 
C 
T 
1.00-1.16 
0.88 
1.31 
1.00-1.20 
23.3-31.7 
20.5 
35.8' 
20.1 
28.4 
25-30 
31.0 
35.5 
Andres & 
Cline 1989 
Boyd, 
1989 
Campbell, 
1989d 
Goodband 
1990 
Krick, 
1990a 
* calculated with standard efficiency coefficient 
Dietary lysine also affects bone mineralization and conformation in pST-treated animals 
(Goodband et al., 1989). When dietary lysine concentration was stepwise increased from 0.8 
to 1.4 % of lysine, bone ash decreased linearly, while bone wall thickness increased. 
The required balance between dietary amino acids is probably not changed essentially by 
pST-treatment. Caperna et al. (1990) studied collagen accretion in barrows, treated with 
rpST during 42 days from 30 kg live weight onwards. They found the increase in collagen 
deposition to be proportional to the increase in protein deposition. Modification of the 
composition of protein accretion might influence the pattern of amino acids required, but so 
far no indications were found for such a shift to occur. 
Contrary to untreated animals, protein deposition in pST-treated animals hardly responds 
to increased energy content of the diet (Campbell et al., 1988, Verstegen & Van der Hel, 
1989; Van Weerden & Verstegen, 1989; Van Weerden et al., 1989). Protein and energy 
requirements seem to be dissociated in pST-treated finishing pigs, if dietary protein is not 
rather low, as was the case in the study by Azain et al. (1989). Young pigs, treated with pST, 
however, seem to respond to increase of dietary energy intake by increasing protein 
accretion (Campbell et al., 1988, 1989b). 
According to the referred studies, protein accretion was enhanced more than dietary 
requirements in pST-treated animals, indicating enhanced dietary protein utilization (Table 
2.). The explanation for improved dietary protein utilization in pST-treated pigs can be 
related to digestibility of dietary protein or by modification of amino acid/protein 
metabolism. Various N balance studies in pST-treated animals did not reveal any changes in 
protein digestibility, as estimated from faecal excretion of nitrogen (Verstegen & Van der 
Hel, 1989; Verstegen et al., 1990; Van Weerden & Verstegen, 1989; Van Weerden et al., 
1990). Gonzales & Easter (1990), however, detected inconsistent, but statistically 
significant changes in apparent ileal (prececal) digestibility of some amino acids in two out 
of four feedstuffs tested in pST-treated pigs, as compared to placebo-treated controls. 
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Tabel 2. Utilization of dietary lysine by finishing pigs, as deduced from an N balance study in 
pigs with an initial weight of 70 kg and fed diets with different protein contents (Van Weerden, 
unpublished results). 
Abbreviations: CP = dietary crude protein content (%); T = total; ID = ileal digestible; 
Plac = placebo-treated, pST = pST-treated. 
CP 
16 
18 
20 
DAILY 
LYSINE 
INTAKE 
T 
18.4 
20.7 
22.5 
(g) 
ID 
14.7 
16.6 
18.0 
DAILY 
LYSINE 
ACCRETION (g) 
Plac 
9.5 
10.5 
10.8 
pST 
11.8 
13.2 
14.3 
LYSINE ACCRETION EFFIC. (%) 
TOTAL 
Plac 
52 
49 
48 
ILEAL DIGEST. 
pST 
64 
64 
64 
Plac pST 
65 80 
61 80 
60 80 
Data on improved dietary protein/amino acid utilisation, blood urea nitrogen and urinary 
nitrogen excretion provide evidence that the effect of pST is mediated by dramatic 
improvement of efficiency of utilisation (Andres & Cline, 1989; Boyd et al., 1989; 
Campbell et al, 1989b; Cäperna et al., 1989b; Etherton et al., 1986; Krick et al., 1990b; 
Verstegen & Van der Hei, 1989; Verstegen et al., 1990; Van Weerden, 1989). Protein 
requirements for maintenance (inevitable metabolic losses due to skin wear, hair loss, 
enzyme secretion, etc.) are estimated to be approximately 1 g/kg ' , or 10 % of an 
appropriate diet. There are no studies that demonstrate modification of maintenance 
requirements for protein by pST-treatment, but even a substantial change in maintenance 
requirements would be minor in comparison to other changes in protein metabolism (Figure 
1.). The utilisation of dietary protein for growth is greatly modified: control animals use 
about 60% of the ileal digestible protein for protein accretion. From data such as those 
presented in Table 2 it is deduced that pST-treated animals utilise at least 75% of the ileal 
digestible protein for protein accretion (Figure 1.). 
300 . 
PROTEIN ACCRETION 
g/d 
M M' 
ILEAL DIGESTIBLE PROTEIN INTAKE 
500 
g/d 
Figure 1. Modelled relationship between ileal digestible protein Intake (g/d) and protein accretion 
rate (g/d) in pST-treated 60 kg pigs as compared to untreated animals. The slope of each curve 
represents efficiency of dietary protein utilization for protein accretion (0.75 and 0.60, 
respectively). The horizontal maximum of each curve represents the maximum protein 
accretion rate for each type of animal. Maintenance requirement for dietary protein (M = 1 g 
of protein per kg of metabolic weight) Is the Intersection with the horizontal axis. M' represents 
a putative enhanced (doubled) maintenance requirement in pST-treated animals. 
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Heat production and dietary energy requirements 
According to Van der Hel et al. (1990), Noblet & Dubois (1990), Verstegen & Van der Hel 
(1989) and Verstegen et al. (1990), heat production is increased by approximately 10 % in 
pST-treated animals, when environmental temperatures are within the thermoneutral zone. 
This increased heat production is not due to changes in activity of the animals, but to 
modification of basal metabolic rate. The thermoneutral zone may be narrowed, when pST 
is administered. Knight et al. (1990) did not detect such an increase in heat production in 
pigs, implanted with a pST prolonged release implant, but the reduction of backfat was 
marginal as well. When subjected to heat stress, pST-implanted animals reduced voluntary 
feed intake, but maintained their improved feed conversion efficiency (Knight et al., 1989 & 
1990). Stoner et al. (1989) reported feed/gain to be unchanged in heat-stressed pST-treated 
animals, whereas control animals had a higher feed/gain ratio at high environmental 
temperatures. 
Dietary energy retention is reduced by pST administration, but positively correlated with 
dietary energy intake (Campbell et al., 1988, 1989a, 1989b, 1990). The enhanced heat 
production seems to have an impact on dietary energy requirements. Efficiency of energy 
deposition is reduced, due to increased maintenance requirement and/or altered coefficients 
for partial efficiency of dietary energy for protein or fat deposition, respectively (Verstegen 
& Van der Hel, 1989). 
Control of the fat content of the animal product may be a matter of concern, because 
product appreciation may be negatively influenced if the pork is too lean. Intramuscular and 
intermuscular fat of the carcass can hardly be manipulated by energy content of the diet. It 
may be controlled by adapting pST-dosage (Etherton,et al. 1987; McLaren et al., 1990), by 
increasing slaughter weight (Kanis et al., 1990a), or the withdrawal period after 
pST-treatment (Campbell et al., 1989c). Adaptation of feed intake by pST-treated animals 
partially compensates for higher dietary energy level (Kanis et al., 1990b). When 
pST-treated pigs are force-fed, the excess feed intake is deposited as an increased carcass fat 
percentage (Newcomb et al., 1990). 
Requirement for minerals and trace elements 
Mineral deposition is influenced by pST-administration as a result of increasing skeletal 
weight rather than mineral content of the bone tissue (Bark et al., 1990; Caperna et al., 
1989a; Evock et al., 1988; Goodband et al., 1989). This is reflected by increased calcium and 
phosphate balance (Van Weerden & Verstegen, 1988). This increase of bone mass, or 
increased mineral retention may be as much as 20 % (Table 3.). According to Goodband et 
al. (1989) pST treatment may alter biomechanical properties of some bones that become 
more flexible. Absorption of dietary minerals may be enhanced by pST-treatment, as is 
suggested by the study of Goff et al. (1988). 
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Table 3. Change in skeletal mass or Calcium/phosphorus retention resulting from pST 
administration to pigs. 
LIVE 
WEIGHT 
55 kg 
115 kg 
90 kg 
PARAMETER ASSESSED 
weight of femur 
without marrow 
carcass bone 
Ca balance 
P balance 
pST-TREATED 
(% over controL) 
5-12 
19 
19 
18 
SOURCE 
Capema 
1989 
Bark 
1990 
Van 
Weerden 
1989 
In several studies, using rather high dosages of pST, mobility problems were encountered 
(Bryan et al., 1987; Evock et al., 1988; Fentener van Vlissingen et al., 1990, data not 
shown). McLaren et al. (1990) detected no differences in mean soundness score, but gave no 
frequency distribution of classes of locomotion problems. Evock et al. (1988) identified the 
problems as disturbed (epiphysial) growth plate development, or osteochondrosis. It seems, 
that these problems cannot be simply related to pST, because they were not reported in all 
papers presenting experiments with rather high doses of pST (exceeding 4 mg/animal/day). 
Housing conditions and dietary mineral supply may play a role. 
Dietary mineral utilization is enhanced, due to the pST-induced increased mineral 
deposition. Dietary calcium and phosphorus requirements may be increased proportionally. 
This increase may be less than proportional, if economy of mineral utilisation is improved 
concomitantly. Caperna et al. (1989a) found Zn-metabolism to be unchanged in pST-treated 
pigs. Hepatic Fe and Cu concentrations, but not total contents, were diminished by 
pST-treatment. Serum Fe concentration and haematocrit were less than in placebo-treated 
controls. Summarizing these findings, dietary Ca, P and Fe may require special attention 
when formulating diets for pST-treated pigs. 
Feed intake and feed composition 
Voluntary feed intake is clearly diminished by pST administration and has been 
compensated for by various feeding strategies in different trials. This phenomenon is a 
serious problem in designing proper experiments to estimate dietary requirements. Daily 
intake of nutrients, for the assessment of utilization, can be estimated afterwards. 
When feed is restricted, somatotropin has a marked influence on growth rate, whereas the 
effect is more marked on the composition of gain in ad libitum-fed animals (Fentener van 
Vlissingen et al., 1990). Voluntary feed intake by pST-treated pigs is clearly influenced by 
dietary protein and energy contents (Andres & Cline, 1989; Azain et al., 1989; Jewell & 
Knight, 1990;) and heat stress as well (Knight et al, 1990). 
Because voluntary feed intake is reduced by pST-treatment the composition of the feed 
should be adapted to provide the daily absolute intake of essential nutrients, such as essential 
amino acids and minerals. 
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It is remarkable, that genetic improvement for growth rate and feed efficiency is reflected 
in both elevated basal plasma growth hormone concentrations (Arbona et al., 1988) and 
reduction of feed intake (Kanis, 1990). Kanis recommends to incorporate feed intake 
capacity in index selection. When.pST-treated pigs were kept to reach a slaughter weight of 
140 kg, a paradoxical effect occurred: voluntary feed intake was enhanced by pST in 
animals growing from 100 to 140 kg (Kanis et al., 1990a). This was accompanied by 
continued enhanced growth rate, feed conversion efficiency, and lean parts percentage. 
The use of pST and breeding strategies 
Breeds of pigs respond differentially to pST-treatment. In general, it can be stated that 
slow growing, rather fat breeds respond more strongly that fast growing, lean breeds (Bark 
et al., 1989,1990; Kanis et al., 1990a; McLaughlin et al., 1989; Noblet & Dubois, 1990; Yen 
et al., 1990). 
When the breeding strategies are aimed to increase lean tissue accretion to a high rate, the 
dissociation between energy and protein requirements, as observed in pST-treated animals, 
may not occur. Also, it will, most likely, not be possible to limit the expression of high 
growth rate to the category of slaughter pigs. Animal reproduction may become less 
productive concomitantly. 
PST-treated animals could provide good models for the determination of nutrient 
requirements of future breeds and hybrids, provided that appropriate partial coefficients of 
nutrient utilization for protein, fat and mineral accretion can be applied. At the moment, 
nutrition research tends to lag behind the genetic improvement of commercial slaughter 
pigs. This frequently results in studies, where the positive control animals do not reach their 
maximal attainable growth rate. Nutrient requirements research is also very elaborate, 
resulting in a time lag between the experimental work and the publication of nutrients 
requirement recommendations. PST, as an experimental tool, may help to overcome these 
limitations by providing adapted models for nutrient requirements calculations. 
Conclusions and definition of priorities in nutrition research in 
pST-treated pigs 
Protein requirements for maximal growth rate and optimal dietary protein utilization are 
modified by pST-treatment. Protein accretion rate seems to be enhanced more than dietary 
protein requirements, due to improved dietary protein utilization. It is not anticipated that 
the dietary amino acid composition needs to be drastically adapted for pST-treated animals. 
Although heat production is enhanced by pST, dietary energy supply is not limiting for 
growth, as is the case in untreated animals. Efficiency of utilization of dietary energy for 
protein and/or fat accretion may be reduced. 
Mineral requirements may be increased by pST-treatment. 
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Voluntary feed intake is reduced by pST-treatment, and diet composition needs to be 
adapted accordingly, in order to provide the required absolute daily intake of nutrients. 
Breeding programs will not result in future breeds and hybrids, that mimic pST-treated 
animals. PST-treated animals may, however, be used to anticipate nutrient requirements of 
modern slaughter pigs. 
For optimalisation of the diet for pST-treated pigs, both protein requirements and mineral 
requirements must be better defined. If pST is considered a powerful tool to minimize the 
potential of environmental pollution by animal wastes, amino acid supply and mineral 
supply should be meeting, but not exceeding, animal requirements, and feed composition 
should be carefully balanced. 
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INFLUENCE OF SOMATOTROPIN ON DISEASE RESISTANCE IN 
FOOD PRODUCING ANIMALS 
B. Lawler Goff and J. A. Roth 
Iowa State University, Ames, Iowa, U.S.A. 
Summary 
An important part of ensuring target animal safety is examining the influence of 
somatotropin on immune function and disease resistance. The consensus from several field 
trials and production studies has been that somatotropin treatment, at doses anticipated to be 
used in food-producing animals, is not associated with detrimental effects on animal health. 
Higher dosages used experimentally have had detrimental effects on the health of treated 
animals. Few studies have been specifically designed to examine the influence of 
somatotropin on variables of immune function in food-producing animals. Extensive studies 
on immune function have been conducted in laboratory rodents, and more limited studies 
have examined humans, dogs, dairy cattle and pigs. From these data it appears that 
somatotropin treatment, at doses anticipated to be used in food-producing animals, is not 
associated with clinically relevant detrimental effects on immune function. In fact, several 
lines of evidence, reviewed in this paper, indicate an immuno-enhancing effect of 
somatotropin. Other investigators have suggested that animals treated with somatotropin 
have physiological demands and health effects similar to untreated, high-producing animals. 
In summary, with attention to management considerations (including diet and environment) 
it appears that somatotropin treatment will probably not impact target animal safety in a 
detrimental manner. 
Keywords: disease resistance, growth hormone, immune function, immunotoxicology, somatotropin 
Introduction 
Biotechnological advances in the control of growth and product quality, especially the use 
of somatotropin, present unprecedented potentials for enhancing meat and milk production. 
The effect of somatotropin on production variables, metabolism, and nutritional 
requirements are well documented, and have been discussed in detail by previous speakers in 
this session. This paper addresses the influence of somatotropin on immune function and 
disease resistance in food-producing animals. This topic is of interest because of concerns for 
animal welfare and because demonstration of target animal safety is required for approval of 
new animal drugs. 
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Summary of the literature 
The literature regarding the use of somatotropin in food-producing animals dates back to 
the 1940's (review: Peel & Bauman, 1987). A summary of these studies is complicated by 
many variables including species examined, breed, gender, the formulation and purity of 
somatotropin used, as well as the dosage administered, duration of treatment, and other 
differences in experimental design (Etherton, 1989). 
Few studies have been specifically designed to evaluate the influence of somatotropin on 
immune function and disease resistance in food-producing animals (Holden, 1990). Much 
data on this topic is available from studies performed in vitro and in vivo in humans, 
laboratory rodents, and non-food-producing domestic animals (such as dogs). In addition, 
there are several reports of the use of somatotropin to improve production in cattle and swine 
in which no adverse health effects were noted. By considering the data available from these 
studies, along with limited data from immunologic studies, we are able to reach some 
consensus on the overall effect of somatotropin on immune function and disease resistance. 
Observations on the influence of somatotropin on animal health from studies 
designed to evaluate somatotropin influence on production 
Most studies of somatotropin in food-producing animals address production and efficacy 
questions. Generalized health assessments are mentioned in some reports, but often the 
methods used for these assessments are not described. While these studies do not address 
specific effects on immune function, it has been suggested that the productivity of animals 
treated with somatotropin may be the best indication of adverse effects on animal health 
(McClary et al., 1990). Several reports specifically state that somatotropin treatment at 
dosages used to improve production is not associated with any adverse health effects 
(Table 1). 
Data reflecting a negative impact on animal health have been reported only from studies 
where relatively high doses of somatotropin were administered, or where transgenic animals 
producing high levels of somatotropin were studied. Machlin (1972) reported liver and 
kidney degeneration, haemorrhage of the stomach, edema, arthritis, and increased mortality 
in pigs receiving 0.22 or 1.10 mg/kg/day of pituitary derived porcine somatotropin (but not 
those receiving 0.13 mg/kg/day). Evock et al. (1988) noted mobility problems in pigs treated 
with 140 ug/kg/day (but not those given 35 or 70 ug/kg/day) of pituitary derived porcine 
somatotropin. Transgenic pigs producing bovine (Pursel et al., 1989) or rat (Ebert et al., 
1988) somatotropin at up to 50 times the normal serum concentration showed a variety of 
detrimental health effects including gastric ulcers, arthritis/joint pathology, cardiomegaly, 
dermatitis, renal disease, and testicular atrophy. Reviews of the literature on the use of bovine 
somatotropin (bST) in cattle note similar relationships between relatively high doses of bST 
(up to five times the anticipated recommended dose) and health 
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Table 1. Reports stating that somatotropin treatment at dosages anticipated to be used in 
food-producing animals is not associated with adverse health effects. 
Type of growth hormone Reference 
porcine 
bovine 
pST 
rpST" 
bST+ 
rbST+' 
Chung et al., 1985 
Evocketal., 1988 
Machlin, 1972 
Meisinger, 1987 
Fronketal., 1983 
Baumanetal., 1985 
Eppardetal., 1987 
McClaryetal., 1990 
Nytesetal., 1990 
Oldenbroek & Garssen. 1990 
Whitakeretal., 1988 
native (pituitary derived) porcine somatotropin 
recombinant porcine somatotropin 
+
 native (pituitary derived) bovine somatotropin 
++
 recombinant bovine somatotropin 
effects such as increased incidence of mastitis, digestive disorders, and lameness 
(Gibbons, 1990; McClary et al., 1990). 
Studies designed to evaluate somatotropin influence on immune function and 
disease resistance 
Somatotropin has been shown to affect several variables of immune function including: 
increasing the size of the thymus gland and enhancing the secretion of the thymic hormone 
thymulin (facteur thymique serique) in aging animals and humans; enhancing the number 
and function of lymphoid cells (lymphocytes and natural killer cells); and enhancing the 
respiratory burst of macrophages and neutrophils (reviews: Kelley & Edwards, 1989; Kelley, 
1989; Dau & Bane, 1990). These observations were mostly in non-food-producing animals 
(i.e. laboratory rodents, dogs, humans). 
More recent data, from experiments performed in food-producing animals, support the 
hypothesis of somatotropin as an immuno-enhancer. In agreement with previous reports in 
other species, phagocyte respiratory burst function is enhanced after somatotropin treatment 
in pigs and cows. Native porcine somatotropin (pST) applied to granulocytes at 
supraphysiologic concentrations (100 ng/ml) in vitro was associated with enhanced 
superoxide anion production (Fu et al., 1990). Such an in vitro effect was not observed with 
bovine neutrophils (Heyneman & Burvenich, 1989). However, in vivo treatment with rbST 
was associated with enhanced superoxide production by bovine neutrophils when 
administered in one dose of 500 mg (Massart-Leen et al., 1990b) and by day 5 of a 10 day 
treatment period at 40 mg/day (Heyneman & Burvenich, 1989). Bovine somatotropin 
treatment of dairy cows (10.3 or 20.6 mg rbST/day for 34 weeks) was associated with an 
increased response to the mitogen concanavalin A, detectable 6 weeks after the initiation of 
treatment (Burton et al., 1990; Burton et al, 1991). The basal rate of proliferation was not 
affected by bST, indicating that it is not itself mitogenic in this assay (Burton et al, 1991). 
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Treatment with bovine somatotropin resulted in an increase in the total white blood cell count 
with associated increase in neutrophil and lymphocyte numbers (one dose of 500 mg: 
Massart-Leen et al., 1990a). 
Not all reports note immuno-enhancement associated with somatotropin treatment. 
Treatment with bovine somatotropin (25 mg/d for 28 d) was not associated with significant 
changes in lymphocyte blastogenic response to phytohemagglutinin or pokeweed mitogen, 
interleukin-2 production, or neutrophil ingestion of Staphylococcus aureus (Estrada et al., 
1990). Bovine somatotropin treatment of heat-stressed dairy cows (25 mg/day for 29 days, 
heat stress from day 10 to 24 of bST treatment) was not associated with any significant 
change in total blood leukocyte count or percentages of B lymphocytes or CD2, CD4, or 
CD8 positive cells (Elvinger et al., 1990). 
Early reports speculated that somatotropin may cause increased production of 
glucocorticoids. This could result in suppression of immune function and predisposition to 
infectious disease. Bryan et al., (1989) noted enlargement of adrenal glands in pigs treated 
with somatotropin, and suggested that this could be associated with an increase in the 
production and secretion of glucocorticoids, although they did not assay those hormones. 
Sillence & Etherton (1989) found that even though adrenal size increased after somatotropin 
treatment, no increase was detected in serum Cortisol or in Cortisol output from adrenal tissue 
in vitro. 
From the literature it is clear that somatotropin has an effect on immune function and that 
this effect, in general, appears to be immuno-enhancing (Kelley & Edwards, 1989; Dau & 
Bane, 1990). However, as Kelley concluded in his presentation at this meeting two years ago, 
"it is not yet known whether the kinds of cells that are affected or whether the magnitude of 
effects that are caused by growth-promoting compounds are sufficient to modify animal 
health in either a positive or negative manner" (Kelley & Edwards, 1989). It is difficult to 
design studies to definitively answer questions regarding the effect of somatotropin on 
disease resistance. Challenge studies with infectious agents are a useful model, but often are 
not reliable or easily replicated. In addition, different infectious agents may be controlled by 
different host defense mechanisms. Therefore, results obtained with one infectious agent 
may not apply to other infectious agents. 
Bacterial challenge studies have been conducted in rats treated with pST. When 
challenged with an infectious dose of Salmonella typhimurium, rats treated with pST (500 
ug/d) had enhanced survival rates over a 14 day period, as compared to controls (Edwards et 
al., 1989). Somatotropin (pST) treatment of alveolar macrophages in vitro, or those from rats 
treated in vivo with pST, had an enhanced ability to kill Pasteurella multocida (Edwards et 
al., 1990). 
There are several reports of studies on somatotropin treatment of dairy cows in which the 
incidence and severity of clinical mastitis was monitored. Recent reviews of the literature 
note that most research has shown no effect of bST treatment on clinical mastitis. A few 
studies have shown an increase in the incidence of clinical mastitis, although only at 
relatively high doses or in groups where pretreatment disease incidence was higher (Eppard 
et al., 1989; Dau & Bane, 1990). Similarly, subclinical mastitis (as evaluated by somatic cell 
count in the milk) was reported by some to be unaffected, and by others to be increased or 
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even decreased by bST treatment. The duration of clinical infections was not affected 
(Eppard et al., 1989). 
Treatment with 40 mg/d of bovine somatotropin for 10 days was associated with a 14 to 
27% decrease in production losses in cows challenged with E. coli by intramammary 
infusion (Burvenich et al., 1989). These authors also reported that somatotropin had a 
beneficial effect on restoring the blood-milk barrier, which is damaged during acute coliform 
mastitis, with complete restoration of milk composition occurring in the infected glands of 
bST treated cows only (Burvenich et al., 1989). 
Some liken the physiological status of the cow treated with somatotropin to that of an 
untreated cow that is genetically a high milk producer. Dietary adjustments must be made for 
such genetically superior cows, and they often are observed to have an increased incidence 
of clinical mastitis. 
Collectively, these data indicate that somatotropin generally is immuno-enhancing and 
that there are no obvious health effects of somatotropin treatment in the field. Results of 
immunotoxicology studies should provide more information on how somatotropin affects a 
wide range of immune function variables. However, such studies, required by the Food and 
Drug Administration in the United States as part of the investigation into the effect of 
somatotropin on target animal safety, have yet to be published in their entirety (Gibbons, 
1990). 
An immunotoxicology study was performed under Good Laboratory Practice (GLP) 
conditions in our laboratory at Iowa State University, in collaboration with Pitman-Moore, 
Inc. (Goff et al., 1991). The study was designed to determine the effect of recombinant 
porcine somatotropin (rpST) on a variety of immune function variables including neutrophil 
and lymphocyte function, antibody response, haematological variables, and antibody titre to 
common pathogens in finishing pigs. Investigating a range of variables involved in both 
native and acquired immunity improved the chances of detecting any potential negative 
effects on immune function, which could potentially affect the incidence or severity of 
disease in pST-treated pigs. 
The 25 gilts and 25 barrows used in this study were of mixed breed and weighed 35 to 50 
kg at the beginning of the 14 day acclimation period. No prophylactic antibiotic treatment 
was administered during the test period. The animals were fed ad libitum a pig growing 
ration containing 16% crude protein, which met or exceeded the NRC nutritional 
requirements for finishing pigs. 
The five experimental groups included: a) 5 mg rpST in 1 ml of vehicle (lx), b) 15 mg 
rpST in 3 ml of vehicle (3x), c) 25 mg rpST in 5 ml of vehicle (5x), d) 3 ml of vehicle, and 
e) 3 ml of 0.01 M phosphate buffered saline, pH 7.2 (PBS). The treatment period lasted for 
57 days. 
There was no consistent significant (P 0.05) effect of rpST treatment on the gross 
pathology of the pigs, histopathology of the immune system organs, total and differential 
white blood cell counts, lymphocyte blastogenic response to mitogens, or the neutrophil 
functions of Chemotaxis, bacterial ingestion, reduction of cytochrome C, iodination, and 
antibody-dependent cell-mediated cytotoxicity. There was no observed gender by treatment 
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interaction, and no effect of the vehicle alone. Those variables that were significantly 
affected by rpST treatment included a decreased haemoglobin and packed red blood cell 
volume (at all three rpST dosages), a decrease in plasma protein level (at 25 mg dose), an 
increase in neutrophil random migration (at all three rpST dosages), and a decrease in IgG 
antibody response to tetanus toxoid at 15 days (but not 21 or 28 days) post-immunization (in 
a dose dependent manner). Additionally, rpST treatment was associated with a decreased rate 
of body weight gain (at 15 mg dose), increased spleen weight (at 5 mg dose), increased liver 
and kidney weights (at all three dosage levels), and an increased incidence of renal tubular 
cytoplasmic vacuolation. There were no observed differences in the overall health of the pigs 
due to rpST treatment, based on clinical observations as well as determination of antibody 
titre to, and isolation of, common swine pathogens. Therefore, there was no evidence that the 
observed influence of rpST treatment on immune function was clinically relevant. 
Management considerations 
Many factors related to diet (protein, calorie, vitamin, and mineral content, as well as level 
of nutrition) and environment (temperature, crowding, and other various stressors) have been 
shown to affect immune function (reviews: Kelley, 1985; Dantzer & Kelley, 1989; Roth & 
Kaeberle, 1982). Immunosuppression appears to play an important role in the pathogenesis 
of many of the economically important diseases associated with intensive animal production 
(review: Roth & Goff, 1989). Although it appears that somatotropin treatment does not have 
detrimental effects on animal health, pigs and cattle treated with somatotropin may have 
altered dietary and environmental (temperature) requirements (Elvinger et al., 1990 ; Bos, 
1989; Zoa-Mboe et al., 1989). Management practices will need to be optimized in 
conjunction with somatotropin treatment to ensure the health and welfare of the treated 
animals, and to enable maximum benefit of the growth enhancer effect. Some authors feel 
that somatotropin use is adaptable within current management systems (Bos, 1989). Peel & 
Bauman (1987) note that management of cows receiving bST need not differ much from that 
of cows producing high quantities of milk due to genetic superiority. 
Conclusion 
The examination of the influence of somatotropin on immune function and disease 
resistance is an important part of ensuring target animal safety. Few studies have specifically 
examined the influence of somatotropin on variables of immune function in food-producing 
animals. However, the results of extensive studies in laboratory rodents, and more limited 
studies in humans, dogs, dairy cattle and pigs indicate that, at anticipated recommended 
dosages, somatotropin is not associated with clinically relevant detrimental effects on 
immune function. The results of several field trials and production studies concur with this 
conclusion. Somatotropin treated animals may have altered physiological demands and 
health effects, which are similar to those of untreated, high producing animals. With attention 
to management considerations, including diet and environment, somatotropin treatment will 
probably not impact target animal safety in a detrimental manner. 
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• The pharmacokinetic profile of endogenously produced and 
exogenously applied growth hormone (rbSTand rpST respectively) has 
been clearly established. Endogenous growth hormone is secreted in 
an episodic manner and concentrations in blood following treatment 
stay within the range marked by the episodic pulses. The few data on 
tissue levels of bST conform with the pharmacokinetic characteristics 
of this compound; they are significantly below blood levels and no 
differences between treated and control animals were observed. In the 
case ofrbST and the doses recommended at present, residues could not 
be measured in milk. 
• Growth hormone at least in part exerts its activity through 
insulin-like growth factor I (IGF I). IGF I levels in blood increase 
following treatment. Absolute levels, however, hardly exceed the 
physiological range, though the total output - as determined by the 
AUC • may be significantly increased. This is also reflected by the 
concentrations measurable in tissues and, to a lesser extent, the 
concentrations measurable in milk. 
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The development of animal (veterinary) drugs containing proteins 
as the active ingredient has forced regulatory agencies to develop 
new concepts along their licensing procedures. As opposed to other 
chemical entities, the chemical nature, biological activity, and potential 
for harmful residues are better understood for protein products; 
important points to be considered are the oral activity, the stability of 
the product in relation to the various food-processing procedures, e.g. 
pasteurization, and the likelihood of absorption of the intact molecule 
or peptidic fragments from the intestinal tract. 
Though still under development, the present stage of procedural 
achievements allowed the United States FDA to develop a final 
opinion on the human safety aspects of rbST; in reference to the 
respective article in Science (Science 249, 875-884, 1990) it was clearly 
stated that the use ofrbST in cattle must be considered "safe". Based on 
similar evaluational procedures also the CVMP of the EEC concluded 
that the use of bST is safe in respect to human health. As became 
obvious during the discussion, the same assumptions must be made for 
rpST. In a wider sense the question of human safety also relates to the 
quality of the resulting product and likely direct or indirect effects of 
treatment on the environment. 
High levels of saturated fatty acids in human diet and elevated 
blood cholesterol levels as a consequence have been viewed as a prime 
nutrition related problem. However, it must be realized that 
consumption of fat only in part influences blood-cholesterol levels 
(effect 20 - 30%), obesity aggregates this effect. Furthermore, also the 
saturated fatty acids stearic-acid has now be shown to belong to the 
group of non-cholesterol enhancers. On the other hand the trans-form 
ofoleic-acid is now considered as a cholesterol enhancer. 
rpST-treated pigs have significantly reduced body stores of fat, also 
intramuscular fat-content, is decreased. However cholesterol 
concentrations are not changed. In fatty tissue itself lipid 
concentrations are decreased. 
Thus the nutritional value of muscular tissue from rpST-treated 
pigs is improved, though the overall effect on human nutrition is 
certainly relative in view of the food array available and the number 
of factors influencing blood cholesterol levels in the human. 
However the reduction of the body stores of fat (reduced trimming!) not 
only improves carcass quality and pig production but also decreases 
animal waste and hence nitrogen output. Similarly beneficial effects 
in respect to reducing the environmental burden from animal 
production are seen following the use ofrbST. 
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HORMONES OF THE SOMATOTROPIN AXIS : OCCURRENCE 
OF RESIDUES IN EDIBLE TISSUES 
J.-D. Puyt, 
Department of Pharmacy & Toxicology, National Veterinary School, C.P. 3013, 
Nantes cedex 03, France 
Summary 
From a pharmacokinetic point of view, residue levels of growth hormone (bST, pST) 
and/or insulin-like growth factors (IGF-I mainly), are not significantly different in treated 
and untreated animals (i.e.ranging from 1 to 10 ng/ml in milk, from 2 to 10 ng/g in muscle 
and from 10 to 30 ng/g in liver). Though most of the data has been obtained with rbST, 
similar results appear with rpST. Administration of rbst does not induce any significant 
change in IGF concentrations in milk (about 5 to 20 ng/ml), in muscle (about 75 to 450 ng/g) 
or in liver (about 75 to 200 ng/g). From a pharmacodynamic point of view, rbST or rpST are 
devoid of any biological activity in humans. From a toxicological point of view, 
toxicological data leads to estimation of a large margin of safety after consumption of these 
residues in edible tissues, so that a zero withdrawal time can be supported. 
Keywords: somatotropin, insulin-like growth factors, residues, human safety. 
Introduction 
The use of growth hormone in animal production has caused a large concern also with 
respect to the occurrence of residues in edible tissues. It should be noted that recombinant 
bovine somatotropin (rbST) may soon be marketed to enhance milk production, and in the 
near future porcine somatotropin (rpST) to enhance pig production. As with any other drug, 
residues of these hormones can occur in edible tissues; therefore one must be assure that the 
product quality and the safety are not affected. Already, before its marketing, growth 
hormone has caused controversy among consumers. The reason being that, although 
hormones of the somatotropin axis are quite different from the sexual steroids or anabolics, 
the negative connotation of the word "hormone" may carry over to the somatotropins. From 
a safety point of view, scientific answers can be given about the residues of growth 
hormone,disproving this emotional reaction. 
The residues of hormones of the somatotropin axis have to be dealt with in three different 
ways, according to their pharmacokinetic, pharmacodynamic and toxicological profile. 
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Nature of residues 
As with any other compound, following treatment with growth hormone, residues are 
composed of the parent drug or the somatotropin, and its metabolites. In addition, growth 
hormone induces secretion of endogenous components or somatomedins (or insulin-like 
growth factors, IGF-I and IGF-2). Therefore, these latter compounds must also be dealt with 
as residues. 
Growth hormone or somatotropin is naturally produced by the pituitary gland. This is a 
protein and its genetically coded amino acid sequence differs among animal species. 
Therefore, there is no one unique somatotropin but different types such as bovine 
somatotropin (bST), porcine somatotropin (pST), etc... For example, the amino acid 
sequence between bovine somatotropin and human somatotropin differs by approximately 
35 % (Table 2) (Birmingham et al., 1988, Santome et al., 1976). 
Table 1. Homology (%) of somatotropins of different species (Santome et al., 1976). 
Animal species 
bovine 
ovine 
equine 
porcine 
rat 
human 
Homology 
(% /bovine) 
100.0 
99,5 
90,5 
90,0 
86,9 
65,1 
Moreover, in the same species, somatotropin appears to be a family of several proteins, the 
major one being a 22 kDa form consisting of 191 amino acids. Thus, pituitary bST exists as 
four variants comprised of 190 or 191 amino acids. Their variations lie in the amino acid 
terminus (phe or ala) and at position 127 in the molecule (val or leu) (Table 2) (Santome et 
al., 1976). pST, on the other hand, has only one natural variant. 
The recombinant somatotropins (rST) are very similar to pituitary natural forms. At 
present, recombinant bovine somatotropins are produced by four different companies, 
Monsanto, American Cyanamid, Elanco and Upjohn, and the products are either exactly the 
same or differ from each other only by virtue of the number of amino acids added at the 
amino terminus of the molecule (range one to nine) (Juskevich et al., 1990). rpST produced 
by Pitman Moore is identical to the natural pST. On the whole, they have the same biological 
properties and profiles as the endogenous ones. For instance, no statistical significant 
differences concerning distribution half-lives, terminal distribution half-lives, total body 
clearances or volumes of distribution has been established between the recombinant bovine 
somatotropin rMet-bST and a recombinant naturally occurring variant, rAla-Val-bST 
(Birmingham et al., 1988). 
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Table 2. Differences In the sequence of amino-acids of the natural varianis of bST (Santome et 
al., 1976). 
127 191 
ALA 
ALA 
PHE 
PHE 
PHE 
PHE 
PRO ... 
PRO ... 
PRO ... 
PRO ... 
....LEU ... 
....VAL ... 
....LEU ... 
....VAL ... 
... PHE 
... PHE 
... PHE 
... PHE 
Pharmacokinetic profile 
Pharmacokinetic profile in non-treated animals 
Somatotropins, or growth hormones (GH) are natural substances and their endogenous 
secretion induces plasma and tissue concentrations even in non-treated animals. 
Somatotropin concentrations in plasma , 
The secretion of GH is episodic. This has been clearly shown in blood plasma of cattle, 
either in a 9 week old calf or in a 10 month old Fleckvieh bull (Figure 1) (Schams et al., 
1989). Endogenous bST blood levels widely vary between 0 and 100 ng/ml plasma. The 
average value is approximately 0.4 ng/ml. 
Schams et al. (1989) also measured blood somatotropin levels in growing Brown Swiss 
cattle up until 6 months of age with more frequent samplings during brief periods (once every 
15 minutes during a 6 hour period). Such a protocol displayed the amplitude and the 
frequency of episodic secretions (Table 3) (Schams et al., 1989). 
bST plasma concentrations 
80 
60 
40 
20 
0 
(ng/ml) 
Time (h) 
T T 
6.00 12.00 18.00 24.00 6.00 
Figure 1. Episodic secretion of bST in a 10 month old Fleckvieh bull (Schams et al., 1989). 
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Table 3. bST levels in plasma of growing Brown Swiss cat t le (Schams et al . , 1989). 
Age 
(mnth) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
overall mean 
male 
14.7 
4.4 
7.8 
11.2 
22.4 
22.8 
15.2 
19.9 
26.4 
20.5 
17.8 
15.1 
12.6 
Milk residues 
female 
11.6 
4.1 
5.0 
3.9 
3.3 
8.7 
19.0 
11.1 
8.7 
6.9 
7.1 
6.3 
7.1 
6.2 
basal 
concentrations 
male 
10.6 
3.7 
5.2 
6.8 
12.2 
15.8 
7.0 
7.3 
8.3 
8.3 
7.0 
7.5 
5.1 
female 
8.8 
2.9 
3.7 
3.1 
2.8 
5.2 
6.2 
6.4 
4.8 
4.4 
4.6 
4.9 
5.5 
5.7 
amplitude 
male 
20.5 
7.6 
11.1 
16.7 
35.1 
37.5 
29.3 
34.5 
48.9 
33.4 
29.1 
23.5 
17.8 
female 
15.0 
5.8 
4.6 
5.7 
3.9 
10.7 
48.3 
16.6 
12.0 
8.4 
9,7 
5.3 
7.3 
4.3 
frequency of 
episodes 
male 
9.1 
10.0 
10.3 
9.4 
8.3 
5.2 
8.6 
9.3 
8.3 
7.2 
7.8 
6.5 
8.3 
female 
8.7 
10.0 
9.0 
8.7 
6.7 
14.5 
6.3 
6.5 
7.0 
5.3 
7.0 
6.0 
4.5 
2.0 
Endogenous bST is hardly detectable in bovine milk and most authors could not measure 
bST in milk. In general, levels were found to be below 0.3 or 0.5 ng/ml, depending on the 
method used. In a recent paper, levels between 0.5 and 1.5 ng/ml milk were reported (Figure 
2) (Ketelslegers et al., 1990, Schams, 1990) ; also, these concentrations are very close to the 
limit of detection of the analytical method. 
bST milk concentrations 
1.8 
1.6 
1.4 
1 . 2 -
(ng/ml) 
Time (days after injection) 
0.8l 
-50 50 100 150 200 
Figure 2. bST concentrat ions in milk of rbST-treated a n d non-t reated cows (Ketelslegers e t a l . , 
1990). 
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Figure 3. IGF-I concentrations in milk of rbST-treated and non-treated cows (Ketelslegers et al., 
1990). / 
IGF-I is also secreted into milk of non-treated cows and were shown to vary between 0 
and 30 ng/ml, depending on the age and stage of lactation of the cow (Figure 3) (Ketelslegers 
et al., 1990, Schams, 1990, Torkelson et al., 1988). During the second half of lactation, the 
IGF-I concentrations (mean s.e.m.) in milk from control cows were 24.2 2.8 ng/ml (n=17) 
(17). On the other hand, higher IGF-I levels have been found in bovine colostrum, up to 150 
ng/g (Malven, 1977, Ronge et al., 1988). 
Pharmacokinetic profile in treated animals 
In treated animals, most of the pharmacokinetic studies have been performed in cattle with 
one recombinant rbST variant (sometribove), a prolonged release formulation intended for 
marketing. Pharmacokinetic studies with rpST are limited, as the final pharmaceutical 
formulation does not seem to be established as yet. 
Somatotropin concentrations in plasma 
After subcutaneous (sc) application of 500 mg sometribove every 14 days, which is 
approximately equivalent to a daily exposure of 36 mg/cow/day, plasma concentrations 
within an animal increased by average from 2 to 10 (Figure 4) (personal communication, 
1989) ; they return to basal values 11 or 12 days after injection. During such a treatment 
cycle, plasma concentrations were from 5 to 20 times higher than in control animals, 
depending on the time of measurement (personal communication, 1989). 
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Figure 4. Immunoreactive bST (bGH) in the plasma of 6 Simmental (DFV) and 6 German Black 
and White (DSB) cows following s.c. administration of 500 mg sometribove (personal 
communication, 1989). 
Another study revealed a 4 to 6 fold increase in bST blood concentrations (Ketelslegers et 
al., 1990). However, on the whole, these plasma concentration variations, though elevated, 
stay within the physiological range (Figure 1). 
In pigs, 1 hour after intramuscular injection of rpST (14 mg as an aqueous solution twice 
a week), starting at 60 kg live weight until four and a half days before slaughter, a dramatic 
increase of pST concentrations in blood was seen beyond 300 ng/g. However, these high 
levels decreased to basal values 26-27 hours later (Table 4) (Schams et al., 1989). 
With respect to IGF-I, in pigs, the values were approximately 2-fold higher than the basal 
values 1 hour after injection and back to basal values 26-27 hours later (Table 4) (Schams et 
al., 1989). 
Table 4. Blood concentrations of pST and IGF-I (ng/g) in non-treated pigs and rpST-treated pigs 
within 1 h and 26-27 h after the last injection (mean ±s.d.) (Schams et al., 1989). 
Blood concentrations (ng/ml) 
1 h post treatment 26-27 h post-treatment 
Fi 
Duroc 
Pietrain 
control 
rpST 
control 
rpST 
control 
rpST 
n 
6 
5 
6 
6 
6 
6 
pST 
2.0 ±1.6 
240 ±113 
2.0 ±1.7 
321 ±84 
2.0 ±0.6 
266 ±46 
IGF-I 
437 ±110 
749 ±346 
391 ± 73 
531 ±172 
193 ±81 
373 ±158 
pST 
2.1 ±0.5 
3.1 ±3.2 
2.9 ± 0.5 
14.9 ±32 
1.7±0.3(n=5) 
2.7 + 0.9 
2.1 ±0.5 
IGF-I 
231 ±37 
793 ± 89 
398 ±58 
1310±217 
183±45 
720 ±296 
14 mg l.m. twice a week from 60 kg (b.w.) up until 120 kg (18 injections) blood collection 1 h or 26-27 
h after last Injection-assay sensitlvlty=0.25 ng/ml 
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Another study revealed a 4 to 6 fold increase in bST blood concentrations (Ketelslegers et 
al., 1990). However, on the whole, these plasma concentration variations, though elevated, 
stay within the physiological range (Figure 1). 
Table 5 .Blood concentrations of pST and IGF-I (ng/g) in non-treated pigs and rpST-treated pigs 
4.5 days after the last injection (mean ± s.d.) (Schams et al., 1989). 
Fi 
Duroc 
Retrain 
n 
14 
17 
16 
Control 
pST 
1.8 ±0.7 
3.7 ±3.1 
2.3 ±0.9 
14 mg i.m. twice a week from 60 kg (b.w 
last injection-assay sensltivity=0.25 ng/ml 
Milk residues 
Blood concentrations (ng/ml) 
Treatment 
IGF-I 
299 ±130 
417 ±136 
264 ±138 
n 
16 
15 
16 
pST 
1.F ±50.8 
1.6 ± 0.8 
1.6 ± 0.5 
IGF-I 
369 ±149 
432 + 217 
276 ±127 
.) up until to 100-140 kg. Blood collection 1 h or 26-27 h after 
Exogenous administration of rbST to dairy cows (500 mg sometribove every 14 days) 
have not been reported to increase the endogenous levels of bST in milk (Hart et al., 1985, 
Mohammed et al, 1985, Schams, 1988, Torkelson, 1988). 
Ketelslegers et al. (1990) observed no significant increase of bST over the control values 
after application of 500 mg sometribove to dairy cows every 14 days (Figure 2). At the same 
time, these bST levels in milk were 3 to 5 times lower than basal plasma concentrations. 
rbST application in similar conditions during 10 cycles did not induce any significant 
increase in milk IGF-I levels (Figure 3) (Ketelslegers et al., 1990) and no increase in milk 
IGF-II levels. Schams (1990) did not find any significant difference in IGF-I levels in milk 
between control and treated animals (about 5 to 20 nanograms per millilitre), even after the 
15th s.c. injection of 500 mg bST (sometribove) every 14 days (Figure 5). Once again, these 
slight increases, if ever shown, lay within the range of the physiological variations observed 
during lactation. 
This data clearly indicates that treatment of cows with a slow release formulation 
(sometribove) does not increase the physiological bST or IGF-I concentrations in milk. 
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Figure 5. Concentrations (mean ± s.d.) of IGF-I in milk of controls (n=6) and bST treated cows 
(n=6) on days 4,6,11 and 13 after the 15th injection (Schams, 1990). 
Muscle and liver residues 
In dairy cows, rbST administration (500 mg s.c. every 14 days during 3 injection cycles) 
did not significantly increase bST levels in muscles compared with control values. The 
highest bST levels indicated a 2-fold increase in muscle and liver when the blood 
concentrations are the greatest in the mid point of the injection cycle (Figure 6) (Hammond 
et al., 1990). The muscle concentrations range from 2 to 6 ng/g, those in liver from 10 to 30 
ng/g (Figure 7) (Hammond et al., 1990). 
No significant differences in IGF-I concentrations in muscle (from 75 to 450 ng/g) (Figure 
6) or liver (from 75 to 200 ng/g) (Figure 7) could be detected after application of 500 mg 
sometribove to dairy cows every 14 days during 3 injection cycles (Hammond et al., 1990). 
This data clearly indicates that IGF-I milk concentrations are much lower than those in other 
edible tissues. 
Though most of the data has been obtained for bST, results are similar for pST. In pigs, 
after intramuscular injection of rpST (14 mg as an aqueous solution twice a week) starting at 
60 kg live weight until four and a half days before slaughter, pST concentrations in muscle 
were quite similar to control values 26-27 hours after the last injection or 4.5 days as well, 
that is to say below 5 ng/g wet tissue (Schams, et al., 1989). 
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Figure 6. bST concentrations (mean ± s.d.) in muscle of control cows (n=5) and cows 
administered sometribove for three injection cycles (n=5), on days 0,14 and 28 (Hammond et 
al., 1990). 
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Figure 7. bST concentrations (mean ± s.d.) in liver of control cows (n=5) and cows administered 
sometribove for three injection cycles (n=5), on days 0,14 and 28 (Hammond et al., 1990). 
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Figure 8. IGF-1 concentrations (mean ± s.d.) in muscle of control cows (n=5) and cows 
administered sometribove for three injection cycles (n=5), on days 0,14 and 28 (Hammond et 
al.. 1990). 
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Figure 9. IGF-1 concentrations (mean ± s.d.) in liver of control cows (n=5) and cows 
administered sometribove for three injection cycles (n=5), on days 0,14 and 28 (Hammond et 
al., 1990). 
Thus, in summary, it can be concluded that bST or IGF-I residues in muscle or liver are 
not different in non-treated cows from cows administered 500 mg s.c. sometribove. Similar 
results have been reported in pigs after pST treatment. In fact, these residue concentrations 
vary according to pharmaceutical formulation (solution, prolonged release formulation), 
dose and route of injection. Although the bST concentrations immediately after treatment are 
usually higher than those obtained in control animals, they generally remain inside the large 
physiological range. 
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Pharmacodynamic profile 
There are several reasons why bST and pST are inactive in humans. From a 
pharmacodynamic point of view,, somatotropins are rather species-specific, bovine (bST) or 
porcine (pST) somatotropins have no pharmacological or toxicological activity in humans. It 
has been shown that bST and pST have no affinity for human somatotropin receptors. This 
explains why the parenteral administration of bovine somatotropin extracted from cattle 
pituitaries totally failed in the dwarfism treatment in man in the fifties. 
Insulin-like growth factors, however, are not specific to animal species : human and 
bovine IGF-I are identical (Honegger et al., 1986) and, hence, they exert the same 
pharmacodynamic profile (Daughaday et al., 1990). 
Toxicological profile 
Whether bound or not to receptors, the somatotropins and IGF-I, as any dietary proteins, 
are strongly broken down into peptidic fragments in the digestive tract by the combined 
action of gastric acids and enzymes. These fragments are almost completely^ devoid of any 
biological activity. Only limited tryptic digestion retained some activity of the unbroken bST 
and peptidic fragments have been shown getting 10 % of the bST activity (Hara et al., 1978). 
Similarly IGF-I is not biologically active following ingestion (Hammond et al., 1990). This 
explains why oral use of insulin in diabetes mellitus is not possible and why insulin has to be 
injected. However, in human neonates, the digestive enzymatic activity is limited, ranging 
from 10 to 100 % of adult enzymatic capacities and intact proteins may be absorbed to a 
small extent, 1 : 10,000 to 1 : 50,000 (Levinsky, 1985). In fact, both bST and IGF-I have 
molecular weights of approximately 22,000 and 7,800 daltons respectively. The large size of 
these molecules prevents any significant oral activity. 
Several toxicological studies have been carried out to ascertain this lack of oral activity 
either with somatotropin or with IGF-I. rbST has been administered to normal or 
hypophysectomized rats by gavage or subcutaneous injection at up to 100 times or more of 
the daily dose proposed in dairy cattle, and as long as 90 days. In any case, these 
toxicological studies on laboratory animals have proven that rbST administered orally up to 
50,000 (J.g/kg/day produced no growth response or deleterious effect (Juskevich, 1990). 
Similar tests have been performed with IGF-I on laboratory animals, either orally or by 
subcutaneous injection. After s.c. application, IGF-I has been shown to enhance growth but 
there is no evidence of any biological or toxicological effect after oral administration of 
IGF-I. In addition there is clear evidence that heat treatment by cooking denatures most of 
the IGF-I residues in meat (Miller et al., 1989). 
Estimation of safety factors 
As shown above, residues of bST or pST and IGF-I do not present any risk for the 
consumer ; thus the calculation of a safety factor, as with any other drug, might be considered 
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obsolete. Nevertheless, such safety factors have been estimated for consumption of bST and 
IGF-I residues in edible tissues from treated cows after application of sometribove in normal 
conditions. With respect to pST, safety factors will be appropriate only when the final 
commercial formulation is available 
Safety factors in milk 
Assuming that a 10 kg child drinks one litre of milk containing 10 ng/ml a day, he would 
be exposed to 1 (ig/kg/day, in other words 50,000 times less than the no-effect level. The 
safety factor is therefore 50,000 (Hammond et al., 1989). 
The same calculation applied to IGF-I gives a safety factor in the range of 200 to 2,000 
(Hammond et al., 1989). 
Safety factors in meat 
Assuming that every day a 60 kg adult person eats 500 g of uncooked meat containing 3.1 
ng/g sometribove, they would be exposed to 0.025 |J.g/kg/day sometribove. If compared to 
the no hormonal effect level of 50,000 (J.g/kg/day, this daily exposure results in a safety 
margin of 2 000 000 (Hammond et al., 1989). 
The same calculation applied to IGF-I with uncooked meat assumed to contain 3 ng/g 
results in a daily exposure of 1.3 (Ig/kg/day. Taking into account 200 or 2,000 (ig/kg/day 
doses as a no effect level, the safety factor ranges from 150 to 1,500 (Hammond et al., 1989). 
Finally, all the data supports the authorization of a zero withdrawal time for human 
consumption of milk or meat from bST (sometribove)-treated cows. 
Conclusion 
There is clear evidence that residue levels of the hormones of the somatotropin axis in 
edible tissues, somatotropins and insulin-like growth factors (IGF-I mainly), are not 
significantly different in somatotropin treated animals from the untreated animals (i.e. 
approximately 1 to 10 ng/ml in milk - from 2 to 10 ng/g in muscle - and from 10 to 30 ng/g 
in liver). Though most of the data has been obtained for bST, similar results appear for pST. 
Furthermore, administration of bST does not induce any significant change in IGF 
concentrations in milk (about 5 to 20 ng/ml), in muscle (about 75 to 450 ng/g) or in liver 
(about 75 to 200 ng/g). 
Moreover, somatotropins are largely species-specific. Somatotropins and IGF-I are 
broken down to a large extent in the digestive tract into inactive peptidic fragments. Finally, 
toxicological tests suggest a large margin of safety after consumption of their residues in 
edible tissues, so that a zero withdrawal time can be supported. 
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SAFETY ASPECTS OF BIOLOGICALLY ACTIVE SUBSTANCES 
J.C. Juskevich 
Food and Drug Administration, Center for Veterinary Medicine, Rockville, Maryland, 
USA (Present address: Consultant, Halifax, Nova Scotia, Canada) 
Summary 
With the advent of recombinant DNA techniques, the investigation of protein products for 
a variety of uses in food animals has increased dramatically. As opposed to new chemical 
entities that are generally developed for use in food animals, the chemical nature, biological 
activity, and potential for harmful residues are better understood for protein products. 
Because of these considerations, the U.S. Food and Drug Administration (FDA) decided that 
the testing requirements generally applied to determine the human food safety of compounds 
used in food-producing animals were not appropriate for protein products. Therefore, new 
procedures were proposed for both toxicological and residue chemistry testing. This paper 
presents the basis for FDA's decision regarding the alternative testing requirements, reviews 
the studies required under the proposed procedures, and describes how these testing 
requirements were applied in determining the human food safety of recombinant bovine 
somatotropin for use in lactating dairy cattle. 
Keywords: human food safety, protein products, somatotropin 
Introduction 
The introduction of recombinant DNA techniques provided a means for producing protein 
hormones in quantities not easily obtained by extracting the proteins from animal tissues. 
The animal drug industry has therefore been able to investigate the potential use of protein 
hormones in animal production. The increase in the number of protein products considered 
for use in food-producing animals prompted the FDA to review the testing requirements 
established for determining the human food safety of these animal drugs because it was 
apparent that the chemical nature, biological activity, and potential for harmful residues are 
better understood for protein products, as compared to non-protein drugs. 
The scientific literature generally provides a good background for understanding the 
biological effects of these products, because many of the protein hormones have been studied 
extensively in both animal models and humans. Due to information available concerning the 
digestion of proteins in the human gastrointestinal tract and because the consumer will be 
exposed to residues of these proteins by the oral route, there is reduced concern for potential 
harmful residues of protein products. 
With the information available in the scientific literature taken into consideration, the 
FDA decided that alternatives to the testing requirements outlined in their "General 
Principles for Evaluating the Safety of Compounds Used in Food-Producing Animals" 
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(FDA, 1987), were more appropriate for determining the human food safety of protein 
products. A new set of guidelines for protein products is under development and basic testing 
requirements, including both toxicology and residue chemistry studies, have been proposed. 
This paper will examine the information available in the scientific literature that was used as 
a basis for establishing the proposed testing requirements, outline the proposed procedures, 
and describe how the testing requirements were used to determine the implications of 
recombinant bovine somatotropin (rbST) use on the safety of food products intended for 
human consumption. 
New Animal Drug Regulation 
The FDA has the responsibility of enforcing the Federal Food, Drug, and Cosmetic Act, 
and the enforcement authority for animal drugs is delegated to its Center for Veterinary 
Medicine. Before a new animal drug can be approved for use in food-producing animals, 
several requirements must be met as outlined in the Code of Federal Regulations (1989). One 
of the requirements is that the pharmaceutical company demonstrate that food products from 
treated animals are safe for human consumption. The FDA established guidelines (FDA, 
1987), for toxicological testing and residue chemistry studies, that would ensure the edible 
tissues from treated animals are safe for consumers. The testing requirements provided in 
these guidelines are discussed briefly below. 
Toxicology Studies 
The toxicology studies that are generally required include a battery of toxicity tests to 
demonstrate whether the compound produces bacterial gene mutations, mammalian cell gene 
mutations, or induces DNA repair; two 90-day feeding studies, one in a rodent species and 
one in a non-rodent species; and a 2-generation reproduction study with a teratology 
component. These studies are considered the basic toxicology studies required for any 
compound submitted for approval for use in food-producing animals. The results of these 
studies, along with knowledge of the particular activity of a compound, dictate whether 
additional toxicity testing is required. 
Additional studies that may be required include: chronic bioassays for carcinogenicity in 
each of two rodent species if the compound has tested positive in any of the genotoxicity 
assays or if the results of the subchronic studies raise the suspicion of carcinogenicity; 
one-year feeding studies in a rodent and non-rodent species when the exposure of people to 
residues of a compound exceeds 25 \i Dg/kg b.w./day or when there is evidence to indicate 
that the residues bioaccumulate in the tissues of target animals; and a teratology study in a 
second species when the compound is structurally related to a known teratogen, when the 
compound has hormonal activity that may affect the fetus, or when the results of the 
reproduction/teratology study indicate that the compound may be a teratogen. 
Other specialized testing is required when necessary to adequately define the biological 
effect of the compound. Examples of specialized testing include testing for neurotoxicity, 
immunotoxicity, hormonal activity, or toxicity following in utero exposure. 
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When data has been obtained from all of the required toxicity tests, a safe concentration 
for residues in the edible tissues is determined for non-carcinogenic compounds, using the 
appropriate toxicity study. For carcinogenic compounds, the concentration of residue giving 
no significant risk of cancer is calculated from the tumour data using a statistical 
extrapolation procedure (Gaylor & Kodell, 1980; Farmer et al., 1982), using a permitted 
lifetime risk to the test animal of 1 in 1 million. 
Residue Chemistry Studies 
In addition to the toxicity studies, the determination of human food safety of a particular 
product requires information regarding the residue of the compound in edible tissues. The 
first study generally required is a total residue study, which provides information on the 
concentration of total residue (parent compound plus metabolites) found in various edible 
tissues. 
In addition to the total residue study, metabolism studies must be conducted in the target 
species. A metabolic profile is established and structural identification may be required for 
major metabolites. FDA may also require a determination of the persistence of metabolites in 
edible tissues and a determination of the amount of residue that is covalently bound. 
Metabolism studies are also required in one species of laboratory animals that was used for 
toxicological testing. This ensures that at least one of the toxicity test species was exposed to 
all of the metabolites found in the target species. 
If the total residues at zero withdrawal are above the safe concentration, then additional 
studies will be required to determine a withdrawal period that ensures that residues will be 
below the safe level when animals go to slaughter. The withdrawal period, or milk discard 
time, is established from a residue depletion study in the proposed target population under 
market conditions of use. 
Regulation of Protein Products 
Because human exposure to the residues of protein products is by the oral route, the 
general toxicological concerns are rather limited. However, several points must be taken into 
consideration: 1) whether the protein has the potential to be active orally; 2) the potential for 
absorption of the intact protein; 3) the possibility that there may be active fragments of the 
protein that may be formed in the gastrointestinal tract and more easily absorbed as compared 
to the parent protein; 4) whether the protein being administered to the food-producing animal 
is an endogenous protein or an analogue of the endogenous protein, and 5) potential local 
effects of the protein on the gastrointestinal tract. 
Protein Digestion and Absorption 
There is an extensive amount of information in the scientific literature regarding the 
digestion of protein in the human gastrointestinal tract (Gray & Cooper, 1971; Horrobin, 
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1968; Matthews, 1975; McNeish, 1984; Nixon & Mawer, 1970), both in adults and neonates, 
which addresses the issues of potential oral activity of proteins and the extent of absorption 
of intact proteins. 
The digestion of protein is generally rapid and protein digestion products usually enter the 
blood almost entirely as free amino acids. There is general agreement that neonates, and even 
preterm infants, have the complement of enzymes necessary to digest protein efficiently, 
although reduced activities of some of the digestive enzymes compared to adults limit the 
capacity for protein digestion (Lebenthal et al., 1983; Lebenthal & Leung, 1987; McNeish, 
1984). 
The time of closure of gut permeability to proteins (gut closure) in the newborn has not 
been definitively determined. The results of some studies indicate that gut closure may occur 
before birth (Roberton et al., 1982), but other studies indicate that it may take place as long 
as 3 months after birth (Eastham et al., 1978; Reinhardt, 1984). The gut of the newly born 
infant is impermeable to a large variety of antibodies administered in colostrum or milk 
(Leissring et al., 1962), however, absorption of foreign proteins must take place to a limited 
extent as evidenced by the appearance of specific antibodies against proteins (Eastham et al., 
1978). Studies performed in other species cannot easily be extrapolated to humans, since the 
time of gut closure appears to be quite variable among species (Lecce, 1979; Morris, 1968; 
Warshaw et al., 1974). 
The conflicting results of studies done with human neonates to determine the extent of 
intact protein absorption points out the complexity of the system being studied. A variety of 
factors may be involved including the type protein, gestational age of the neonate, and 
perhaps feeding regimen. Studies indicate that the fullterm neonate absorbs similar amounts 
to non-atopic adults given equivalent antigen loads according to body weight, however, 
preterm neonates may absorb more antigenically intact protein as compared to fullterm 
neonates (Levinsky, 1985). 
Based on the information available in the scientific literature, one would expect that most 
protein and polypeptide drugs would have minimal, if any, activity when administered orally 
because of digestion in the gastrointestinal tract. However, it would be inappropriate to 
assume that a compound does not have oral activity simply because it is a protein. 
For example, some of the releasing factors appear to be orally active in animals and/or 
humans. This is due, in general, both to their low molecular weight and their high specific 
activity. Synthetic thyrotropin releasing factor, a tripeptide has limited oral activity in 
humans (Kaupilla & Ylikorkala, 1982). It has also been shown that synthetic gonadotropin 
releasing hormone (GnRH), a decapeptide, and its analogues can cause a significant increase 
in luteinizing hormone when administered by the oral route (Amoss et al., 1972; de la Cruz 
et al., 1975; Gonzalez-Barcena et al., 1975; Humphrey et al., 1973; Nishi et al., 1975; 
Yamazaki et al., 1977). Because GnRH is susceptible to proteolytic enzyme degradation, the 
oral activity is most likely accounted for by its high specific activity (active parenterally in 
picogram doses) and its relatively rapid diffusion across the gastric mucosa. 
However, without a low molecular weight, high specific activity, and/or absorption 
directly from the stomach, it is highly unlikely that a protein hormone could be absorbed 
intact in high enough concentrations to produce any biological effects. 
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Other Considerations 
The potential production of biologically active fragments of a protein and subsequent 
absorption of the fragment needs to be taken into consideration in designing human food 
safety studies for protein products. In some cases, information may be available in the 
scientific literature regarding whether these fragments are likely to be produced in the 
gastrointestinal tract. For example, although fragments of bovine somatotropin (bST) can be 
produced in vitro that are active when administered parenterally to test animals (Sonenberg 
et al., 1972; Yamasaki et al., 1970) and possibly to humans (Nadler et al., 1967; Sonenberg 
et al, 1965 & 1972), there is a progressive loss of growth-promoting activity in the rat with 
the increase in the number of peptide bonds hydrolysed and a substantial reduction in activity 
when the number of bonds split is greater than three (Sonenberg et al., 1968). The mild 
hydrolysis conditions necessary to obtain active fragments of bST will not be present in the 
human gastrointestinal tract. Coupled with the large doses necessary to obtain parenteral 
activity in humans, it appears extremely unlikely that the production of active fragments of 
bST will be of any human food safety concern. 
Analogues of proteins can be synthesized that have a greater potency or longer duration 
of action than the endogenous protein (for examples see, Brewster & Ranee, 1980; de la Gruz 
et al., 1980; Pless et al., 1986; Velicelebi et al., 1986). Therefore, the chemistry of any protein 
analogue must be considered in light of the fact that changes in amino acid sequence may 
increase the oral potency of the protein by conferring an increased resistance to hydrolysis in 
the gastrointestinal tract. This would appear to be of greatest concern for polypeptide 
hormones rather than large proteins. 
Finally, while most proteins may not be absorbed intact in concentrations necessary to 
produce biological effects, the potential local effects on the gastrointestinal tract may need to 
be taken into consideration. This would be done on a case-by-case basis, depending on the 
biological activity of the protein and the amount of protein that would be consumed. 
Proposed Testing Requirements for Protein Products 
The first obvious data to require is a determination of the potential for oral activity of the 
protein drug in test animals, which would address oral activity per se, absorption of intact 
protein, and absorption of biologically active fragments. In addition, safety of residue in milk 
needs to be addressed because of the use of cow's milk in infant formulas, as well as the 
safety of residues at the injection site for products using a sustained-release formulation, 
which may increase the exposure of consumers to residues of the product originating from 
the injection site. 
It was decided that residue chemistry studies would not generally be required for protein 
products, unless certain conditions were in effect. First, if the product was for use in lactating 
dairy animals residue chemistry studies would be required because of the possibility that 
neonates might absorb more intact protein than adults. Second, if the protein is found to be 
orally active in test animals then a safe concentration may be required for the product and 
residues studies would need to be conducted to determine an appropriate withdrawal time. 
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Lastly, if no biological endpoint can be determined for toxicity testing, it may be necessary 
to conduct residue studies to determine the potential exposure of humans to the protein. 
Proposed Toxicity Tests 
An initial study is conducted to determine the potential for oral activity of the protein. The 
FDA decided that a 2-week oral feeding study would be adequate for this purpose, as studies 
conducted with proteins demonstrate that their biological effects can be observed in less than 
2 weeks. 
The design of the study consists of groups of rats treated with IX, 10X, and 100X the 
dosage administered to the target species on a mg/kg basis. Two other groups are also 
included, a vehicle control group and a positive control group (i.e. a group of rats treated with 
the protein parenterally). A specific biological endpoint is monitored depending on the 
biological activity of the protein. For example, for rbST growth indices were determined 
including body weight, weight gain, tibia length, and tibial epiphyseal width. In addition to 
the specific biological endpoint, standard toxicological profiles are measured including 
clinical signs, body weight and food consumption, haematology and clinical chemistry 
parameters, organ weights, and microscopic examination of organs if necessary. The FDA 
also decided that a determination of the concentration of the protein in the serum by 
radioimmunoassay would provide valuable information on the potential absorption of the 
intact protein. The protein is determined in the serum of animals from the positive control 
group and animals treated with the protein orally. 
If this initial study indicates that the protein is orally active, then additional studies may 
be required to determine a no-observed-effect level. The design of these studies is of a longer 
duration and is based on the biological activity of the protein. Therefore, the study design 
will vary from one protein to the next. 
In order to determine the safety of residues in milk, the 2-week oral feeding study just 
outlined may not provide sufficient information because of the possible differences in protein 
absorption between neonates and older animals. However, additional information is needed 
only if the protein is biologically active in humans. If the protein is not biologically active in 
humans then any potential increase in intact absorption of the protein will have no biological 
effect. 
The first study suggested is a demonstration that the protein does not retain biological 
activity under the conditions commonly used for processing milk for infant use or after 
pasteurization. If, however, the protein is heat stable, then additional information may be 
required. Alternatives to the heat lability study may include data to determine to what extent 
the product is absorbed intact in neonatal animals, or data to demonstrate that the product is 
not active in neonates when administered orally. 
To determine the safety of residues at the injection site, another oral feeding study is 
suggested, either as a separate study or incorporated into the previously described 2-week 
oral feeding study. This study contains two groups of animals, a vehicle control group and a 
group treated with 2X the total protein administered divided by 60. This provides for a 2-fold 
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safety factor if a 60-kg person were to consume the entire injection site just after the product 
was administered. Because it is highly unlikely that a person would consume an injection site 
or that the entire dose of drug would be found at the injection site at the time of slaughter of 
the animal, the 2-fold safety factor should be sufficient. 
Proposed Residue Chemistry Studies 
Residue chemistry studies may not always be required for protein products. If the product 
will be used in lactating dairy animals, no residue studies are required if the protein has 
adequately been shown to be biologically inactive in humans. However, if it is biologically 
active in humans, which is usually the case, the residue concentration in milk must be 
determined. These data are used in conjunction with the results of the oral feeding study and 
the heat lability study, or a demonstration that residues are not increased over endogenous 
concentrations, to determine whether residues in milk are safe. It should be pointed out that 
a recombinant product is considered biologically equivalent to the endogenous protein unless 
changes in amino acid sequence affect the potency as compared to the endogenous protein. 
If the protein was found to be orally active and a safe concentration is necessary then the 
following residue chemistry studies would be needed: 1) For products that are administered 
as a single injection and not as a sustained-release formulation, the firm must conduct a 
residue depletion study to determine when the residues deplete below the safe concentration 
or to baseline levels in the case of an endogenous compound; 2) For products that are 
administered as an implant or sustained-release formulation the concentration of residues 
must be determined to demonstrate that residue levels are below the safe concentration at 
zero withdrawal. It should be pointed out that for all residue chemistry studies a validated 
method would need to be submitted along with the results of the studies to ensure that the 
method is capable of adequately measuring the protein in question. 
If no biological endpoint can be measured for the protein product, it is difficult to 
determine what type of testing will be necessary to demonstrate the human food safety of that 
product. If the protein product is an endogenous compound, then safety may be demonstrated 
by determining when residue levels deplete to baseline levels. However, if the product is an 
analogue of an endogenous protein, then it will be more difficult to demonstrate safety by 
conducting a residue study. In this case FDA would ask for a determination of the residue 
levels, but this information must be combined with other information regarding the protein 
to determine safety. Because of a lack of a definite endpoint it would not be possible to 
conduct toxicology studies as discussed previously. The types of additional studies that will 
be necessary have not been determined in general, but would most likely need to be 
discussed on a case-by-case basis. 
Additional Testing 
In addition to the studies just outlined, there are cases where additional testing will be 
necessary to determine the human food safety of a protein product. Additional toxicology 
and/or residue studies may be required for secondary proteins when it is known that the 
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effects of the protein product administered to the target animal are mediated through the 
increase in a separate protein. An example of this is rbST whose effects are mediated through 
an increase in the insulin-like growth factors. 
It may also be necessary to demonstrate that additional amino acids present due to the 
recombinant process, or any changes in amino acid sequence, do not affect the binding of the 
protein to the endogenous receptors or the potency of the protein as compared to the 
endogenous protein. In particular, changes in amino acid sequence which could affect the 
absorption or degradation of the protein will be taken into consideration. These studies are 
used to determine the biological equivalency of recombinant proteins with the endogenous 
protein so that a distinction need not necessarily be made between the two. 
Human Food Safety of Bovine Somatotropin 
These proposed testing requirements were applied to determine the human food safety of 
rbST. To begin with, there was substantial information in the scientific literature regarding 
bST, which provided a basis for determining the types of studies that would be necessary to 
demonstrate human food safety. 
It was well known from studies conducted in the 1950's that bST is not biologically active 
in humans; there is a well-established biological endpoint that could be used to determine the 
oral activity of rbST; the amino acid sequence of bST and each rbST is known; information 
is available in the scientific literature that demonstrates the biological equivalence of bST 
and rbST; a substantial amount of information is available in the scientific literature 
regarding active fragments of bST and the hydrolysis conditions necessary to obtain active 
fragments; and it is known that the effects are mediated through insulin-like growth factors. 
Based on the information already available regarding bST, a 2-week oral feeding study in 
rats was requested for the human food safety section of the approval of rbST. No milk residue 
data was required because bST is not biologically active in humans. 
The FDA had concluded that an increase in growth factors secondary to rbST treatment 
was unlikely to present any human food safety concerns, based on the mechanism of action 
of insulin-like growth factors, the concentration of IGF-I found in human milk, preliminary 
information on the concentration of IGF-I in milk of rbST-treated cows, the way in which 
milk is processed for infant formula, and our knowledge of protein absorption and digestion 
in adults and neonates. Nonetheless, the FDA felt it was important to establish the range of 
concentrations of growth factors after rbST treatment and the potential for oral activity 
because of the widespread use of milk-based infant formulas. IGF-I was chosen as the 
growth factor for study because it is the major factor that mediates the effects of 
somatotropin. While not critical for ascertaining the human food safety of bST, FDA 
requested the following studies with IGF-I: a 2-week oral feeding study in rats, a 
determination of IGF-I residues in milk, and a heat lability study with IGF-I under the 
conditions used for processing infant formula. 
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Results of Studies with Recombinant Bovine Somatotropin 
The results of all of these studies confirmed that the use of rbST in dairy cattle would 
present no increased health risk to consumers (Juskevich & Guyer, 1990). 
Five oral feeding studies were conducted with rbST. Negative results were obtained with 
oral administration of rbST in all studies. The length of the studies conducted varied from 14 
days to 90 days. The high dose of rbST administered in these studies varied according to the 
pharmaceutical companies' proposed dosage for treatment of dairy cattle and ranged from 5 
to 50 mg/kg/day. 
Two oral feeding studies were conducted with IGF-I. Negative results were obtained with 
oral adminstration of IGF-I in both studies. The duration of both studies was 14 days and the 
high dose administered was 1 and 2 mg/kg/day. 
Although a determination of milk residues of bST were not required, several milk residues 
studies were conducted. The results of these studies demonstrated that there was no increase 
in bST in the milk of dairy cows treated with rbST at the proposed dosage. 
Studies were requested to determine the increase in IGF-I in the milk of dairy cows treated 
with rbST. Survey studies were conducted to determine the concentration of IGF-I in milk of 
untreated cows. The baseline concentration is quite variable, ranging from less than 0.7 to 8.2 
ng/ml in 95% of the cows, with a maximum of 30.5 ng/ml. The concentration depended on 
parity and stage of lactation of the cow. Several studies were conducted to determine the 
increase in IGF-I concentrations in milk after treatment with the proposed dosages of rbST. 
Results of the studies showed that, in some cases, there were minor increases after rbST 
treatment, and some of the increases were statistically significant. However, the 
concentrations were in the physiological range found in human breast milk. 
Heat lability studies demonstrated that 90% of bST activity is destroyed during 
pasteurization. The heat lability studies requested for IGF-I demonstrated that pasteurization 
did not alter the concentration of IGF-I in milk, but processing conditions used for preparing 
infant formula decreased IGF-I activity. Prior to heat treatment, raw milk and pasteurized 
milk contained 5.6 and 8.2 ng/ml, respectively. After heat treatment of these samples, less 
than 0.5 ng/ml was detected. Approximately 0.7 ng/ml was found in a commercial infant 
formula. 
Conclusions 
In summary, the FDA is developing an alternative set of guidelines for the determination 
of the human food safety of protein products, taking into consideration that the chemical 
nature, biological activity, and potential for harmful residues are better understood for 
protein products. While these alternative testing requirements present a different series of 
studies than those generally required, the approach is scientifically well-founded and the 
studies supply the information necessary to determine the human food safety of protein 
products. These proposed guidelines are continuing to be revised as new protein products are 
presented and further experience is obtained with the regulation of protein drugs. 
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Summary 
Daily administration of a wide range of porcine somatotropin (0, 50,100,150 and 200 \ig 
rpST/kg live weight) increases total skeletal muscle mass 28 to 38% and reduces separable 
adipose tissue mass 35 to 74% in carcasses of market barrows. Bone mass is increased 10 to 
17% and skin mass is increased 14 to 38%. Similar changes in tissue distribution are 
observed among the four wholesale lean cuts, and greater reductions in percentage fat are 
observed in the fat cuts. Distribution of primal cut weights is altered toward decreased 
percentage of carcass weight in the fat cuts (belly and jowl), and increased percentage of 
carcass weight in lean cuts (ham, loin, butt and picnic). Muscle weight distribution within the 
ham is not changed. Proximate composition of skeletal muscle exhibits a dose-dependent 
decrease in lipid concentration and a small, but significant increase in protein concentration. 
Longissimus cholesterol concentration is not altered, and only minor increases in percentage 
of polyunsaturated fatty acids are observed in subcutaneous or intramuscular fat in rpST 
treated animals. Adipose tissue of rpST treated pigs contains 14% to 50% lower lipid 
concentrations, and 50% to 150% higher water and protein concentrations. Despite these 
changes in proximate and nutritional composition, sensory characteristics of fresh pork are 
only influenced at very high doses of rpST, and these changes are small. Consumer 
acceptance of fresh pork from rpST treated pigs is equal or greater than for pork from 
untreated animals. 
Keywords: somatotropin, tissue distribution, nutritional composition. 
Introduction 
As the relationships between human health and over-consumption of cholesterol and total 
calories, calories from fat or saturated fat became better understood, dietary guidelines were 
developed and promoted. These include the recommendations that we limit consumption of 
calories from fat to less than 30% of total calories consumed, that we reduce intake of 
calories of both saturated and unsaturated fatty acids to less than 10% of total calories, and 
that we reduce cholesterol intake to 100 mg or less per 1000 calories consumed per day 
(National Research Council, 1988). Because red meat and animal fats contribute over 37% 
of the total fat and over 30% of all cholesterol consumed per capita in the U.S., implications 
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for reduced consumption of these foods is clear, unless nutrient composition of fresh meat 
and processed meat products is improved. 
The potential for improving efficiency of pork, beef and lamb production through 
commercial application of biotechnology products like somatotropin (ST) and somatotropin 
releasing factor (SRF) is greater than has been demonstrated by genetic selection or any other 
management strategy currently available (see summaries by Campbell et al., 1988; Enright et 
al., 1989; Beermann and DeVol, 1990; Bonneau and McBride and Moseley, these 
proceedings). Dramatic reductions in carcass and empty body lipid accretion rates and 
concurrent large increases in protein accretion rates are observed with daily administration of 
ST or SRF in both nonruminants and ruminants. Change in absolute yield and distribution of 
carcass tissues and possible changes in nutrient composition of the edible tissues of the 
carcass have only recently been investigated. Whether or not lipid, cholesterol or fatty acid 
concentrations are consistently altered in tissues of somatotropin treated animals is not 
known. The nature of sex or genotype interactions in these changes have not been well 
characterized. Therefore, this paper will evaluate recent information concerning yield, 
distribution and nutrient composition of edible tissues from pigs treated with porcine 
somatotropin (rpST) or somatotropin releasing factor. 
Table 1. Dose-response effects of porcine somatotropin on carcass yield and wholesale cut 
distribution in barrows treated from 30 to 90 kg live weight.1 
Dressing percentage, % 
Chilled carcass wt, kg 
Ham 
untrimmed 
trimmed 
Loin 
untrimmed 
trimmed 
Belly 
untrimmed 
trimmed 
Butt 
untrimmed 
trimmed 
Picnic 
untrimmed 
trimmed 
Jowl 
untrimmed 
trimmed 
Feet 
Spareribs 
Neckbönes 
Daily somatotropin dose, ngkg"1 
0 
76.6° 
67.2a 
23.5a 
21.4° 
24.7° 
17.9a 
17.2° 
13.5° 
10.2 
7.9a 
10.8° 
10.3° 
5.10° 
2.87° 
3.38a 
3.09° 
1.56 
50 
75.5ab 
66.2° 
25.8° 
24.5° 
23.3° 
20,4° 
15.7° 
12.4° 
10.0 
8.6° 
11.3° 
11.0° 
4.23° 
2.19° 
3.51a b 
3.42° 
1.63 
100 
74.1°'c 
65.0° 
25.8° 
24.3° 
22.5°'° 
20.0° 
15.5°'° 
11.8°'c 
10.1 
9,0°'e 
11.4°'c 
11.2°'c 
4.13°'c 
1.96°'° 
3.72°'° 
3.61 °'c 
1.76 
BWd'1 
150 
73.2e 
64.1° 
26.3° 
24.9° 
21.9e 
19.7° 
14.9°'c 
10.9e 
10.1 
9.1°'° 
11.7b-c 
11.4°'c 
4.01 °'e 
1.73° 
3.86e 
3.85e 
1.74 
200 
73.5e 
64.2° 
26.1° 
24.8° 
22.6°'c 
20.4° 
14.6e 
11.5°'e 
10.3 
9.4e 
11.9e 
11.6e 
3.76e 
1.76e 
3.99e 
3.82e 
1.81 
1
 Least square means represent 10 pigs per rpST dose. 
a
° '
e
 Means within a row with different superscripts differ (P<.05). 
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Wholesale Cut Yield and Distribution 
Early studies demonstrated a dose-dependent increase in weights of skinned hams from 
finishing pigs treated with pituitary derived rpST (Etherton et al., 1987), but these increases 
were influenced by increased live weight gain over the 35-day treatment period. We 
subsequently conducted studies, in which confounding effects of live weight differences 
were eliminated, and found differences in weights of trimmed wholesale cuts of pork 
carcasses from pigs treated with increasing doses of rpST (Table 1). When a large dose range 
was evaluated in barrows treated from 30 to 90 kg live weight, percentage of carcass weight 
in the ham, trimmed loin, picnic and trimmed butt were increased with rpST (P<.05), while 
proportions present in the belly and jowl (fat cuts) were reduced (P<.05). Differences 
increased with increasing rpST dose. These data are similar to those reported by Demeyer et 
al. (1989), and our previous observations in which weight of the trimmed ham was increased 
in a dose-dependent manner (P<.001) without significant effects on other trimmed wholesale 
cuts in pigs treated with 0, 30, 60 or 90 |ig recombinant pST/kg live weight from 45 to 105 
kg live weight (D. H. Beermann, unpublished data). Goodband et al. (1990) recently reported 
that trimmed ham and loin weights were not different in control and rpST treated pigs fed 
.6% lysine from 57.6 kg to 105 kg live weight, but increasing dietary lysine concentrations 
increased trimmed weights of both cuts in rpST treated pigs. / 
Table 2. Dose-response relationships between porcine somatotropin administration and dissected 
carcass tissue weights in 90 kg barrows.1 
Daily somatotropin dose, mjkg^BWd"1 
Observation 0 50 100 150 200 
Number of animals 10 10 9 8 10 
Percentage difference from control (%) 
Muscle mass, kg 
Adipose mass, kg 
Bone mass, kg 
Skin mass, kg 
30.92 
22.78 
7.28 
3.66 
+27.9 
-35.7 
+ 10.2 
+ 14.8 
+30.3 
-54.6 
+ 14.3 
+36.1 
+32.7 
-65.7 
+ 16.2 
+35.0 
+37.6 
-74.1 
+ 17.3 
+38.3 
' Somatotropin was administered by daily injections and adjusted biweekly to increased live 
weight. Carcass data are summarized from Thiel et al., (1990). 
'# (P<.05) vs. control 
(P-c.01) vs. control 
Separable Tissue Yield and Distribution 
Although dressing percentage and carcass weight are reduced (P<.05) with high doses of 
rpST (Table 1), yield of physically separated skeletal muscle trimmed of adhering fat and 
connective tissue is increased in a dose-dependent manner by 28% at 50 g/kg to 38% more 
mass at a dose of 200 g/kg (Table 2). This magnitude of increase in skeletal muscle yield 
exceeds previous measurements of approximately 12% to 18% increases in weights of major 
muscles in the hind leg of pigs administered rpST (Beermann et al., 1990; Solomon et al., 
1989). However, these data are in good agreement with recent observations by Bark et al. 
(1990), who observed 28% and 24% increases in muscle mass of rpST treated pigs (70 M-g/kg 
BW) from genotypes expressing moderate or high rates of skeletal muscle growth. 
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Somatotropin administration at doses of 100 (J-g/kg or higher cause both a greater relative 
and absolute reduction in adipose tissue content of the carcass than is observed for the 
reciprocal effects on skeletal muscle (Table 2), suggesting independent effects on these two 
tissues. Weight changes of muscle and adipose were essentially the same at the lowest dose. 
Separable bone weight was increased by 10% to 17% with increasing rpST dose, and skin 
mass was increased to the same relative extent as muscle mass. 
Table 3. Dose-dependent effects of porcine somatotropin on ham tissue distribution and 
proximate composition.1 
Daily somatotropin dose, (igkg^BWd"1 
SM/A/G2 
weight, g 
protein, % 
water, % 
lipid, % 
ash, % 
ST/BF3 
weight, g 
protein, % 
water, % 
lipid, % 
ash,% 
Quadriceps 
weight, g 
protein, % 
water, % 
lipid, % 
ash, % 
Other Muscles 
weight, g 
protein, % 
water, % 
lipid, % 
ash, % 
Adipose 
weight, g 
protein, % 
water, % 
lipid, % 
ash, % 
0 
1194° 
21.7 
74.3° 
3.4a 
1.3 
1462a 
20.8 
73.4a 
5.0a 
1.4 
825° 
20.9 
75.3 
3.1° 
1.3 
1323° 
20.6 
73.2a 
5.6a 
1.2 
1428° 
5.0a 
22.0a 
72.6a 
0.3° 
50 
1527.b 
22.2 
74.9ab 
2.0b 
1.3 
1860.b 
21.7 
74.2a 
3.2b 
1.2 
1004b 
21.2 
75.6 
2.2b 
1.3 
1678b 
21.1 
74.2b 
3.8b 
1.1 
1017b 
6.5a 
28.9b 
63.4b 
0.4a'b 
100 
1510.b 
22.1 
75.4bc 
1.6b'c 
1.3 
1774.b 
21.6 
75.0b 
2.4C 
1.2 
1025b 
21.4 
75.8 
1 9 b . c 
1.4 
1715b 
20.8 
74.3b 
3.7b 
1.2 
772.c 
8.4b 
34.4b 
56.2b 
0.5b'c 
150 
1557.b 
22.0 
75.8C 
1.3C 
1.2 
1779b 
21.6 
75.6bc 
1 9 c d 
1.3 
1057b 
21.3 
75.9 
1.6° 
1.4 
1759b 
21.6 
74.6b 
3.0b'c 
1.4 
633.° 
9.9b 
42.2C 
46.5° 
0.6° 
200 
1578b 
21.8 
75.9C 
1.3C 
1.3 
1885.b 
21.2 
76.2° 
1.5d 
2.9 
1048b 
21.5 
76.0 
1.8° 
1.3 
1800b 
21.2 
75.0b 
2.7C 
1.5 
470.d 
12.5° 
49.8d 
36.6d 
0.7C 
Sx 
44.3 
0.27 
0.25 
0.18 
0.04 
48.1 
0.25 
0.26 
0.24 
0.70 
31.9 
0.17 
0.18 
0.15 
0.06 
58.2 
0.28 
0.30 
0.27 
0.11 
0.56 
1.97 
2.38 
0.05 
1
 Least square means represent 10 pigs per treatment group; data are expressed on a 
wet-weight basis. 
2
 Semimembranosus, adductor and gracilis. 
3
 Semitendinosus and biceps femoris. 
a
'
b,c
'
d
 Means within a row with different superscripts differ (P<.05). 
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Table A. Dose-dependent effects of porcine somatotropin on belly tissue distribution and 
proximate composition.1 
Muscle 
weight, g 
protein, % 
water, % 
lipid, % 
ash,% 
Adipose 
weight, g 
protein, % 
water, % 
lipid, % 
ash,% 
Daily somatotropin dose, jigkg" 
0 
1827° 
19.9 
68.4° 
10.9° 
1.2 
2285° 
4.4° 
19.1° 
76.0° 
0.1 
50 
2499.° 
21.0 
70.8b 
7.4b 
1.2 
1773° 
7.2° 
26.9° 
65.2b 
0.5 
100 
2508* 
20.7 
71.4b'° 
7.1b 
1.2 
757.b 
8.7b'c 
31.3b 
58.9b 
0.8 
'BWd"1 
150 
2500* 
20.8 
72.6° 
5.8b 
1.2 
467.b 
9.9° 
38.2° 
50.8° 
0.5 
200 
2751° 
20.4 
74.6d 
3.7° 
1.2 
362* 
14.3d 
49. l d 
36. l d 
0.3 
1
 Least square means represent 10 pigs per rpST dose; data are expressed on a 
wet-weight basis. 
° *
, c , d
 Means within a row with different superscripts differ (P<.05). 
Table 5. Dose response effects of porcine somatotropin on longissimus muscle nutrient 
composition in boars and barrows.1 
Protein concentration, % 
Fat strain barrows 
Lean strain barrows 
Lean strain boars 
Water concentration, % 
Fat strain barrows 
Lean strain barrows 
Lean strain boars 
Ash concentration, % 
Fat strain barrows 
Lean strain barrows 
Lean strain boars 
Lipid concentration, % 
Fat strain barrows 
Lean strain barrows 
Lean strain boars 
Cholesterol concentration 
Fat strain barrows 
Lean strain barrows 
Lean strain boars 
Daily somatotropin 
0 
22.8 
22.4° 
22.3 
73.0° 
73.2° 
74.3 
1.4 
1.4 
1.4 
3.4° 
3.4° 
2.6° 
mg/100g 
56.0 
56.4 
55.4 
50 
23.5 
23.5b 
22.7 
73.5°* 
74.3°* 
74.8 
1.4 
1.4 
1.4 
2.5°* 
1.5b 
1.5° 
58.9 
58.9 
55.7 
dose, ngkg" 
100 
23.4 231 ab 
23.1 
74.0b'° 
74.2°* 
73.4 
1.4 
1.4 
1.4 
1.8b'° 
1.6° 
1.0b'c 
55.4 
58.4 
54.0 
BWd"1 
150 
23.3 
23.3b 
22.6 
73.3°* 
74.6b 
75.0 
1.4 
1.4 
1.4 
2.6°* 
1.2° 
1 0 b , o 
62.2 
57.4 
55.9 
200 
23.3 
23.3° 
22.9 
74.8° 
74.9b 
75.3 
1.4 
1.4 
1.4 
1.3° 
0.7b 
0.5° 
57.2 
61.2 
57.1 
1
 Data reflect 10 animals per subclass; data are expressed on a wet-weight basis for muscle 
cross sections trimmed of all adhering fat and connective tissue. 
°*'° Means within a row with different superscripts differ (P<.05). 
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Tissue Distribution and Nutrient Composition 
Nutrient composition of the tissues is best evaluated within subdivisions of the carcass. 
Wholesale cut muscle groups are separated for further processing (i.e. ham inside and outside 
cushion, tip and trimmings), and individual muscles comprise the major portion of fresh 
retail cuts. Therefore, proximate composition of a lean cut, the ham, was evaluated by muscle 
group and separable adipose tissues (Table 3). Proximate composition of separated skeletal 
muscle and adipose tissue was evaluated in a fat cut, the belly (Table 4), and more detailed 
nutritional composition information was assessed in an individual muscle, the longissimus 
(Table 5). 
Ham Composition 
The 50 Hg/kg dose of rpST increased muscle mass approximately 28% in all muscle 
groups of the ham (Table 3), while the highest dose appeared to produce a slightly more 
variable response (27% to 36%). Percentage protein and ash were not significantly increased 
in any muscle group, and percentage water was increased about one percentage point (P<.05) 
in the larger muscles. Percentage lipid in the muscle groups was reduced in a dose-dependent 
manner by 29% to 70%. Although separable adipose tissue mass in the ham was reduced 
28% to 67%, extractable lipid concentration was also reduced in a dose-dependent manner 
by 12% to 49%. This resulted in a 37% to 83% decline in absolute lipid content of the 
adipose tissue in the ham, across the range of rpST doses evaluated. As a result, percentage 
protein, water and ash in adipose tissue were more than doubled. Similar magnitudes of 
change in muscle and adipose distribution and composition were observed in the other lean 
cuts (data not shown). 
Belly Composition 
Skeletal muscle mass in the belly was increased 36% at the 50, 100 and 150 |ig rpST/kg 
doses, and was increased 50% with the highest dose (Table 4), despite an 8% to 15% 
reduction in untrimmed or trimmed cut weight. Percentage protein and ash in the muscle was 
not affected, but water concentration was increased with each increment of rpST dose. 
Separable adipose tissue content was reduced in a dose-dependent manner by 22% at the 
lowest dose to a maximum of 84% at the highest dose. Percentage lipid was also reduced 
stepwise with increasing rpST dose, leading to a 33% to 92% decline in absolute lipid 
content of the belly. Percentage protein more than tripled and percentage water more than 
doubled across the rpST dose range, while ash concentration was unchanged. 
Longissimus Composition 
Daily administration of rpST at a dose of > 50 |ig/kg live weight clearly decreases 
intramuscular lipid concentration when administered during the final 50 to 60 kg live weight 
gain in finishing pigs (Beermann et al., 1988; Prusa et al., 1989a,b; Beermann et al., 1990; 
Mourot et al., 1990). This reduction of intramuscular lipid concentration is dose-dependent, 
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is observed in muscles from different regions of the carcass and generally parallels the 
relative reduction in other carcass fat depots. The effect appears to be no greater in fat-strain 
barrows, and no less in boars (Table 5). Percentage lipid in the longissimus was reduced to 
less than 1% in barrows and boars administered 200 (ig rpST/kg live weight (Table 5), and in 
barrows and gilts administered 90 ^g rpST/kg (Beermann et al., 1988). Protein and water 
concentration in the longissimus was increased less than one percentage point, and ash 
concentration remained unchanged. 
Because consumption of cholesterol and saturated fatty acids have been identified as 
possible contribution to the development of cardiovascular disease in humans, we also 
evaluated the cholesterol concentration and fatty acid profile in longissimus samples taken 
from fat-strain and lean-strain barrows and lean-strain boars (Tables 5, 6). Cholesterol 
concentration was not affected by rpST administration, and was similar among all three 
genotype-sex groups. Therefore, it appears that nutritional contributions to total intake of 
calories as fat may be reduced with rpST administration in finishing pigs, but intake of 
cholesterol is not affected. These data are relatively low for fresh pork (USDA Handbook 
8-10). Prusa et al. (1989) observed a significant (8% to 9%) increase in cholesterol 
concentration in broiled boneless loin chops of pigs treated with 8 mg rpST/day. 
Few data are available for assessing the influence of rpST on fatty acid profile of lipids in 
the various adipose depots in pork carcasses. Prusa et al. (1989a) observed no significant 
change in percentage of saturated, monounsaturated or polyunsaturated fatty acids in the 
intramuscular fat of broiled, boneless rib chops from pigs administered 4 or 8 mg rpST per 
day from 45 to 100 kg live weight. Mourot et al. (1990) observed that backfat was more 
unsaturated in pigs either injected with 4 mg rpST daily from 60 to 100 kg live weight or 
implanted with a rpST preparation designed to deliver 2 mg per day. Significant increase in 
percentage of polyunsaturated fatty acids and significant decrease in percentage of saturated 
fatty acids was observed. Similar results were reported by Ender et al. (1989). Intramuscular 
lipid of the longissimus from rpST treated barrows and gilts exhibited significant reduction 
of nonpolar lipids, and no change in polar lipids in the studies by Mourot. Differences were 
also present in fatty acid profile. Barrows and gilts administered rpST exhibited 48% and 
22% greater percentages of CI8:2, respectively, when compared to their control 
counterparts. Very similar differences in percentage of total polyunsaturated fatty acids were 
also observed. Total saturated fatty acid percentage was approximately one percentage point 
lower in intramuscular lipid from rpST treated pigs. Interestingly, the increase in 
polyunsaturated fatty acid percentage was not observed, in lipid extracted from the adductor 
muscle from the same animals. 
We evaluated the fatty acid profile of intramuscular lipid extracted from the longissimus 
of barrows and boars administered 0,50 or 100 Lig rpST/kg from 30 to 90 kg live weight. Our 
data confirm those of Mourot et al. (1990), indicating that percentage C 18:2 is elevated 
approximately 25% (P<.05), and percentage total monounsaturated fatty acids is reduced 
5.7% (P<.05) in both sexes at both levels of rpST administration (Table 6). Because sex 
differences were not significant, data from barrows and boars were combined. Dose-response 
relationships were not evident. 
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1.45° 
24.86ab 
3.80a 
l l .óó 
45.78a 
12.62a 
37.96 
49.57° 
12.62° 
19 
1.13b 
24.24° 
3.28b 
12.38 
43.47b 
15.80b 
37.77 
46.75b 
15.80b 
17 
1.22b 
25.42b 
3.43ab 
11.69 
42.61b 
15.50b 
38.34 
46.04b 
15.50b 
BEERMANN. THIEL AND PRUSA 
Table 6. Dose-dependent effects of somatotropin on fatty acid composition of longissimus 
intramuscular lipid in 90 kg barrows and boars.1 
Daily somatotropin dose, ugUg^BWd"1 
0 50 100 
Number of pigs 
C14:0(myristic) 
CI6:0 (palmitic) 
CI 6:1 (palmitoleic) 
CI 8:0 (stearic) 
CI 8:1 (oleic) 
C18:2(linoleic) 
Total saturated 
Total monounsaturated 
Total polyunsaturated 
1 Data are expressed as percentages of the total lipid. The following fatty acid concentrations 
were below the level of detection: C12:0, C14:1, C18:3, C20:0, C20:1, C20:2, C20:4, C22:0, 
C22:l, C22:6, C24:0, C24:l. No sex effects were observed (P<.05). 
°'
b
 Means within a row with different superscripts differ (P<.05). 
Discussion 
The rapidly accumulating body of data indicates that administration of porcine 
somatotropin to finishing pigs alters the yield and distribution of wholesale cuts in the 
carcass, modestly increasing weight and percentage of lean cuts and significantly reducing 
the belly and other fat cuts. Greater changes in tissue distribution, toward greater skeletal 
muscle mass and less separable adipose tissue, are observed with the same rpST dose range. 
It is apparent that inadequate levels of limiting amino acids in the diet will reduce the 
magnitude of the response. Goodband et al. (1990) observed that stepwise increments of 
lysine concentration in the diet from .6% to 1.2% increased muscle mass, reduced carcass 
and muscle lipid concentrations and increased muscle crude protein and water concentration 
in pigs administered 4 mg rpST daily from 57.6 kg to 105 kg live weight. These data 
demonstrate the importance of supplying adequate nutrients to meet requirements for growth 
as defined by an animal's capacity for rate of protein accretion. It is possible that amino acid 
content or profile of diets used in some studies of rpST effects on tissue growth, distribution 
and composition may have influenced (dampened) the response to rpST. 
Significant changes in yield and distribution of pork carcass tissues have also been 
demonstrated with daily administration of a synthetic human somatotropin releasing factor 
(hSRF) analogue in finishing barrows and gilts (Pommier et al., 1990). Muscle mass was 
increased 13 to 17% and adipose mass was reduced 13 to 30% in lean cuts from pigs 
administered 6.66 Lig hSRF/kg three times daily from 50 to 105 kg live weight. These results 
are of smaller magnitude than those achieved with single daily administration of rpST. The 
transient elevation of circulating concentrations of ST which result from hSRF 
administration, and the lower mean concentration achieved over a 24-hour period most 
probably account for the differences. 
The major change in nutrient composition of tissues from pigs treated with rpST appears 
to be the marked reduction in fat concentration and content. Percentage total lipids is reduced 
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in a dose-dependent manner in both skeletal muscle and adipose tissue from all wholesale 
cuts from pigs treated with rpST. At lower doses (50 (Xg/kg BW) absolute weight of skeletal 
muscle mass increase is nearly identical to the reduction in adipose tissue weight. The major 
portion of the reduction in absolute lipid mass is observed in the adipose tissue. Absolute 
changes in lipid content are greater for the fat cuts in the carcass. Differences in magnitude, 
or the lack of reduction which has been observed in some studies (summarized by Prusa, 
1989) may be explained by administration of minimally effective doses or administration of 
fixed daily mass of rpST which results in declining effective dose (per kg live weight) during 
the treatment period. Our data indicate that large changes are achieved with a dose equivalent 
of 50 (ig rpST/kg live weight injected daily, and that increments above this dose result in less 
rapid or lesser magnitude of change, although significant. Similar but smaller reductions of 
lipid concentration in muscle and adipose tissue are achieved with multiple daily 
administration of hSRF in finishing pigs (Pommier et al., 1990). 
The rpST-induced reduction in intramuscular lipid concentration does not result in any 
consistent change in cholesterol concentration of longissimus muscle, at any dose tested. 
Fatty acid profile of backfat and intramuscular lipid is altered to increase the percentage of 
total polyunsaturated fatty acids, with the major change consisting of increased C18:2. These 
changes are relatively small, and they have not been consistently observed in some cases. 
Solomon and Pursel (1990) observed marked reduction in total lipid and total fatty acids, and 
similar shifts in fatty acid profile in transgenic pigs expressing a bovine growth hormone 
gene. 
The sparse data available indicate that little if any change in mineral concentrations 
(Goodband et al., 1990) or vitamin content of muscle (Prusa, 1989) occur with 
administration of rpST. Therefore, we would conclude that the most significant effects of 
rpST on nutrient composition of edible tissues, excluding organ meats, is to reduce neutral 
lipid concentration. Several investigations indicate that cooking loss and sensory 
characteristics of fresh pork are not adversely affected by rpST administration, unless very 
high doses are employed (Beermann et al., 1988,1990; Evock et al., 1988; Novakofski et al., 
1988; Prusa et al., 1989a; Goodband et al., 1990; Thiel et al., 1990b). 
Conclusions 
Daily administration of porcine somatotropin during the finishing stages of growth 
markedly improve the nutrient composition of pork carcass through marked reductions in 
separable adipose tissue weight and lipid concentrations in all adipose depots evaluated, plus 
concurrent increases in skeletal muscle mass. Nutrient composition of skeletal muscle is 
altered toward reduced lipid concentration, however, cholesterol concentration is not 
changed and fatty acid profile exhibits small increases in percentage C18:2 and total 
polyunsaturated fatty acids. 
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Summary 
The contribution of meat consumption to major chronic diseases - CHD and cancer -- has 
not been adequately defined. Without question, the fat of meat contributes to a relatively high 
intake of saturated fatty acids in affluent countries, and high-fat meats may be one factor 
responsible for diet-induced, "mass hypercholesterolemia". Further, high-fat meats may 
enhance risk for certain kinds of cancer. Therefore, the general recommendation for the 
public to switch from high-fat meats to low-fat meats seems prudent. Another advance would 
be the development of techniques to specifically reduce the palmitic-acid content of both 
beef and pork. Such a process would specifically lower the one cholesterol-raising, saturated 
fatty acid in meat products. 
Keywords: Red meat, fat content, human health. 
Introduction 
During the past two decades the idea has grown in the minds of many people that red meat 
is not healthy for the general public. Two concerns have been expressed. First, the 
consumption of red meat has been linked to the development of coronary heart disease 
(CHD), and second, it has been associated with increased risk for cancer. These ideas have 
led many investigators to recommend that consumption of red meat should be curtailed by 
the general public. However, the link between meat and major chronic diseases is based on 
limited epidemiologic evidence, and the validity of this connection can be questioned. 
Therefore, in this article, the nature of the evidence will be examined along with the strength 
of the link between consumption of red meat and chronic disease. CHD will be considered 
first, and then cancer. 
Coronary Heart Disease 
By what mechanisms might red meat increase risk for CHD? 
If red meat raises the risk for CHD, the primary mechanism appears to be through an 
increase in the serum-cholesterol level. Many epidemiologic studies indicate that high levels 
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of serum cholesterol are a major risk factor for CHD (Keys 1970); thus, any factors that raise 
the serum-cholesterol concentration should increase the danger for CHD. Three dietary 
factors have been identified that increase the serum cholesterol. These are saturated fatty 
acids, dietary cholesterol, and obesity (Grundy et al., 1982 and Expert panel 1988). 
Therefore, if dietary consumption of red meat increases the risk for CHD by raising the 
serum cholesterol, it presumably would have to be due to its content of saturated fatty acids 
and cholesterol, or its high caloric density, leading to obesity. Of course, obesity increases 
CHD by ways other than raising the cholesterol level; it promotes the development of 
hypertension, predisposes one to diabetes mellitus, raises the serum triglycerides, and 
reduces high density lipoproteins (HDL) (Grundy and Barnett 1990). 
Do the fatty acids of red meat raise serum-cholesterol levels? 
The fat of red meat is widely considered to be "saturated", hence, it is a cholesterol-raising 
fat. However, the term "saturated" as applied to whole fat can be misleading, as it is in the 
case of meat fat. There are several types of fatty acids in the fats of different kinds of meat, 
as shown in Table 1. This table compares the fatty-acid composition of beef tallow and lard 
with other animal fats ~ chicken fat and butter fat - and three "saturated" fats from plant oils 
— coconut oil, palm oil, and cocoa butter. The table shows that all of fats listed are relatively 
rich in saturated fatty acids, but all of them in addition contain unsaturated fatty acids, mainly 
oleic acid. There is abundant evidence that unsaturated fatty acids do not raise the 
serum-cholesterol concentration (Keys et al., 1965, Hegsted and McGandy 1965, Mattson 
and Grundy 1985, Grundy and Denke 1990.). In contrast, saturated fatty acids as a class 
appear to raise cholesterol levels, although growing evidence indicates that not all saturates 
are cholesterol raisers. Three saturated fatty acids — lauric acid (C12:0), myristic acid 
(C14:0), and palmitic acid (C16:0) — almost certainly are cholesterol-raising fatty acids 
(Keys et al., 1965; Hegsted et al., 1965). In contrast, medium-chain fatty acids (C8:0 and 
C10:0) seemingly are not cholesterol raisers (Hashim et al., 1960), and recent evidence 
(Bonanome and Grundy 1988) indicates that stearic acid (CI8:0) likewise does not increase 
the serum-cholesterol concentration. With these relationships, we might look at the relative 
cholesterol-raising potential of different fats. 
Table 1. Fatty Acid Compositions of Several Fats 
% Fatty Acid 
Fat" 
Butter fat 
Palm kernel oil 
Coconut oil 
Palm oil 
Beef fat 
Pork fat (lard) 
Chicken fat 
Mutton fat 
Cocoa butter 
4-10:0 
9.2 
8.2 
14.9 
-
0.1 
0.1 
-
0.2 
-
12:0 
3.1 
49.6 
48.5 
0.3 
0.1 
0.1 
0.2 
0.3 
-
14:0 
17.7 
16.0 
17.6 
1.1 
3.3 
1.5 
1.3 
5.2 
0.1 
16:0 
26.2 
8.0 
8.4 
45.1 
25.5 
24.8 
23.2 
23.6 
25.8 
16:1 
1.9 
-
— 
0.1 
3.4 
3.1 
6.5 
2.5 
0.3 
18:0 
12.5 
2.4 
2.5 
4.7 
21.6 
12.3 
6.4 
24.5 
34.5 
18:1 
28.2 
13.7 
6.5 
38.8 
38.7 
45.1 
41.6 
33.3 
35.3 
18:2 
2.9 
2.0 
1.5 
9.4 
2.2 
9.9 
18.9 
4.0 
2.9 
18:3 
0.5 
-
-
-
0.6 
1.1 
1.3 
1.3 
-
Other 
.. 
0.1 
0.1 
0.5 
4.6 
3.0 
0.6 
5.1 
1.1 
The numbers for the fatty acids represent carbon chain length: number of double bonds. 
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Three fats emerge has highly potent for increasing cholesterol levels. These are butter fat, 
palm oil, and coconut oil (Table 1). Butter fat is particularly rich in palmitic acid and myristic 
acid, and it contains about 50% of its fatty acids as cholesterol-raising saturated acids (C12:0, 
C14:0, and C16:0); in addition, butter fat contains small quantities of trans monounsaturates 
which recently have been shown to increase the cholesterol level (Mensink and Katan 1990). 
On the other hand, some of the saturates (C8:0, C10:0, and C18:0) in butter fat do not 
increase the serum cholesterol. Likewise, the oleic-acid (C18:1 ) content of butter fat does not 
contribute to a rise in cholesterol levels (Keys et al., 1965; Hegsted et al., 1965; Mattson and 
Grundy, 1985; Grundy and Denke, 1990). Still, butter fat appears to be one of the more 
potent cholesterol-raising fats. Coconut oil is extremely high in cholesterol raisers (C12:0, 
C14:0, and CI 6:0), and should be the most hypercholesterolemic of all the fats; however, 
lauric acid (C12:0) may be somewhat less hypercholesterolemic than palmitic and myristic 
acids (Hegsted et al., 1965), and coconut oil hence may not raise the cholesterol level more 
than butter fat. Palm oil is extremely rich in palmitic acid (45% of calories), and it too is 
hypercholesterolemic (Mattson and Grundy, 1985; Bonaome and Grundy, 1988). 
It is interesting to compare beef tallow with the three fats discussed above. Beef tallow has 
approximately 50% of its fatty acids as saturates. However, about 20% of these are stearic 
acid, which is not a cholesterol raiser (Bonaome and Grundy, 1988). Thus only about 30% of 
calories are of the cholesterol-increasing variety, i.e., palmitic and myristic acids. Hence, 
beef tallow should be less hypercholesterolemic than butter fat, palm oil, and coconut oil. 
The same is true for lard, which likewise has only about 30% of its fatty acids as cholesterol 
raisers. Indeed, from the point of view of fatty acid composition, beef tallow and lard are no 
more hypercholesterolemic than chicken fat. This is not to say that these animal fats have no 
cholesterol-raising potential. Thirty percent of their calories consists of cholesterol-raising 
fatty acids, and this effect is not offset by the other fatty acids. Although stearic and oleic 
acids do not increase the cholesterol concentration, neither do they lower it. Thus, they must 
be considered neutral in their action on cholesterol levels. Still, even though meat fats must 
be considered "cholesterol raisers", they are less hypercholesterolemic than widely believed. 
Does the cholesterol in meat increase cholesterol levels? 
Cholesterol is found both in muscle and fat of meat. The cholesterol content of both is 
similar, about 70 to 90 mg per 100 grams. In general, red meats (beef and pork) do not 
contain significantly more cholesterol than white meats (fish and poultry) (Expert panel, 
1988). Thus, red meat is not uniquely hypercholesterolemic because of its cholesterol 
content. Furthermore, if consumption of red meat does not exceed six ounces per day, the 
intake of cholesterol will be in the range of 140 to 180 mg/day, which is within acceptable 
limits. The recommended intake of cholesterol is less than 300 mg/day. Normally, about 
one-third of dietary cholesterol comes from meat, one-third from eggs, and one-third from 
butter fat. It is relatively easy to essentially eliminate the latter two sources of cholesterol, 
and when this is done, consumption of meat in moderate amounts will not lead to an 
excessive intake of cholesterol. Thus, while the cholesterol content of meat/fat may raise 
serum-cholesterol levels, the rise will not be appreciable if other sources of cholesterol are 
eliminated. One way to reduce the cholesterol intake from meat is to remove excess fat. 
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Although the fat does not contain more cholesterol than the muscle, removal of excess fat 
will lower the absolute intake of cholesterol. 
Does red meat promote obesity? 
Yet another factor that may raise the serum-cholesterol level is obesity. Therefore, if red 
meat in the diet promotes development of obesity, it could contribute to higher cholesterol 
levels by this mechanism. There is the general impression that meat-eating populations are 
more obese than those that abstain from meat. There are several possible reasons for this 
impression. First, those who can afford meat tend to be more affluent than those who cannot, 
and affluence may promote overeating simply because people can buy more food. And 
second, if large amounts of fatty meats are consumed, they will be a concentrated source of 
calories; and in this way, meat can contribute to obesity. Fat-rich hamburger meat and 
processed meats are particularly high in calories, and their consumption could promote 
obesity if taken in excess. Thus, to the question of whether red meat promotes obesity, one 
must consider both the type of meat and amounts consumed. 
If one restricts meat consumption to six ounces per day, this will provide approximately 
only 350 to 450 calories per day. Considering that red meat is high in protein and iron, this 
certainly is not a high caloric price to pay for a good source of protein and essential minerals. 
Thus, we must conclude that red meat need not contribute significantly to obesity. If 
anything, lean meat could be a valuable part of a weight-reduction diet. 
How can meat be modified to reduce risk for CHD? 
The major change that can be made in red meat to reduce risk for CHD is to reduce its total 
fat content. Certainly the outside fat should be trimmed away, and this is being done 
increasingly in the preparation of fresh meat for sale. In fact, the public is becoming 
unwilling to pay for this excess fat, which is perceived by many people to be unnecessary and 
unhealthy. When the meat industry realizes that it costs excess money to put on unacceptable 
fat and then have it discarded, then animal-feeding techniques will be adopted to minimize 
the amount of outside fat on meat. When this occurs, the fat contained within the muscle (i.e., 
marbling) likewise will be reduced. By decreasing the fat content of muscle, fat intake 
accompanying meat consumption will be reduced even more. 
Once the idea is widely accepted by both the general public and the meat industry that 
low-fat meat is both healthier and less expensive, there are a variety of ways in which 
lower-fat meat can be produced. Use of recombinant somatotropin to stimulate protein 
accretion may be one way. Developing of new breeds of cattle that are more muscular and 
lower in fat may be another. Modification of the feeding pattern throughout the life of the 
animal may be yet another way to decrease the fat content of the whole animal. Still other 
ways may be found. The goal is to produce lean animals with a minimum of excess fat. 
In the case of pork, the type of fat as well as amounts of fat can be altered. By feeding 
unsaturated fatty acids to pigs, their fat can be made less saturated, i.e., the content of 
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palmitic acid can be reduced. The fat that is fed can be rich in either polyunsaturated fatty 
acids (linoleic acid) or monounsaturated fatty acids (oleic acid). In our view, diets high in 
oleic acid are preferable because of several theoretical advantages of oleic acid over linoleic 
acid in the diet. Although lean pork is preferable to fatty pork, the latter can be acceptable if 
its content of palmitic acid is reduced from the usual 28 to 30% to approximately 15 to 17% 
(St. John et al., 1987). Still, high-fat pork, regardless of fatty acid composition, can promote 
weight gain if too much is consumed. Therefore, technology should emphasize the 
production of low-fat pork, although replacement of palmitic acid with oleic acid to the 
extent possible can be a secondary goal. 
In the case of beef, it is difficult to modify the fatty-acid composition by feeding of 
unsaturated fats. In general, cattle do not readily absorb exogenous fat, and thus it is not 
possible to enrich adipose tissue with exogenous fat. And moreover, unsaturated fatty acids 
tend to be saturated in the rumen of cattle through bacterial hydrogénation. Previous research 
has shown that special treatment of feed will allow fat to pass through the rumen and thus be 
absorbed without alteration. By this procedure, the adipose-tissue content of unsaturated 
fatty acids can be increased (Nestel et al., 1973). Although this approach has never been 
appealing to the beef industry, more research is needed to develop ways tp accomplish a 
change in fatty-acid composition of beef to a healthier pattern. 
Cancer 
By what mechanisms might red meat increase risk for cancer? 
As reviewed recently by Prentice et al. (1990), several epidemiologic studies indicate that 
rates of certain types of cancer, particularly breast cancer and colon cancer, are higher in 
societies that consume large quantities of meat than in those in which intakes are low. These 
links have been noted in between-country studies, in migration studies, and to a lesser extent 
from within-country surveys. These relationships have led to speculations on possible 
mechanisms whereby high meat consumption might increase risk for cancer. 
One question that has been raised is whether the putative "cancer-causing" action of meat 
is due to its muscle or fat component. Since high intakes of fat have been implicated in the 
development of certain cancers, the effects of meat in cancer causation could be related 
exclusively to its fat content. If this is so, then the relation between meat and cancer 
presumably could be eliminated by use of low-fat meats. In epidemiologic studies, the 
overall link between fat and cancer is stronger than for meat per se, and a reasonable first step 
to eliminating the meat-cancer connection would be to switch from high-fat meat to low-fat 
meat. This change should reduce the risk for CHD as well, which is another reason to support 
this approach. Some workers believe that dietary fat itself is not a cause of cancer, but rather 
obesity resulting from high-fat diets is the cause. If so, this provides still another reason to 
switch from high-fat meat to lean meat. 
Alternatively, how might the muscle component of meat enhance the development of 
cancer? Are these substances in muscle that are directly or indirectly carcinogenic or cancer 
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promoters? Certainly, muscle contains a variety of compounds that theoretically might 
stimulate carcinogenesis. These compounds might become actively carcinogenic upon 
cooking, or they might enter meat during barbecuing. At present these possibilities are 
largely speculation, but perhaps are worthy of more investigation. On the other hand, 
theoretical carcinogens also exist in most other natural foods, especially fruits and 
vegetables. Thus, to condemn red meat as a possible carrier of carcinogens seems premature, 
and a recommendation to the public for dietary change cannot be made on the basis of a 
possibility. 
If anything, red meat in principle should be relatively free of carcinogenic properties. 
Both fat and muscle components of meat should be protected from acquiring exogenous 
carcinogenic factors derived from animal diets. Thus, beef and pork should not differ in 
composition from human flesh, and hence should contain little carcinogenic potential. If red 
meat plays a role in human cancer, it most likely acts by the promotion of cancer, rather than 
initiation. And if red meat is a cancer promoter, the fat component probably plays a greater 
role than the muscle. In other words, lean meat probably is less of a cancer promoter than 
fatty meat. Thus, on theoretical grounds, recommendations to avoid lean red meat because of 
its potential to induce cancer or to promote carcinogenesis cannot be justified. 
Does red meat increase risk for breast cancer? 
If consumption of red meat increases the risk for breast cancer, a relationship most likely 
can be explained by its fat content. World-wide epidemiologic studies suggest that high 
intakes of fat are accompanied by increased rates of breast cancer (Prentice and Sheppard 
1990). A relationship was not noted in a recent case-control study (Willnett et al., 1987), but 
many investigators still believe that high-fat diets predispose to breast cancer. Since 
consumption of high-fat meats is one contributor to high-fat diets, it is possible that fatty 
meats add to the dietary fat-cancer connection. It should be pointed out however that meat is 
only one of many sources of fat in the diet, and if the recommendation is made to curb meat 
intake to reduce fat consumption, this recommendation would have to extend to many other 
foods as well. There is no reason to single out meat as a source of dietary fat. 
By what mechanism might a high-fat diet predispose to breast cancer? One possibility is 
that such a diet will lead to obesity, which in turn may enhance the risk for cancer. For 
example, obesity is known to raise oestrogen levels, and high levels of circulating oestrogens 
may promote breast cancer. 
Some workers have suggested that high-fat diets promote growth early in life, and since 
tall women seem to be at higher risk for breast cancer than short women, rapid growth early 
in life might be diet related. Whether dietary fat in some way directly stimulates the growth 
of breast tissue and thereby predisposes to cancer is a matter for speculation. Another 
question is whether all types of fatty acids are potentially cancer promoting. For example, 
Prentice and Sheppard (1990) recently concluded that only saturated and polyunsaturated 
fatty acids predispose to cancer, whereas monounsaturated fatty acids do not have this 
potential. If this were true, it would suggest that specific fatty acids have a direct role in 
carcinogenesis, and further, the saturated fatty acids of beef might be a contributor. In spite 
of speculation about possible mechanisms, little or nothing is known with certainty about the 
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mechanisms whereby a high-fat diet might promote breast cancer. Until such a mechanism 
has been identified, there will remain serious doubt whether the apparent relation between 
dietary fat and breast cancer is real, or is merely the result of confounding factors. 
Does red meat increase risk for colon cancer? 
There are at least three ways in which red meat in the diet might predispose to colon 
cancer. First, the fatty portion of meat might be involved; second, the muscle of meat could 
contain carcinogenic substances that remain unabsorbed and pass into the colon; and third, 
meat might be consumed in the place of other foods that have a protective action against 
colon cancer. Each of these possibilities can be considered. 
If the fat of meat promotes development of colon cancer, the mechanisms might be similar 
to those described previously for breast cancer, e.g., promotion of obesity. Some workers 
have speculated that bile acids may have cancer-promoting properties, and obese people 
definitely make more bile acids than thin people. As this excess of bile acids pass through the 
colon on their way to excretion, they could promote development of colon cancer. Note here 
should be made of the misconception that a high percentage of fat in the diet, Independent of 
body weight, stimulates formation of bile acids; this is not the case (Grundy and Metzger 
1972). But it is true that obesity stimulates bile-acid synthesis (Nestel et al., 1973), and if a 
high intake of fat promotes obesity, this response could favour any bile acid-cancer 
relationship. Of course, obesity might promote colon-cancer development in other ways, 
such as overstimulating cell division by providing high circulating levels of glucose and free 
fatty acids. 
Second, does the muscle of red meat have carcinogenic substances, or cancer promoters? 
Little information is available to answer this question. In a recent case control study (Willnet 
et al., 1990), based on reported consumption at baseline, there appeared to be a relationship 
between meat consumption (independent of its fat content) and colon cancer in American 
women. This apparent connection however was relatively weak, and firm conclusions could 
not be drawn. Perhaps various substances might be extracted out of fresh meat (and cooked 
meat) to test in animals for their carcinogenic potential; but to date, little direct evidence 
supports the notion that the muscle portion of meat contains carcinogenic substances. 
Finally, diets high in meat could be deficient in fruits, vegetables, and fibre, and if these 
foods have a protective action against colon cancer, this could explain a meat-cancer 
relationship. If so, meat would not be a cause of cancer but only would be guilty by lack of 
association. Certainly, protective foods could be added to diet without the elimination of 
meat. 
How can red meat be modified to reduce risk for cancer? 
The above considerations raise a serious question as to whether meat consumption truly is 
related to development of cancer. The evidence is not strong enough at present to make 
public recommendations for reduction in meat intake. If there is a connection between meat 
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and cancer, it is most likely related to a high-fat content. Whether a high-fat intake is related 
to cancer through promotion of obesity or by direct effect on susceptible tissues has not been 
determined. The available evidence suggests that saturated fatty acids are more closely 
related to cancer development than monounsaturates (Prentice and Sheppard 1990). Since a 
moderately high proportion of fatty acids in meat are saturated, and since some of these fatty 
acids also raise the serum-cholesterol level, it is reasonable to attempt to reduce intake of 
meat-derived saturated fatty acids. Actually, this can be accomplished best by reducing the 
total fat content of meat. Thus, the most appropriate modification of meat for the purpose of 
reducing risk for cancer is to reduce its fat content. At the same time, a general 
recommendation for liberal amounts of fruits, vegetables, and fibre can be made (Committee 
on Diet and Health Food and Nutrition Board, Commission on Life Sciences, National 
Research Council, 1989); in other words, meat eaters should not cut back on these other 
foods, which may offer some protection against cancer. Finally, further research should be 
carried out on the components of the muscle portion of meat to determine whether it contains 
substances of carcinogenic potential. 
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Chairman: 
M.A. Norcross, United States Department of Agriculture, 
Food Safety and Inspection Service - USA 
Discussion moderator: 
R.R. Straughan, Department of Arts and Humanities, 
University of Reading - UK 
Participants readily agreed that biotechnology is an emerging 
factor of great significance for the world food industry, and that 
the way must be prepared if biotechnology is to be accepted smoothly 
and efficiently into our society and the world at large. If adequate 
preparatory work is not done, the benefits of biotechnology may be 
diminished or missed altogether. 
Preparation is necessary, the participants affirmed, because of 
potential consumer mistrust and fear of the process of 
biotechnology and its products. Harlander noted that educating 
consumers about biotechnology is crucially important, but may be 
difficult because of the decline of scientific literacy in our society and a 
deep-rooted mistrust of technology. Taverner reported that in Australia 
there is both a low level of knowledge of biotechnology and various 
concerns, differing among regions, as to its desirability. Hoban noted 
that consumer acceptance of biotechnology in meat and milk 
production is at best uncertain; significant percentages of major 
demographic groups - women, religious fundamentalists, the less 
educated - may be resistant to its introduction. Those who tend to be 
suspicious of institutional information and policies - seemingly, a 
growing number - are more likely to oppose the use of biotechnology. 
Foster stated that consumer anxieties centre on safety, but also include 
social and ethical issues and a strong fear of the new and unknown. 
She noted a study in the Netherlands indicating that increased 
knowledge of the subject is just as likely to lead to greater resistance. 
Meeker cited surveys showing a very low level of scientific literacy in the 
United States and the United Kingdom, and noted that decisions 
affecting the fate of agriculture are often made on the basis of a public 
opinion far more influenced by the news media than by actual scientific 
knowledge. 
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All participants agreed that in order for biotechnology to be accepted, 
the critical task of educating consumers about biotechnology must be 
performed. This will not be simple or easy. 
Harlander stated that scientists could play a vital role in 
educating the public, but few scientists are trained or experienced in 
such endeavours. Institutions seldom acknowledge the value of 
communicating complex scientific information to the public, and 
scientists who become "explainers" may be held in less esteem by their 
colleagues. 
Harlander identified university scientists as the most appropriate 
individuals to interact with the public regarding biotechnology. 
University scientists who perform this role must be skilful at personal 
interaction, patient and imaginative. These individuals will likely 
require media training and substantial support from the university 
administration. Their key objective will be building coalitions that 
involve industry, government, and consumer groups in the making of 
biotechnology research policy. In conclusion, she quoted Abraham 
Lincoln who said that "Public opinion may not always be right, but it 
always prevails. " 
Taverner cited the commitment of the Australian government to a free 
and open public debate on biotechnology, but also noted that 
scientists seem to possess a low level of credibility with the public. 
Further surveys in this regard are needed. 
Hoban's research agreed with Harlander's, in that both identified 
academic scientists as the most appropriate educators of the public 
regarding biotechnology. Hoban affirmed the need for extensive 
educational efforts and for public involvement in 
decision-making on this issue, but cautioned that some segments of 
the population may remain sceptical. 
Foster detailed European Community and United Kingdom legislation 
designed to provide adequate safeguards in the approval of 
biotechnology applications. She further reported on the results of a 
recent workshop of the International Organization of Consumer 
Unions, which urged active government enlistment of consumer groups 
in impact assessment and decision-making and called for government 
support of consumer research. She noted that consumers' concerns 
and rights should be respected and considered, and paternalistic 
prescriptions and attempts at persuasion should be avoided. 
Meeker asserted that research scientists and administrators must 
assume some responsibility for communicating with the public, 
and noted that the public does perceive the world as being improved by 
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the existence of modern science. Scientists must maintain the trust of 
the public in order to be involved as experts in risk-assessment. The 
public should be treated with respect, their concerns addressed, and 
their questions answered. Further, public confidence in regulatory 
agencies is crucial. Industrial organizations should support the 
decisions of the regulatory agencies, should make available to the 
public as much information as possible and should assist in consumer 
education to ensure the smooth implementation of biotechnology. 
• Summarizing the presentations, Straughan commented on three 
recurrent themes: 
- Safety 
- Naturalness and 
- Education. 
• Safety can never be absolute, and in weighing potential risks 
and benefits, value judgements must enter in. Concerns about the 
"unnaturalness" of genetic manipulation stem from a variety of beliefs 
and value systems, which a significant number of consumers may 
share. Consumer education is needed to raise awareness, but it cannot 
guarantee consumer acceptance; scientific experts can explain the 
science but there are no moral experts to prescribe what is right and 
wrong. 
• The cumulative thrust of these presentations is that biotechnology will 
pose major challenges to the scientific, regulatory, and industrial 
communities in educating the public regarding its benefits and 
risks and preparing the way for timely implantation. Many skills in 
the art of communication must be acquired and mastered and new 
working coalitions will be required. It is possible that even with the best 
efforts, the complete acceptance of biotechnology by the public may be 
an elusive goal. Clearly, the key individuals in this complex process are 
research scientists who, encouraged by government and industry, will 
work with the public toward a more perfect understanding of the 
benefits and risks of biotechnology. Further, there must continue to be a 
mutually respected working relationship between industry, academia 
and government based on impeccable scientific principles that are 
comprehensible to the layman. 
• It undoubtedly would be beneficial to have the proceedings of this 
Symposium prepared in summary form for wide-spread 
distribution. In this way, the conclusions and recommendations 
resulting from this Symposium could be broadly shared with the 
public. 
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COMMUNICATION BETWEEN SCIENTISTS AND CONSUMERS 
S. K. Harlander 
Department of Food Science and Nutrition, University of Minnesota, St. Paul, 
MN 55108 
Summary 
After years of speculation and promise, agricultural and food biotechnology are beginning 
to move from the research laboratory to the barn, the field and the processing plant. The 
orderly transition from research and development to application and commercialization will 
depend greatly upon acceptance by the consuming public. For this reason, educating 
consumers about biotechnology is critically important. Many believe this is an extremely 
difficult, if not impossible task, due to the erosion of science literacy in this country; a 
growing mistrust of technology, especially biotechnology; and, fear of the potential long 
term unanticipated effects of technological innovations. Scientists involved in 
biotechnology research in industry, government and academic institutions could play vital 
roles in fostering public understanding and rational discussion of biotechnology issues. 
Unfortunately, many scientists have had little or no formal training or practical experience in 
interfacing with the public or the press, and are often ill-prepared to meet the challenges 
posed by this new educational format. Few institutions recognize the need for and value of 
communicating complex scientific information in nontechnical and understandable language 
to the lay public, and the scientist who does become visibly involved in educating the public 
may be rebuked by fellow scientists. This paper will deal with the changing role of the 
scientist in society and will provide some suggestions for effective communication of 
biotechnology issues between consumers and scientists. 
Keywords: biotechnology, communication, scientists, consumers 
Introduction 
Being a self-proclaimed cheerleader for biotechnology, I am frequently asked to discuss 
the potential impact of biotechnology on agriculture and food processing to diverse 
audiences. I vividly recall my first experience with an audience that was less than 
enthusiastic about the potential benefits of science and technology for improving the food 
supply. It was astonishing to me that not everyone shared my enthusiasm for genetically 
engineered dairy starter cultures, insect-resistant plants, and recombinant bovine 
somatotropin (rbST). 
This audience was not enamoured with the technology I predicted would revolutionize 
agriculture and food processing in the next decade. They raised concerns about the potential 
long term unanticipated affects of impacts of products resultant from biotechnology being 
used to improve efficiency and quality of food production. They were concerned about the 
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escalating loss of plant germplasm and the potential negative effect of biotechnology on 
biological diversity, ecology and the environment. Although willing to accept risks imposed 
by nature, they were outraged by involuntary imposition of man-made risks, especially if risk 
would be disproportionately imposed on particularly vulnerable members of society — 
infants, children, pregnant women, the elderly, or the chronically ill. They were frightened 
by the pace of discoveries in biotechnology and its pervasive impact on every scientific 
discipline. 
The group was opposed to any technology that might undermine the survival of small 
family farmers and questioned why the public should support the development of technology 
that would line the pockets of large corporate agribusinesses while providing few tangible 
benefits for consumers. They were appalled at the amount of public and private funds being 
devoted to biotechnology at the expense of research on sustainable agriculture, alternative 
crops and groundwater contamination. They were disillusioned with the hype and the 
promises of agricultural biotechnology and the paucity of commercially viable products. 
They challenged the results of university research funded by manufacturers of biotechnology 
products and attacked the integrity of university scientists who accepted funding from 
industry. 
They had lost confidence in the ability of federal and state regulatory agencies to protect 
the safety, wholesomeness and nutritional quality of the food supply. They wanted some 
reassurance that I and the other scientists and administrators involved in food biotechnology 
had considered the social, moral, ecological, environmental, economic and ethical 
implications of this new and revolutionary science. Obviously, the technical and scientific 
information that I felt most comfortable discussing were not the issues of utmost concern to 
that audience. 
This experience was important to me for a number of reasons: 
(1) It sensitized me to the complex issues that surround the acceptance and adoption of new 
technology, especially biotechnology, by the public. 
(2) The issues raised by the audience were representative of the kinds of consumer concerns 
the scientific community must address in order to convince the public that the products of 
biotechnology are safe and effective. 
(3) It made me painfully aware of the fact that nothing in my previous training or experience 
had prepared me to deal with these issues in an objective, rational, nondefensive, and 
compassionate manner. 
(4) It marked the first step of a personal journey that has changed my view on the role of the 
scientist in society -- a view that is not necessarily shared by scientific peers or 
administrators. 
To meet the challenges facing agriculture in the next decade will require the development 
of new and innovative technologies. Acceptance of these technological advances by the 
consuming public will be an important prerequisite to implementation. University scientists 
may be the most appropriate individuals to instill the enthusiasm, explain the benefits, and 
garner the trust of the public in agriculture and food biotechnology. 
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Challenges Facing Agriculture 
The U.S. is one of the most efficient producers of food in the world; therefore, much of 
the burden for feeding the rapidly expanding global population may fall on our shoulders. It 
is predicted that the world's population will increase at a rate of approximately 90 million 
people annually. At the present time, most of the world's good agricultural land is already in 
production, and nearly all available irrigation water is being exploited. 
In spite of the agricultural chemicals used to control plant pests, 37% of the food supply 
is lost annually to insects, weeds and plant pathogens. Developing countries experience 
losses as great as 60-80% of the annual food crops to plant pests and spoilage. The food 
supply is also vulnerable to natural catastrophes such as droughts, floods, and frost damage. 
Satisfying global food needs will require increased productivity and efficiency. At the same 
time, it is critical that increasing agricultural output be done in ways that will not degrade the 
environment and the natural resource base on which agriculture depends. 
Understanding the Food Chain 
In spite of these challenges, U.S. consumers have come to expect a safe, nutritious, 
abundant and affordable food supply. We are accustomed to spending less than 18% of our 
disposable income on food; yet, few understand how that food is grown, processed, or 
distributed. Eliminating the use of agricultural chemicals could result in produce that differs 
in appearance, taste, texture, nutritional quality, shelf-life, safety, and cost, when compared 
to traditional products. Only 2% of the population is involved in growing food for the entire 
nation. Unfortunately, although agriculture, food and nutrition are central to human 
existence, these topics are rarely emphasized, or even discussed, in elementary and 
secondary schools. With the lack of knowledge about food, one can understand why the 
public becomes outraged when they hear reports about Alar in apples, pesticides in ground 
water and Salmonella in poultry or eggs. 
Assuring the Safety of the Food Supply 
The United States enjoys the safest food supply in the world. The U.S. Food and Drug 
Administration has primary responsibility for insuring the safety of the food supply, and they 
have done an exemplary job. Unfortunately, few understand the regulatory process for 
approval of new food ingredients or animal drugs and biologies. As part of the approval 
process, companies are required to provide extensive evidence of human safety and efficacy. 
Although much testing may be done internally, results must be confirmed by independent 
laboratories. Human drugs are frequently evaluated by University Medical Schools that 
conduct well-controlled human clinical trials. In the same way, animal biologies may be 
evaluated by Animal Science departments or Veterinary schools; food ingredients may be 
tested for performance and nutritional impact by Food Science and Nutrition departments. 
Such testing is expensive and absolutely essential, and federal funds are not available. The 
expense is, and should be, born by the companies developing the products. Approval is 
dependent upon a rigorous review of all available data by the regulatory agencies. Although 
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this can be a painfully slow and expensive process for companies developing new products, 
it has worked very effectively for assuring the safety of the food supply. Such a system is 
absolutely essential. 
Who Supports Your Research? 
Just as few consumers understand how the safety of the food supply is ensured by 
regulatory agencies, how research is funded by industry at universities is also not well 
understood by the general public. Universities have developed guidelines for interaction with 
industry that protect the rights of University scientists to design research protocols, conduct 
research unhindered, and publish their data in peer-reviewed journals. Confidentiality, 
financial arrangements, and patent and licensing rights are established in agreements 
generated and approved by the University. 
Despite these personal and institutional safeguards, some believe that it is inappropriate 
for universities to accept research funding from industry. They suspect that industry will 
control the outcome of research or suppress the open communication and dissemination of 
facts if the results are not favourable to industry's purpose. The integrity of an 
industry-funded University scientist may be questioned by consumer groups or the news 
media. This will become increasingly troublesome as federal funding for basic research 
continues to decline, and pressure for universities to seek alternative sources of funding from 
industry or non-profit institutions to support research and training activities increases. 
It goes without saying that rigorous standards to guide industry funding of research at 
universities must be maintained, and these standards shared openly and honestly with the 
public. The vast majority of scientists will not jeopardize their most precious asset — their 
scientific integrity — and the public needs to know this fact. Industry must openly 
acknowledge and support the requirement that universities be objective and unbiased in their 
research pursuits. 
In general, University scientists have enjoyed the confidence and support of the majority 
of the consuming public. Numerous surveys indicate that scientists are one of the most 
trusted sources of information; therefore, University scientists may be the most appropriate 
individuals to instill the enthusiasm, explain the benefits, and garner the trust of the public in 
agriculture and food biotechnology. 
Who Should Communicate with Consumers? 
Not all scientists should be involved in communicating with consumers. It is important to 
recognize that some scientists lack the communication skills necessary to simplify complex 
information in language that is understandable to the lay public. An arrogant and defensive 
scientist would not gain public trust. Scientists cannot expect to be trusted simply because 
they are the experts. When challenged or threatened, it is common for some scientists to 
resort to familiar technical jargon. These scientists best serve society by staying in the 
laboratory. 
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The scientists that communicate with consumers must be people-oriented individuals who 
are sincere and compassionate. They must be able to empathize without trivializing 
consumer concern. They must accept and affirm those concerns, even if they fly in the face 
of all scientific evidence or appear irrational to the majority of the scientific community. The 
concerns are real to the consumers who believe them, and it is the role of the scientist to bring 
to bear all of the scientific evidence available to address the concern. Scientists must also be 
willing to acknowledge where data is insufficient to answer the question. They must be open 
to divergent opinions, be honest, forthright and nondefensive, and not fearful of being 
personally and professionally challenged. Patience, a sense of humour, and a thick skin are 
also definite assets. 
Interacting with Advocacy Groups and the Press 
The public receives much of their science education from the news media. Advocacy 
groups are also frequently involved in educational efforts that espouse their particular cause. 
Consumers may perceive that advocacy groups and the press provide information not readily 
available from industry or government, or intended to counterbalance information provided 
by these agencies. Scientists are often reluctant to interact with the press for fear they will be 
misquoted. As a result, articles that appear in the press do not always contain balanced, 
factual information. To interact effectively with the press, it is essential that scientific 
information be presented in understandable language. Yet to the scientific purist, 
simplification of technical information could lead to misunderstanding by consumers, or 
worse yet, peers, who might question their motives for speaking to the press on controversial 
issues. 
Many academic scientists who have had to respond to inquiries from the press or 
advocacy groups are quick to share their bad experiences. In addition, they are frequently 
ill-prepared to be challenged and may respond very defensively if they perceive they are 
being attacked. If the press handles an issue unfairly or incorrectly, it is important that they 
be challenged and corrected. Scientists need to be encouraged to develop personal 
relationships with science or food editors of local newspapers and take time to educate them 
on complex scientific issues, realizing that it will take a proactive approach and lots of time 
will need to be invested. 
The scientist must be recognized as a trusted, responsive and reliable source of 
information to the news media. Although we are often quick to criticize the press, it is 
important for scientists to understand the pressures and time restraints inherent in the job of 
reporting the news. Advocacy groups have developed sophisticated communication systems 
to keep the press informed on various issues. Scientists, on the other hand, rarely 
communicate with the press unless contacted. If scientists are not available or willing to 
provide balanced information on an issue, the reporter has little choice but to report what 
information is available. Scientists should and must provide accurate and objective 
information to the press and assist in their efforts to translate the technology for the general 
public. 
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Professional TVaining 
For those scientists that elect to become involved in educational outreach activities, 
professional media training on the most effective ways to communicate with the public and 
the press must be provided on an ongoing basis. It is important to recognize that classroom 
teaching is very different than communicating with consumers or the press, and few faculty 
members have any practical experience in these areas. Any scientist who has been misquoted 
may likely avoid future encounters with the press, and few understand how to control an 
interview. Proficiency comes only with a great deal of practice. Role playing, video and 
audio recording of mock interviews, testing of responses to hostile questions or personal 
attacks, assistance in capturing key thoughts in "sound bites", instructions on how to 
effectively communicate key points in interviews with newspaper, radio and TV reporters, 
and peer evaluation, are critical activities for improving communication skills. Each 
successful experience builds confidence and reinforces the value of the activity for the 
scientist. 
Administrative Support 
It is critical that administrators recognize and affirm that communication with the public 
is an obligation of University scientists and is a highly valued activity. Administrators must 
provide continuous and visible support for those scientists willing and able to participate in 
outreach activities. This could include release time from other academic responsibilities, 
verbal support, and recognition of contributions as an expected and valued activity for 
promotion and tenure considerations. Highlighting consumer education as an integral part of 
the mission statement of the unit is also important. In at least some cases, the best 
communicators may also be the best researchers and teachers, and commitment to consumer 
education will necessarily detract from these activities. 
Building Coalitions 
Academic institutions could serve a vital function by bringing together groups with 
divergent opinions to discuss issues related to agriculture and food biotechnology. Although 
this may be a painful process, particularly if advocacy groups with radical or anti-technology 
viewpoints are represented, this activity is extremely important. Open discussion of the 
concerns of farmers, consumers, advocacy groups, industrial scientists, and government 
agencies provides valuable information that could help guide research programs at 
land-grant institutions. These groups do not need to control the research agenda at academic 
institutions, but their input should be actively sought and acknowledged. If these groups 
participate and take ownership in the process of providing input and feel their opinions are 
valued, implementation of biotechnology in agriculture and food will be more readily 
accepted. Not all scientists and administrators need to participate in this process. Individuals 
who are compassionate, sensitive to the needs of people, and unafraid of being challenged 
should be encouraged to participate. 
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Prospects for the Future 
Biotechnology appears to offer viable solutions to many of the challenges that face 
agricultural and food systems; however, if the public does not accept the technology, it 
simply will not be used. Eroding scientific literacy coupled with growing mistrust of 
technology creates an enormous educational challenge — a challenge that demands our 
attention. To be successful, we must: 
- Encourage enthusiastic, communicative, and caring scientists to discuss biotechnology with 
consumers. 
- Communicate in language understandable to the general public. 
- Acknowledge public concern and listen to consumer fears in a sensitive, compassionate and 
sincere manner. 
- Involve the public in making decisions that will impact their communities and their lives. 
- Provide both sides of the story to the public so they can make informed choices. 
- Reassure the public that appropriate regulatory systems are in place to protect the safety of the 
food supply. 
- Provide administrative support and training for those scientists who are willing and able to 
communicate with the public. ' 
In the long term, it is essential that we begin to address the problem of eroding scientific 
literacy in this country. We must institute educational programs at the elementary and 
secondary school level on how food is grown, processed and distributed. Colleges and 
universities need to recognize that a basic understanding of agriculture, food and nutrition 
should be a component of a liberal arts education, and work to develop appropriate courses 
of general interest to all students. It is also important to recognize that industry, government 
and academic scientists must share the responsibility of educating the public about 
challenges that face agriculture and food systems and the potential benefits of science and 
technology. 
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DETERMINANTS OF PUBLIC ACCEPTANCE IN AUSTRALASIA 
OF BIOTECHNOLOGY FOR THE CONTROL OF GROWTH AND 
PRODUCT QUALITY IN MEAT PRODUCTION 
M.R. Taverner, 
Pig Research and Development Corporation, Canberra, Australia 
Summary 
Within this region there is extreme variation in the methods of meat production and 
marketing. Different socio-economic conditions throughout the region will affect public 
attitudes to biotechnology. 
In determining attitudes to biotechnologies affecting the production and quality of their 
dietary meat, the public will "weigh" perceived advantages of price and product quality 
against perceived disadvantages of product safety, animal welfare, ethical and moral issues 
and environmental concerns. 
The public is making this assessment with little understanding of biotechnology: in NZ, 
only 9% of the public claimed they could explain biotechnology to a friend. 
Scientists, environmental groups, authoritative public agencies and government will help 
form public perceptions regarding the acceptability of biotechnology in the production of 
meat. However, studies in NZ show that scientists have poor credibility with the public while 
in Australia, environmental groups have gained high exposure and credibility. 
There is a need for greater public awareness of the social and economic benefits, possible 
hazards and the controls used to minimise these risks. However, the task is made difficult by 
the lack of clear government and meat industry policy on the issue and the lack of specific 
studies of public attitudes to biotechnology in meat production. 
Keywords: Australasia, biotechnology, acceptability. 
Introduction 
Australasia is a very diverse and rather ill-defined region. In the past, it has been taken to 
include Australia and its geographical neighbours New Zealand (NZ), Papua New Guinea, 
Indonesia, Singapore, Malaysia and the major island groups in the Pacific Ocean. 
While the production and marketing of meat in Australia and NZ have much in common, 
these two countries have little in common in this regard with other countries in the 
Australasian region. 
219 
TAVERNER 
In Australasia, the major and distinct markets likely to influence the production and 
marketing of meat and hence public acceptance of new biotechnologies in meat production, 
are those in Australia and NZ, S.E. Asia and Japan. 
This paper will cover the general features of these markets, but will focus on the situation 
in Australia and NZ where there is more data, experience and activity in the area of 
biotechnology for the control of animal growth. 
Features of the meat markets 
The meat markets of Australasia and other countries around the Pacific rim have little in 
common. They vary from the extremes of finesse in presentation and hygiene in Japanese 
supermarkets to the market stalls of South East Asia where the consumers demand freshly 
slaughtered (warm) pork. 
The consumers of Australia and NZ purchase the majority (70%) of their meat from 
specialist meat retailers (butcher's shops) rather than supermarkets. 
The projected per capita consumption of meat (excluding fish) in 1990 in these regions is 
greatest by Australians (77 kg) and New Zealanders (79 kg) with considerably lower figures 
in countries such as Taiwan (39 kg) and Japan (27 kg). 
The countries also vary in their self sufficiency for meat. Australia exports nearly half 
(46%) of its total red meat production, while Japan is only 70 - 80% self sufficient for meat. 
In competing for this share of the lucrative Japanese meat market, the Japanese standards 
and expectations for meat quality and safety become highly influential. They influence 
events in the Asian region and beyond. 
Features of consumer perceptions of biotechnologies in meat production 
In assessing their acceptance of biotechnologies affecting the production and quality of 
their dietary meat, consumers will be looking at the "trade-offs" i.e. balancing the advantages 
and disadvantages from their perspectives. 
Perceived advantages 
Price 
Studies of the economic impact of agricultural biotechnology, such as that reported by 
Lemieux and Wohlgenant (1988) for porcine somatotropin suggest that through its influence 
in reducing pork prices, the net benefits to the consumers will be between 2 and 3 times 
greater than to the producer. 
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Biotechnologies are expected to have a major influence in ensuring minimal meat price 
increases. The extent to which this advantage is perceived by consumers has not been 
established. Indeed, ironically it might be that by making food cheaper than it would be 
otherwise, biotechnology could be encouraging consumers to become more indulgent in their 
demands of food products. 
Product quality 
In most markets and for most meats, the major determinants of quality appear to be colour 
and leanness. 
For example, surveys of consumer behaviour with pork in Japan in both 1983 (Takase et 
al., 1985) and 1989 (Koizumi et al., 1990) found that meat colour and the amount of fat in 
the meat were the most important determinant of quality - in both surveys between 19 and 
20% of housewives judged fatness to be a major determinant of quality. Pork colour 
however, was judged by more than one third of respondents as the most important 
determinant. 
The Australian public is well exposed to the health benefits of lean meat. Consumers have 
been under constant pressure to decrease dietary intake of saturated fats. 
Although in the early 1980's consumers had overriding concerns regarding the adverse 
health implications of eating meat, advertising has changed consumer attitudes towards meat. 
Recent consumer research reported by the Australian Meat and Livestock Corporation in its 
Meat Marketing Trends (March 1990), indicates that consumers now believe that they had 
earlier been misinformed by the media on meat. 
More consumers now regard nutritional value as a reason for their continual use of meat. 
For example as shown in Figure 1, the proportion of consumers throughout Australia who 
believe beef and lamb to be "good for you", increased from 69% in 1985 to 87% in 1988. 
'Lamb & Beef Are Good For You -
. They're Full of Protein, Vitamins and Minerals' 
Figure 1. Consumer awareness of the nutritional benefits of meat (from Meat Marketing Trends (March 
89) 
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Advertising in Australia has promoted "new" meat i.e. lean and served in smaller portions, 
in contrast to "old" meat described as thick and fatty, i.e. created the impression of a new 
meat with improved quality. There are possible analogies for meat produced using new 
biotechnologies. 
In their survey of over 2,000 of the New Zealand public, Couchman and Fink-Jensen 
(1990) found that 66% of respondents perceived benefits on genetic engineering of animals. 
(In contrast, 88% perceived benefit from the genetic engineering of plants.) 
Of those who recognised the benefits, only 11% said it would contribute to better meat. 
The most recognised benefit of genetic engineering (38%) was that it would help improve 
stock and animal products. 
Perceived disadvantages 
The debate on these biotechnologies for meat production will inevitably be associated 
with the increasingly public debate in Australia and NZ on genetic engineering. 
Couchman and Fink-Jensen(1990) found that while 73% of the NZ public had heard of 
genetic engineering, just over half (57%) had heard of biotechnology. Furthermore, although 
only 9% claimed they could explain biotechnology to a friend, more than 20% said they 
could explain genetic engineering. 
Among the NZ public, the survey indicated that the highest level (48%) of concern among 
various products of genetic engineering was for the use of meat. However, more than half of 
the respondents were not concerned about eating meat of genetically engineered animals. 
Table 1. Incidence of concern about using genetic engineered produce (%) 
Subject Incidence % 
medicine 34 
meat 48 
vegetable 38 
dairy 43 
(Couchman and Fink-Jensen, 1990) 
The nature of the concerns of the public with eating this meat were primarily that the meat 
was unnatural (27%). However, they were also concerned that there may be unknown effects 
from eating such foods (21%), that they did not know what they were eating (15%), product 
safety (9%), lack of information (9%), animal cruelty (5%) and other minor concerns. 
Product safety 
In Japan, consciousness among housewives of the 'sanitary condition of pork' rated 3.2 on 
a scale of 1 to 7. 
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In both 1983 (Takase et al., 1985) and 1989 (Koizumi et al., 1990), nearly 40% of 
Japanese housewives considered the safety/sanitation of pork an issue. Of these, the major 
problem (86%) was thought to arise from the use of medicines for the pig. 
In another survey conducted in Japan by a Consumers Co-operative who provide 
"chemical free" meat to their members through special contracts with farmers, about 40% of 
their consumers were concerned about the residue of "hormone and antibiotic". 
Although this might be an extreme group and while the Japanese housewife might be 
more sensitised to food safety than those in Australia, there does appear to be a growing 
public awareness of potential residues in meat. 
Nevertheless, while media prominence in Australia has been provided to pesticide 
residues in beef and while about half of Australia's beef is produced using hormone therapy, 
public attitudes towards beef in general have maintained a positive profile. 
Animal welfare issues 
Couchman and Fink-Jensen (1990) asked an open-ended question regarding the nature of 
concerns about using meat from genetically modified animals. Only 5% of respondents 
mentioned animal cruelty and these concerns were with the wellbeing of the animal as well 
as the moral issues of animal use. Similarly, of those (58%) who considered that there were 
serious risks involved in genetic engineering of animal cells, only 6% identified the risk of 
animal abuse. 
Thus in New Zealand, animal welfare issues appear not to be perceived by the public as a 
major disadvantage of biotechnology in meat production. 
Ethical and moral issues 
In a recent Australian report, the Victorian Law Reform Commission focused on 
identifying aspects of genetic manipulation work that may present particular risks or arouse 
particular public concern. 
They found general moral concerns about genetic manipulation; despite the achievements 
of genetic manipulation and its future promise, some people are deeply concerned about the 
fundamental moral implications of this technology. 
Because it "interfered with nature", genetic manipulation of human cells was least 
acceptable to all groups in the NZ survey (Couchman and Fink-Jensen 1990). However, more 
than half (56%) of the respondents considered that the manipulation of the genetic material 
of animals was acceptable. 
Environmental concerns 
The apparent concern of Australian consumers for environmental issues was reflected in 
recent consumer research that identified the desire of consumers for "environmentally 
friendly" packaging of meat products. 
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Indeed, the Victorian Law Reform Commission identified widespread public concern 
about the potential environmental effects of releasing recombinant organisms. 
This is an emotive area upon which pressure groups have seized for their advantage. 
Major influences on public opinion 
There are a number of major influences which help form these perceptions of consumers 
regarding the acceptability of biotechnology in the production of their meat. 
Scientists 
Couchman and Fink-Jensen (1990) assessed the credibility among the NZ public of both 
public sector and corporate sector scientists. They sought the reaction of respondents to 
statements of either public or corporate sector scientists endorsing the safety of a research 
project. While 36% would believe the public sector scientist, only 28% would believe the 
company scientist. 
There were 20% of the respondents who would not believe the public sector scientist, and 
the remaining 52% remained undecided. 
Despite a strong positive perception of science among New Zealanders, Couchman and 
Fink-Jensen (1990) found strong concerns about possible hazards of science and the desire 
among the public for tighter regulation. 
Clearly, because of their poor credibility in relation to product safety, scientists may not 
be the most appropriate group to influence public opinion. 
Environmental groups 
The environmental movement has the Australian farming community on the defensive. 
Everyday farming practices are under scrutiny from a lobby movement and a media that is 
suspicious of the environmental credentials of scientists and farmers. 
For example, the Australian Conservation Foundation (ACF) issued a press release stating 
that there had been a cover-up with regard to the release of transgenic pigs in Australia. They 
indicated there had been unauthorised sale of genetically modified pigs in South Australia. 
They were concerned with three points: 
• the possible impact of biological diversity if extra hormone genes transferred into feral 
pigs or other domestic animals; 
• human health aspects of eating engineered animals and, 
• welfare considerations. 
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The media reported this story with enthusiasm: following this press release there was a 
front page headline, "Mutant Meat", describing the ACF release in some graphic detail. 
Three or four days later on page 13 of the same newspaper there were some further stories 
which presented a more reasoned and detailed account of the whole incident. It was clear, for 
example, that many of the allegations made by the ACF were not true but in fact that the 
National Health & Medical Research Council (NH&MRC) had assessed the human health 
aspects of eating these particular animals and approved them for human consumption. 
All the correct protocols involved in transportation of these animals so that there was 
minimal risk to their release to the environment were followed and, similarly, in terms of 
animal welfare, this aspect had also been covered. 
Indeed it seemed that many details of every transaction had been scrutinised by ethics 
committees at various levels. 
The NH&MRC and the State Health Commission both approved the slaughter and sale of 
the pigs which they agreed were no different to normal animals. This has been public 
information. Nevertheless this manipulative misreporting of the incident has,, almost killed 
this research project. 
The ACF has now called for a moratorium on the further release of genetically engineered 
organisms "into the environment". 
Environmental groups such as the ACF, will ensure that developments in genetic 
engineering in agriculture will be a debate that will occupy the nation in the 1990's. 
However, apart from this incident with transgenic pigs, the Australian public have had 
little exposure to these biotechnologies and there is little general understanding or 
knowledge of biotechnology. 
While the NZ study of Couchman and Fink-Jensen suggests that the concern and an 
apparent lack of knowledge of these new technologies in agriculture may hamper vital 
research, this same lack of knowledge could used to the advantage in their introduction. 
There has been little reporting in Australia of research relating to the use of hormones in 
animal production. There has been no rbST issue and no public reaction and alarm 
concerning perceived risks to human health through milk supplies etc. 
Public health authorities in Australia and New Zealand have not stated any clear position 
for or against the technologies. 
Authoritative public agencies 
The Australian National Heart Foundation has endorsed lean meat as a healthy product. 
The support for biotechnologies leading to leaner meat production from respected groups 
such as these would be extremely influential with the public. 
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In recommending legislation on the issues involved with genetic manipulation, the 
Victorian Law Reform Commission recommended: 
• Genetic manipulation should not be limited in any general way. 
• The Genetic Manipulation Advisory Committee should continue to advise and monitor 
genetic manipulation work. 
• Specific legislation should be enacted to control experimental releases of recombinant 
organisms into the environment. 
• Regulation of products manufactured by genetic manipulation techniques should not 
be specifically regulated for quality control. They should continue to be regulated on 
the basis of their intended use in the same way as other biological products. 
The Law Reform Commission did not believe that genetic manipulation was wrong on 
either religious or ethical grounds: 
• The use of genetic manipulation to improve agricultural animals was judged to be 
basically a more controlled and refined means of the long-established practice of 
planned breeding. 
• DNA is not a sacred substance. 
They did recommend however, that to assuage public fears on this issue there is a need for 
community education on recombinant DNA techniques. Despite the fact that public 
information and participation: 
(a) might unduly hinder and delay scientific progress; 
(b) might seem unnecessary considering that government agencies generally approve and 
oversee the work and represent the public; 
(c) would impinge on the confidentiality of new procedures and products that must be 
protected for commercial reasons, 
the Commission believed it is not justified to withhold information from the public about 
proposed releases. 
The Australian Shadow Federal Minister for Science and Technology, Mr Peter McGauran 
stated: 
"We must endeavour to ensure the public discussion takes place in a sober atmosphere 
which enables a balanced assessment of both the risk and benefit of genetic engineering. 
Public confidence is essential and it must be built on an understanding there will be a 
rational and scientifically based assessment of all risks associated with the release of genetic 
material." 
3.d.Government policy and legislation 
The Australian Government Agricultural and Veterinary Chemicals Committee are 
currently considering their policy on rbST and rpST. 
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Trade issues will clearly play a major role in deciding government attitudes to specific 
biotechnological products. 
As Australia exports nearly half of its total red meat production, the relevant requirements 
of importing countries regarding the use of these biotechnologies will influence regulatory 
authorities in Australia on this issue. The Australian Quarantine and Inspection Service must 
comply with importing country requirements for the purposes of export trade. For example, 
with the EEC ban on the use of hormonal growth promotants, a system has been developed 
to ensure that meat and offals from animals treated with growth promotants are not exported 
to the EEC. 
Government policy on these issues is currently being formed: the Australian government 
are currently holding a Parliamentary Inquiry into genetically modified organisms. 
The timing of this inquiry would appear to be stimulated by the publicity surrounding the 
"unauthorised release" i.e. the transporting of genetically altered pigs from the research 
facility to the abattoir (see 3.b). Preliminary statements from the inquiry committee include: 
" Clearly the time has arrived for a detailed public examination of these issues and of the 
regulatory framework that should be in place to provide whatever safeguards might be 
needed 
In NZ, legislation governing the release of genetically modified organisms is to be 
tightened under a new environmental body - the Hazards Control Commission, which will be 
responsible for all phases of genetic engineering. 
Conclusion 
The public in various parts of this diverse region of Australasia could be assumed to have 
different determinants of non-acceptance of new biotechnology in meat production. In Japan, 
food safety appears to be the major factor; in Australia and NZ, ethical and environmental 
issues appear to be important; while in Southeast Asia there appears to be very few specific 
public attitudinal barriers to new biotechnology. In all cases however, there is a lack of data 
to support these assumptions. 
Experience in Australia with public reaction to genetically engineered pigs indicated that 
the risk to human health was not the major issue. At the heart of the controversy concerning 
the sale of meat from genetically engineered pigs to South Australian consumers was the 
community's concern that it be involved in decisions about products arising from 
controversial biotechnologies such as genetic engineering. 
The data presented by Couchman and Fink-Jensen (1990) indicate that in NZ, the level of 
public understanding of genetic engineering is low and that of "biotechnology" even lower. 
It would be expected that the level of public awareness and understanding of biotechnology 
in Southeast Asia would be even lower than in NZ or Australia. 
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As suggested by Couchman and Fink-Jensen (1990) a dialogue between scientists and the 
public is needed to: 
• inform the public of the social and economical benefits of biotechnology, the possible 
hazards, and the controls in place to minimise these risks; 
• ensure that research organisations are aware of public concerns and that they take 
account of them in their research practice (especially ethical and safety 
considerations). 
It would seem however, that because of the low credibility of scientists with the public, 
research is required to determine how to implement an effective and credible dialogue. 
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Summary 
Consumer response to the products of biotechnology is neither well understood nor fully 
appreciated. Relatively little attention has been paid to public attitudes about biotechnology, 
relative to the time and money spent on research and product development. This is 
problematic because consumer acceptance will determine the ultimate success of any new 
biotechnology products used in meat and milk production. Such acceptance is, by no means, 
assured. / 
This paper presents a case study of public attitudes about the use of biotechnology in 
meat and milk production. Results are presented from a telephone survey of 332 North 
Carolina consumers. We examine consumer attitudes toward animal biotechnology along 
four main dimensions: desirability of bovine somatotropin; desirability of genetic 
engineering to produce larger or faster growing livestock; belief that genetic engineering of 
animals is morally wrong; and concern over eating genetically engineered meat or dairy 
products. We develop and test a theoretical model that analyzes the factors that influence 
these attitudes. Our model builds on theories of risk perception and ethics. 
Definite concerns exist among consumers along a number of dimensions. We find that 
certain groups will be less likely to accept the use of biotechnology in meat and milk 
production. Women and people with less formal education will find genetically engineered 
products to be less acceptable. Acceptance of the use of biotechnology will be conditioned 
by underlying beliefs and values. People who are more concerned over the risks of 
biotechnology will be more likely to find the products less desirable. Finally, people who 
have more trust in institutional information and policies are more likely to accept the use of 
biotechnology in meat and milk production. 
Keywords: public attitudes, consumer acceptance, social implications, ethical values. 
Introduction 
Biotechnology is clearly developing under intense public scrutiny. Citizens are becoming 
increasingly concerned about new technologies. In particular, the public now considers 
certain agricultural technologies (e.g., farm chemicals) as potentially dangerous because 
residues and byproducts have been identified in the food and water supply. The use of 
biotechnology in meat and milk production could elicit concerns like those expressed about 
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agricultural chemicals. In addition, other dimensions of biotechnology will also raise public 
concerns. Bentley (1987) argues convincingly that public opinion will influence the future 
direction of biotechnology. 
We need to realize that some people may react negatively to the perceived impacts 
associated with anything new. If the gap between public understanding and technological 
advance becomes too large, research and development will be slowed. Our challenge is to 
explain biotechnology in a way that the public can understand. This presents a serious 
challenge given the complexity of biotechnology and the prevailing climate of public 
opinion about science and government. Public attitudes and concerns should be more 
thoroughly researched, understood, and considered before developing new products, 
educational programs, and public policies. It is clear that the public and scientists need more 
information so our society can determine whether biotechnology will have any adverse 
impacts. 
Because very few products have yet reached the market place, it is very difficult at this 
point to accurately describe public opinion about biotechnology. Berrier (1987) suggested 
that because we are early in the development of agricultural biotechnology public awareness 
is still very low. Another problem is that the public is very heterogeneous in its attitudes and 
knowledge toward biotechnologies (Klassen 1987). The few attempts that have been made 
to anticipate public concerns over biotechnology have been based more on informed 
speculation than careful analysis. 
The Office of Technology Assessment (1984) summarized five main arguments 
frequently raised in public debates about genetic engineering and biotechnology. The first 
involves debate over what levels of health, environmental, or social risk should be 
considered acceptable and allowed. Benefits and risks are complex and difficult to 
systematically evaluate. A second reason biotechnology may prove controversial is that 
scientists will be increasingly able to modify and manipulate living organisms. Some 
opponents of genetic engineering argue that humans should not "play god" by manipulating 
the genes of humans or other organisms. Proponents of genetic engineering argue that we 
have manipulated genes for thousands of years through selective breeding. Opponents 
respond that genetic changes have so far been limited and did not involve crossing 
fundamental species barriers. Moral and ethical issues associated with biotechnology, 
therefore, deserve greater attention. 
A third area of controversy involves concerns over loss of genetic diversity. Opponents of 
biotechnology argue that genetic manipulation may result in decreased genetic diversity 
with a resulting loss of species' resistance to future threats. Others argue that biotechnology 
will, instead, increase the gene pool available for human exploitation. The fourth 
controversial area involves freedom of scientific inquiry. Some people argue that scientists 
should be able to pursue any line of inquiry they choose. Others feel that some forms of 
research should be subject to greater restraint. As science starts to involve some form of 
action (rather than just thought) it becomes subject to legal and moral constraints like all 
types of action. The debate centres over who should regulate scientific inquiry and 
technology development. The final area of controversy described by OTA involves the 
notion of a technological imperative. Some argue that what is technologically possible will 
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eventually be done, regardless of ethical or moral guidelines. A variety of factors, including 
the profit motive, influence the development of scientific knowledge and technology. 
Several specific factors could limit consumer acceptance of the use of biotechnology in 
meat and milk production. Recent public concerns over risks associated with food safety 
may cause consumer opposition if they are led to believe their food is "contaminated by 
biotechnology". We must realize that the public does not respond to technology based on a 
rational calculation of the actual hazards (Sandman 1987). They respond based on values, 
emotions, and outrage rather than rational and scientific analysis. Public understanding of 
science and technology is low, even among people with a lot of formal education. Public 
reaction to technology is easily manipulated by mass media coverage and special interest 
groups. Rogers (1987) explains that "we are faced with a level of scientific illiteracy in this 
country that is truly frightening." Biotechnology is moving too quickly for the public to 
integrate its advances into their existing educational, religious, and social frameworks. As 
the gap between public understanding and scientific advance grows too wide, people may 
try to slow progress in order to have time for further analysis and understanding. 
Moral or ethical issues could also limit consumer acceptance of the use of biotechnology 
in meat and milk production. People with strong, fundamental religious convictions may 
oppose genetic engineering, especially when applied to animals and humans. They may feel 
we are "playing god". The growing animal rights movement can be expected to become very 
concerned with genetic engineering of animals. Moral and ethical concerns also arise over 
equity issues. Many groups are concerned about potential socio-economic impacts on 
farmers and rural communities. Some members of the public will believe that biotechnology 
may lead to an uneven distribution of benefits and costs. 
Even if public concerns do not fit technical reality, (in terms of the health, ecological, and 
social impacts) these concerns could greatly limit the application of even safe 
biotechnological applications. MacKenzie and Berrier (1987) explain the public's perceived 
risk of genetic engineering experiments or products may not necessarily be the same as the 
real risks. A portion of that perceived risk will represent fear created by lack of knowledge 
or understanding. Although these risks may not be well founded from a scientific standpoint, 
they deserve to be addressed. In most cases, what people believe to be real is often translated 
into real consequences, especially as related to public policies and consumer behaviour. 
Wyse and Krivi (1987) argue that biotechnology is "destined to become a major 
component of our society, one that will greatly impact our lives, one that can stir people's 
strongest emotions, and one they know little about." They argue that biotechnology has the 
potential to elicit strong public outrage for the following reasons: 
1. The public does not now understand biotechnology or its potential uses. A huge 
non-attentive public exists that can be easily influenced by emotional appeals. 
2. Biotechnology has important social, economic, ethical, and moral implications 
associated with its use. Therefore, it has the potential to arouse strong public reaction. 
3. Some products of biotechnology could have a component of environmental risk 
associated with the release of engineered organisms into the environment. Although the 
probability of this risk is low, the potential impacts are high. 
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There can be little doubt that the new biotechnology has generated, and will continue to 
generate, considerable controversy and debate both within the scientific community and in 
the larger public forum. Agricultural biotechnology and its commercial products are in then-
infancy relative to the medical and pharmaceutical fields. However, consumer advocates, 
environmentalist groups, and even some farm groups have begun to challenge the legitimacy 
of certain types of research and product development. Lawsuits have been brought against 
both public and private researchers and research institutions. Two state legislatures (i.e., 
Wisconsin and Minnesota) have placed a moratorium on the marketing of a 
biotechnologically-produced product (i.e. rbST). Other state governments (e.g., North 
Carolina) and the federal government have become involved in the oversight of this 
technology to an extent unprecedented except perhaps for nuclear technologies. 
Although debate and disagreement have long surrounded science and technology 
development, agricultural biotechnology will provide a major "test case" for a variety of 
long-standing ethical and public policy issues associated with the practice of agricultural 
science and the larger public interest. Among these are: 
1. The mission of agricultural research: Toward whom and to what ends should 
publicly-sponsored science be directed? 
2. Agenda Setting: How are and should the clientele and goals of agricultural research be 
determined? 
3. Technology transfer: What is the proper role of public institutions, private industry and 
individual scientists in transferring the technologies that agricultural science produces? 
4. Science and technology policy: What are the legitimate roles of government at all levels 
in supporting, promoting, or constraining agriculturally-related technologies with an 
eye toward the public interest? 
A full examination of these and related issues is beyond the scope of this paper (see Busch 
et. al., 1991). There is, however, a deeper background issue, that could help orient discussion 
of these kinds of questions. This issue concerns the larger public context in which decisions 
on agricultural science and technology are now made. Observers have noted for many years 
that agricultural science is no longer an "island empire" (Mayer and Mayer, 1974). Decisions 
about research goals, clients, extension efforts and even farm-commodity policy are now 
made with an eye toward the larger public, both rural and urban. Indeed, decisions must now 
recognize that various groups are monitoring the real or potential effects of science and 
technology on a variety of "publics." Consideration of these effects, and these nonfarm 
publics, must increasingly be a part of the agenda for decision-makers from the Federal level 
down to the bench science level. 
There are both philosophical and practical reasons for this. Philosophically, both public 
and private science should ultimately serve and not undermine the public interest, however 
that might be defined. From a practical standpoint, failing to consider these publics may 
result in reduced levels of support, lawsuits, rejected patents, and even enforced redirection 
of the research effort. We believe that public attitudes and beliefs about the use of 
biotechnology in meat and milk production must be given greater attention for both 
philosophical and practical reasons. 
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There can be little doubt the larger public has revealed preferences for biotechnology 
products, as well as deeper attitudes toward science and technology. Public reliance on 
communication, transportation, and biomedical technologies is a given. The rate of adoption 
of new consumer technologies is staggering. Our culture has been characterized as having a 
pro-technology or "technophilic" attitude (Drengson, 1982). Nevertheless, there is an 
undercurrent of "technophobia" as well, particularly among some groups. In this paper we 
describe research on the extent of technophilia and technophobia with respect to the use of 
biotechnology in meat and milk production. We offer some tentative explanations for these 
differential attitudes. We then draw some conclusions regarding the significance of these 
differential attitudes for the agenda-setting, extension, and governmental oversight efforts 
with respect to biotechnology. 
The goal of this paper is to analyze some factors that could influence consumer 
acceptance of the use of biotechnology in meat and milk production. To do this we develop 
and test the conceptual model shown in Figure 1. We have included several demographic 
variables and religious orientation as background characteristics that reflect inherent 
differences among respondents in our sample. Two sets of intervening variables are included 
that mediate the influence of background characteristics on acceptance of biotechnology, in 
meat and milk production: awareness of and attitudes toward genetic engineering; and 
confidence in institutions to manage genetic engineering. 
A g e 
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Figure 1 Conceptual model of determinants of consumer acceptance of the use of biotechnology in 
meat and milk production. 
Research methods and results 
After we describe our data collection procedures, we present our analysis at three levels. 
First, we present the univariate frequencies for all the variables included in the model. 
Second, we describe the bivariate relationships among certain independent variables, as well 
as the relationships between the independent variables and a four-item scale of consumer 
acceptance. Finally, we use multiple regression to analyze the relative influence of the 
various independent variables on consumer acceptance of biotechnology in meat and milk 
production. 
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Data Collection Methods 
This research involved telephone interviews with a random sample of people over 18 
years old drawn from specific areas of North Carolina . 
Telephone interviews, lasting about 20-25 minutes, were conducted during December of 
1988. A total of 332 telephone interviews were completed. After removing ineligible phone 
numbers, the overall response rate for the survey was 62 percent. Telephone interviews were 
conducted by the Applied Research Group at North Carolina State University which has 
extensive experience conducting these types of interviews. 
Our goal was to interview respondents from two main areas: highly agricultural rural 
areas and the state's three largest urban areas. Counties ultimately included in this study 
were selected based on several criteria. The three largest urban areas in North Carolina (by 
population) were selected: Charlotte, Raleigh, and Greensboro. Our goal was to complete 
the same number of interviews (55) in each metropolitan area. Selecting the rural 
agricultural areas presented more of a challenge. Given the diversity of North Carolina 
agriculture, we wanted to obtain information from counties representing the full range of 
agricultural enterprises and geographical areas in the state. We sampled counties to represent 
major conditions in the state. Our goal was to balance crop and livestock areas and complete 
about the same number of interviews (32) in each of the rural counties. Five highly 
agricultural rural counties were selected that had 70 percent or more of their population 
living outside of incorporated areas. Telephone numbers were generated using random digit 
dialling from the telephone exchanges from the areas of interest. 
One other methodological point is important to note. The interviews focused exclusively 
on genetic engineering, instead of the more general set of techniques included under the term 
"biotechnology". We made this decision for two reason. First, genetic engineering is a more 
concrete concept then biotechnology. On the other hand, biotechnology" means different 
things to different people. The second reason for focusing on genetic engineering was that it 
will be the most controversial type of biotechnology and will, therefore, raise the most 
public concern. We defined genetic engineering for respondents, as follows: "Scientists have 
new knowledge about biology that they can use as tools to solve problems. Genetic 
engineering is one of these new tools. In genetic engineering, genes are taken from one kind 
of plant or animal and put into another kind." 
Univariate results 
Several background demographic variables (i.e., age, gender, education, and income) are 
included in the model. More (59%) women were interviewed than men (41%). Respondents' 
ages ranged from 18 to 85. The average age of all respondents was 42 years. Respondents' 
Support for this research was provided by the following: the N.C. Biotechnology Center, the N.C. 
Agricultural Extension Service, The N.C. Agricultural Research Service, and Ciba Geigy. The conclusions 
presented in this paper are those of the authors and do not necessarily reflect those of the sponsoring 
organizations. 
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educational levels were as follows: eight years or less (4%); eight to eleven years (8%); high 
school graduate (29%); some college (24%); college graduate (24%); graduate work or 
degree (10%). Mean family income was between $25,000 and $30,000. 
We anticipate that certain religious beliefs will influence public attitudes about 
biotechnology. Religious salience was measured by asking "How important is religion in 
your daily life?" Religion was a very important part of most (63%) respondents' lives. 
Another 23 percent indicated religion was somewhat important. Only four percent said 
religion was not important. Fundamentalism in religious orientation was measured by two 
questions. Most respondents (79%) believed that the story of creation as recorded in the 
Bible is true. Almost three quarters (74%) believed the biblical version of creation should be 
given equal weight with the theory of evolution in public schools. We combined these two 
questions to form an index of religious fundamentalism. This index is moderately reliable 
with a Cronbach's Alpha of .59. 
We also measured a number of indicators of respondents' awareness of and attitudes 
toward genetic engineering. Respondents varied in their awareness of genetic engineering. 
Over one third of the respondents had read or heard either a lot (7%) or some (32%) about 
genetic engineering. Almost half (44%) said they had heard a little 'about genetic 
engineering. Another 16 percent claimed to have heard or read nothing about genetic 
engineering. Two statements were used to assess respondents' general orientation toward 
genetic engineering. To assess the tradeoffs between the benefits and risks of genetic 
engineering, respondents were asked how much they agreed or disagreed with the following: 
"The potential benefits of genetic engineering are greater than the possible risks." Almost 
three quarters (71%) agreed that the benefits will be greater than the risks. Just over one 
fourth felt that the benefits will not be greater than the risks. Respondents were also asked 
how much they agreed or disagreed with the following statement "It would be better if 
scientists did not know how to use genetic engineering." Only three percent of all 
respondents strongly agreed with this statement. Another 13 percent agreed. Most (64%) 
disagreed that it would be better if scientists did not know how to use genetic engineering. 
In fact, 19 percent strongly disagreed with this statement. 
The final set of intervening variables involves the level of trust or confidence that 
respondents have in the ability of government and other institutions to inform and involve 
the public in decisions about biotechnology. To determine concerns with too little regulation, 
respondents were asked how much they agreed or disagreed with the following statement 
"Too little regulation of genetic engineering poses serious risks to human health." Over one 
fourth (29%) of the respondents strongly agreed with this statement. The majority (55%) 
agreed that too little regulation is a risk to human health. Only 13 percent disagreed with the 
statement, while three percent strongly disagreed. Respondents were asked the extent to 
which they thought the public should play a greater role in genetic engineering regulation by 
voicing their agreement with the following "The public should have more say in government 
regulation of genetic engineering." Over 20 percent strongly agreed and about two thirds 
agreed with this statement. Few consumers feel that the public should not have a greater role 
in the regulation of genetic engineering. 
In order to determine how much confidence consumers have in information provided by 
institutions, respondents were asked how much trust they would have in information about 
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genetic engineering provided by different individuals or organizations. Respondents would 
have the most faith in university scientists. Respondents reported the next greatest amount 
of trust in environmental groups. Of the three levels of government, respondents would have 
the most faith in local public health officials. The next most trustworthy source would be 
state government. Public confidence in the federal government would be slightly lower. The 
public will clearly have relatively little faith in the company making the product. We 
developed an additive scale including these six information sources. This scale is reliable 
with a Cronbach's Alpha of .73. 
We measured consumer acceptance of biotechnology in meat and milk production by four 
questions. Respondents were asked how desirable they thought two applications of genetic 
engineering would be. The first application was bovine somatotropin (rbST). Respondents 
were not asked about the product by name; but were asked how desirable it would be if 
"genetic engineering were used to produce a hormone that increased the amount of milk that 
dairy cows produce." Only 10 percent of the respondents thought rbST would be very 
desirable. Many (40%) felt rbST would be somewhat desirable. However, half the 
respondents (50%) believed that rbST would be undesirable. Less than one third (32%) of 
all respondents thought the use of genetic engineering to produce larger or faster growing 
livestock would be very desirable. Almost as many (31%), in fact, thought this would be 
undesirable. 
The two final indicators of consumer acceptance of biotechnology in meat and milk 
production involve two related issues. Respondents were asked how concerned they would 
be about eating genetically engineered meat or dairy products. Most respondents would be 
either very concerned (45%) or somewhat concerned (37%). As a final indicator, 
respondents were asked if they thought that genetic engineering of animals was morally 
wrong. Respondents were almost evenly divided on this question. A significant number 
(45%) of respondents thought genetic engineering of animals was morally wrong. Almost as 
many (43%) did not think genetic engineering of animals was morally wrong. A sizeable 
number of respondents (12%) did not have an opinion about the morality of animal genetic 
engineering. They were coded intermediate to the two other responses. These four items are 
combined into an additive scale. This scale is reliable with a Cronbach's Alpha of .73. This 
four item scale appears to be normally distributed which indicates that it can be treated as 
almost a continuous level variable for purposes of our analysis. The four-item scale just 
described will serve as our main measure of consumer acceptance of biotechnology in meat 
and milk production. 
Bivariate Relationships 
This section will provide a preliminary interpretation of the determinants of consumer 
acceptance of biotechnology in meat and milk production. Results of this bivariate analysis 
are given in Table 1. We will first describe some of the observed relationships between 
certain groups of the independent variables themselves. We will consider how the 
background characteristics are related to the intervening variables. Finally, we will turn our 
attention to the relationships between the independent variables and consumer acceptance of 
biotechnology in meat and milk production. 
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Table 1. Bi-variate relationships (zero-order correlation coefficients) among variables in 
conceptual model 
Xi 
x2 
x3 X4 
x5 
x6 
x7 
x8 
x9 Xio 
Xn 
Xl2 
Y 
X2 X3 X4 
Gender (Female) .10 -.14* -.12 
Age -.17' -.18" 
Education .40" 
Family Income 
Religious Salience 
Religious Fundamentalism 
Awareness of Genetic Engineering (GE) 
GE Benefits Exceed Risks 
Better if No GE 
Too Little Regn is Risk 
Greater Role for Public 
Faith in Information 
Acceptance of Biotechnology 
X5 
.19" 
.19" 
-.19" 
-.18" 
x6 
.15' 
-.00 
- .31" 
- .21" 
.44" 
x7 
-.18" 
-.10 
.34" 
.25" 
-.19" 
-.22" 
x8 
-.11 
-.01 
.18" 
.17" 
-.14' 
-.19' 
.17' 
X9 
.18" 
.05 
-.24" 
-.24" 
.21" 
.20" 
-.23" 
-.24" 
Xio 
-.01 
-.08 
.16* 
.02 
-.02 
-.03 
.10 
.00 
-.02 
Xn 
.18" 
-.00 
-.18" 
-.16" 
.05 
.10 
-.16' 
-.19' 
.13 
.15" 
X,2 
-.13 
-.13 
.14' 
.17' 
-.02 
.01 
.17" 
.08 
-.15" 
-.03 
-.06 
Y 
-.34" 
-.07 
.31" 
.20" 
-.24" 
-.23" 
.25" 
.31" 
-.43" 
-.15' 
-.26" 
.27" 
-
* means that correlation coefficient is significant at p< .01 
" means that correlation coefficient is significant at p< .001 
Several demographic characteristics appear to influence awareness of genetic 
engineering. Male respondents had heard or read more about genetic engineering than had 
women. Those with higher levels of education and income also reported greater awareness 
of genetic engineering. Respondents who held more fundamental religious beliefs or who 
believed religion was more important reported less awareness of genetic engineering. 
Several types of respondents were more likely to believe that the benefits of genetic 
engineering will be greater than the possible risks. People with higher educational and 
income levels were more likely to express this view. Greater awareness of genetic 
engineering was also positively related to the belief that the benefits will exceed the risks. 
On the other hand, respondents with stronger and more fundamental religious beliefs were 
more likely to disagree that the benefits will exceed the risks. 
Similar relationships were found when we examined agreement with the statement that 
"It would be better if scientists did not know how to use genetic engineering." Women were 
more likely to feel this way, as were respondents with lower income and educational levels. 
Religious fundamentalism and salience were also positively related to this viewpoint about 
genetic engineering. Disagreement was greater among those respondents with greater 
awareness of genetic engineering and those who thought the benefits of genetic engineering 
would be greater than the risks. 
Only one variable is related to agreement that "Too little regulation of genetic engineering 
is a risk to human health." In this case, respondents with more education were more likely to 
agree with that statement. On the other hand, people with less education were more likely to 
agree that "The public should have more say in the regulation of genetic engineering." 
Income was also negatively related to agreement with this statement. Women were more 
likely to want more public involvement in regulation, as were respondents who had read or 
heard less about genetic engineering. Respondents who did not agree that the benefits of 
genetic engineering will exceed the risks wanted a greater public role in regulation. Those 
who wanted more public involvement in regulation were also more likely to believe that too 
little regulation posed risks for human health. 
237 
HOBANANDBURKHARDT 
Certain groups of respondents claimed to have greater overall faith in sources of 
information about the risks of genetic engineering. Respondents with higher education and 
income levels reported greater faith in the information sources, as did respondents who had 
heard or read more about genetic engineering. People with greater faith in information 
sources were also more likely to disagree that it would be better if scientists did not know 
how to use genetic engineering. 
Finally, we can examine how the background characteristics and intervening variables are 
related to consumer acceptance of the use of biotechnology in meat and milk production. 
Women were less likely than men to accept biotechnology. Higher education and income 
levels were positively associated with acceptance of biotechnology. Religious salience and 
fundamentalism had a negative relationship with consumer acceptance of biotechnology. 
People who had read or heard more about genetic engineering were more likely to accept 
products, as were respondents who believed the benefits of genetic engineering were greater 
than the risks. On the other hand, people who felt it would be better if scientists did not know 
how to use genetic engineering were less likely to accept biotechnology. Respondents who 
felt that too little regulation posed a risk to human health were less likely to accept 
biotechnology, as were those who felt the public should have a greater role in the regulation 
of genetic engineering. Finally, respondents who had more faith in information sources 
appear more likely to accept the use of biotechnology in meat and milk production. 
Multivariate analysis 
We have observed inter-relationships among a number of the variables in our conceptual 
model. It will, therefore, be useful to analyze the relative contribution of the background 
characteristics and intervening variables as determinants of acceptance of biotechnology in 
meat and milk production. We do this through multiple regression of these various factors on 
our four-item scale of consumer acceptance (see Table 2). This section tries to paint a fairly 
Table 2. Multiple regression of the relative influence of independent variables on consumer 
acceptance of biotechnology in meat and milk production. 
Xi 
x2 
x3 X4 
X6 
x6 X7 
Xs 
x9 
Xio 
Xn 
Xl2 
Gender (Female) 
Age 
Education 
Family Income 
Religious Salience 
Religious Fundamentalism 
Awareness of Genetic Engineering (GE). 
GE Benefits Exceed Risks 
Better if No GE 
Too Little Regn is Risk 
Greater Role for Public 
Faith in Information 
Standardized 
Regression 
Coefficient 
-.20 
.01 
.16 
-.05 
-.08 
-.04 
,04 
.15 
-.27 
-.17 
-.09 
.16 
T-Value 
3.72" 
.14 
2.56" 
.81 
1.30 
.62 
.63 
2.73' 
.85" 
3.17" 
1.57 
3.03" 
means that standardized regression coefficient is significant at p < .01 
' means that standardized regression coefficient is significant at p < .001 
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clear picture of which types of consumers will be more likely to accept the use of 
biotechnology in meat and milk production. We will also suggest some reasons why such 
acceptance may not occur. In fact, we are able to explain much of the variance in consumer 
acceptance of biotechnology. The adjusted r-square value for our full model is .37, 
indicating that the variables in our model account for over one-third of the differences 
between respondents in terms of acceptance. 
In terms of the background characteristics included in our model it seems clear that 
certain groups of consumers will more readily accept the use of biotechnology in meat and 
milk production. Men will be more likely to accept biotechnology than will women. This 
could be problematic in that most food purchase decisions are made by women, not men. 
Even if the male in a household buys food, he will rarely go against a woman's wishes when 
it comes to whether or not certain foods are purchased. People with higher educational levels 
will be more likely to accept biotechnology. Years of formal education is a reasonable 
indicator of technological sophistication and scientific literacy. This findings presents a 
challenge for educational efforts because those with less education will be less interested in 
or knowledgeable about scientific issues. Family income is no longer significant which 
indicates that educational levels account for most of the influence of income. The items 
measuring religious orientation are no longer significant after controlling on the other 
variables. This indicates that the influence of religious orientation is probably accounted for 
by differences in education and gender. 
Acceptance of the specific application of biotechnology to meat and milk production will 
be conditioned by consumers' general attitudes toward genetic engineering. Respondents 
who agreed that the benefits of genetic engineering will be greater than the potential risks 
were more likely to accept biotechnology in meat and milk production. On the other hand, 
those who feel the risks of genetic engineering are greater will be less likely to accept these 
uses. As another indicator of general orientation toward genetic engineering, it is clear that 
people who believe it would be better if scientists did not know how to use genetic 
engineering will be less likely to accept the use of biotechnology in meat and milk 
production. This indicates that consumer acceptance or rejection of the use of biotechnology 
in meat and milk production reflects underlying beliefs or values about the appropriateness 
of genetic engineering in general. 
Our results suggest that a higher level of confidence in the institutions responsible for 
developing and controlling biotechnology will be an important determinant of consumer 
acceptance of the use of biotechnology in meat and milk production. We found that 
consumers who believe that too little regulation of genetic engineering poses serious risks to 
human health will be less likely to accept the use of biotechnology. Those respondents who 
have a higher level of trust in statements about genetic engineering made by various groups 
will be more likely to accept the use of biotechnology in meat and milk production. It is 
important to keep in mind that consumers will have a lot more trust in some groups (i.e., 
university scientists and environmental groups) than they will in others (i.e., the company 
making the product). 
It is interesting to note awareness of genetic engineering is no longer significantly related 
to acceptance of biotechnology in meat and milk production. After controlling on the 
background characteristics (e.g., educational level and gender), respondents who had heard 
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or read more about genetic engineering were not more likely to accept biotechnology. It 
could also be that awareness influences acceptance indirectly through the attitudes that 
people hold about genetic engineering and the confidence they have in government to 
manage genetic engineering. 
Conclusions and implications 
Consumer acceptance of biotechnology in meat and milk production is uncertain, at best. 
As we draw our conclusions, it is important to recognize that the evidence from social 
science research is far from conclusive. We have very little empirical research on which to 
recommend policies or programs. To date, far too little attention has been paid to consumer 
acceptance of biotechnology. More social science research, like the type described in this 
paper, is clearly needed if the agricultural biotechnology enterprise is to succeed in winning 
consumer acceptance. 
Our results suggest that certain groups of consumers may either support or oppose the use 
of biotechnology in meat and milk production on several grounds. We find that men will be 
more likely than women to accept the use of biotechnology in meat and milk production. As 
a group, men tend to be more interested in and supportive of new technology than do 
women. On the other hand, women tend to be more concerned about health risks of new 
technologies than men. Respondents with higher educational levels will also be more likely 
to accept biotechnology products. This suggests that knowledge and intellectual 
sophistication could prove to have a positive relationship with acceptance of biotechnology. 
It is not, however, necessarily true that more information about biotechnology will change 
existing attitudes. Increased information may, in fact, strengthen already held beliefs 
(positive or negative). 
We also predict that consumer acceptance of biotechnology in meat and milk production 
will be strongly influenced by attitudes about genetic engineering more generally. This 
indicates that more general orientations toward science and technology may be at the root of 
beliefs about animal biotechnology. Finally, it seems clear that consumers confidence in the 
organizations that manage biotechnology will have an important influence over whether or 
not they accept the use of biotechnology in meat and milk production. We can conclude that 
opposition to biotechnology could become intense unless the public is confident that the 
organizations involved with biotechnology are "playing by the rules." 
Concerns related to human health and environmental risks can be addressed through 
public policies and regulations. If the public can gain confidence that government and 
industry are doing their best to protect human health and the environment, these types of 
concerns may not present a serious obstacle to consumer acceptance. However, if 
government and industry are unable or reluctant to take all necessary safety precautions, 
consumer acceptance of biotechnology could be justifiably low. Based on recent experience 
with Alar, and other food safety concerns, we can predict that if the media publicizes any real 
or perceived risks to human health from the products of biotechnology consumer opposition 
will become intense. How deep or sustained such opposition will be depends on a number of 
factors. One of the key determinants will be consumer confidence in government to 
adequately protect them from risk. Education about government regulation and oversight 
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could play an important role in addressing consumer concerns about health and 
environmental risks. 
Concerns over moral and ethical issue could represent much more serious and 
challenging obstacles to consumer acceptance of the use of biotechnology in meat and milk 
production. These are not, however, the kind of issues that can or should be addressed 
through government regulations. Even if government agencies and lawmakers were willing 
to address these types of ethical concerns, it is unlikely that they would be able to satisfy the 
opponents of biotechnology. Likewise, it is unlikely that educational efforts will be very 
effective in attempts to address the difficult moral and ethical issues raised by 
biotechnology. This will be especially true if educational efforts continue to be grossly 
under-funded and aimed at public relations, rather than public education. We will need, 
instead, to foster meaningful dialogue among all parties. This must include a greater role for 
the public in the decisions about new technology. 
From the standpoint of the overall biotechnology enterprise, rbST may prove to be a poor 
choice as a test case. It will be much more difficult to obtain consumer acceptance of rbST 
than it will be for some plant-related products such as disease resistant fruit. The public 
tends to be more opposed to genetic engineering of animals than they are to plant 
applications (Hoban and Woodrum, 1990). Furthermore, rbST may suffer from the stigma of 
being a "hormone in milk." Milk has always had a strong tie to children and, therefore, it is 
important to maintain a wholesome image. Adverse public response to rbST may adversely 
affect that image. Moreover, rbST has drawn a lot of attention because of potential 
socio-economic impacts on dairy producers. Whether the socio-economic impacts of rbST 
will actually materialize will depend on many factors, including the price of rbST for dairy 
producers and the effectiveness of educational programs to help producers learn how to use 
rbST. The point is that rbST has already become a lighting rod for considerable controversy. 
This may have unfortunate consequences for consumer acceptance of other biotechnologies 
used in meat and milk production. 
We will now try to put some of the ethical issues in a larger context and offer some 
insights into the role of social science and philosophy in this important area. In general, 
public attitudes toward biotechnology may ultimately be connected with attitudes toward 
acceptable levels of risk (Berrier, 1987; Heimer, 1988). Attitudes toward risk are 
conditioned by a variety of factors, including knowledge level, age, gender and the like. 
However, attitudes toward biotechnology and science in general are also conditioned by 
ethical beliefs, (i.e, beliefs about what is right and wrong). As we have suggested, some of 
these beliefs may be based on religious convictions. In the case of biotechnology, some are 
based on beliefs about the "naturalness" or appropriateness of genetic engineering with 
respect to animals, whether these beliefs are religious or secular in origin. Some of these 
beliefs may be based on concern for the environment, or food safety. Moreover, some are 
based on beliefs about the value or virtues associated with family farming. Indeed, whether 
the general attitude toward science and technology is pro or con, deeper beliefs about values 
are undoubtedly involved. 
Values can be variously defined as ideals, standards, or principles. In practice, they are 
sets of beliefs to which people implicitly or explicitly appeal in making decisions. People's 
beliefs (particularly their ethical values) are notoriously vague, inconsistent, and transitory. 
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Ethical values clearly vary among people. One person's or group's values may appear 
irrational or myopic to others. Nevertheless, our society has a long-standing commitment 
toward respecting each other's differences. Ours is a pluralistic society. Different and even 
conflicting ethical values make public decision-making in a democracy so delicate. Value 
differences also can make the role of the scientist an extremely complicated matter. It is one 
thing, for example, to communicate research information to an ethically like minded 
community of scholars, that has either explicitly or implicitly accepted the legitimacy of 
research in the first place. It is quite another to communicate that same information to a 
group whose ethical values are in stark contrast to one's own. This would appear to be the 
case for people whose values lead to a scepticism (if not outright rejection) of 
biotechnological research. 
Philosophers have long noted that one cannot derive an "ought" from "is". Increased 
knowledge and information will not logically lead to an ethical judgement. New knowledge 
or information may cause individuals to change their ethical beliefs: reprioritize them, 
render them consistent, or even abandon them. As intimately connected as facts and values 
may be, they remain different categories of experience. Public debate on such issues as 
abortion illustrate the depth of divergence between fact and value. People may agree on the 
fact that a fetus is a living being, yet hold profoundly different beliefs about the morality of 
aborting it. 
Pluralistic, democratic societies typically resolve value conflicts in terms of tradeoffs and 
balancing of interests. Conflicting values are evaluated based on available information and 
potential consequences of pursuing a given value. Within the scientific community, there is 
also a tendency to think in terms of tradeoffs. Alternative courses of action are considered in 
light of relevant information and ethical values. Indeed, many feel this "weighing of 
alternative values" is the only rational way to make decisions, at whatever level those 
decisions are to be made (Aiken, 1987). 
When subjected to this sort of risk-benefit or cost-benefit appraisal biotechnology 
arguably comes out on the plus side. However, our research suggests that when it comes to 
public attitudes about biotechnology, different values and rationalities may be involved. For 
some people and groups, it may be fundamentally unreasonable to even consider trading 
some values for others when some things, (e.g., the environment or the sanctity of life) are 
thought to be placed at risk. Many people believe, right is right and wrong is wrong, 
whatever the harmful or beneficial consequences of the action. As Thompson (1988) has 
shown, some individuals and groups believe that any change from the status quo represents 
an unacceptable risk. 
These points suggest some profound challenges for scientists, administrators, and policy 
makers at all levels of authority and responsibility. Ethical issues arise with respect to most 
new technologies. Public attitudes vary, often for reasons beyond the influence of more or 
better information about potential personal, environmental, or socio-economic 
consequences of the technology. Recognizing this is a first step. Some values and attitudes 
are affected by more and better information. As we have suggested, more highly educated 
and better-informed individuals will likely have more favourable attitudes toward 
biotechnology. An important question is whether more information will lead those with less 
education to accept certain applications of biotechnology. If so, this would suggest that 
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certain kinds of information should be made available to the public in usable form. 
Information about public knowledge and attitudes must also be provided to scientists, 
extension personnel, and administrators at all levels. 
The danger in all this is that scientists, extension educators, and administrators may find 
themselves in the role of advocating not only particular products such as rbST, but the 
unfettered practice of science and technology development as well. And this, ultimately, 
may place "pro-science" individuals in the role of advocating what can be called an ethical 
world view (i.e., a view of what is both ultimately right as well as how that should be 
decided). To this we can only note, that all communication is essentially persuasion. Even 
the communication of ostensibly value-neutral data or scientific results has the element of 
"buy this" (Knorr-Cetina, 1981). Even within a scientific discipline or community there is an 
element of persuasion and trust. We are persuaded to accept the data as real. We have 
confidence that the results are truly reported, because we trust the author or purveyor of that 
information. 
In the area of public attitudes, and the larger public agenda for agricultural research, the 
matter of trust is the key. As we have shown, people are inclined to trust academic scientists, 
but not trust privately-employed ones. Perhaps this is because academic scientists, for all 
their jargon and occasional obfuscation, have told the truth in the past. This suggests an 
ethical responsibility that we must continue to foster and act upon. We must be honest with 
those who are concerned about rbST and about genetic engineering in general. Let us tell 
them honestly and candidly about both the benefits and the risks. Let us recognize and admit 
up front that our concerns are with more knowledge, better technologies, and a stronger 
agricultural economy. Let us also recognize that despite the hidden agendas of some critics 
of agricultural science and technology development, there can be honest disagreement about 
both facts and values. 
In the final analysis, it is up to decision-makers to determine and acknowledge the public 
interest in science and technology development. Policy-makers will dictate whether rbST or 
any other product of the new biotechnology will be allowed on the market. Awareness of 
public attitudes can provide some assistance in this task. However, given inevitable ethical 
conflicts in a democratic and pluralistic society, some people's values must invariably be 
"discounted." Some publics will win and some will lose, despite the prima facie legitimacy 
of most, if not all, the values people hold. That is perhaps the tragedy of public decisions in 
a pluralistic, democratic society. It is neither a new problem, nor an issue we can resolve 
here. We can only hope that social scientific research can contribute toward a more open and 
complete discussion of ethical issues and scientific knowledge in the public debate. 
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Present address: 20 Grosvenor Gardens, London, SW1W ODH, UK 
Summary 
Public perception will be of paramount importance in determining the growth and 
progress of biotechnology. The depth of public feeling should not be under-estimated. 
Some consumer concerns relate to the safety of the process or product, others are based on 
social or ethical issues, but most probably relate to "the fear of the unknown". These 
concerns have to be acknowledged and addressed by appropriate policies and strategies. 
Keywords: consumer acceptance, biotechnology 
Introduction 
Biotechnology embraces a wide and complex set of scientific and industrial disciplines. 
Biotechnology is usually interpreted as involving some element of genetic manipulation of 
plants, animals or micro-organisms, even although at present this aspect represents a small 
proportion of the total range of activities classed as biotechnology. The Organisation of 
Economic co-operation and Development (OECD) refers to a "new biotechnology" which 
embraces recent developments such as genetic engineering and cell fusion. In its recent 
report, "Biotechnology and Wider Impacts", OECD states that, "The new biotechnology 
is distinguished from other major technologies of the 20th Century by the fact that its impact 
on the quality of life, its human and social consequences, are arriving earlier and may 
go deeper than macro-economic impacts measured by productivity, investment or GDP 
growth". 
The impact will be pervasive. Biotechnology will be used extensively in food production 
to enhance the useful and desirable characteristics of plants, animals and micro-organisms. 
The overall aim will be to improve the yield, performance, quality and, ultimately, 
profitability of food products. 
In principle, the techniques of improvement in the selection and breeding of plants and 
animals have been around and accepted for centuries. But biotechnology will add a new,, 
dimension, achieving a greater speed and precision than ever before. It will also be possible 
to achieve certain outcomes, which were previously impossible. It is these aspects which 
create uncertainty and unease in consumers. Their concerns fall into two broad categories, 
those relating to safety issues and those relating to the social and ethical issues. These 
concerns must also be seen against a general background of "fear of the unknown". In other 
words, are the scientists pushing out the boundaries of scientific achievement towards 
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unknown and uncharted territory, where unforeseen consequences and catastrophes could 
occur? 
The Challenge 
The challenge to all of those involved in the biotechnology industry is to find the correct 
balance between meeting these concerns and creating the appropriate environment for 
industries to develop, innovate, and take full competitive advantage of the commercial 
opportunities open to them. 
The Problems 
The problem is that very little is known about the likely attitudes and behaviour patterns 
which consumers will adopt in relation to biotechnology. Nor do we have a real 
understanding of how these attitudes and behaviour patterns are developed and influenced. 
Recent experience of consumer attitudes in Europe towards the potential use of recombinant 
bovine somatotropin (rbST) in milk production and the use of irradiation as a food 
preservation technique suggest that biotechnology will become a highly sensitive area, likely 
to attract strong opinions and inspire polarised views. 
Consumer Research 
Some useful research in this area has been carried out by the Netherlands Institute for 
Consumer Research (SWOKA). For this research 1729 Dutch consumers over the age of 16 
were interviewed by means of a tele-panel. The results of this research indicate that while 
more than half the respondents, had heard of the word biotechnology, only about one third 
knew its meaning. Opinions about biotechnology - either the risks or the benefits - were 
poorly formed, and they were only able to explain positive or negative reactions in very 
general terms. The research results do, however, highlight the gap between the scientists' and 
the public's perception of biotechnology. The English language summary of the results 
concludes, 
"The arguments that were brought out up by the participants in the interviews differ from 
the arguments that are used by biotechnology experts and other authors who write about the 
benefits and risks of biotechnological developments and applications. Experts can weigh 
detailed information about specific applications, while consumers - with their low level of 
knowledge - have to depend on more general feelings and expectations about technology in 
general and some rough information (mostly from the news media) about some 
biotechnological applications". 
The study also went on to test the assumption that more information and knowledge will 
lead to lower levels of anxiety and, hence, greater public acceptance of biotechnology. The 
SWOKA study suggests that this is not the case. Increased knowledge is just as likely to lead 
to greater resistance. It should be remembered that the purpose of education is to open up 
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people's attitudes and encourage them to question and challenge. The biotechnology industry 
sometimes appear to fall into the trap of believing that the function of information and 
education is solely to ensure acceptance. Clearly, much more research needs to be undertaken 
and it should focus on the following objectives; 
- to review the current levels of knowledge and consumer perceptions of biotechnology in food 
and agriculture. 
- to develop methods of measurement of perceived risks and benefits. 
- to understand how such perceptions of risks and benefits are formed. 
- to develop and test information strategies. 
Risk Perception 
It is essential that this kind of research is carried out so that it will be possible to identify 
with greater certainty the crucial determinants of consumer acceptance. It may be a difficult 
concept for scientists to grasp, but for the vast majority of people, it is the perception that 
counts, not necessarily the facts and it is essential to address these perceptions. If consumers 
perceive biotechnology to be a more unpredictable science, therefore in need of more 
safeguards and controls, then this must be the starting point for addressing the consumer 
protection requirements. 
Consumers are only likely to accept biotechnology if they perceive the benefits to be greater 
than the risks. They are likely to make this assessment in relation to themselves as 
individuals, other people or animals, society as a whole and the worldwide environment. So 
if biotechnology can offer them benefits, can benefit other people and does not do harm to 
other parts of society or the environment then acceptance is likely to be greater. 
Safety Assessment 
Clearly, safety is the most important aspect for consumers. As individuals, they are in no 
position to make that assessment for themselves, so they must rely on others to make that 
decision on their behalf and in their best interest. This places considerable demands on the 
system of safety assessment. This implies a rigorous assessment procedure, and a system of 
assessment that is open, accountable, independent and representative. This is the only way to 
reassure people that a proper balance is being drawn between commercial interest and 
consumer protection. 
Labelling 
Consumer organisations believe that biotechnology products should be clearly labelled 
(eg rbST milk) so that individual consumers can exercise an informed choice in a free 
market. The labelling argument becomes less clear cut the further back in the process the 
biotechnology application occurs. 
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EC legislation on the development and use of genetically modified 
organisms 
The European Community adopted two Directives in April 1990 to regulate the 
development and use of genetically modified organisms. These Directives have to be 
implemented by Member States by 23 October 1991. 
I Council Directive 90/219/EEC on the Contained Use of Genetically Modified 
Micro-Organisms. 
The Contained Use Directive establishes a common regime to protect humans and the 
environment regarding the use in laboratories and industry of genetically modified 
micro-organisms (GMM's). Although "micro-organisms" are not defined in the Directive, 
the terms would include yeasts and bacteria but not vertebrate animals or seed-bearing plants. 
The Directive requires users of GMM's to prepare a safety assessment, to notify the 
competent authority 90 days in advance of proposals to work with GMM's, obtain consent to 
the proposed work in specified (less safe) cases, keep records and prepare emergency plans 
(again for specified, less safe cases). The Member State's competent authority has to provide 
the EC Commission with summary information, publish information (not commercially 
sensitive) and arrange inspections of the sites where the work is carried out. 
II Council Directive 90/220/EEC on the Deliberate Release into the Environment of 
Genetically Modified Organisms 
The Deliberate Release Directive establishes a common regime for the release into the 
environment of genetically modified organisms (GMO's) (eg planting a (GMO) crop) and for 
the marketing of GMO's and products containing GMO's. Unlike the Contained Use 
Directive, all living things are included in its scope. 
As with the Contained Use Directive, a system of safety assessment, prior notification and 
prior consent in appropriate cases (including all proposals to market GMO's) is established. 
The competent authority of any Member State in which a proposal is made to market a GMO 
for the first time in the EC takes an initial view on whether the Directive's safeguards have 
been complied with. If the Member State is satisfied that they have, the proposal (and 
supporting evidence) is sent to the Commission who will send it to all other competent 
authorities. Any competent authority may present a reasoned objection to the proposal within 
60 days and, if the two competent authorities are unable to reach agreement within this 60 
day period, the Commission has to decide (subject to regulatory committee process) whether 
the GMO may be marketed throughout the EC. Once approved for marketing, the GMO's 
would be given free circulation within the EC. Provision for the public availability of certain 
information, and for reports to be made (annually by competent authorities and triennially by 
the Commission) on approvals, is included. 
Directive 90/220/EEC thus provides a common market for GMO's throughout the EC 
from October 1991. Although Member States' competent authorities may object to a 
proposal, the objection has to be on the basis of a reasoned argument. As the basic purpose 
of the Directive is to protect human health and to safeguard the environment, it is unlikely 
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that an objection would succeed solely on the grounds of public disquiet about the GMO's 
unusual parentage or that there was a possibility that it would suffer discomfort. 
The EC Commission's draft proposal on novel foods is similarly directed at ensuring 
consumer safety and so, if a GMO-sourced food were demonstrably safe, would offer no 
greater opportunity for banning GMO's which might cause some public disquiet for other 
reasons. 
EC draft novel foods regulation 
The draft Community proposal on novel foods (which is yet to be published) defines a 
"novel food ingredient" as one which 'in the Community has not been used hitherto for 
human consumption or which has been consumed in only small amounts or has not been used 
for that purpose.' The Community proposal would establish a Community-wide prior 
approval system for all novel foods. All novel food ingredients would have to be notified to 
the Commission and a decision on their approval given by vote of a regulatory committee 
made up of Member Stages. Any novel food ingredient likely to "have an effect on public 
health" would be referred to the Community's Scientific Committee for Food foi their advice 
before a decision on its approval was made. 
EC climate of opinion 
The general climate of opinion in Europe on the application of biotechnology to food and 
agriculture is cautious. There is a deep suspicion about more intensive methods of production 
and that is a clear indication that political and socio-economic arguments may overrule the 
strict scientific assessment. These attitudes have already been reflected in recent decisions 
about growth hormones and rbST. 
UK legislation 
Food Safety Act 1990 
Section 18 of the Food Safety Act contains the provisions relating to novel foods. 
All food produced by genetic modification are likely by their nature to fall within the 
definition of "a novel food" in section 18(3) of the Act in that they have "not previously been 
used for human consumption". However, at least in theory, it might be possible to produce 
virtually the same food by conventional breeding. A further difficulty could arise in 
controlling any conventionally bred off-spring of a genetically modified plant etc which 
might not be considered "novel" because of the passage of time since the original 
modification. The purpose of sub-section (4) is to clarify the scope of section 18 to ensure 
that all foods produced by genetic modification are covered whether or not they are similar 
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to foods produced by conventional breeding or cease to be strictly speaking "novel" because 
of the passage of time. 
Ministers made clear during the passage of the Food Safety Bill that they proposed to use 
these section 18 powers to introduce a prior approval system for foods produced by genetic 
modification based on advice from the Advisory Committee of Novel Foods and Processes. 
Section 18 Food Safety Act 1990 (extract) 
Section 18(l)The Ministers may by regulations make provision 
(a) for prohibiting the carrying out of commercial operations with respect to novel foods, or 
food sources from which such foods are intended to be derived, of any class specified in 
the regulations; 
(b) for prohibiting the carrying out of such operations with respect to genetically modified food 
sources, or foods derived from such food sources, of any class so specified; or 
(c) for prohibiting the importation of any food of a class so specified, and (in each case) for 
excluding from the prohibition any food or food source which is of a description specified 
by or under the regulations and, in the case of a prohibition on importation, is imported at 
an authorised place of entry. 
Section 18 (4)For the purposes of this section a food source is genetically modified if any 
of the genes or other genetic material in the food source-
(a) has been modified by means of an artificial technique; or 
(b) is inherited or otherwise derived, through any number of replications, from genetic material 
which was so modified; 
and in this subsection "artificial technique" does not include any technique which involves 
no more than, or no more than the assistance of, naturally occurring processes of 
reproduction (including selective breeding techniques or in vitro fertilisation). 
Social and Ethical Concerns 
The social and ethical concerns cover a wide area of issues which raise questions about 
moral values, principles, obligation and rights. These issues can be summarised by four key 
questions 
- Is it fair? 
- Is it right? 
- Is it natural? 
- Do we need it? 
The social, ethical, economic and even political implications of biotechnology raise 
fundamental questions about individual choice, freedom and rights. New techniques, 
whether or not they are "unnatural", are not necessarily wrong. Difficult value judgements 
may have to be made, balancing potential benefits for one group of people against potential 
disadvantages for others. Many of the arguments which will undoubtedly be used for and 
against biotechnology may rest upon shaky foundations, and obscure concepts and are likely 
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to be presented in emotive terms. Important issues about animal welfare also have to be 
addressed. 
In many cases, answers to questions may not even be possible. Against such a 
background, how can a wider view be taken? Various suggestions have been made, usually 
along the lines of establishing "Ethical Committees", whose task would be to consider these 
issues and draw up guidelines for the industry and the legislators. Some observers have gone 
further, suggesting that a "fourth hurdle" (after safety, quality and efficacy) should be a 
condition of approval. These issues underline the conflict between the ability of individual 
consumers to make their own "value" judgements about food products and processes and the 
need for certain limitations to be placed upon that individual freedom in the interests of 
society as a whole. 
IOCU views 
Many of these issues were discussed at a recent workshop (May 1990) in, the Hague, 
Netherlands organised by the Regional Office in Europe and North America (ROENA) of the 
International Organisation of Consumer Unions (IOCU). The participants discussed the 
aspects of biotechnology on which IOCU and individual consumer organisation should 
concentrate. That summary is as follows. 
IOCU workshop - the Hague - Netherlands - May 1990 
Government level 
— governments should be more open for consumer input. Consumers sometimes are allowed to sit 
on advisory committees, but this kind of representation should be stepped up. 
- governments should also fund research carried out by consumer organisations. 
Consumer aspects 
- IOCU and national organisations should establish a 'platform', as working group and forum for 
exchange of information and ideas. 
Such a group should seek information on the progress and status of biotechnology in their 
countries. The example of the consumer founded platform was mentioned. 
- novel products of biotechnology should be assessed for social, economic, and environmental 
impact. Expert committees involving consumer organisations should be established to evaluate 
these aspects. 
- full labelling is important. 
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Environmental aspects 
- need for information on the effects of genetically manipulated products and the processes 
involved. 
- need for information on how decisions are reached and what kinds of criteria are used. 
- need for more safety research. 
- more public participation in decision making. 
Criteria for evaluation 
- clarify the most important criteria for evaluating biotechnology. 
- calling for manufacturers to be required to publish a justification at the early stages of the 
approval process. 
- request more money for consumer research. 
Conclusion 
Progress on biotechnology must take place - preventing such progress would not be in the 
consumer interest. Nor would it be in anyone's interest to ignore the factors which will 
determine consumer acceptance. The emphasis must be on learning from the past, identifying 
consumer requirements and ensuring that the appropriate policy and strategy is in place to 
satisfy these requirements. 
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Summary 
Biotechnology is playing an increasing role in nearly all scientific fields. The decision to 
reject these tools in any one industry or country will leave that industry or country 
noncompetitive. It is vital that new products and processes be developed and publicly and 
commercially accepted. 
Producers and processors will implement new technologies if they will benefit from them. 
The public will accept new processes and products if they perceive them as safe. If 
consumers do not perceive a new technology as being safe, producers will hesitate to 
implement the technology. 
Public opinion is the consensus derived from open discussion of food safety, risk 
assessment and cost-benefit analysis. However, science education and communications 
among scientists, producers and the public must improve if consensus is to be based on 
informed decisions. 
Keywords: biotechnology, education, communication, agriculture, public opinion. 
Introduction 
A workable definition of biotechnology can be derived by examining the two parts of the 
word. "Bio" stands for biology, the science of life that includes all living things. 
"Technology" is collectively the tools and techniques which include animal breeding, 
embryo transfer, genetic engineering, fermentation, tissue culture, and so forth. 
Biotechnology is applying those tools to living organisms to get them to do what you want 
them to (Witt, 1990). 
Biotechnology can be used to improve the performance and composition of animals, 
value-added processes, diagnostics for disease, vaccines and other aspects of animal 
production. These tools have the potential of improving the animals' well-being, in addition 
to improving industry competitiveness. Increased efficiency also decreases waste production 
and can improve the environment. 
Biotechnology is playing an increasing role in nearly all scientific fields. To choose not to 
implement these tools in any one industry or country will leave that industry or country 
noncompetitive. The application of biotechnology to agriculture has lagged behind human 
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health applications due to a lack of investment which would yield needed basic knowledge 
in animal physiology, biochemistry and microbiology (National Agricultural Research and 
Extension Users Advisory Board, 1990). 
It is vital that new products and processes be developed and that they become publicly and 
commercially accepted so the growing world population can be provided a reliable food 
supply. 
Farmers and processors base their decisions to purchase and implement new technology 
on its expected benefits. These benefits are normally in the form of increased efficiency, 
decreased input costs, lower labour requirements or higher quality of production. The bottom 
line is that producers must see increased profits or improvement in their quality of life to 
justify changes. 
The Decision Making Process 
Today's world presents few new concepts in the decision-making process of producers. 
However, the information age we live in, with its instant communications, changes the 
formula somewhat (Sweet & Meeker, 1990). The average citizen has more media awareness 
now than ever before, but at the same time is woefully ignorant of science and technology. If 
someone of notoriety has something important to say or if someone famous has anything at 
all to say, that opinion of technology is heard around the world almost instantly. Little time 
is spent verifying stories or finding perspective. It is news because someone said it, not 
because the message was important. 
Producers are aware of consumer needs and expectations and are responding well to the 
market place. At the same time, political activists are attempting to shape consumer 
perceptions of safety, quality and risk with little regard for scientific thought. Thus, for 
perhaps the first time in history, producers are considering consumer perceptions as they 
ponder the use of new technologies. Some critics use their own "science" or find a scientist 
who agrees with them but not the majority of other scientists. Producers fear the market 
consequences of public misunderstanding. 
We have heard much about the standards to be met for the approval process in recent years 
- safety (to humans, the target animal, and the environment), efficacy and quality. The 
credibility of government agencies responsible for making these decisions must be 
maintained. 
The FDA recently departed from tradition by publishing information on the safety of 
recombinant bovine somatotropin (rbST) prior to approval of the drug. This new, more open 
attitude of the agency improves public opinion of the FDA and reduces concerns about the 
quality of the data or the safety of rbST (Juskevich & Guyer, 1990). Publishing rbST safety 
data in the scientific literature moves the debate away from the popular press. This improved 
openness and responsiveness by a government agency should be applauded and encouraged. 
Safety is important to everyone. However, it must be defined in reasonable benefit versus 
risk terms. Zero risk is not possible for any presently used technology or any other facet of 
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life. It should not be expected of new technology either. As Voltaire said, we should not let 
the perfect be the enemy of the good. 
The "fourth hurdle" - socio-economic impact of new technologies - has not been added to 
the list of criteria for agencies such as the FDA to evaluate. Anti-technology critics consider 
socio-economic impact to be second only to safety. The evaluation of socio-economic impact 
should be made by the public or third party experts, not the FDA. 
Perhaps the arguments about socio-economic impacts should be raised to a higher level. 
Is it fair to society to reject technology because it may change the structure of an industry? 
What industry is saved and what industries are prevented from developing? What about the 
socio-economic impact on a large portion of the six billion people that will inhabit the earth 
in the early 21st century? Can we be so selfish as to protect existing societal and industrial 
structures and not address the food needs of the future? 
One pork producer urged caution with respect to the use of "hormones" (Braaten, 1990). 
He said negative consumer perception would combine with the increased tonnage of pork 
due to increased efficiency to lower pork prices. He acknowledged rpST would make pork 
more competitive with chicken, but was not interested in pork becoming capable of mass 
producing cheap meat if profit margins are less. In his eyes, the consumers would benefit, the 
drug companies would have a new market, and producers would be the victims. His 
arguments cannot be ignored. Those scenarios should be considered. However, I believe the 
majority of producers who agree with this point of view would still adopt the technology if 
they were comfortable that consumers would accept their products and demand would not 
suffer. A longer term view could be developed if a world food policy showed promise that a 
large world population would, in fact, have access to abundant production and producers 
would be fairly compensated. 
We should learn lessons from history. Robert Cassens (1990), in his new book about the 
ten-year struggle over nitrites in cured meat said three forces contributed to the "shock wave" 
which almost destroyed the meat industry. These forces were: 
1. An unsuspecting and unprepared industry which was basking in previously 
achieved technological advances and preoccupied with business, marketing and 
labour. 
2. A fundamental scientific community delving into toxological and analytical areas 
and knowing something, but not enough. 
3. The consumers being swept along in tremendous sociological changes and being 
led by a new breed of activist who received vital assistance from the media. 
These three well-explained forces could be summarized as such: 
1. An unprepared industry; 
2. A weak commitment to basic research; 
3. Consumer concern. 
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Education and Information 
Those of us associated with animal agriculture should design a strategy to enlighten the 
consuming public about useful technologies that result in the production of wholesome, safe, 
nutritious food. People who produce food should be proud and project a positive public 
image. 
The National Science Foundation, through Northern Illinois University, recently surveyed 
2,041 people in the U.S. and found that 5.6% were sufficiently literate in the sciences to 
make informed decisions about issues such as nuclear power or toxic wastes. In the U.K., 
7.1% of respondents were scientifically literate (Miller, 1989). But, in spite of these findings 
about the level of public knowledge, decisions affecting the fate of agriculture are being 
made on the basis of public opinion. That opinion is influenced more by public education and 
the news media than it is with knowledge of production technology. This tells us that both 
producers and biotechnology companies need to be more involved in informing the 
consumer. More important, however, we all must work to improve our educational systems 
so more citizens can responsibly understand and participate in the formulation of public 
policy. 
The authors of Megatrends 2000, Naisbit and Aburdene (1990), say that the issue of 
biotechnology will not go away and that it is too important to delegate to the experts! The 
experts should improve their credibility. An observer of the ozone layer issue (Brodeur, 
1986) said the failure of society to deal with technical issues depends on: indecisiveness of 
the scientific community, timidity of regulatory agencies, ignorance of the public, 
inconsistency of the press, indifference of many nations, and obstruction and obfuscation of 
industry. 
Research scientists and administrators must assume some responsibility for 
communicating with the public. The public continues to believe the world is better off 
because of science. The scientific community is generally highly regarded, ranking second 
only to medicine among 13 institutions surveyed (Anon, 1989). They should explain 
biotechnological principles in understandable terms. Predictions of the impact of new 
developments should be realistic. Unrealized promises hurt the credibility of science. The 
public should be treated with respect, their concerns addressed, and their questions answered. 
Scientists must maintain the trust of the public so they are allowed to help make risk 
assessments. 
NPPC Plans on Biotechnology and Communication 
NPPC plans to be involved in consumer attitude research and focus groups to determine 
what aspects of technology development concern the public. Briefing sessions with opinion 
leaders and government officials, keeping them informed, will help alleviate surprise. 
Regular contact with researchers, manufacturers and regulators will keep up-to-date 
information flowing among these groups and help NPPC keep its member producers well 
informed. 
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When a new product such as somatotropin is approved, fast action to get correct 
information to the public will be needed before marketing of the product. This may include 
news releases, advertising and briefings to widely disseminate the facts about the new 
product or process. 
The industry is best served if the public has full confidence in the FDA and USDA. 
Industrial organizations and commodity groups should support the decisions of these 
agencies, supply them with industry information, and assist in consumer education to ensure 
smooth implementation of new technology. 
Conclusions 
Producers and processors will implement new technologies if they will benefit from them. 
The public will accept new processes and products if they perceive them as safe. Public 
opinion must be the result of informed consensus derived from open discussion of food 
safety, risk assessment and cost benefit analysis. However, science education and 
communication among scientists, producers, media and consumers must improve to 
accomplish this. 
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ENVIRONMENTAL AND SOCIO-ECONOMIC IMPLICATIONS 
Environmental implications 
Socio-economic implications 
Implications for animal production system 
ENVIRONMENT AND SOCIOECONOMICS SESSION CONCLUSION 
SUMMARISED AND ADOPTED CONCLUSIONS 
FROM PAPERS AND DISCUSSION 
ON 
ENVIRONMENTAL AND SOCIO-ECONOMIC 
IMPLICATIONS 
Chairman: 
D. Lister, CAB International - UK 
Discussion panel: 
LJVÏ. Crawford, USDA Food Safety Inspection Service - USA 
J. van Hemelrijck, FEDESA, Brussels, Belgium 
V.W. Ruttan, University of Minnesota - USA 
Session VI reviewed the environmental and economic issues and the 
role governments might have in determining the prospects for, and 
acceptability of the developing technologies. 
The first paper by Colin Tudge took the view that considering rST 
technology in relation to environmental matters was largely a 
question of what was sought from agriculture in general which might 
be to feed the world's population whilst maintaining the 
biodiversity of species. This could be achieved by approaches based 
on intensive systems of agricultural production in which rST would 
have an obvious role but there were strongly held beliefs emerging that 
greater reliance should be put on extensive agriculture where a role for 
rST might be more difficult to support. The use of rST in intensive 
systems not only permits a reduction in the number of animals required 
for a given level of production but is nitrogen sparing and gives rise to 
less pollution from nitrogen sources. Land could be freed for 
other purposes and the risk of decline in predominantly animal 
species reduced. 
Dr. Boussard presented the argument that, based simply on economic 
grounds, rST technology was likely to prove beneficial perhaps 
especially so in developing countries. For milk, the cost of rbST 
use is very much less than the anticipated returns although the net 
costs per extra unit of yield of milk are little changed. rpST ought also 
to provide economic benefit and such complications as are conceivable 
pertain to land use and availability. Using rpST will save land 
which will create problems where land is plentiful but can offer 
solutions where land is in short supply. 
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Technical progress will be increased by rST technology but its adoption 
will depend on politico I socio I economic pressure to support or deny it. 
Either way there will be transitional difficulties caused by the freeing 
of land, manpower and capital. There will, therefore, be a pressing 
need for ameliorative government intervention to accommodate 
the changes which the introduction ofrSTinto animal agriculture will 
inevitably generate. 
The socio/politicial dimension was brought into more immediate 
focus by Drs. Fallert and Crawford who had concurrent involvement 
with the NIH hearings on somatotropin. Dr. Fallert recounted the 
agricultural scenario into which the new technology would need to be 
fitted. In particular there is a national and international reduction in 
the number of farms matched by a compensatory increase in the size 
and output of those remaining. There is universal pressure to reduce 
agricultural support and make agriculture more responsive to market 
forces. 
History acknowledges the effective uptake of new inventions, 
developments and technologies by farmers but recently concerns have 
been voiced by the general public which have impeded and even 
halted the introduction of new science into agriculture. The 
safety and wholesomeness of food are matters which are widely felt not 
to be safely left to government. The same applies to animal welfare, 
safety and pollution. But governments and regulatory authorities find 
difficulty in accommodating these socio-economic issues in the 
regulatory process. Professor Ruttan felt that many of the background 
problems to be of our own making and that scientists should have 
prepared the way for the current innovations rather more 
carefully. rST technology, it can be argued, is in essence no different 
so far as its role in agricultural production is concerned from any other 
development presented to the agricultural and food sectors in previous 
times. It is the rate of progress and the changing public perceptions 
which are at heart of today's problems and the agricultural science 
community should recognise this and take the appropriate action. 
Dr. van Hemelrijk pointed out that there are further features of the 
debate which have emerged in the European Community though they 
are also readily acknowledged in other regions of the world. The 
notions of efficacy, safety and environmental impact are 
paramount in the acceptability of any new product or technology. 
They are dealt with in various ways from one regulatory authority to 
another and there is some overlapping of the standards to be met. In the 
U.S.A, the Animal Health Institute concerns itself with public 
education. In the European Community more emphasis is placed on 
Community law. The chain of legislation is, however, adequate by itself 
and must be accompanied by effective control measures which 
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unfortunately are not always policed. There are now moves in 
Europe to create quality assurance schemes for the food chain as a 
whole rather than its component parts. 
• Whatever the concerns, there was a clear recognition that intellectual 
arrogance, political naivete and lack of public awareness by scientists 
will neither help the cause of science nor the introduction of new 
technologies for the public good. Science, at least, can begin to put its 
own house in order. 
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GROWTH HORMONE BIOTECH AND THE ENVIRONMENT 
Colin Tudge 
London - UK 
Introduction 
I am very much on the side of the environment, which I suppose is why I have been 
invited to talk at this meeting. But I do not share the view that I felt is held by many who 
apparently espouse the same cause. I am not anti-science and anti-high tech (which I define 
as the kind of tech that depends upon science and comes out of science). I am certain that the 
world's food and environmental problems, which are so closely linked, cannot be solved 
without the application of some very fine science indeed, and some very sophisticated high 
tech. Specifically, I have no doubt that molecular biology in general, and genetic engineering 
in particular, will play many important roles in helping human beings to feed themselves and 
in helping us to protect the rest of nature. So, that means I am not prejudiced against the 
specific high technologies that surround growth hormones. But at the same time the needs of 
the environment and the needs of humanity are more important than any one technology or 
any one industrial company, and if we find any technology lacking, we should not be afraid 
to throw it out. "If thy right hand offends thee, cut it off". 
To be sure, at first sight - or as a ploughman might say, "at the first pass" - the growth 
hormone technologies look very good from an environmental point of view. 
Intensive livestock production 
First, we should observe that these technologies, as they now stand, and as they have been 
developed, are geared towards intensive livestock production. This is inevitable. Intensive 
production concentrates cash as well as output, and makes it possible to finance 
technological innovation. Secondly, of course, in intensive systems the many variables are 
largely controlled, so it becomes possible to measure accurately the impact of any new 
development. Hence we can see that treated animals convert more of the nitrogen they are 
given into protein; we can see that they produce relatively less fat; we can see that their urine 
contains less nitrogen, and hence may be less polluting; all as described to us by Pieter van 
der Wal. 
We should obverse, too, that nitrogen pollution - like most forms of pollution - is in 
general far more complicated and potentially even more pernicious than it is usually given 
credit for. Thus, people commonly think of N pollution purely in terms of run-off. But that is 
only a small part of the tale. Recent studies at Rothamsted Experimental Station in England 
have shown that every hectare of Britain - except perhaps in the remotest areas - receives 40 
kg of nitrogen from the atmosphere. This is a staggering amount; perhaps a third of what a 
farmer might apply to an arable field. Some of these nitrogen compounds come from car 
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exhausts but much originates as ammonia and oxides of nitrogen released from agricultural 
fields. For commercial foresters and organic farmers (who don't like to add artificial 
fertilisers) this nutrient from the sky is a bonus. However, its effects on wild floras have not 
been directly assessed but are likely to be disastrous. 
The indirect effect of these oxides of nitrogen is their contribution to acid rain - which has 
been widely discussed, although there are still several mysteries to clear up. In addition, 
however, wild plants in general are adapted to soils with a very low nitrogen content. 
Infertility is the usual order of things in nature. Most wild plants languish if N is too high, or 
simply fail to respond to it - and thus they are ousted by that minority of plants that are 
adapted to a high N input, and do grow rapidly in response to it. These, of course, are the 
plants that customarily flourish on agricultural land and are classed as "weeds". 
In semi-arid Australia the native flora is of the kind known as "bush". It is extraordinarily 
varied. The bush of Western Australia includes 9000 species of flowering plants - about six 
times the number found in Britain. However, in much of Western Australia the bush is 
reduced to 'remnants', dotted among arable fields. Studies at the CSIRO's Division of 
Wildlife and Rangelands Research in Western Australia have shown that species variety is 
declining rapidly within these remnants - in other words, many species are becoming locally 
extinct - and that one of the main reasons for this is the encroachment of N from surrounding 
fields. Now this probably is, mainly, a direct seepage effect, rather than a descent of oxides 
from on high. It seems likely, too, that wild plants in other parts of the world might not be 
quite so nitrogen-sensitive as those of Australia - which is an ancient continent that is 
fabulously infertile. But the point is made nonetheless. Wild plants flourish in infertile soils. 
Indeed, we might even infer an inverse relationship between number of species and degree 
of fertility - a point that seems paradoxical at first but becomes less so as you start to think 
about it. But we can sensibly extrapolate from the Australian studies; and infer that the 
showering of nitrogen compounds on to the wild floras of the world in general is liable to 
prove extremely damaging simply because of over-nutrition. Reducing the amount of N that 
is wasted by cattle and is ripe for sublimation may not make a huge contribution. But the 
generalisation is that surplus N is even worse than is usually appreciated; and anything that 
reduces it is helpful. 
But we should never be content to discuss any issue simply in its own terms. We should 
always ask about content. Given that - at present - growth hormone technologies are part of 
intensive livestock production, we must ask, "is intensive livestock production good for the 
environment?". In other words, "are the growth hormone technologies being used in a 'good' 
context?" 
Well, to many people who think of themselves as "environmentalists", intensive livestock 
production is the bete-noire. But again, we can make very powerful environmentalist 
arguments in its favour. 
In general, there are two main ways in which to design an environmentally friendly 
agriculture. The first is to produce as much food as possible from the smallest possible area, 
and so leave a great deal of other land for other purposes, including wildlife conservation. 
The second is to devise "extensive" systems, producing far less food per unit area, but 
hospitable to other species. Let us compare these two approaches. 
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In terms of production per unit area, intensive systems look very good indeed. They 
commonly produce several times as much food per unit area as extensive systems - and in the 
case of livestock, often several hundreds of times more per unit area. "Per unit area" is what 
counts, for of all the inputs of agriculture, land (together perhaps with light) is the one that is 
least expandable; and the one whose expropriation effects other species most directly. 
Of course, to some extent - even to a large extent - the land economy of intensive systems 
is deceptive. Intensive units are like factories: they process inputs from far and wide. In 
ecological terms, intensive livestock units are like estuaries: the animals within them convert 
nutrients brought in from entire catchments. 
The true area of an intensive livestock unit is its own patch of land plus all the hectares of 
cereal, pulse, and other fodder that feed into it. This of course will be many times - even 
hundreds of times - greater than the unit itself. Even so, though, if you do all the sums, well 
run intensive livestock units that are supplied by intensive arable systems come but very well 
in terms of animal energy and protein produced per unit area. 
Then again, all production systems, livestock or factory, produce waste. Intensive 
livestock units have often pushed out effluent in offensive and damaging quantities, this, too, 
is deceptive, however. Extensive systems seem far less polluting because the organic 
nitrogen produced by the animals is processed locally by soil bacteria, and most of the 
inorganic nitrogen thus released is taken up by pastures or oxidised into the atmosphere. 
Cows in a field do not smell, as those in an intensive dairy unit may do. 
But each individual animal in an intensive unit is liable to process its food more efficiently 
than an extensive animal, because it spends less energy moving about and keeping warm, and 
because it will probably have been bred specifically for feed conversion efficiency rather 
than for the ability to survive in the great outdoors. So the total amount of effluent N 
produced will be less in an intensive system than in an extensive, per unit of feed consumed, 
and per unit of meat, milk, or eggs produced. When intensive unite are polluting it is because 
the appropriate technology has not been installed. But in general we could say - at least if we 
kept our fingers crossed while saying it - that the effluent from intensive systems should in 
principle be more controllable than from extensive systems. 
In general, then - intensive systems are often under-engineered, and therefore can be 
polluting and non-friendly to the environment. But this is not inevitable. If they are designed 
and operated properly, they can, taken all in all, be less polluting. 
Extensive production systems 
What of extensive systems? How friendly are they to the environment? 
Well, some extensive fanning systems have been around for so long, and are so interesting 
in their range of species, that they have become accepted even by biologists as part of the 
proper order of things. Some extensive systems create ecosystems that are in some way 
richer than the pristine environment. Thus plants are still surviving on the chalk downlands 
of England that in other parts of Britain became extinct soon after the Ice Age. Reason? 
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They are plants that naturally grow north of the tree line - which in the last Ice Age was in 
Southern England. But trees have been kept at bay from the downs in the millennia since the 
Ice Age by grazing sheep. Similarly, the loss of sheep from around England's south-west 
coast has endangered the local chough, which like to take invertebrates from grassland - but 
prefer short grass. Admittedly, deer probably did the job before there were sheep (not rabbits, 
which came to Britain some millennia after sheep); but it's the sheep that kept the chough in 
business. 
Australian aborigines are thought of as the world's great hunter-gatherers; not as farmers 
at all. But Rhys Jones, anthropologist from Canberra, argues rather that for the past 40.000 
years aborigines have practised what he calls "firestick farming"; setting fire to the bush at 
regular intervals and in a very orderly fashion, to encourage fresh growth and provide foci of 
huntable animals. That is extensive farming of a kind; and it has created a flora and fauna that 
must be profoundly different from that of pre-aboriginal times (when there were many 
mega-marsupials and giant reptiles in addition to the present fauna) but is a rich end "valid" 
ecosystem in its own right. And anything 40.000 years old deserves to be called "natural". 
On the other hand, we know that extensive farming systems can be extremely delicate; 
and if extensive farming is insouciantly carried out, or if too many people farm extensively 
at once, then extensive farming can be very destructive indeed. Vast areas of Australia have 
been laid waste by excess cattle brought in by Europeans; Africa's Sahel and India's 
commons are severely overgrazed; much of South America rushes straight from tropical 
forest, through pampas to desert in a few brief years; and so on. 
In Britain, at present, under the auspices of the Agricultural and Food Research Council, 
there are quite a few projects to reconcile extensive agriculture with environmental 
friendliness and stability. Scientists at what is now the Macualey Land Use Research Institute 
seek to optimise the use of heather and gorse, as well as of grass, by sheep, to create an 
upland landscape that is also hospitable to other species such as grouse. At the Institute for 
Grassland and Environmental Research there was until recently a prolonged study of the 
effects of grazing by cattle on the native pastures of the Somerset moors - the notion being to 
reconcile the two. 
Extensive farming at its best, in short, can be beautiful, species-rich, and productive -
though only at its best; and in general, the more productive it becomes the more the wildlife 
suffers. Wildlife in significant numbers plus food in significant amounts is a very difficult -
interesting, but difficult - equation to get right. Much of extensive agriculture in Britain at 
least is a whited, or rather a greened, sepulchre. It looks terrific, but there's not a lot living 
out there, except the cows and the grass. 
Systems between the extremes 
There are, I should say, positions between the extremes, in which areas of land on farms 
of whatever degrees is intensity are ear-marked for wildlife - such as hedgerows and areas of 
marsh; the trick being (again under study by AFRC) to know which wild species need what. 
For example, a scheme masterminded from Oxford University currently seeks to define 
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stopping-off spots for wildfowl, as they migrate through Britain, and farmers will no doubt 
be compensated in some way for keeping those spots intact. 
In short, our second pass suggests that there are good environmentalist cases both for 
intensive farming and for extensive. In general, the world's land should be laid out as a 
mosaic; some land devoted to food production; some devoted to wilderness; and some 
seeking to combing the two, with extensive regions artfully - ideally - designed to 
accommodate wild creatures as well as to produce food. The model, perhaps, is already 
provided by Australia's Great Barrier Reef, some of which is devoted to intensive fishing, 
some of which is apportioned for tourists, and some of which is left pristine. 
What is intriguing, though, - and contrary to many "environmentalists" expectations - is 
that intensive agriculture probably should play a much bigger role in this mosaic, than 
extensive. The loss of efficiency in extensive systems (in terms of amount produced per unit 
input) is rarely balanced by overall environmental friendliness, and in practice, extensive 
systems can be extremely unfriendly to the environment, and often downright destructive. 
Thus, at this second pass too, it seems that the specific technologies surrounding growth 
hormones come out of environmentalist discussion very well. They increase efficiency. They 
reduce inputs relative to outputs. They reduce wastes, relative to outputs. Even if they are 
considered solely in the context of intensive livestock production they come out well, 
because intensive livestock production itself comes out well. If they can be extended to 
livestock in extensive systems - well, that is a bonus. 
What do human beings actually need? 
But if we are really taking the world's problems seriously; if we are, really seeking to feed 
the many billions of people who will soon be on Earth and at the same time to save the 
majority of other species, we cannot leave matters there. So far, after all, we have tacitly 
assumed that the world's agriculture, taken all in all, is already producing the right things. All 
we have asked, is how those things can be produced most efficiently. The bigger question -
if we are really taking the planet's problems seriously - is whether, in fact, the things we are 
now producing are the right things. 
To answer that larger question, we must go back to basics and ask, "what do human beings 
actually need?" 
The answer that is now forthcoming from nutritionists runs roughly as follows: 2000 kcals 
of energy per head per day, of which 5-10 per cent should be protein; plus a mixed bag of 
minerals, vitamins, and essential fats, all laced with fibre. Some commodities - notably 
non-essential fats - should be avoided in excess; and even protein in enormous quantities, has 
its detractors. Why de-aminate what shouldn't need de-aminating? Why burden yourself with 
surplus organic nitrogen? 
To be environmentally friendly, we should contrive to produce these nutrients with 
minimum resource - and, in particular, with minimum input of land. So how can that be 
done? 
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Well, as everyone now appreciates, human beings eat most economically (in terms of 
environmental input) if they derive the bulk of their energy and protein directly from seeds; 
which usually though not necessarily means cereal and pulse. Vegetables, fish, meat and 
dairy products then serve merely as trickers-out - suppliers of vitamins, minerals, and 
essential fats; and, essentially, of flavour. You may argue that such a diet would be tedious in 
the extreme. In fact, of course, all the great cuisines of the world - Indian, Chinese, South 
East Asian, North African, Mediterranean including French Provincial, North European, 
Central American - are based on precisely this apportionment of foods. The basis of Chinese 
and Indian cuisine is the bowl of rice or the wheat-based "pancake" or bread - chapatti, nan, 
paratha, dosa and the rest. Scotland has haggis and neaps - oat-based. French cooking in its 
present form - which is the root of haute cuisine - is remarkably austere; excellent bread, 
cassoulet, etcetera. There is no hardship, no austerity, no real self-Manial in eating the way 
that the modern nutritionists recommend. We merely have to re-discover traditional cooking. 
Now- here's a revolutionary thought. Wouldn't it be a good idea to design agriculture 
expressly to feed people? Designed, that is, to meet nutritional needs and also to respect 
gastronomic aspiration? In the recent history of the world, funnily enough this has not been 
attempted very often. Britain did it in World War II, when we were under seige. China 
attempted it in the years after Mao's revolution - and although the Chinese did not succeed in 
feeding everybody, they did a lot better than the pundits predicted. In general, though, 
present-day agricultures are designed (or at least they "happen") in response to a whole 
number of different pressures; those of the west in accord with the business demands of 
capitalism (albeit much modified); those of Soviet Russia designed to show that collectivism 
works (which in this context it clearly didn't); and those of the Third World, a series of 
political footballs. 
Suppose, though, we did design agricultures primarily to feed people - and to do so while 
making best use of land. Such an agriculture could truly be called "rational"; and all 
agricultures that were not so designed, could properly be considered "irrational". Rational 
agriculture would by definition be the most environmentally friendly that we could conceive 
of. How would it be designed? 
Well, clearly, the most suitable areas would in general be devoted to cereal and pulse, 
which would be eaten directly. Especially favoured areas would produce vegetable and fruit. 
Much as at present. 
The major change, however, would be in livestock. There wouldn't be none at all, as the 
vegetarians advocate. Nutritionists demand livestock - if only as a source of minerals and 
essential fats, though it also has advantages as a source of energy and protein. But there 
need not be much: meat in a "rational" diet would be the garnish, rather than the centrepiece. 
In general, then, livestock would primarily be raised either on odds and ends - agricultural 
by-products such as pigeon-pea stalks, or swill; or it would be raised on land that could not 
reasonably be used for major crops, such as the Scottish or the Ethiopian hills. In the latter 
cases, it would be raised in extensive systems that were designed to be friendly. 
There would be two exceptions to this, however. First, a society that elected to subsist 
primarily on cereal and pulse should strive to produce surpluses, Because yields are innately 
variable, and in some years there will be shortfall. But in most years there will, indeed, 
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be surpluses; and livestock should be kept as a sump population, to mop them up. Of course, 
if animals are kept through the winter on surplus cereals and pulses, there will be more 
around to make better use of grazing in the following summer, so this makes sense on two 
counts. 
Secondly - and very importantly - animals in the Third World are not mere food. They are 
also sources of fuel and clothing (as they are everywhere, of course) and, vitally, of transport 
and traction, neither is it the case what animal traction is merely a stop-gap, waiting for 
tractors to be introduced. Many engineers as well as agriculturalists, including some at the 
AFRC's institute of Engineering Research, feel that animals are the best form of transport 
and traction in may Third World contexts. 
So - where does this leave growth hormone technologies? 
Clearly, the crucial question is not, "how do these technologies affect the friendliness of 
present-day agriculture?"; but, "how could they be Fitted into "rational" agriculture, that was 
truly designed to feed people without wrecking the environment?" 
And there, it seems to me, the jury must remain out. 
Clearly, the growth hormone technologies do enhance the efficiency of animals in 
intensive livestock systems, which, environmentally, is a good thing. But it remains to be 
seen whether and how much importance would be attached to intensive livestock production 
in a truly rational system. I suspect it will have some importance; there will, after all, be 
cereal and pulse surpluses. But I suspect, too, much less than at present; because cereal and 
pulse would not, in a rational system, be grown in large amounts specifically for livestock, as 
it is at present. 
On the other hand, FAO now advocates zero grazing in the Third World. If fodder is taken 
to animals in byres, they do not poach the ground or trample what they do not eat, and their 
dung-can later be distributed much more evenly. Zero grazing also provides labour, which in 
Third World countries is almost always a good thing. In general, zero grazing is 
environmentally friendly, because it increases efficiency (the same food for less input) and 
because it should increase control over potential pollutants. There seems to me no reason 
why growth hormone technologies should not improve the efficiency of animals eating 
pigeon pea stalks. But there could be a price to pay. So far as I know, the necessary research 
has still to be done. 
Then again, cattle are not and would not be kept in the Third World just to eat pigeon pea 
stalks. The desire, now, is for multi-purposes animals; cows, indeed, that can pull a plough 
while pregnant, produce a beefy calf, and give milk, all at the same time. Would these new 
technologies enhance the abilities of such animals in such a context? If so, then this seems to 
be a social and an environmental plus. But again, the research has to be done. Among the 
possible caveats are the other variables; the difficulty, for instance, of controlling disease in 
Third World livestock, without which it becomes hard to measure the impact of any 
refinements. 
One last environmental point. One reason for keeping cattle intensively is that it enables 
the world to keep more cattle than they could if they simply grazed on natural pasture. It is 
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now clear that methane contributes significantly to the greenhouse effect: nothing like as 
much as carbon dioxide, but still enough to be measurable. It is also clear that significant 
amounts of methane are generated in the guts of termites and of cattle. There is an argument 
- perhaps not a huge one, but still and argument - for keeping fewer cattle, to alleviate global 
warming. 
Conclusions 
At first sight - pass one - these new growth hormone technologies seem environmentally 
excellent. They reduce unit input per unit output. They reduce pollution per unit output. 
At second sight - pass two - they still hold up. They are at their best - we may presume -
in the context of intensive livestock production. And if we set out to produce the kind of food 
we produce now by the most friendly methods, then intensive livestock production emerges 
as a valid and extremely valuable system. 
At third sight, however - pass three - the picture becomes murkier. If we truly took the 
problems of humanity seriously, and those of the planet as a whole; if we truly set out to 
provide food for the 10 billion people who could inhabit this Earth by the middle of the next 
century, and for several centuries after that: and if we truly set out to conserve the larger 
proportion of the 30 million or so other species with whom, at present, we may share this 
planet - then we would set out to design a new kind of agriculture. This could be called 
"rational" agriculture; and rational agriculture would be different in several highly significant 
ways from those of the present. In particular, livestock production would be less significant, 
and multi-purpose animals would be more significant. 
How the new technologies would fit into a system that was truly rational remains to be 
explored. Clearly, though, if the new technologies are employed merely to enhance systems 
that are not rational then they cannot truly be considered to be environmental friendly. 
I think it would be possible, if we applied our best science in a rational context, effectively 
to re-create Arcadia. But as they say in Ireland, if I was going there, I wouldn't start from 
here. 
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SOMATOTROPIN: AN ECONOMIC VIEW 
J.M. Boussard 
INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE, Station d'Economie 
et de Sociologie Rurales, 63 Boulevard de Brandebourg, 94205 - IVRY CEDEX 
FRANCE 
Summary 
The land, capital or labour saving character of somatotropin is discussed. In the case of 
bST, the innovation is moderately land saving, whereas it saves capital, and substitutes 
skilled for unskilled labour. In the case of pST, it is firmly land saving, thus encouraging 
intensification. As a consequence, in Europe, it will exacerbate the detrimental consequences 
of the Common Agricultural Policy. In the US, it may provide pork producers with additional 
comparative advantages, but depress the price of land, and increase regional specialisation. 
It is not sure that the technique can be made use of by developing countries. If it were true, 
livestock production could be transformed in a way similar to the transformation of cereal 
production by the "green revolution", the more as the two movements are likely to mutually 
reinforce themselves. 
Keywords: Technical progress, land use, production location, farming intensity, Common 
Agricultural Policy. 
Introduction 
The possibility of administering large quantities of elements of the somatotropin (ST) 
family to most domestic animals undoubtedly opens a new era of technical progress in the 
livestock business. But because developed countries agricultures have a general tendency to 
overshoot demand expectation, and since, most of the time, public budget are in charge of 
creating artificial demands for unwanted quantities, most public decision makers will 
consider the mere possibility of any productivity increase in agriculture as, at least, a mixed 
blessing. As a consequence they will actually make considerable efforts to prevent such an 
event to occur. The point of view of an economist is somewhat different, however. In fact, no 
economist would deny technical progress its virtues. The real problem, with ST as well as 
with any similar change in the production possibility set, is whether is it really a technical 
progress, with which consequences. In addition, it is also to assess to what extent adverse 
consequences, if any, could be avoided by suitable policies. This is the subject of this paper. 
The notion of technical progress 
For an economist, "modernization" is not necessarily a technical progress. In fact, two 
very distinct kinds of change are involved in what is commonly called a technical progress, 
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such as, for instance, harvesting with a combine harvester instead of with a scythe. First, 
there is a substitution of capital to labour. Such kind of technical progress occurs in response 
to price movements, for instance an increase in the price of labour, and a decrease in the price 
of capital. Such changes do not necessarily imply any change in technology, that is, in the 
stock of human knowledge. Actually, horse powered harvesters were put in use as early as 
during the 4 th century BC, in what is now northern France, precisely because, for many 
reasons which encompass the scope of this paper, labour was going to be scarce at that time. 
In technical economic language, this is moving along an isoquant. 
Second, there are also "true" technical progresses, that is changes which occur because the 
new technique, for a given production level, uses less than at least one input, without 
requiring more of any other. This is described in technical language as "move of the isoquant 
toward the origin". Such moves take place whatever the price system, because, in that case, 
the advanced technology dominates the other ones for any price setting. Of course, such 
technical improvements spread over very quickly as soon as farmers are aware of their 
existence. 
Actually, most of actual technical progresses are complex moves, combining both kinds 
of change . For instance, modern harvesters associate a capital/labour substitution effect 
with a true change in the production possibility set, because all the capital which would be 
necessary to sustain the army of workers required for scythe harvesting the area which is 
processed by one such craft would probably be enough to buy two of them. For that reason 
(and for that reason only), combine harvesters represent a true technical progress over scythe. 
In addition, it is clear that the discussion just outlined must not be reduced to the case of 
a two input / one output problem: Agriculture produces many outputs from many inputs. As 
a consequence, the preceding observations must be considered within a multidimensional 
setting, with as many dimensions as the total number of inputs and outputs. 
Is somatotropin a technical progress? 
In this context, what can be said of ST? I have not the honour of deserving the name of a 
biologist, and I may be wrong in interpreting your discussions. For that reason, I do not 
pretend that what follows is factually correct. What is true is that it represents the idea (right 
or wrong) that many economists have presently about the technical effects of ST. To some 
extent, this conference will precisely serve to determine whether this interpretation is 
correct . In short, this interpretation is as follows: The consequences of ST are quite different 
for meat and milk productions. In the case of milk, there is a production increase per animal. 
But there are no significant changes in the quantities of energy and of protein which are 
see especially, the classical work by Hayami and Ruttan (1971). 
My technical information comes from synthesis, second hand, papers from which such an august audience 
is not likely to learn anything, but which are invaluable for an ignorant as I am: Chillard et al (1989) or 
Colleau (1990) for bovine somatotropin, Bonneau (1990), Bonneau et al (1990) for porcine somatotropin. 
See also the important and comprehensive report of the USDA, as well as an unpublished document 
(CREA, 1990) 
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necessary to make one additional kg of milk. As a consequence, it reduces the costs which 
are genuinely tied with the existence of one individual animal: In the case of milk, this is 
mainly the working time necessary for milking, as well as milking parlour number, stables, 
etc... .This is also the nutrient requirements for the maintenance of one animal. Given the 
already high ratio: production requirement/maintenance requirement, this last item is not 
very large. In addition, this lowering of the maintenance feed requirements is offset by a 
corresponding reduction in meat production of the milk cows. 
From another point of view, bovine somatotropin (bST) is generally considered (Mouchet, 
1989 ; Cordonnier and Bonnafous, 1989 ; Cordonnier, 1989) as a potential regulating device 
in herd management: Since it is possible to give or not to give the drug to animals, it is 
possible to use it for increasing production when markets or general conditions are good, and 
decrease it in the opposite case. Again, such a usage would increase the general efficiency of 
a farm, and improve most of input/output ratios. 
Thus, somatotropin, in the case of milk production, saves capital and labour, mainly 
unskilled. Conversely, it requires skilled labour, and some capital to buy and administer the 
drug. Will this skilled labour be that of a veterinarian? As far as I know, this point is still 
pendant. This is important, because, if a veterinarian is required, this implies a large lumpy 
cost for a herd (obviously, the veterinary will charge travel costs on a lump sum basis), thus 
making economy of size important. Otherwise, there is no reason for the innovation not 
being adopted by very small part time farmers. In any case, since these costs are very small, 
and almost negligible by comparison with benefits, ST, in this context, is a quasi true labour 
and capital saving technical progress, the adoption of which is likely to be very quick if the 
drug is to be authorized. 
In the case of meat the problem is slightly different: The effect of ST is to reduce the 
proportion of fat in meat. Since fat is more demanding in energy than muscle making, the net 
result is an increase in the conversion coefficient of starch to meat. Again, this is a technical 
progress, but very different from the previous one. 
First, bovine meat does not seem to be affected, insofar as bovines in general do not 
produce much fat. This is an exception for third world herds, with some breeds (such as 
African Zebus ) which could very quickly benefit from the innovation, if not too costly. But 
since data are scarce on that point, the discussion, here, will be mainly focused on pigs. For 
pig enterprises,in addition to the reduction of animal related costs, (labour and capital, as 
seen above), ST will significantly decrease the quantity of nutrients required for a given meat 
production. The importance of this observation will be made apparent after a discussion of 
the production intensity concept. 
The notion of production intensity 
An agricultural production process is said to be more intensive than another if it uses more 
non land inputs per unit of output. The importance of the concept spurs from the fact that land 
is always the ultimate fixed factor in agriculture: It is always possible to increase the capital 
or labour involved in agricultural production, if the price of output justifies it. But land, this 
"free gift of nature", is fixed by the boundaries of states, or even by the radius of the earth. 
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Thus, even if the agricultural production function is genuinely "with constant returns to 
scale . "the fixity of land makes it "with decreasing returns to scale", implying, in a fixed 
technology context, the necessity of increasing prices to increase production, unless free land 
be available. 
Conversely, in case of excess production, the fixity of land guarantees that decreasing 
agricultural prices would decrease production, by inducing farmers to choose more extensive 
production techniques. Thus, in a fixed technological environment, the farming intensity 
level seems to be the key determinant of agricultural production, and the instrumental 
variable which will govern the correspondence between needs and production possibilities. 
Now, technology is never constant, and is basically unpredictable. It turns out that the 
recent evolution of technical progress in agriculture is such that, at current agricultural 
prices, intensifying, hence increasing per ha production, is often profitable, up to the point 
that current food solvable needs are much more than met. As a consequence, in developed 
countries, land is presently in excess, as shown, among other symptoms, by the existence of 
land set aside programs in operation on both sides of the Atlantic. This raises a host of 
problems, the discussion of which is clearly out of the scope of this paper, but the existence 
of which helps to understand the importance of answering the question about the nature of 
the relationships between land and somatotropins. In effect, if ST is a "land saving" technical 
progress, it will exacerbate the above mentioned difficulties. In the opposite case, it will 
alleviate them. 
Bovine somatotropin and land: the interferences of international trade 
From the above discussion, it is clear that rbST is practically neutral with respect to land 
in the case of milk, (because it requires basically the same quantity of nutrients per kg of 
milk, and assuming no change in the per ha yield of nutrients), and noticeably land saving in 
the case of pork. As a consequence, rbST should leave political decision makers rather 
indifferent. On the contrary, rpST should be a matter of concern. Things are a little more 
complicated than that, especially with rbST, and especially in Europe. 
In effect, in Europe, milk cows nutrients are seldom produced "on the farm". This is 
partially a consequence of the inconsistencies of the Common Agricultural Policy: For 
various reasons, the starch equivalent has two quite different prices when locally produced 
(as a grain crop) or imported (as a "cereal substitute"). As a consequence, the European 
farmer has all the reasons to sell his grain to the government (this grain will eventually be 
reexported at the expense of the treasury, which will pay the difference between the 
international and guaranteed prices) and to buy back American or Brazilian soybean, to feed 
his cows. For that reason, the European produced milk is not only made of European land, 
but also of the American, or Asian land which is necessary to produce the large quantities of 
Technically, it is said "homogenous and of degree one", for if it is possible to produce a given quantity of 
agricultural commodities with 1 ha of land, 10 hours of labour, etc then it is possible to obtain twice this 
quantity with 2 ha of land, 20 hours of harvester, 40 hours of labour, etc... In that case, production can reach 
infinity if all inputs are available and if outputs are sold at fixed prices. 
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imported feedstuffs used in European agriculture. The magnitude of these surfaces are 
enormous: between 10 and 30 millions of ha, that is, the same order of magnitude as the 
french agricultural area. 
In that context, since the introduction of ST is likely to increase the proportion of 
concentrates in the total herd calories intake, it will be viewed by European authorities as an 
additional trouble, since it will increase the chances of Brazilian, Asian, or northern 
American land to substitute to European land in the feeding of European cattle. 
It must be noticed that this particular problem arises only as a consequence of the 
unfortunate decision of stopping halfway in the protectionist policy which was decided at the 
beginning of the common market: Without any protection, or with a full, starch content 
based, protection of feedstuffs, the difficulty of indirect import of non European land in 
Europe would vanish almost completely. 
Apart from this problem, rbST may actually increase intensity, but through a slightly 
different process, because of the limited stomach capacity of cows. Because of this limit, the 
quantity of roughage a given cow can ingest is limited, and, therefore, all feed increases will 
be made of concentrates, either cereals or oilseeds. Now, it turns out that these "commodities 
are relatively easy to transport and stockpile (which means that the location of milk cows will 
be easily made distinct from the nutrients producing land) and also that the technical progress 
is quicker in their case than for rough fodders (which means that, in addition to the slight land 
saving effect of the small reduction of nutrient requirements at the cow level, there will also 
be a land saving effect due to the substitution of land extensive grains and oilseeds to the land 
intensive rough fodders in total cows calories intake). In that sense, rbST will reinforce an 
evolution which it did not trigger. In addition, in view of the large number of involved 
parameters, it is very difficult to assess the extent of its role in this evolution, and to predict 
its direction in the future. 
Thus, the general impression coming out of this discussion is that rbST will have an effect 
toward more intensive farming, but that this effect is slight, and without many practical 
consequences if one is not too worried that European cows can use more Brazilian land, or 
that Wisconsin can produce milk from Iowa maize. 
The case of rpST is quite different. 
Porcine somatotropin and land: toward important reallocations 
In the case of pork, clearly, rpST, in addition of being capital and labour saving, is also 
land saving. The consequences are important. First, geographical reallocations will occur, 
because all kinds of pork will not react in the same way. Maybe the Danish pork, already 
It must be added that such a rebalancing of Common Agricultural policy, so " wishable" as it may be, (and 
whatever its sense, that is, toward more or less protectionism) would create serious transition problems: The 
dutch herd, for instance, which relies mainly on foreign land through imported feedstuffs, would be 
submitted to very hard pressures, involving dramatic reallocations of virtually all agricultural assets. 
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selected for their ability to produce small quantities of fat and large quantities of muscle, will 
loose a part of their comparative advantage, by comparison with many middle western pork 
plants. Although such reallocations may trigger interesting discussions at government level, 
they may not be the most important. Two other consequences deserve consideration. 
First, large areas of land will become available for other usages. Of course, if the gain in 
feeding efficiency is 15 %, this does not mean that 15 % of the surfaces presently devoted to 
pork feeding will be made free. With such a gain in productivity, a similar fall in average 
price is to be expected. This will encourage pork consumption, and create a comparative 
advantage for this meat against its direct competitors, mainly chicken meat. In the present 
situation of our knowledge about consumption and consumption demand elasticities, it is 
certainly premature to give too precise figures in this respect, for consumption models are 
still too dependant on secondary assumptions for that we could have a full confidence in their 
numerical results. Yet, it is possible to imagine that a permanent fall of, say 10 % in the price 
of pork will induce a shift in the quantities of demanded pork and chicken of the same order 
of magnitude. This means that not only will land be released by the technical progress in pork 
production, but additional areas will come from displaced chicken production. In the whole, 
this should lead to significant falls in land prices, in locations which remain to be determined, 
unless new demands emerge for other usages. 
Second, there is the question of the geographical concentration of pork production plants. 
In the case of pork, the reasons for having production geographically disconnected from the 
corresponding land are the same, and even much stronger, as in the case of milk. ST will 
reinforce these reasons, by decreasing the cost of transporting the feedstuffs necessary for a 
given meat production. As a consequence, pork production plants should become larger. But 
the consequences of larger pork production plants are well known. Not only do they produce 
meat, but also unwanted and bad smelling effluences which, with small plants, would easily 
be dispersed in the wild life, but which, because of their size, are very difficult to dispose of. 
And since the society detrimental externalities thus produced are not charged to them, they 
have no incentive to adopt different, less harmful techniques. 
In this context, by reducing the number of pigs per kg of pork meat, rpST will decrease 
the overall pig generated pollution. But by encouraging larger pork production plants, it will 
locally increase this problem in the vicinity of surviving plants (In effect, the above 
reasoning implies that some plants will disappear).Is this a reason to forbid rpST use in pork 
production? Probably not, because the problem does not arise from the drug itself. It arises 
from the pollution market failures, and should be solved at this level, rather than by indirect 
and imperfect restrictions on secondary aspects. 
Conversely, if efficient steps were taken in order to prevent too large pork production 
plants, would the incentives to make use of rpST be lowered? Probably not, because this 
would not suppress the yield increase effect of rpST. Simply, in that case, the production cost 
of pork would be higher, and even more without than with rpST. 
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Somatotropin and sheep production 
As far as I know, ST has not been envisaged for sheep, and, of course, there is still a 
possibility for that the technique does not work at all with that species. The above analysis, 
however, suggests that it could be highly valuable if it were feasible: sheep are more likely 
to develop undesired fat than young bovine. They are less likely to have exhausted their 
possibilities for roughage ingestion increase. Therefore, they may represent a unique 
possibility of non intensifying somatotropin-like substance usages. Of course, I admit that 
the technical basis for such a statement are lean. But dreaming a little is not necessarily 
forbidden in an international meeting. 
Who will adopt somatotropin? 
Thus, the introduction of rST is a true technical progress, always capital and labour 
saving, moderately land saving in the case of rbST, definitely land saving in the case of rpST. 
No doubt it will be quickly adopted if allowed, although the adoption pace may depend upon 
a variety of secondary circumstances, such as the availability of veterinarians to administer 
it, if the intervention of such skilled manpower is really necessary. 
The political problem tied with such an innovation is that it will reshuffle many cards, be 
harmful to vested interests, and create real adaptation costs, as any other technical 
innovation. It fact, it will modify the technical basis of comparative advantage. For instance, 
if it is true that the response to rpST is smaller for highly selected (such as Danish pigs) than 
for more traditional (as many midwestern) animals, then it will suddenly provide the latter 
with some of the laboriously acquired qualities of the formers. And since midwestern pigs 
have other, different qualities of which the Danish ones are deprived, and which will not 
disappear from the introduction of rpST, they may very well override them in international 
competition. However, in the present state of our knowledge about the effects of ST, such a 
precise forecast is probably rather premature. In fact, the completely opposite view could be 
supported as well. 
More important is the discussion about which kind of farmer will adopt the innovation. 
There is a pervasive creed according to which the "most advanced farmers" will adopt it . 
This opinion is supported by the observation that the introduction of ST will raise many day 
to day problems for animal feeding schemes tuning, and that only very skilled and informed 
people can be successful in such a task. Obviously, this is at least partially true. Another 
observation leading to the same conclusion is that "the most advanced farmers" are those 
having already pushed all possibilities of substituting land and (or) capital to labour as far as 
possible, and who will therefore be the most anxious to go further in the same direction. 
But these reasonings do not preclude the possibility of ST being used by more traditional 
farmers, especially in the third world. Actually, in many countries, it is difficult to know 
Cf, for instance Mouchet (1989) who provides an estimate of proposition of adopting fanners in France: 
15-25% before 1995, assuming an authorisation this year. 
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whether fodder resources or genetics are the real limiting factor to meat or milk production, 
even if it is possible to assume that both of them are important. 
The genetic potential of a herd is difficult to improve in most third world countries, 
because this would require heavy and difficult to operate projects that governments are 
generally unable to properly manage. If the lack of suitable genes was demonstrated to be the 
most binding factor for livestock production increase in these countries, then ST could be a 
suitable runabout. In that case, it could play a role similar to (and, in fact, perfectly 
complementary with) the "green revolution". 
The latter was extensively developed in many countries of the third world, mainly in the 
South Asia, as a "package" including irrigation, credit and fertilizer supply. It succeeded in 
massively increasing agricultural supply, especially wheat and rice. It had severe drawbacks, 
displacing poors and making the rich richer (Griffin, 1974 ; Petit, 1990). But it helped in 
favouring the displacement of manpower from agriculture to industry and services. In the 
whole, it was rather beneficial to most consumers, especially the poorest. 
Similarly, ST is complementary with other techniques, especially fodders cultivation, with 
which it could constitute a "package". It will also release manpower, and, more importantly, 
capital, which is particularly scarce in developing countries. It is therefore possible to 
imagine significant increases in milk and meat supply due to ST in these countries. I admit 
this is an optimistic view. I am an optimist. 
Conclusion 
Finally, ST will create difficulties in the transition period before full adoption. If it frees 
manpower, will this manpower find alternative employment? If it frees capital, where is this 
capital to be reinvested? If it frees land, what to do with this land? Here is the classical debate 
about any innovation:In the long run, it is beneficial. But in the short run, it may even create 
ruin and misery. The history of the 19th century is full of stories of workers burning new 
pieces of machinery, or opposing technical progress. Often, these actions were not without 
justification, simply because these people were fighting for their own survival or out of fear 
of change. In principle, the correct functioning of markets should avoid such detrimental 
effects of innovation. But markets, often, fail to perform their tasks, and public intervention 
is required to substitute for their shortcomings. This is the case, especially, for large 
innovations, such as steampower, or electricity. Is ST of this size? obviously not ! In addition, 
the state intervention in failing market should never be directed toward forbidding 
innovation: The problem is not to prevent it, only to alleviate the damages it could cause. 
From this point of view, it is to be hoped that, rather than forbidding ST, governments will be 
able to find different means of intervention, and imagine new agricultural policies capable of 
avoiding the detrimental effects of not only ST, but also all kinds of technical progresses in 
agriculture, without preventing them to take place. 
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Summary 
This paper examines the perceived differences between recombinant-DNA and earlier 
technology, the likely economic effects of commercial use of both rbST and rpST, and why 
both rbST and rpST used for meat production may have less difficulty in gaining the market's 
confidence. Contrary to typical new animal drug applications with the U.S. Food and Drug 
Administration (FDA) where the industry and the general public are not generally aware of 
the individual pharmaceutical company applications, rbST has been in the public's eye 
almost continually since the mid-1980's. Critics have attempted to discredit the potential 
benefits of rbST in milk production, and to spurn biotechnical development in general. In 
contrast, criticism of both rpST and rbST for meat production has been less visible, less 
vocal, and less persistent. The primary reasons appear to be: (1) rbST was one of the first 
areas of recombinant-DNA research in animal agriculture and was a prime target for activists 
and critics, so early reports of its likely effects were over-dramatized; (2) milk has been 
promoted as a natural, healthful and unadulterated product for both infants and adults, so 
critics of rbST have taken advantage of this image and have attempted to portray milk from 
rbST-treated cows as being unsafe; (3) rbST and rpST use for meat production results in 
products having attributes perceived by consumers as being more healthful—less fat, less 
cholesterol, and fewer calories—in contrast, rbST use does not significantly alter the 
composition of milk; (4) there is a larger selection of meat and meat substitutes for 
consumers to choose from than in the milk and dairy products area; (5) efficiency gains are 
more likely to be passed on to consumers in the more market-oriented meat industries than in 
the regulated dairy industry; and (6) socio-economic issues may differ between the meat and 
dairy industries because of differences in the structure and organization of the sectors. 
Keywords: biotechnology, somatotropin, dairy, swine, meat, acceptance. 
Introduction 
Both recombinant porcine somatotropin (rpST) and recombinant bovine somatotropin 
(rbST) have been under review by the U.S. Food and Drug Administration (FDA) under the 
program of New Animal Drug Application (NADA) for several years to determine whether 
or not these products meet the requirements for approval of a new drug. Under this 
procedure, all data derived from studies conducted under the Investigational New Animal 
Drug Applications (INADA) must be submitted to FDA's Center for Veterinary Medicine 
(CVM) to obtain a final determination as to whether or not the new animal drug is 
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efficacious; is safe for the target animal; has no adverse effect on the environment; has 
acceptable quality control; and most critical of all, that edible products from the treated target 
animal are safe for human consumption. 
Each company interested in developing and marketing a new animal drug in the United 
States must submit sufficient data for CVM to make a determination. In contrast to the usual 
procedure, the four companies filing INADAs for rbST gave the FDA permission to inform 
the general public that investigational studies were underway. This action on the part of the 
companies in the mid-1980's, in conjunction with rbST being one of the first major products 
of the science of biotechnology for animal agriculture, set the stage for considerable 
academic, industry and public scrutiny that continues today. This paper examines the 
underlying issues fueling the controversy surrounding rbST use for milk production and why 
both rbST and rpST used for meat production would likely have less of a problem in gaining 
public acceptance. Other than the issue of more likely consumer acceptance of rbST in its 
potential role in meat production rather than milk production, this paper will focus primarily 
on issues related to rbST use in milk production and rpST use in pork production. Unless 
specified otherwise, rpST and rbST refer to the recombinant-DNA product. 
Overview of the pork and dairy industries 
The pork industry in the United States, and in most developed countries, relies primarily 
on market forces rather than government regulations to generate signals for guiding pork 
production, processing and marketing. In contrast, the United States and almost every major 
developed dairy-producing nation operates government programs which regulate their 
domestic dairy industries. Many subsidize part or all of domestic production, imports are 
commonly restricted, and exports are frequently subsidized. 
History has shown that price enhancement above market-clearing levels by dairy 
programs in many major milk producing countries generates excess milk supplies. The 
Government costs of handling the excess add to budget pressures. In some instances, 
subsidized exports are required to maintain price-enhancing domestic dairy programs. 
The U.S. dairy industry 
Federal dairy programs play an important role in the pricing and marketing of milk in the 
United States (Fallen, Blayney, and Miller, 1990). The major dairy programs are dairy price 
supports, Federal milk marketing orders, import restrictions, and State regulations. The U.S. 
dairy industry is primarily a domestic industry. Restrictive import quotas are used to prevent 
lower cost and subsidized dairy products from undercutting U.S. dairy price supports. The 
import quotas on manufactured dairy products normally limit imports to just under 2 percent 
of U.S. milk production. Exports of around 2 percent of U.S. milk production have 
historically been concessional sales or food aid donations from Government supplies. 
Since the mid-1980's, there have been significant strides taken in some major producing 
countries to address dairy industry problems. The implementation of production quotas in the 
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European Community (EC-12) in 1984 dramatically reduced the world's largest dairy 
product surpluses. Legislation authorizing the milk diversion program and the dairy 
termination program in the United States are examples of alternative approaches for 
attacking the excess supply issue. In addition to the voluntary supply management programs, 
the United States implemented a flexible dairy price support mechanism. 
The history of excess resources in dairying leads some to suggest that further 
cost-reducing and output-enhancing technology such as rbST will only exacerbate dairy 
industry problems. Ironically, other emerging milk production technology such as artificial 
insemination, embryo transfers, computerized feeding, total mixed rations, and nutritional 
supplements appear to have the industry's blessing. For example, a recent article on total 
mixed rations (TMR) in a large regional cooperative's newsletter (MID-AM, Aug. 1990) 
indicated that "Most nutritionists and dairy scientists feel comfortable in projecting a five to 
ten percent increase in milk production when implementing TMR." It is difficult to sort out 
the reasons for the entirely different perceptions and reactions to rbST and TMR 
technologies. 
Other controversial dimensions of the changing structure of the U.S. dairy industry are the 
issues of larger herd sizes, a decline in "family" farms, and the changing location of milk 
production. The number of farms with milk cows dropped from 2.8 million in 1955 to around 
205,000 in 1989. Commercial dairy farms declined from 600,000 to around 160,000 (Table 
1.). The number of milk cows declined from 21 million in 1955 to 11.1 million in 1975, and 
10.1 million in 1989. A 143-percent increase in milk production per cow enabled milk 
production to more than keep pace with commercial needs over the 1955-89 period. 
Table 1. U.S. dairy industry changes, 1955-89 
Change per year 
Item 
Cows 
Farms with milk cows 
Average cows per farm 
Milk per c o w (annual) 
Total milk production 
1955 
21,044 
2,763 
8 
5,842 
122,945 
1975 
Thousand 
11,139 
444 
Number 
25 
Pounds 
10,360 
Million pounds 
115,398 
1989 
10,127 
205 2 
49 
14,244 
145,252 
1955-75 
Percent ' 
-3.1 
-8.7 
5.9 
2.9 
-0.3 
1975-89 
-0.7 
-5.4 
4.9 
2.3 
1.7 
1
 Compound annual rate. 
2
 Commercial dairy farms (farms with 10 or more milk cows) are estimated at around 160,000 in 1989 
with an average of around 65 cows per farm. 
Source: Fallertetal., 1990, 
A regional shift in milk production from the traditional dairy areas of the Upper Midwest 
and Northeast to the West and Southwest began about three decades ago and has accelerated 
in the last 20 years. Wisconsin is still far ahead as the number one milk producing State, but 
California is rapidly closing the gap. Some critics of rbST assert that the trends toward larger 
dairy farms and the shift in milk production to the Southwest would be accelerated with rbST 
use. The question again arises as to why there is this concern about rbST when use of other 
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technologies such as TMR—which would likely have similar structural effects as rbST—do 
not appear to generate these same concerns. 
The U.S. pork industry 
The United States ranks second to China in pork production, is the world's largest pork 
importer and a major pork exporter (Shagam, 1990). Pork production in the U.S. has 
increased slightly over the past 29 years, despite a small decline in the hog inventory. More 
effective use of the breeding herd appears to be a major factor in the growth of pork output, 
along with some increase in the average dressed weight of hogs (Futrell, forthcoming). 
Like the dairy industry, U.S. pork production is taking place on fewer and larger farms. 
The National Agricultural Statistics Service (NASS), USDA defines a hog operation as any 
place having one or more hogs and pigs on hand during the year. By this measure, the number 
of U.S. hog operations declined from 871,000 in 1970 to 309,700 in 1989. However, a better 
indicator of commercial hog operations is Census of Agriculture data which shows that the 
number of farms that sold hogs and pigs decreased from 1,273,000 in 1959 to 230,000 in 
1987. Forty six percent of the farms selling hogs in 1987 sold 99 head or less but accounted 
for only 3.7 percent of the total sold. In contrast, 10 percent of the farms sold 1,000 head or 
more and accounted for 57.5 percent of the hogs sold. This was a significant change from 
1969, when 6.1 percent of the farms had sales of 1,000 head or more and marketed one-third 
of the hogs (Tables 2 & 3). 
Table 2. Farms with sales of hogs and pigs, by number sold per farm, U.S. 
Total farms Hogs sold per farm 
Year 1-99 100-499 500-999 1,000+ 
Percent of farms 
1969 
1974 
1978 
1982 
1987 
536,351 
449,841 
470,518 
315,095 
238,819 
53.6 
57.9 
59.8 
51.8 
46.0 
40.3 
33.9 
30.5 
31.8 
32.5 
4.8 
5.8 
+6.4 
9.5 
11.5 
1.3 
2.4 
3.3 
6.9 
10.0 
Source: Futrell, forthcoming; derived from Census of Agriculture, Bureau of the Census, U.S. 
Department of Commerce. 
Table 3. Hogs and pigs sold, by number sold per farm, U.S. 
Year 
Total hogs 
sold 1-99 
Hogs sold per farm 
100-499 500-999 1,000+ 
Percent of Hogs Sold 
1969 
1974 
1978 
1982 
1987 
86,771 
79,897 
92,141 
94,784 
96,569 
13.6 
11.1T42.1 
9.6 
5.4 
3.7 
53.5 
21.7 
34.9 
24.7 
19.2 
19.6 
25.1 
21.8 
21.7 
19.6 
13.3 
33.7 
48.2 
57.5 
Source: Futrell, forthcoming; derived from Census of Agriculture, Bureau of the Census, U.S. 
Department of Commerce. 
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According to a University of Missouri study (Rhodes, 1990) one of the dramatic changes 
in structure is the increasing size of that boundary line between hog farms that decline and 
those that grow. The boundary line is now at 1,000 head annual sales-and approaching 
2,000-whereas in the 1960's it was at 200 head. Another dramatic change in structure is the 
growth of hog firms controlling multiple farms or production units. Each of about 6,600 
firms in 1988 controlled more than one "farm" through purchase, lease or contract. Thus the 
concentration of marketing in farm firms is greater than the concentration shown by the 
Census data based on farms. A University of Missouri (UMC) survey in 1989 suggests that 
nearly 70 percent of 1988 market hogs in the United States came from farm firms marketing 
1000+ hogs/pigs, Rhodes indicates. 
From a regional standpoint, the location of U.S. hog and pig production appears to be 
more closely tied to grain and protein production areas and thus is not shifting as much 
regionally as is milk production. Regional shares of pork production have increased slightly 
in the Northern Plains and Southeast since 1970 and have declined in the Southwest. Within 
the Southeast region, North Carolina has shown a substantial gain in share of national 
production—from 2.9 percent in 1970 to 5.4 percent in 1989, primarily because of large 
contract arrangements with several large meat-packing firms (Table 4). 
Table 4. Regional distribution of U.S. hog production ' 
Region 
Cornbelt-Lake States 
Eastern 2 
Illinois 
Western 3 
Iowa 
Northern Plains 4 
Southeast5 
North Carolina 
Southwest6 
Other7 
1970 
Percent of U.S 
28.6 
12.2 
37.2 
23.4 
13.7 
14.4 
2.9 
2.6 
3.5 
1980 
production 
25.4 
11.3 
39.6 
24.5 
13.0 
15.8 
3.6 
2.0 
4.2 
1985 
27.3 
11.2 
41.0 
27.1 
13.0 
13.4 
4.4 
1.3 
4.0 
1987 
27.1 
10.5 
39.9 
26.4 
13.9 
13.3 
4.5 
1.5 
4.3 
1989 
26.7 
10.6 
38.6 
25.4 
14.4 
14.9 
5.4 
1.5 
3.9 
1
 Based on liveweight production. 
2
 OH, IL, IN, Ml. Wl. 
3
 MN, IA, MO. 
4
 ND, SD, NE. KS. 
5
 AK. LA, KY, TN, MS, GA, FL, SC, NC, VA, AL. 
6
 TX, OK, NM. 
7
 Remaining States. 
Source: Futrell, forthcoming; derived from Meat Animals: Production, Disposition, and Income, NASS, 
USDA (various issues). 
Family hog operations are still important in the U.S. According to Futrell's analysis of 
Census data, two-thirds of the hogs sold were from individual or family operations and 
one-sixth were from partnerships. Corporations, three-fourths of them family-held, 
accounted for 15 percent of hog sales in 1987; and less than one percent were from all other 
sources. 
287 
FALLERT, SHAGAM. STILLMAN AND BLAYNEY 
In contrast to the U.S. dairy industry where little contract production takes place, contract 
production of pork has increased moderately in recent years. Contract production is fairly 
common in some southeastern states, but is limited in the more traditional midwest 
production area. According to Futrell, interest in contracting has continued as more firms 
have offered production contracts and some producers seem to like the low capital 
requirement and low-risk option provided by some contracts. The 1989 study by Rhodes 
indicated that around 10 percent of the hogs in the U.S. were produced under contract in 
1988. Based on personal communication, both Rhodes and Futrell feel that some further 
increase in contract production seems likely over the next few years. 
Biotechnology in U.S. 
promotants 
agriculture: the different classes of growth 
A number of different agents influence animal agriculture (Table 5). While some are 
naturally occurring, others are produced (or refined) outside the animal and then introduced 
to alter the productivity of the animal. Each class has its own characteristics and often 
different impacts. An agent may be efficient with one species or sex but not with another. In 
the United States, livestock hormones are used extensively (Kenney and Fallen, 1989); their 
use is regulated by the Food and Drug Administration (FDA) and USDA's Food Safety and 
Inspection Service (FSIS). Under current technology, hormones must be administered by a 
time-release pellet inserted under the skin of the animal's ear, which is then discarded at 
slaughter. 
Table 5-Anabolic agents can be classified into four categories 
Category Source Metabolic Action Anabolic 
agents 
Natural 
steroids 
and 
hormones 
Synthetic 
steroid 
hormones 
Natural 
xenobiotic 
hormones 
Growth 
promoting 
compounds 
Produced in 
animals and 
humans 
Produced 
Synthetically 
Derived 
from 
plants 
Recombinant 
DNA 
technology 
Regulates growth. 
maturity. 
and sexual 
characteristics 
Same molecular 
structure and 
action of natural 
steroid hormones 
Although not 
technically 
steroids, they 
have similar 
effects 
Improves feed 
efficiency 
through nutrient 
partitioning 
Estradiol, 
testosterone, 
progesterone 
Melengestrol 
acetate and 
trenbolone 
acetate 
Zeranol 
Bovine 
Somatotropin 
and porcine 
Somatotropin 
Source: Kenney and Fallert (1989). 
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Anabolic agent (hormone) use in beef production 
Hormones used in beef and veal production are technically known as anabolic agents. 
These substances affect animal metabolism by improving the use of nutrients absorbed from 
feed. Nutrients, such as nitrogen, calcium, and phosphorus, are more likely to be channelled 
for use in muscle (lean meat) growth than for fat. Anabolic agents can be classified as 
follows: 
- Natural steroid hormones are normally produced by nearly all animals. The hormones generate 
sexual characteristics, maintain reproductive functions, stimulate growth, and are essential for 
regular body functioning. 
- Synthetic steroid hormones have similar hormonal actions as natural steroid hormones. They are 
produced in a laboratory and then administered to cattle to enhance the effects of the animals' 
natural hormones. 
- Natural xenobiotec hormones are derived from plants and produce effects comparable to those of 
steroids. 
- Growth-promoting compounds include substances such as somatotropins, growth-hormone-
releasing factors, and somatostatins. Somatotropins, which are also referred to as growth 
hormones, are naturally occurring animal hormones that regulate growth and metabolic 
processes. They can be reproduced in the laboratory through recombinant DNA technology. 
Since they are proteins, they would be broken down by the digestive system if used as a feed 
additive. Therefore, to be effective, the product must be injected into animals. 
Growth-hormone releasing factors and somatostatins regulate an animal's production of 
somatotropin. These substances are highly species specific. None of them has been approved 
for commercial meat or milk production in the United States. However, rbST and rpST are 
currently under review by FDA. 
Why Use Hormones? Cattle require more feed per pound of weight gain than hogs or 
poultry. Anabolic agents are used to improve feed efficiency. These substances also help U.S. 
producers compensate for the practice of raising steers (castrated males) and heifers rather 
than bulls. Bulls have better feed efficiency and higher growth rates than steers or heifers 
because of naturally occurring hormones. They also produce leaner meat and can be fed to 
heavier weights. But bulls behave aggressively and steers are easier to manage, so U.S. 
farmers and feedlots generally raise steers instead of bulls. Further, meat from steers is 
considered more desirable than bull meat, which is usually less tender, less marbled, and a 
darker red colour, owing to the greater maturity of bulls at slaughter. Castration, however, 
results in lower internal androgen production. Therefore, androgen implants allow steers to 
achieve the higher growth rates of bulls. 
Scientists at the World Health Organization and FDA have concluded that residues from 
hormones, when properly administered in both dose and method, pose no threat to human 
health. Food safety and other issues associated with animal growth promotants have been 
reviewed extensively (Grueff and Bylenga, 1989; Krissoff, 1989; Kuchler, McClelland, and 
Offutt, 1989; Norcross etal., 1989; Sachs, 1989; Schams, Kanis, van der Wal, 1989). Some 
observers maintain, however, that the misinformation and sensationalism surrounding the 
hormone issue are the main problems. Thus, the real challenge lies in finding ways to educate 
producers, consumers, and policymakers about the benefits, degree of risk, and other issues 
associated with hormone use in livestock production. 
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Bovine Somatotropin (bST) use in milk production 
bST is a naturally occurring protein hormone produced in the pituitary gland of cattle that 
regulates body metabolism and therefore, milk production. Through recent breakthroughs in 
genetic engineering techniques, the bST gene can be transferred from animals to ordinary 
bacteria cells. These bacteria can be reproduced on a large scale at relatively low cost, 
making the purified product available for commercial use. The process is similar to that used 
to produce human insulin and interferon. 
rbST has not yet been approved by the Food and Drug Administration (FDA) for 
commercial use in the United States. However, it has been approved for research purposes 
under controlled conditions, and the sale of milk and meat from experimental cows injected 
with rbST has been approved. 
The economic impact of rbST adoption 
In October 1987 the Economic Research Service (ERS) of USDA published an in-depth 
study of the likely effects of rbST on the U.S. dairy industry (Fallert et al., 1987). The focus 
of the study was the effect of rbST on U.S. milk supplies, commercial use of milk, milk 
prices, dairy industry structure, the dairy price support program, and the international 
competitiveness of the U.S. dairy industry. The major findings of that study, which assumed 
the commercial availability of rbST, were: 
- The effects of rbST on the dairy industry would likely be less dramatic than often suggested. 
- rbST would reinforce, but not fundamentally change, structural change already underway in the 
industry. 
- Effects of rbST would ultimately depend on the flexibility of the dairy price support program. 
- rbST would have little effect on the U.S. position in the international dairy market under 1987 
trade policies. 
As in any economic study, results are greatly affected by assumptions of the study. The 
major assumptions of the 1987 study, which were developed from an extensive review of the 
available literature and personal contacts with university, industry, and pharmaceutical 
company representatives, were: 
- FDA approval is given and the product is available by early 1990. 
- rbST will be available as a once-a-month injectable sustained release product. 
- rbST will increase daily milk production per cow by 8.4 pounds during the 215 day treatment 
period. 
- There are no size or regional effects on response. 
- The cost of rbST is 24 cents per treated cow per day. 
- The adoption rate allows most effects of rbST to work through the dairy sector by 1996. 
- rbST has minimal effects on long-term animal health and reproduction. 
- No adverse consumer reaction to milk and meat from rbST-treated cows. 
- There are no constraints on rbST production and availability. 
290 
ENVIRONMENT AND SOCIOECONOMICS ANIMAL PRODUCTION SYSTEM 
The 1987 study examined an option with January 1, 1990 price supports at $10.10 per 
cwt, which now is the current support price and, according to the recently proposed farm bill 
provisions, will be the minimum support price until January 1996. The assumed introduction 
of rbST in 1990 would lower the cost of producing milk by 50 to 60 cents per cwt by 1990. 
The number of dairy farms would decline by 3 percent as rbST increases milk production. 
Commodity Credit Corporation (CCC) purchases by 1996, assuming the milk price support 
is held at $10.10 per cwt, were estimated to be close to 8 billion pounds (milk equivalent, fat 
basis) higher with rbST than without. 
Another option of the study maintained the price support at the relatively high 1987 level 
of $11.10 per cwt through 1996 in spite of high government costs. Under the scenario 
government purchases of dairy products reached 31 billion pounds by 1996. This illustrates 
the need for a flexible dairy price support program to accommodate cost-reducing and 
output-enhancing technologies such as rbST. An inflexible program with high supports 
generates significantly higher returns to producers who adopt the new technology, but 
government program costs are increased substantially, and consumers do not benefit through 
reduced dairy product prices. 
In May 1989, Senator Patrick Leahy, Chairman of the Senate Committee on Agriculture, 
Nutrition and Forestry, requested that ERS update and extend the earlier study emphasizing 
the effects of rbST on small-and medium-sized dairy operations and the potential for 
exporting additional U.S. milk and dairy products that might result from its adoption. Results 
of the updated study were published in mid-1990 (Blayney and Fallen, 1990). The findings 
of the more recent study reconfirmed the general results reported in the 1987 study. 
The effects of rbST as it relates to the size of dairy farms have not yet been fully 
determined. The 1987 USDA study indicated, on the basis of analyzing representative farms, 
that small farms would be better off with rbST than without it. In general, rbST is considered 
size neutral because no significant investment in capital and equipment is required to use the 
product. The additional milk production from rbST use does require more high-quality feed 
and good management. Revenues generated by the additional milk production more than 
offset the costs of additional inputs under most market situations. 
More recent studies at Texas A.& M. University (Yonkers, Richardson, and Knudsen, 
1989) and at the University of Arizona (Angus, 1989) support this conclusion. Overall, the 
trend toward larger and fewer dairy farms will continue with or without rbST. 
Effects of rbST use on international competitiveness of various countries is unclear. A 
recent study of the costs of producing milk in seven major milk-producing countries (Baker 
et al., 1990) indicates that milk production costs per cwt in the United States and the 
Netherlands are quite similar and are in the middle of the range of costs estimated for the 
seven countries included in this analysis. New Zealand is the lowest-cost milk-producing 
country in the world, while costs in France and West Germany are substantially higher than 
in the United States. Costs in Ireland are somewhat lower than in the United States, while 
milk production costs in Canada are also quite high compared with the United States, but 
significantly lower than in France or West Germany. 
The United States is probably as well positioned as any country to take advantage of rbST 
to improve its international competitive position because of not having a quota program and 
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because of having relatively low-cost concentrate feed available. A major factor in the 
competitiveness issue would be the willingness of importers to accept dairy products 
produced with milk from rbST-treated cows. 
Porcine Somatotropin (rpST) use in pork production 
Results from numerous experimental studies (van der Wal et al., 1989; Lemieux and 
Richardson, 1989) indicate that pork production can be changed through the use of 
laboratory synthesized compounds normally produced by the hog itself. One of these 
compounds is rpST which offers the opportunity to produce leaner pork and to substantially 
increase feed efficiency. By altering the way in which the animal's body utilizes nutrients, 
rpST reduces feed intake while increasing muscle mass and rate of gain. Although producers 
can expect cost reductions, increased production could reduce prices to pork producers and 
thus offset at least some of the net income gain from rpST use. Research indicates that 
management changes will be required. In contrast to milk production where dairy cows are 
handled on a daily basis, use of rpST in hogs will depend heavily upon availability of a 
convenient rpST delivery system. Profitability of rpST use and consumer acceptance of 
leaner pork produced with the use of a laboratory synthesized growth promotant will also 
affect rpST adoption rates. 
So far as rpST is concerned, much of the public information in the U.S. surrounding this 
product is being developed and disseminated through the Animal Health Institute's Porcine 
Somatotropin Public Information Group in response to continued requests for information on 
the product. One such information document is PST: AT A GLANCE which briefly presents 
various issues raised about rpST in scientific forums. It also cites references. An expanded 
version of this document is under development and should be released shortly. 
Consumer demand in the U.S. for various meats is reflected in per capita consumption 
data over the past 33 years. For example, U.S. combined per capita red meat and poultry 
consumption at the retail level has increased steadily from 165 pounds in 1955 to 246 pounds 
in 1988 (Stillman and Weimar, 1990). During this period, per capita pork consumption at 
retail in the U.S. has fluctuated between 55 and 69 pounds but has shown little growth over 
time. In contrast, per capita poultry consumption at retail increased dramatically from 27 
pounds in 1955 to 81 pounds in 1988. Per capita retail beef consumption increased from 61 
pounds in 1955 to a peak of 94 pounds in 1976 when the size of the beef herd reached 
unprofitable levels and then began a continued downward trend to 72 pounds in 1988. The 
combined U.S. per capita veal, lamb and mutton consumption declined drastically from 
about 12 pounds in 1955 to slightly under 3 pounds in 1988. 
Much of the decline in pork's share of meat consumption can be traced to two factors 
(Shagam, 1988). First, pork tends to be less competitive than poultry because, among other 
factors, hogs require almost twice as much feed per pound of gain as broilers. There also have 
been substantial increases in productivity in the poultry sector aided by vertical integration 
and automation that have not been matched in the hog sector. Second, consumers have 
become far more health conscious and perceive pork as a "fatty" meat that is detrimental to 
their health, while perceiving poultry as more healthful than beef or pork. To enhance pork's 
image, packers and retailers are trimming more fat from retail cuts and the industry has begun 
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a promotional effort to dispel negative perceptions. Although trimming fat improves pork's 
appeal to consumers, the increased costs are passed on through higher retail prices. 
The pork industry, therefore, is faced with a joint task: first, producing a product that 
appeals more to consumers; and secondly, increasing productivity to make pork more price 
competitive with other meats and foods. From all indications, producing and marketing lean 
pork with desirable sensory qualities at a reduced price would be desirable pork industry 
objectives. 
Significant progress has been made in reducing fat and increasing feed efficiency of hogs 
through selective breeding. However, genetic selection is a time-consuming procedure and 
based on attempts to breed lean hogs in the early 1960's and 1970's, there appears to be limit 
as to how far this can be carried to achieve lean muscle production. Although some countries 
are far ahead of others in genetic selection, the structure of the breeding segment and the 
pricing and marketing system in the United States has retarded the process of producing pork 
of a quality most desired by consumers. 
One could reason that if the U.S. pork industry is truly severaF years behind the 
progressive Danish hog industry in producing the quality of pork desired by consumers 
(Fleming, 1990), that use of rpST or other growth promotants might be more advantageous 
to U.S. producers than to producers in some other major pork-producing countries (Steele et 
al., 1989; Fowler and Kanis, 1989; Fung and Qi, 1989). Given the experience with the EC's 
reaction to anabolic steroid use in U.S. beef production and the associated restrictions on 
international beef trade, this issue could become associated with rpST use in pork production 
as well. 
Economic impact of rpST adoption 
Several studies have addressed the economic impact of rpST adoption on the livestock 
industry (Hayenga et al., 1989; Lemieux and Wohlgenant, 1989, Stillman et al., 
forthcoming). Each of these studies differs in its focus. Hayenga and co-workers address the 
impacts of rpST adoption on the livestock industry as a unit, addressing cost and demand 
changes. Lemieux and Wohlgenant, on the other hand, looks at the effects on both the 
domestic and international markets. Stillman et al. (forthcoming), focus on the impacts on 
the livestock industry much like the Hayenga study. 
In the Stillman et al. study, feed costs were adjusted proportionally to total production 
costs. Corn costs are reduced by 22 percent, while soybean meal costs are increased by 11 
percent. Other costs are adjusted to reflect the reduced number of days on feed, which are 
reduced by 8 days or 6 percent. rpST costs per hog were set at $2.50 per hog. This level was 
based on simulating the cost impacts of the rpST over the 1980's and using the average 
change in returns and a 2-to-l returns-to-cost ratio for pricing growth promotants. 
Demand changes for hogs were assumed to occur at the packer level. rpST results in a 
higher yielding hog which requires less fat trimming for the retail products. This was 
assumed to result in a 3.3 percent increase in the value of the live hog in a carcass merit 
pricing system (Hayenga et al„ 1989). Presently, retail pork products are being trimmed to 
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about 1/4 inch of outside fat. With the adoption of rpST, the reduction of fat would not likely 
be seen by consumers and, therefore, they would not pay a premium for the product. No 
changes in consumer demand were assumed in this analysis. 
Stillman et al. examines four scenarios relating the effects of rpST adoption on the pork 
industry from changes in production costs, packer demand for the hog, and varying rpST 
costs. The impacts of the cost changes due to the adoption of rpST can be explored using 
ERS costs of production estimates for farrow to finish hog operations and adjusting for the 
non-adoption of rpST for the breeding herd. 
Simulation assumptions 
Four basic scenarios were analyzed by Stillman and co-workers over the period 1991 to 
2000 assuming the adoption of rpST would start in 1992, using the annual livestock model 
developed by ERS (Weimar and Stillman, 1989). The results are presented as percent 
changes from a base solution of the model assuming no impacts from rpST. The first scenario 
(pstl) only analyzed the impacts of the cost reduction resulting from the adoption of rpST. 
The second scenario (pst2) analyzed the combined impacts of the cost reduction and the 
carcass merit price increases realized by producers adopting rpST. The third scenario (pst3) 
is similar to the second, but the price of rpST is lowered from $2.50 per hog to $ 1.00 per hog. 
In the last scenario (pst4), the cost of rpST is increased to $5.00 per hog. 
In each of these scenarios, the adoption rate was set at the same level. In the first year, 50 
percent of the producers were assumed to adopt rpST. In each year thereafter, a 10 percent 
increase in the number of producers were assumed to adopt rpST, until the level reached 90 
percent. The cost advantage of rpST would force the vast majority of producers to adopt the 
technology or exit the industry. The feed prices and macro economic assumptions are based 
on the latest analysis of the 1990 farm bill provisions and remain the same for all scenarios. 
Simulation results 
Scenario 1 (pstl): 
The impacts of the cost reductions due to rpST on the pork industry are increased 
production and increased returns per head. By the end of the simulation period, pork 
production was about 1 percent higher than the base solution (Figure 1). Initial reaction of 
pork producers was to lower production by the removal of gilts from slaughter and to place 
them in the breeding herd. Returns per hog show a large initial increase due to higher prices 
from reduced production and lower costs from the rpST adoption (Figure 2). By the end of 
the period, returns per hog return to near the base levels. The impact on consumers from the 
adoption of rpST are about 1 percent lower prices and larger levels of consumption. As a 
result of pork's increased competitiveness, production of other meats decline. Retail prices of 
pork remain higher than they would have been had only pork production changed (Figure 3). 
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Figure 3. Changes in retail pork prices resulting from pST assumptions 
Scenario 2 (pst2): 
By combining the impact of increased hog receipts from carcass merit pricing and the 
reduced cost assumptions from the use of rpST, pork production increased about 2.3 percent 
above the no-rpST base by the year 2000. The basic time path of adjustment of the pork 
sector is similar to the first scenario, but the levels are greater. Again, the returns per hog 
cyclically decline to near the base level as production increases. Retail pork prices decline 
2.2 percent by the end of the analysis period. 
Scenario 3 (pst3): 
The impacts of reducing the cost of rpST to $ 1.00 per hog results in even larger increases 
in pork production, about 2.7 percent by the year 2000. Returns per hog approach the base 
simulation level by the end of the analysis. Retail pork prices are 2.6 percent lower than in 
the base solution. 
Scenario 4 (pst4): 
By increasing the cost of rpST to $5.00 per hog, the gains to producers from carcass merit 
pricing are offset. The results of this scenario are very similar to scenario 1. 
Summary of impact of rpST on the livestock industry 
Pork producers and consumers are better off with the adoption of rpST from a consumer 
and producer surplus standpoint. Producers receive the same returns per head by the end of 
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the analysis and are able to sell more hogs ~ thus increasing their total profits. Consumers 
face larger supplies and lower prices for pork. Although pork producers and consumers 
benefit from rpST, other meat producers are worse off. Under scenario 2, steer prices are 0.2 
percent lower and beef production is 0.03 percent lower. The same impacts can be shown for 
poultry. However, there is an overall net gain to the livestock industry from rpST availability 
and use. 
Issues in the adoption of recombinant rbST in the dairy industry 
In August, 1990, FDA scientists (Juskevich and Guyer, 1990) summarized in the journal 
Science more than 120 studies they say document the safety of milk and meat from dairy 
cows treated with genetically engineered duplications of the cows' own growth hormone, 
used to increase milk production. The author-scientists say the studies have led FDA to 
conclude that the use of recombinant bovine somatotropin (rbST) presents "no increased 
health risk to consumers." 
In their summary report, the authors discuss previously unpublished data from 16 studies 
supported by manufacturers, who are seeking approval to market the substance, along with 
publicly available studies. These data demonstrate that: 
- "bST is harmless when consumed orally, as in milk or meat, because it is broken down into 
inactive fragments in the gastrointestinal tract while being digested. 
- Even if bST were injected in humans, as it is in treating cows, it would remain inactive 
because bovine somatotropin is 'species specific.' 
- Ninety percent of bST in milk is destroyed upon pasteurization. 
- A protein controlled by bST is increased in the milk of bST-treated cows, but data show that 
concentrations are within the normal physiological range found in human breast milk." The 
FDA authors go on to state that this protein (an Insulin-like Growth Factor I or IGF-I) is 
denatured under the conditions used to process milk for infant formulas. Other data 
demonstrate that oral toxicity studies have shown that IGF-I lacks oral activity in rats at even 
exaggerated doses. 
In addition, the authors concluded that rbST, produced in quantity by recombinant DNA 
technology, is identical in biological activity to growth hormone made by the cow's pituitary 
gland. They indicate that milk from cows treated with rbST would have bST residues within 
the normal range of the naturally occurring substance. 
The report underwent extensive and lengthy peer review by a panel of expert scientists 
selected by the editors of Science before it was published. The National Milk Producers 
Federation (NMPF) had sought this review as part of its ongoing commitment to ensure the 
public a pure and wholesome milk supply. After the report was published, a memorandum 
(1990) from Jim Barr, CEO of NMPF stated that "This report, and others like it, will help 
dispel public concerns about the safety of the milk supply, biotechnology andrbST. As you'll 
see from the attached peer-reviewed Science article of FDA's bST studies, all the extensive 
scientific research done to date shows rbST poses no health concern to the American public." 
Two days prior to the Science article, the Journal of the American Medical Association 
(JAMA) also published a review of data showing that "bovine somatotropin causes no 
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changes in milk composition of any practical importance to consumers..." (Daughaday and 
Barbano, 1990). The authors reviewed the FDA process of assuring that all new products 
used by dairy farmers are safe and how bST works. They went on to list the reasons why milk 
from bST-treated cows is safe for human consumption~and went on to conclude that "Based 
on scientific evidence, comments from health professionals can play an important role in 
reassuring the public about the safety of milk and refuting misstatements or misconceptions 
about bST." 
Along this line, it is ironic to observe the different reactions to peer-reviewed scientific 
articles in these two prestigious journals. Two reactions appeared in print on September 3, 
1990—within two weeks of the articles' publication. In the Editorial/Opinion column of 
Feedstuff s magazine the heading read "FDA won in several ways as bST controversy ends." 
The editorial goes on to state "...The controversy is over because FDA delivered blows to the 
opposition that cannot be overcome. The critics cannot come up with any worthwhile 
response to the articles published recently that carefully define the reasons why bST can be 
called completely safe for humans. The conclusions are irrefutable, because the science is 
sound and presented completely to the public..." The column heading on the front page of 
the September 3 issue of Biotechnology Newswatch read "Flouting FDA's pro-bST finding, 
Rifkin says: 'It's war'." The article goes on to say that "Jeremy Rifkin's Foundation for 
Economic Trends (FET) here revealed plans last week to launch an 'international boycott' of 
bovine somatotropin (bST), says John C. Stauber, director of the organization's anti-bST 
educational campaign. They plan to launch their global war against the growth hormone, 
even before the drug is approved by the U.S. Food and Drug Administration (FDA)." 
Partially in response to the latter type of reaction to rbST issues, the National Milk 
Producers Federation and the National Dairy Promotion and Research Board formed the 
"Dairy Industry Coalition" which will represent the two organizations with regard to milk 
safety issues. They state that "...The Dairy Industry Coalition intends to neither endorse nor 
oppose the use of Bovine Somatotropin (bST) in dairy herds at such time as the Food and 
Drug Administration approves the product as safe for commercial use. While remaining 
neutral on bST use by dairy farmers, the Dairy Industry Coalition is committed to 
communicating the facts concerning the continuing safety and wholesomeness of milk and 
milk products. The Dairy Industry Coalition is embarking on a public education campaign to 
communicate its neutrality on the bST issue and its commitment to preserving the integrity 
of milk." In conjunction with this effort, a Dairy News and Information Center was created 
with a telephone number "1-800-34-DAIRY". 
Another review of bST will take place at a National Institute of Health (NIH) Technology 
Assessment Conference on Bovine Somatotropin to be held on December 5-7, 1990 on the 
NIH Campus, Bethesda, Maryland. The Conference will take another look at the human 
health data on bST and FDA's biotechnology approval procedures. This meeting will bring 
together experts in fields relevant to a thorough discussion of bovine Somatotropin. At this 
meeting, besides presentations from concerned individuals and organizations, experts 
speaking from different points of view will present scientific information regarding relevant 
areas of concern. A panel of experts (non federal government) from several relevant fields 
with non-advocacy positions and with no financial interests regarding the conference issues 
will listen to the proceedings and determine points of agreement and areas of inadequate 
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information regarding the questions. The panel will develop recommendations based on the 
evidence and discussion. 
In the European Community (EC), the evaluation of bST for use in milk production is 
progressing through both national reviews and the new EC approval procedure for biotech 
products. To date, the only decision reached has been in the United Kingdom (U.K.), and in 
that instance, the regulatory authorities have issued a preliminary decision to not allow 
product licenses for Eli Lilly and Monsanto at this time. Both sponsoring companies are 
expected to supply additional data and appeal this preliminary ruling. An opinion by the EC 
Commission on the Eli Lilly and Monsanto applications is expected on November 27,1990. 
The EC findings will be advisory in nature and not in the form of a "yes or no" decision. 
Elsewhere in the world,rbST has been approved for commercial use in the Soviet Union, 
Czechoslovakia, Mexico, Brazil, Bulgaria, Namibia and South Africa. 
Issues in the adoption of recombinant Somatotropin in the meat sector 
There has been considerably less debate over somatotropin technology in the meat sector 
than in the dairy sector. A number of factors could be responsible for this. First,rbST is closer 
to approval than rpST, hence activists are likely concentrating their efforts and resources on 
dairy. Perhaps most importantly, both the nature of the food products and the structure of 
sectors are sufficiently different that some of the issues which dominate the debate in the 
milk production sector may not spill over into the meat sector. 
First and foremost, milk and meat (especially pork) are viewed differently by consumers. 
Milk is marketed as a "pure, unadulterated, wholesome" product with positive health benefits 
from consumption. Proponents of rbST argue that its adoption would not change the 
composition and quality of milk, but that rbST will only improve the efficiency of milk 
production. Opponents claim that adoption will have a negative impact on the quality of the 
product and have used this potential detrimental health reasoning to form one of the prongs 
of the argument against rbST. 
Pork, on the other hand, is currently suffering from a negative image as an "unhealthy" 
product, high in fat and cholesterol. In addition to improved feed efficiency, rpST alters the 
quality of pork; imparting those attributes perceived by consumers as more "healthful", 
increased meat muscle area and reduced fat. Thus in the case of rbST, critics claim a "good" 
product is being made "bad", whereas in rpST it is clearly shown that "bad" attributes are 
replaced by "good". 
Secondly, the structure of the dairy and other livestock sectors differ greatly. While there 
is considerable intervention by the government in the dairy sector, there is almost no 
intervention in either the beef or pork sectors (Blayney and Fallen, 1990; Hahn et al., 1990; 
Shagam, 1990). As a result of government intervention, dairy surpluses have been a chronic 
problem. Therefore, increased milk production from rbST use and the surpluses which would 
be generated under the current pricing structure are viewed as a potential burden on the 
public purse. 
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Concerns over producer revenue and income impacts from the adoption of rbST have 
been lessened with the passage of the 1990 Farm Bill. Under the previous Farm Bill, there 
were automatic reductions in support prices if milk production increased beyond certain 
targets. This shifted the burden of overproduction from the public treasury to the producer. 
Under the current Farm Bill, the support price is a floor and the burdens to the producers are 
minimized. However, all producers will be assessed for inventory management if 
Government purchases exceed a set level. 
No such policies exist for the meat sector. As studies have indicated, adoption of rpST in 
the pork sector tends to leave producer returns per unit unchanged and total profits increase 
from larger sales. Since there is no government wedge between production and consumption, 
consumers reap the benefits of lower prices from increased supplies. Use of somatotropin in 
the meat sector should have no direct cost to the government. 
A final argument, similar for both sectors, would be that there is an impact on the structure 
of the farm sector and there may be an adverse effect on "family" farms. Studies have 
indicated the trend towards fewer and larger farms in dairy and hog production. It has been 
argued that the adoption would speed this trend and therefore, force small, family farms out 
of business. Since somatotropins require little additional capital investment, this technology 
should be of benefit to farms of all sizes. There is general agreement, however, that 
somatotropin technology will be of the greatest benefit to better managers. 
This, of course, becomes a political decision, i.e. what should be the structure of the farm 
sector and what should be the role of government policy in achieving these goals. If the 
principles of the manufacturing sector are applied, the government's role should be limited 
to ensuring that there is fair competition and not collusive behaviour. Hence, the marketplace 
might be a better vehicle for determining the most efficient industry structure based upon 
increased efficiency and economies of size and scale. If there is a political desire to maintain 
an established social structure, the so-call "fourth hurdle", then perhaps the government 
should look towards more transparent means of achieving these goals. This could be through 
direct income transfers or other policies. It is questionable whether these policies should 
include the suppression of technology to maintain a status quo. 
Conclusions 
Each side in the fight over recombinant technology is undoubtedly a "true believer" in the 
righteousness of their particular stance. Thus, while one side claims that, based on scientific 
evidence, "the war is over", the other claims the "battle has just begun". Emotion and 
sensationalism cloud the basic issues, screaming headlines tend to garner more attention than 
reasoned arguments; as a result, both sides have at times exaggerated their claims. 
What is often lost is that in many cases the two sides are talking everywhere but to each 
other. A common ground must be achieved and each argument must be examined for both its 
relevance and strength. Some of the questions are only peripherally related to the issue of the 
safety of recombinant technology and should be addressed outside that context. 
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However, all relevant arguments must be examined. Failure to do so will lead to imposing 
a technology from the top down and risking rejection. 
Acceptance of recombinant technology will depend upon the choices of consumers, 
producers, industry leaders, and policy-makers. Whether these decisions are formed by 
sound evidence or manipulated perceptions will depend upon the efforts of "sensible 
centrists." 
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